{
  "drug_name": "upadacitinib",
  "generic_name": "Upadacitinib",
  "mechanism": "Janus Kinase Inhibitor",
  "target": null,
  "approved_indications": [
    "rinvoq (upadacitinib) for the treatment of inflammatory bowel disease",
    "giant cell arteritis (gca)",
    "pediatric patients two years and older with polyarticular juvenile idiopathic arthritis and psoriatic arthritis",
    "moderately to severely active crohn's disease in adults",
    "adults with active non-radiographic axial spondyloarthritis",
    "adults with active ankylosing spondylitis",
    "adults with moderately to severely active ulcerative colitis",
    "adults and children 12 years and older with refractory, moderate to severe atopic dermatitis",
    "active psoriatic arthritis",
    "moderate to severe rheumatoid arthritis"
  ],
  "opportunities": [
    {
      "extraction": {
        "source": {
          "pmid": "38242552",
          "doi": "10.1136/rmdopen-2023-003837",
          "url": "https://pubmed.ncbi.nlm.nih.gov/38242552/",
          "title": "Upadacitinib therapy in refractory inflammatory myositis: a case series of 10 patients.",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "Inflammatory Myositis (Dermatomyositis and Antisynthetase Syndrome)",
        "disease_normalized": "Inflammatory Myopathies",
        "is_off_label": true,
        "is_relevant": true,
        "evidence_level": "Case Series",
        "patient_population": {
          "n_patients": 10,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "methotrexate",
            "azathioprine",
            "mycophenolate mofetil",
            "cyclosporin A",
            "cyclophosphamide",
            "intravenous immunoglobulin",
            "rituximab",
            "tofacitinib"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "5 classic dermatomyositis, 3 amyopathic dermatomyositis, 2 antisynthetase syndrome; treatment-refractory patients who failed average of 4 immunosuppressants"
        },
        "treatment": {
          "drug_name": "upadacitinib",
          "generic_name": "Upadacitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": null,
          "frequency": null,
          "duration": "median 9.5 months (range 2-33 months)",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": null,
          "responders_n": null,
          "responders_pct": null,
          "time_to_response": null,
          "duration_of_response": null,
          "effect_size_description": "Statistically significant improvement in cutaneous disease activity with median CDASI reduction from 10.5 to 2.5",
          "primary_endpoint": "CDASI score reduction",
          "endpoint_result": "CDASI improved from median 10.5 to 2.5 (p=0.014)",
          "durability_signal": null,
          "efficacy_summary": "Upadacitinib demonstrated statistically significant improvement in cutaneous manifestations of dermatomyositis in the aggregate analysis of classic DM and amyopathic DM patients. Three patients who had failed tofacitinib showed further improvement when switched to upadacitinib."
        },
        "safety": {
          "adverse_events": [
            "severe facial acne"
          ],
          "serious_adverse_events": [],
          "sae_count": 0,
          "sae_percentage": 0.0,
          "discontinuations_n": 1,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [
            "severe facial acneiform eruption"
          ],
          "safety_summary": "Upadacitinib was well tolerated with only one discontinuation due to severe facial acne. Nine patients remained on treatment with no other reported side effects.",
          "safety_profile": "Favorable"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Moderate",
        "comparator_baseline": null,
        "follow_up_duration": "median 9.5 months",
        "key_findings": "First report of upadacitinib in inflammatory myositis showing significant improvement in cutaneous disease activity in treatment-refractory patients, including those who failed tofacitinib.",
        "detailed_efficacy_endpoints": [
          {
            "endpoint_name": "CDASI score - Classic DM subtype",
            "endpoint_category": "Primary",
            "timepoint": "Current follow-up",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "score",
            "total_n": 5,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 12.0,
            "final_value": 4.0,
            "change_from_baseline": -8.0,
            "change_pct": null,
            "p_value": "0.0625",
            "confidence_interval": null,
            "statistical_significance": false,
            "notes": "Median values with IQR reported",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "MMT8 score - Classic DM subtype",
            "endpoint_category": "Secondary",
            "timepoint": "Current follow-up",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "score",
            "total_n": 5,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 150.0,
            "final_value": 150.0,
            "change_from_baseline": 0.0,
            "change_pct": null,
            "p_value": "0.371",
            "confidence_interval": null,
            "statistical_significance": false,
            "notes": "Median values with IQR reported",
            "organ_domain": "Musculoskeletal",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "CDASI score - Amyopathic DM subtype",
            "endpoint_category": "Primary",
            "timepoint": "Current follow-up",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "score",
            "total_n": 3,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 9.0,
            "final_value": 1.0,
            "change_from_baseline": -8.0,
            "change_pct": null,
            "p_value": "0.174",
            "confidence_interval": null,
            "statistical_significance": false,
            "notes": "Mean values with IQR reported",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "CDASI score - Aggregate classic DM and ADM",
            "endpoint_category": "Primary",
            "timepoint": "Current follow-up",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "score",
            "total_n": 8,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 10.5,
            "final_value": 2.5,
            "change_from_baseline": -8.0,
            "change_pct": null,
            "p_value": "0.014",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "Median values with IQR reported",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "Prednisone discontinuation rate",
            "endpoint_category": "Secondary",
            "timepoint": "Current follow-up",
            "measurement_type": "Responder",
            "value": null,
            "unit": "percentage",
            "total_n": 7,
            "responders_n": 4,
            "responders_pct": 57.1,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Patients able to discontinue steroid therapy",
            "organ_domain": "Systemic",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Intravenous immunoglobulin discontinuation rate",
            "endpoint_category": "Secondary",
            "timepoint": "Current follow-up",
            "measurement_type": "Responder",
            "value": null,
            "unit": "percentage",
            "total_n": 2,
            "responders_n": 1,
            "responders_pct": 50.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Patients able to discontinue IV IG therapy",
            "organ_domain": "Systemic",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Treatment retention rate",
            "endpoint_category": "Secondary",
            "timepoint": "End of study period",
            "measurement_type": "Responder",
            "value": null,
            "unit": "percentage",
            "total_n": 10,
            "responders_n": 9,
            "responders_pct": 90.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Patients remaining on upadacitinib at study end",
            "organ_domain": "Systemic",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Duration of treatment",
            "endpoint_category": "Secondary",
            "timepoint": "Current follow-up",
            "measurement_type": "Absolute value",
            "value": 9.5,
            "unit": "months",
            "total_n": 10,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Median months of upadacitinib therapy",
            "organ_domain": "Systemic",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "CDASI improvement post-tofacitinib failure - Patient 1",
            "endpoint_category": "Exploratory",
            "timepoint": "After switch to upadacitinib",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "score",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 7.0,
            "final_value": 1.0,
            "change_from_baseline": -6.0,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Individual patient who switched from tofacitinib",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "CDASI improvement post-tofacitinib failure - Patient 2",
            "endpoint_category": "Exploratory",
            "timepoint": "After switch to upadacitinib",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "score",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 27.0,
            "final_value": 5.0,
            "change_from_baseline": -22.0,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Individual patient who switched from tofacitinib",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "CDASI improvement post-tofacitinib failure - Patient 3",
            "endpoint_category": "Exploratory",
            "timepoint": "After switch to upadacitinib",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "score",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 14.0,
            "final_value": 7.0,
            "change_from_baseline": -7.0,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Individual patient who switched from tofacitinib",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          }
        ],
        "detailed_safety_endpoints": [
          {
            "event_name": "Severe facial acneiform eruption",
            "event_category": "Discontinuation",
            "severity_grade": "Severe",
            "patients_affected_n": 1,
            "patients_affected_pct": 10.0,
            "events_total": 1,
            "relatedness": null,
            "outcome": "Ongoing",
            "action_taken": "Discontinued",
            "notes": "Occurred in anti-MDA5 classic DM patient shortly after starting upadacitinib, only partially responded to topical benzoyl peroxide treatment",
            "category_soc": null,
            "infection_type": null,
            "malignancy_type": null,
            "cv_type": null,
            "thromboembolic_type": null,
            "is_class_effect": false
          }
        ],
        "extraction_timestamp": "2025-12-08T18:16:50.699486",
        "extraction_confidence": 0.6,
        "extraction_confidence_detail": null,
        "extraction_method": "multi_stage",
        "extraction_stages_completed": [
          "section_identification",
          "efficacy_extraction",
          "safety_extraction"
        ],
        "data_sections_identified": {
          "baseline_tables": [
            "Table 1: Patient baseline characteristics, treatments and individual response to upadacitinib therapy - Contains age, sex, race, disease phenotype, duration of disease, myositis antibodies identified, prior DMARDs, prednisone doses pre and current, current DMARDs, time on upadacitinib, CDASI scores pre and current, MMT8 scores pre and current"
          ],
          "efficacy_tables": [
            "Table 2: Summary of response to upadacitinib - Shows pre-upadacitinib vs current CDASI and MMT8 scores with p-values for classic DM subtype, amyopathic DM subtype, and aggregate classic DM and ADM groups"
          ],
          "safety_tables": [],
          "efficacy_figures": [
            "Figure 1: The improvement in cutaneous disease activity in a dermatomyositis patient who transitioned to upadacitinib after failing tofacitinib - Clinical photos showing progression from pre-tofacitinib (A), post-tofacitinib (B), and post-upadacitinib (C) treatment"
          ],
          "results_sections": [
            "Results section describing patient identification and baseline characteristics",
            "Quantitative analysis of response to upadacitinib with CDASI and MMT8 outcomes",
            "Safety assessment reporting adverse events",
            "Individual patient responses including steroid tapering and immunoglobulin discontinuation",
            "Interstitial lung disease outcomes in patients with ILD",
            "Response in patients who previously failed tofacitinib therapy"
          ],
          "patient_count": 10,
          "study_type": "Case Series",
          "has_quantitative_outcomes": true,
          "notes": "Study includes online supplemental table 1 with additional patient details. Safety data is reported narratively rather than in tabular format. Aggregate analysis of classic DM and amyopathic DM groups showed statistically significant improvement in CDASI scores (p=0.014). Three patients had prior tofacitinib therapy and showed improvement after switching to upadacitinib."
        }
      },
      "market_intelligence": {
        "disease": "Inflammatory Myopathies",
        "parent_disease": null,
        "epidemiology": {
          "us_prevalence_estimate": "14.0 to 25.32 per 100,000",
          "us_incidence_estimate": "5.8 to 7.9 per 100,000 person-years",
          "global_prevalence": null,
          "patient_population_size": 67000,
          "prevalence_source": "Muscle & Nerve journal",
          "prevalence_source_url": "https://pubmed.ncbi.nlm.nih.gov/22499094/",
          "trend": null,
          "source_quality": "Primary",
          "data_year": 2008,
          "geographic_scope": "US",
          "confidence": "High",
          "notes": "Multiple US studies with consistent prevalence ranges of 14.0-25.32 per 100,000; incidence higher than previously reported; claims-based analysis may have limitations"
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Prednisone/Prednisolone (corticosteroids)",
              "drug_class": "Corticosteroid",
              "is_branded_innovative": false,
              "fda_approved": true,
              "fda_approved_indication": "Anti-inflammatory conditions (generic approval)",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "First-line treatment but generic corticosteroid, not branded innovative",
              "approval_year": null,
              "approval_confidence": "High",
              "approval_evidence": "Standard of care referenced in multiple treatment guidelines"
            },
            {
              "drug_name": "Methotrexate (generic)",
              "drug_class": "Antimetabolite immunosuppressant",
              "is_branded_innovative": false,
              "fda_approved": true,
              "fda_approved_indication": "Autoimmune conditions (generic approval)",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "Second-line treatment but generic drug, not branded innovative",
              "approval_year": null,
              "approval_confidence": "High",
              "approval_evidence": "Referenced as second-line agent in treatment guidelines"
            },
            {
              "drug_name": "Rituximab",
              "drug_class": "Anti-CD20 monoclonal antibody",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L/3L",
              "notes": "Used off-label, particularly for anti-SRP myopathy, but not FDA approved for inflammatory myopathies",
              "approval_year": null,
              "approval_confidence": "Low",
              "approval_evidence": "Mentioned as treatment option but no FDA approval for inflammatory myopathies confirmed"
            },
            {
              "drug_name": "IVIG products",
              "drug_class": "Intravenous immunoglobulin",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L/3L",
              "notes": "Used as second-line therapy, particularly for anti-HMGCR myopathy, but not specifically FDA approved for inflammatory myopathies",
              "approval_year": null,
              "approval_confidence": "Low",
              "approval_evidence": "Mentioned as treatment option but no FDA approval for inflammatory myopathies confirmed"
            },
            {
              "drug_name": "Anifrolumab (Saphnelo)",
              "drug_class": "Type I interferon receptor antagonist",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": null,
              "notes": "Has orphan designation for treatment of idiopathic inflammatory myopathies but not FDA approved for this indication",
              "approval_year": null,
              "approval_confidence": "High",
              "approval_evidence": "FDA orphan designation for idiopathic inflammatory myopathies but not yet FDA approved"
            }
          ],
          "approved_drug_names": [],
          "num_approved_drugs": 0,
          "num_pipeline_therapies": 0,
          "pipeline_therapies": [],
          "pipeline_details": null,
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "First-line treatment consists of high-dose corticosteroids (prednisone 1 mg/kg/day), often combined with immunosuppressive agents like methotrexate. Second-line options include azathioprine, mycophenolate mofetil, tacrolimus, rituximab, and IVIG for refractory cases.",
          "unmet_need": true,
          "unmet_need_description": "Fewer than half of dermatomyositis and polymyositis patients achieve adequate disease control with current therapies. There is urgent need for more effective, steroid-sparing options due to significant long-term toxicity risks of corticosteroids and limited efficacy of current second-line agents.",
          "competitive_landscape": "The inflammatory myopathies treatment landscape lacks FDA-approved branded innovative therapies specifically for this indication. Current treatment relies heavily on off-label use of generic immunosuppressants and biologics approved for other autoimmune conditions. The pipeline shows promise with anifrolumab receiving orphan designation and emerging therapies like JAK inhibitors and FcRN blockers in development.",
          "soc_source": "Treatment guidelines for idiopathic inflammatory myopathies - Oxford Academic",
          "phase_3_count": 0,
          "phase_2_count": 0,
          "key_catalysts": null,
          "pipeline_data_quality": "Unknown",
          "recent_approvals": null,
          "data_quality": "Medium",
          "data_quality_notes": "No branded innovative drugs found with specific FDA approval for inflammatory myopathies. Treatment guidelines reference off-label use of various agents. Anifrolumab has orphan designation but not full approval."
        },
        "market_size_estimate": "$3.4B",
        "market_size_usd": 3350000000.0,
        "growth_rate": "5-8% CAGR (high unmet need)",
        "tam_usd": 252000000.0,
        "tam_estimate": "$252M",
        "tam_rationale": "Of ~70,000 US patients with inflammatory myopathies, ~60% are diagnosed (42K), ~75% receive systemic treatment (31.5K), and ~40% are candidates for advanced therapy due to steroid inadequacy/intolerance (12.6K). A new drug could capture 20% market share (~2.5K patients) in this underserved rare autoimmune market with high unmet need. At $100K/yr orphan drug pricing, TAM = $252M.",
        "tam_sources": [
          "https://www.cabalettabio.com/investors/sec-filings/all-sec-filings/content/0000950170-25-047201/caba-20241231.htm",
          "https://www.cabalettabio.com/investors/sec-filings/all-sec-filings/content/0000950170-25-047201/0000950170-25-047201.pdf",
          "https://argenx.com/content/dam/argenx-corp/media-documents/Annual_Report_2023_argenx.pdf"
        ],
        "pipeline_sources": [
          "https://clinicaltrials.gov",
          "https://clinicaltrials.gov/study/NCT06904937?cond=Inflammatory%20Myopathies&viewType=Table&rank=3",
          "https://clinicaltrials.gov/study/NCT06455449",
          "https://www.clinicaltrials.gov/study/NCT05454527?term=AREA%5BConditionSearch%5D(Acquired%20idiopathic%20inflammatory%20myopathy%20OR%20%22idiopathic%20inflammatory%20myopathies%22%20OR%20%22%20idiopathic%20inflammatory%20myositis%22%20OR%20%22%20IIm%22%20OR%20%22%20IMM%22)%20AND%20AREA%5BOverallStatus%5D(NOT_YET_RECRUITING%20OR%20RECRUITING)&rank=7",
          "https://clinicaltrials.gov/study/NCT05454527"
        ],
        "attributed_sources": [
          {
            "url": "https://pubmed.ncbi.nlm.nih.gov/22499094/",
            "title": "Epidemiology of adult idiopathic inflammatory myopathies ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2022.842586/full",
            "title": "The Geospatial Distribution of Myositis and Its Phenotypes in the ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=876522",
            "title": "Search Orphan Drug Designations and Approvals - FDA",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://emedicine.medscape.com/article/1343513-treatment",
            "title": "Connective Tissue Disease-Associated Interstitial Lung ...",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3383519/",
            "title": "Diagnosis and treatment of inflammatory myopathy",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://clinicaltrials.gov",
            "title": "ClinicalTrials.gov API",
            "attribution": "Pipeline/Clinical Trials (Primary)"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT06904937?cond=Inflammatory%20Myopathies&viewType=Table&rank=3",
            "title": "Renal Manifestations During Idiopathic Inflammatory Myopathies",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT06455449",
            "title": "NCT06455449 | A Study to Investigate the Efficacy and ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.cabalettabio.com/investors/sec-filings/all-sec-filings/content/0000950170-25-047201/caba-20241231.htm",
            "title": "10-K",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.cabalettabio.com/investors/sec-filings/all-sec-filings/content/0000950170-25-047201/0000950170-25-047201.pdf",
            "title": "10-K",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 9.0,
        "evidence_quality": 8.1,
        "market_opportunity": 9.3,
        "overall_priority": 8.9,
        "clinical_breakdown": {
          "response_rate_quality_weighted": 7.5,
          "safety_profile": 10.0,
          "organ_domain_breadth": 10.0,
          "safety_categories": [
            "discontinuation"
          ],
          "regulatory_flags": [],
          "efficacy_endpoint_count": 11,
          "efficacy_concordance": 0.9
        },
        "response_rate_score": 7.5,
        "safety_profile_score": 10.0,
        "endpoint_quality_score": null,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 8.0,
          "publication_venue": 10.0,
          "response_durability": 7.0,
          "extraction_completeness": 7.2
        },
        "sample_size_score": 8.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 7.0,
        "extraction_completeness_score": 7.2,
        "market_breakdown": {
          "competitors": 10.0,
          "market_size": 8.0,
          "unmet_need": 10.0
        },
        "competitors_score": 10.0,
        "market_size_score": 8.0,
        "unmet_need_score": 10.0
      },
      "rank": 1
    },
    {
      "extraction": {
        "source": {
          "pmid": "39990017",
          "doi": "10.1093/omcr/omae199",
          "url": "https://pubmed.ncbi.nlm.nih.gov/39990017/",
          "title": "Efficacy of Upadacitinib in refractory Polyarteritis Nodosa: a case report.",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "Polyarteritis nodosa (refractory)",
        "disease_normalized": "Polyarteritis Nodosa",
        "is_off_label": true,
        "is_relevant": true,
        "evidence_level": "Case Report",
        "patient_population": {
          "n_patients": 1,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "azathioprine",
            "mycophenolate mofetil",
            "methotrexate",
            "tacrolimus",
            "cyclophosphamide",
            "tocilizumab"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "44-year-old Japanese man with refractory polyarteritis nodosa unresponsive to multiple immunosuppressants"
        },
        "treatment": {
          "drug_name": "upadacitinib",
          "generic_name": "Upadacitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": null,
          "frequency": null,
          "duration": "1 year",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "1/1 (100%)",
          "responders_n": 1,
          "responders_pct": 100.0,
          "time_to_response": "relatively rapid",
          "duration_of_response": "1 year with no relapses",
          "effect_size_description": "Complete response with ability to discontinue all other medications",
          "primary_endpoint": "Clinical symptom improvement (joint pain, myalgia, rashes)",
          "endpoint_result": "Relatively rapid improvement in symptoms allowing discontinuation of prednisolone, MTX, and NSAIDs",
          "durability_signal": null,
          "efficacy_summary": "Upadacitinib led to relatively rapid improvement in joint pain, myalgia, and rashes in a patient with refractory PAN unresponsive to multiple immunosuppressants. Treatment allowed for tapering and eventual discontinuation of prednisolone, methotrexate, and NSAIDs."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": 0,
          "sae_percentage": 0.0,
          "discontinuations_n": 0,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "No adverse events or side effects were reported during the 1-year follow-up period. The treatment was well tolerated.",
          "safety_profile": "Favorable"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": "1 year",
        "key_findings": "Upadacitinib successfully treated refractory PAN that was unresponsive to multiple conventional immunosuppressants including tocilizumab, suggesting JAK inhibitors may provide a breakthrough for refractory cases.",
        "detailed_efficacy_endpoints": [
          {
            "endpoint_name": "C-reactive protein (CRP) level",
            "endpoint_category": "Secondary",
            "timepoint": "Baseline (at referral)",
            "measurement_type": "Absolute value",
            "value": 0.66,
            "unit": "mg/dl",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 0.66,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "CRP level at time of referral to hospital while on PSL 10mg and AZP 25mg",
            "organ_domain": "Systemic",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "CRP normalization",
            "endpoint_category": "Secondary",
            "timepoint": "During tocilizumab treatment",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 1,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": 0.66,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "CRP levels normalized with tocilizumab but no clinical symptom improvement",
            "organ_domain": "Systemic",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Clinical symptom resolution",
            "endpoint_category": "Primary",
            "timepoint": "After upadacitinib treatment",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 1,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Resolution of joint pain, myalgia, and painful rashes with relatively rapid improvement",
            "organ_domain": "Systemic",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Joint pain resolution",
            "endpoint_category": "Secondary",
            "timepoint": "After upadacitinib treatment",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 1,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Resolution of polyarthritis symptoms",
            "organ_domain": "Musculoskeletal",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Myalgia resolution",
            "endpoint_category": "Secondary",
            "timepoint": "After upadacitinib treatment",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 1,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Resolution of muscle pain symptoms",
            "organ_domain": "Musculoskeletal",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Skin rash resolution",
            "endpoint_category": "Secondary",
            "timepoint": "After upadacitinib treatment",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 1,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Resolution of painful subcutaneous nodules and rashes",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Prednisolone discontinuation",
            "endpoint_category": "Secondary",
            "timepoint": "After upadacitinib treatment",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 1,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Successful tapering and discontinuation of prednisolone",
            "organ_domain": "Systemic",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Methotrexate discontinuation",
            "endpoint_category": "Secondary",
            "timepoint": "After upadacitinib treatment",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 1,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Successful discontinuation of methotrexate",
            "organ_domain": "Systemic",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "NSAID discontinuation",
            "endpoint_category": "Secondary",
            "timepoint": "After upadacitinib treatment",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 1,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Successful discontinuation of NSAIDs",
            "organ_domain": "Systemic",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Disease relapse-free survival",
            "endpoint_category": "Secondary",
            "timepoint": "1-year follow-up",
            "measurement_type": "Responder",
            "value": 12.0,
            "unit": "months",
            "total_n": 1,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "No relapse observed during 1-year follow-up period",
            "organ_domain": "Systemic",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          }
        ],
        "detailed_safety_endpoints": [],
        "extraction_timestamp": "2025-12-08T18:36:36.106496",
        "extraction_confidence": 0.6,
        "extraction_confidence_detail": null,
        "extraction_method": "multi_stage",
        "extraction_stages_completed": [
          "section_identification",
          "efficacy_extraction",
          "safety_extraction"
        ],
        "data_sections_identified": {
          "baseline_tables": [
            "Table 1: Laboratory data before public hospital treatment - contains complete blood count, coagulation tests, immunochemistry, and biochemistry values"
          ],
          "efficacy_tables": [],
          "safety_tables": [],
          "efficacy_figures": [
            "Figure 2: Photographs showing skin findings on lower limbs and left forearm before and after upadacitinib treatment, demonstrating resolution of painful rashes",
            "Figure 4: Treatment course schematic showing temporal changes in prednisolone dose and CRP levels, demonstrating symptom improvement and medication tapering after upadacitinib initiation"
          ],
          "results_sections": [
            "Case report section describing patient presentation, treatment course, and clinical outcomes",
            "Treatment response description showing relatively rapid improvement in joint pain, myalgia, and rashes with upadacitinib",
            "One-year follow-up results showing no relapses or side effects"
          ],
          "patient_count": 1,
          "study_type": "Case Report",
          "has_quantitative_outcomes": true,
          "notes": "Single patient case report with quantitative CRP values and medication dosing over time, but no formal structured efficacy or safety tables. Clinical improvement demonstrated through photographs and treatment timeline figure."
        }
      },
      "market_intelligence": {
        "disease": "Polyarteritis Nodosa",
        "parent_disease": null,
        "epidemiology": {
          "us_prevalence_estimate": "3-4 per 100,000",
          "us_incidence_estimate": "3-4 per 100,000 annually",
          "global_prevalence": null,
          "patient_population_size": 11725,
          "prevalence_source": "Vasculitis Foundation",
          "prevalence_source_url": "https://vasculitisfoundation.org/education/vasculitis-types/polyarteritis-nodosa/",
          "trend": null,
          "source_quality": "Secondary",
          "data_year": null,
          "geographic_scope": "US",
          "confidence": "Medium",
          "notes": "Incidence and prevalence figures used interchangeably in sources; inpatient prevalence much higher at 11.6 per 100,000 discharges suggesting aggressive nature requiring hospitalization"
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Rituximab (rituximab)",
              "drug_class": "Anti-CD20 monoclonal antibody",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "Used off-label for refractory PAN based on case reports, not FDA approved for polyarteritis nodosa",
              "approval_year": null,
              "approval_confidence": "Low",
              "approval_evidence": "Only mentioned in case reports for refractory disease"
            },
            {
              "drug_name": "Tocilizumab (tocilizumab)",
              "drug_class": "IL-6 receptor antagonist",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "3L",
              "notes": "Used off-label when rituximab fails, not FDA approved for polyarteritis nodosa",
              "approval_year": null,
              "approval_confidence": "Low",
              "approval_evidence": "Only mentioned in case reports for rituximab-refractory disease"
            },
            {
              "drug_name": "Immune Globulin (IVIG)",
              "drug_class": "Immunoglobulin therapy",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": null,
              "notes": "Documented efficacy in childhood polyarteritis nodosa but no specific FDA approval for this indication",
              "approval_year": null,
              "approval_confidence": "Low",
              "approval_evidence": "Mentioned as having documented efficacy in childhood PAN but no FDA approval specified"
            }
          ],
          "approved_drug_names": [],
          "num_approved_drugs": 0,
          "num_pipeline_therapies": 0,
          "pipeline_therapies": [],
          "pipeline_details": "No active Phase 2 or Phase 3 clinical trials were identified specifically for Polyarteritis Nodosa in the ClinicalTrials.gov API data. Web search results primarily reference historical trials and case reports of off-label biologic use, suggesting limited dedicated drug development activity for this rare vasculitis condition.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "Treatment of PAN follows a severity-based approach with corticosteroids as the cornerstone. Mild disease is treated with glucocorticoids alone, while moderate to severe disease requires combination therapy with cyclophosphamide and steroids for induction, followed by maintenance therapy with agents like azathioprine or methotrexate.",
          "unmet_need": true,
          "unmet_need_description": "No FDA-approved branded innovative therapies exist specifically for polyarteritis nodosa. Treatment relies primarily on generic immunosuppressive drugs with significant toxicity profiles. Biologic therapies are only used off-label in refractory cases based on limited case reports.",
          "competitive_landscape": "The treatment landscape for PAN is dominated by generic immunosuppressive agents including corticosteroids, cyclophosphamide, azathioprine, and methotrexate. Biologic agents like rituximab and tocilizumab are used off-label in refractory cases but lack FDA approval for this indication.",
          "soc_source": "Medscape and ACR/Vasculitis Foundation Guidelines",
          "phase_3_count": 0,
          "phase_2_count": 0,
          "key_catalysts": null,
          "pipeline_data_quality": "Low",
          "recent_approvals": null,
          "data_quality": "High",
          "data_quality_notes": "Comprehensive review of multiple authoritative sources including ACR guidelines, but no FDA-approved branded innovative therapies identified for this rare disease"
        },
        "market_size_estimate": "$1.2B",
        "market_size_usd": 1172500000.0,
        "growth_rate": "5-8% CAGR (high unmet need)",
        "tam_usd": 47250000.0,
        "tam_estimate": "$47.3M",
        "tam_rationale": "Of ~11,725 US patients with PAN, ~60% are diagnosed (7,035), ~80% receive treatment given severity (5,628). With no approved drugs and high unmet need, a new therapy could capture 50% market share (~2,815 patients). At $150K/yr pricing (typical for rare autoimmune orphan drugs), TAM = 2,815 \u00d7 $150K = $47.3M. Premium pricing justified by orphan status and complete lack of approved alternatives.",
        "tam_sources": [
          "https://www.imarcgroup.com/polyarteritis-nodosa-market",
          "https://www.datainsightsmarket.com/reports/vasculitis-drug-1214784",
          "https://www.dennisgong.com/blog/newmedicines/"
        ],
        "pipeline_sources": [
          "https://clinicaltrials.gov",
          "https://clinicaltrials.gov/study/NCT00647166",
          "https://clinicaltrials.gov/study/NCT02257866",
          "https://clinicaltrials.gov/study/NCT05168475",
          "https://www.clinicaltrials.gov/study/NCT04229004"
        ],
        "attributed_sources": [
          {
            "url": "https://www.wikidoc.org/index.php/Polyarteritis_nodosa_epidemiology_and_demographics",
            "title": "Polyarteritis nodosa epidemiology and demographics - wikidoc",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8633913/",
            "title": "Global epidemiology of vasculitis - PMC - PubMed Central - NIH",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://emedicine.medscape.com/article/330717-treatment",
            "title": "Polyarteritis Nodosa Treatment & Management",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.drugs.com/health-guide/vasculitis.html",
            "title": "Vasculitis Guide: Causes, Symptoms and Treatment Options",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.mdpi.com/1422-0067/24/23/16668",
            "title": "Polyarteritis Nodosa: Old Disease, New Etiologies - MDPI",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://clinicaltrials.gov",
            "title": "ClinicalTrials.gov API",
            "attribution": "Pipeline/Clinical Trials (Primary)"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT00647166",
            "title": "Polyarteritis Nodosa or Eosinophilic Granulomatosis With ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT02257866",
            "title": "Studies of the Natural History, Pathogenesis, and Outcome ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.imarcgroup.com/polyarteritis-nodosa-market",
            "title": "Polyarteritis Nodosa Market Size, Epidemiology, In- ...",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.datainsightsmarket.com/reports/vasculitis-drug-1214784",
            "title": "Vasculitis Drug Market Expansion: Growth Outlook 2025-2033",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 10.0,
        "evidence_quality": 6.2,
        "market_opportunity": 9.3,
        "overall_priority": 8.9,
        "clinical_breakdown": {
          "response_rate_quality_weighted": 10.0,
          "safety_profile": 10.0,
          "organ_domain_breadth": 10.0,
          "safety_categories": [],
          "regulatory_flags": [],
          "efficacy_endpoint_count": 10,
          "efficacy_concordance": 1.15
        },
        "response_rate_score": 10.0,
        "safety_profile_score": 10.0,
        "endpoint_quality_score": null,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 1.0,
          "publication_venue": 10.0,
          "response_durability": 9.0,
          "extraction_completeness": 7.2
        },
        "sample_size_score": 1.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 9.0,
        "extraction_completeness_score": 7.2,
        "market_breakdown": {
          "competitors": 10.0,
          "market_size": 8.0,
          "unmet_need": 10.0
        },
        "competitors_score": 10.0,
        "market_size_score": 8.0,
        "unmet_need_score": 10.0
      },
      "rank": 2
    },
    {
      "extraction": {
        "source": {
          "pmid": "39568752",
          "doi": "10.3389/fmed.2024.1476793",
          "url": "https://pubmed.ncbi.nlm.nih.gov/39568752/",
          "title": "Successful treatment of refractory palmoplantar pustulosis by upadacitinib: report of 28 patients.",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "Palmoplantar pustulosis",
        "disease_normalized": "Palmoplantar Pustulosis",
        "is_off_label": true,
        "is_relevant": true,
        "evidence_level": "Case Series",
        "patient_population": {
          "n_patients": 28,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "Acitretin",
            "Tripterygium wilfordii Hook F",
            "cyclosporine",
            "methotrexate",
            "adalimumab",
            "secukinumab"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "28 patients (10 males, 18 females) with refractory palmoplantar pustulosis, mean age 36.3 \u00b1 10.5 years, 8 patients also had SAPHO syndrome"
        },
        "treatment": {
          "drug_name": "upadacitinib",
          "generic_name": "Upadacitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "15 mg daily",
          "frequency": null,
          "duration": "12 weeks",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "25/28 (89.3%)",
          "responders_n": 25,
          "responders_pct": 89.3,
          "time_to_response": "Progressive improvement over 12 weeks",
          "duration_of_response": "Maintained at 12-week follow-up",
          "effect_size_description": "PPPASI50 achieved in 89.3%, PPPASI75 in 71.4%, PPPASI90 in 64.3% of patients",
          "primary_endpoint": "PPPASI score reduction",
          "endpoint_result": "PPPASI score decreased from 13.86 \u00b1 2.76 to 5.56 \u00b1 1.08",
          "durability_signal": null,
          "efficacy_summary": "Upadacitinib demonstrated significant efficacy with PPPASI scores decreasing from 13.86 to 5.56 after 12 weeks. 89.3% of patients achieved PPPASI50 and 71.4% achieved PGA score of 0/1."
        },
        "safety": {
          "adverse_events": [
            "acneiform rash",
            "transient transaminitis",
            "slight increase in creatinine levels"
          ],
          "serious_adverse_events": [],
          "sae_count": 0,
          "sae_percentage": 0.0,
          "discontinuations_n": 0,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "No severe adverse events were reported. Minor adverse events included acneiform rash in 4 patients, transient transaminitis in 2 patients, and slight creatinine increase in 1 patient, all of which resolved.",
          "safety_profile": "Favorable"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": "12 weeks",
        "key_findings": "Upadacitinib showed strong efficacy in refractory palmoplantar pustulosis with 89.3% achieving PPPASI50 and excellent safety profile.",
        "detailed_efficacy_endpoints": [
          {
            "endpoint_name": "PPPASI score",
            "endpoint_category": "Primary",
            "timepoint": "Week 12",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "score",
            "total_n": 28,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 13.86,
            "final_value": 5.56,
            "change_from_baseline": -8.3,
            "change_pct": null,
            "p_value": "< 0.001",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "t = 2.418",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "PPPASI50",
            "endpoint_category": "Primary",
            "timepoint": "Week 4",
            "measurement_type": "Responder",
            "value": 64.3,
            "unit": "percent",
            "total_n": 28,
            "responders_n": 18,
            "responders_pct": 64.3,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "50% improvement in PPPASI score",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "PPPASI50",
            "endpoint_category": "Primary",
            "timepoint": "Week 8",
            "measurement_type": "Responder",
            "value": 71.4,
            "unit": "percent",
            "total_n": 28,
            "responders_n": 20,
            "responders_pct": 71.4,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "50% improvement in PPPASI score",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "PPPASI50",
            "endpoint_category": "Primary",
            "timepoint": "Week 12",
            "measurement_type": "Responder",
            "value": 89.3,
            "unit": "percent",
            "total_n": 28,
            "responders_n": 25,
            "responders_pct": 89.3,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "50% improvement in PPPASI score",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "PPPASI75",
            "endpoint_category": "Primary",
            "timepoint": "Week 4",
            "measurement_type": "Responder",
            "value": 28.6,
            "unit": "percent",
            "total_n": 28,
            "responders_n": 8,
            "responders_pct": 28.6,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "75% improvement in PPPASI score",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "PPPASI75",
            "endpoint_category": "Primary",
            "timepoint": "Week 8",
            "measurement_type": "Responder",
            "value": 53.6,
            "unit": "percent",
            "total_n": 28,
            "responders_n": 15,
            "responders_pct": 53.6,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "75% improvement in PPPASI score",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "PPPASI75",
            "endpoint_category": "Primary",
            "timepoint": "Week 12",
            "measurement_type": "Responder",
            "value": 71.4,
            "unit": "percent",
            "total_n": 28,
            "responders_n": 20,
            "responders_pct": 71.4,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "75% improvement in PPPASI score",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "PPPASI90",
            "endpoint_category": "Primary",
            "timepoint": "Week 4",
            "measurement_type": "Responder",
            "value": 10.7,
            "unit": "percent",
            "total_n": 28,
            "responders_n": 3,
            "responders_pct": 10.7,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "90% improvement in PPPASI score",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "PPPASI90",
            "endpoint_category": "Primary",
            "timepoint": "Week 8",
            "measurement_type": "Responder",
            "value": 39.3,
            "unit": "percent",
            "total_n": 28,
            "responders_n": 11,
            "responders_pct": 39.3,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "90% improvement in PPPASI score",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "PPPASI90",
            "endpoint_category": "Primary",
            "timepoint": "Week 12",
            "measurement_type": "Responder",
            "value": 64.3,
            "unit": "percent",
            "total_n": 28,
            "responders_n": 18,
            "responders_pct": 64.3,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "90% improvement in PPPASI score",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "DLQI score",
            "endpoint_category": "Secondary",
            "timepoint": "Baseline",
            "measurement_type": "Absolute value",
            "value": 12.55,
            "unit": "score",
            "total_n": 28,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 12.55,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Quality of life baseline measure",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 2
          },
          {
            "endpoint_name": "DLQI score",
            "endpoint_category": "Secondary",
            "timepoint": "Week 4",
            "measurement_type": "Change from baseline",
            "value": 7.98,
            "unit": "score",
            "total_n": 28,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 12.55,
            "final_value": 7.98,
            "change_from_baseline": -4.57,
            "change_pct": null,
            "p_value": "< 0.001",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "t = 16.083",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 2
          },
          {
            "endpoint_name": "DLQI score",
            "endpoint_category": "Secondary",
            "timepoint": "Week 8",
            "measurement_type": "Change from baseline",
            "value": 4.49,
            "unit": "score",
            "total_n": 28,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 12.55,
            "final_value": 4.49,
            "change_from_baseline": -8.06,
            "change_pct": null,
            "p_value": "< 0.001",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "t = 21.463",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 2
          },
          {
            "endpoint_name": "DLQI score",
            "endpoint_category": "Secondary",
            "timepoint": "Week 12",
            "measurement_type": "Change from baseline",
            "value": 2.03,
            "unit": "score",
            "total_n": 28,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 12.55,
            "final_value": 2.03,
            "change_from_baseline": -10.52,
            "change_pct": null,
            "p_value": "< 0.001",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "t = 19.968",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 2
          },
          {
            "endpoint_name": "PGA 0/1 response",
            "endpoint_category": "Secondary",
            "timepoint": "Baseline",
            "measurement_type": "Responder",
            "value": 0.0,
            "unit": "percent",
            "total_n": 28,
            "responders_n": 0,
            "responders_pct": 0.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Physician Global Assessment clear or almost clear",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "PGA 0/1 response",
            "endpoint_category": "Secondary",
            "timepoint": "Week 4",
            "measurement_type": "Responder",
            "value": 14.3,
            "unit": "percent",
            "total_n": 28,
            "responders_n": 4,
            "responders_pct": 14.3,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Physician Global Assessment clear or almost clear",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "PGA 0/1 response",
            "endpoint_category": "Secondary",
            "timepoint": "Week 8",
            "measurement_type": "Responder",
            "value": 42.9,
            "unit": "percent",
            "total_n": 28,
            "responders_n": 12,
            "responders_pct": 42.9,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Physician Global Assessment clear or almost clear",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "PGA 0/1 response",
            "endpoint_category": "Secondary",
            "timepoint": "Week 12",
            "measurement_type": "Responder",
            "value": 71.4,
            "unit": "percent",
            "total_n": 28,
            "responders_n": 20,
            "responders_pct": 71.4,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Physician Global Assessment clear or almost clear",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "PPPASI score in SAPHO patients",
            "endpoint_category": "Secondary",
            "timepoint": "Week 12",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "score",
            "total_n": 8,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 11.76,
            "final_value": 7.56,
            "change_from_baseline": -4.2,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Subset analysis of patients with SAPHO syndrome",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "VAS bone and joint pain score",
            "endpoint_category": "Secondary",
            "timepoint": "Week 12",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "VAS score",
            "total_n": 8,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 4.5,
            "final_value": 0.5,
            "change_from_baseline": -4.0,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "SAPHO patients, baseline range 4-5, post-treatment range 0-1",
            "organ_domain": "Musculoskeletal",
            "is_validated_instrument": true,
            "instrument_quality_tier": 2
          }
        ],
        "detailed_safety_endpoints": [
          {
            "event_name": "Acneiform rash",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": 4,
            "patients_affected_pct": 14.3,
            "events_total": null,
            "relatedness": "Related",
            "outcome": "Resolved",
            "action_taken": "None",
            "notes": "Lesions gradually improved after using topical adapalene gel and fusidic acid cream for 2 weeks",
            "category_soc": null,
            "infection_type": null,
            "malignancy_type": null,
            "cv_type": null,
            "thromboembolic_type": null,
            "is_class_effect": true
          },
          {
            "event_name": "Transient transaminitis",
            "event_category": "AE",
            "severity_grade": "Mild",
            "patients_affected_n": 2,
            "patients_affected_pct": 7.1,
            "events_total": null,
            "relatedness": "Related",
            "outcome": "Resolved",
            "action_taken": "None",
            "notes": "Both had normal liver function tests before treatment. Elevation did not exceed twice the normal upper limit. Liver enzymes gradually returned to normal levels after taking Polyene phosphatidylcholine orally",
            "category_soc": "Hepatotoxicity",
            "infection_type": null,
            "malignancy_type": null,
            "cv_type": null,
            "thromboembolic_type": null,
            "is_class_effect": true
          },
          {
            "event_name": "Slight increase in creatinine levels",
            "event_category": "AE",
            "severity_grade": "Mild",
            "patients_affected_n": 1,
            "patients_affected_pct": 3.6,
            "events_total": null,
            "relatedness": "Possibly related",
            "outcome": "Resolved",
            "action_taken": "None",
            "notes": "After excluding organic lesions and other potential causes, no specific intervention was needed. Renal function returned to normal after 3 weeks",
            "category_soc": "Renal",
            "infection_type": null,
            "malignancy_type": null,
            "cv_type": null,
            "thromboembolic_type": null,
            "is_class_effect": false
          }
        ],
        "extraction_timestamp": "2025-12-08T18:13:50.561429",
        "extraction_confidence": 0.6,
        "extraction_confidence_detail": null,
        "extraction_method": "multi_stage",
        "extraction_stages_completed": [
          "section_identification",
          "efficacy_extraction",
          "safety_extraction"
        ],
        "data_sections_identified": {
          "baseline_tables": [],
          "efficacy_tables": [
            "Table 1: Comparing the different treatment time to achieve PPPASI50/PPPASI75/PPPASI90 cases of patients - shows response rates at 4, 8, and 12 weeks",
            "Table 2: Comparison of DLQI scores and number of patients with PGA0/1 before and after treatment in PPP patients - shows quality of life scores and physician global assessment over time"
          ],
          "safety_tables": [],
          "efficacy_figures": [
            "Figure 1: Clinical photos showing progression of palmoplantar pustulosis in Case 5 - (A) Before upadacitinib treatment, (B) 2 weeks treatment, (C) 12 weeks treatment"
          ],
          "results_sections": [
            "3.1 Clinical efficacy evaluation",
            "3.2 Patient self-assessment scores",
            "3.3 Safety assessment"
          ],
          "patient_count": 28,
          "study_type": "Case Series",
          "has_quantitative_outcomes": true,
          "notes": "Baseline demographics presented in text rather than formal table. Safety data described narratively without tabular presentation. Primary outcomes include PPPASI scores, DLQI scores, and PGA assessments measured at multiple timepoints."
        }
      },
      "market_intelligence": {
        "disease": "Palmoplantar Pustulosis",
        "parent_disease": "Psoriasis",
        "epidemiology": {
          "us_prevalence_estimate": "3.0% of adults 20 years or older",
          "us_incidence_estimate": null,
          "global_prevalence": null,
          "patient_population_size": 7550000,
          "prevalence_source": "JAMA Dermatology",
          "prevalence_source_url": "https://pubmed.ncbi.nlm.nih.gov/34190957/",
          "trend": "stable",
          "source_quality": "Primary",
          "data_year": 2021,
          "geographic_scope": "US",
          "confidence": "High",
          "notes": "Prevalence has not differed since evaluation in 2003. Approximately 600,000 adults in the US live with undiagnosed psoriasis. Prevalence varies by race/ethnicity with highest in whites (3.6%) and lowest in blacks (1.5%)"
        },
        "standard_of_care": {
          "top_treatments": [],
          "approved_drug_names": [],
          "num_approved_drugs": 0,
          "num_pipeline_therapies": 0,
          "pipeline_therapies": [],
          "pipeline_details": null,
          "avg_annual_cost_usd": null,
          "treatment_paradigm": null,
          "unmet_need": false,
          "unmet_need_description": null,
          "competitive_landscape": null,
          "soc_source": null,
          "phase_3_count": 0,
          "phase_2_count": 0,
          "key_catalysts": null,
          "pipeline_data_quality": "Unknown",
          "recent_approvals": null,
          "data_quality": "Unknown",
          "data_quality_notes": null
        },
        "market_size_estimate": "$188.8B",
        "market_size_usd": 188750000000.0,
        "growth_rate": "3-5% CAGR (stable prevalence)",
        "tam_usd": 113400000.0,
        "tam_estimate": "$113.4M",
        "tam_rationale": "Of ~7.55M US adults with palmoplantar pustulosis, ~60% are diagnosed (4.5M), ~15% receive systemic treatment due to limited effective options (675K), representing moderate-severe cases. A new drug would likely be positioned as 1L systemic therapy given zero approved drugs currently. A first-to-market drug could capture 25-30% market share (~189K patients). At $60K/yr pricing typical for specialty dermatology biologics, TAM = $113.4M.",
        "tam_sources": [
          "https://ir.moonlaketx.com/news-releases/news-release-details/moonlake-immunotherapeutics-reports-second-quarter-2025",
          "https://stocklight.com/stocks/us/nasdaq-mltx/moonlake-immunotherapeutics/annual-reports/nasdaq-mltx-2025-10K-25666138.pdf",
          "https://investors.abbvie.com/static-files/62df4b7e-2544-4d8b-88cd-c863e8f23003"
        ],
        "pipeline_sources": [
          "https://clinicaltrials.gov",
          "https://cdn.clinicaltrials.gov/large-docs/51/NCT03611751/Prot_000.pdf",
          "https://cdn.clinicaltrials.gov/large-docs/87/NCT03478787/Prot_000.pdf",
          "https://clinicaltrials.gov/study/NCT01107457",
          "https://cdn.clinicaltrials.gov/large-docs/98/NCT02718898/Prot_000.pdf"
        ],
        "attributed_sources": [
          {
            "url": "https://pubmed.ncbi.nlm.nih.gov/34190957/",
            "title": "Psoriasis Prevalence in Adults in the United States - PubMed",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.psoriasis.org/prevalence-of-psoriasis/",
            "title": "Prevalence of Psoriasis",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.drugs.com/medical-answers/new-drugs-treatment-plaque-psoriasis-3511670/",
            "title": "What are the new drugs for plaque psoriasis?",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.fda.gov/news-events/press-announcements/fda-approves-new-psoriasis-drug-taltz",
            "title": "FDA approves new psoriasis drug Taltz",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.aad.org/member/clinical-quality/guidelines/psoriasis",
            "title": "Psoriasis clinical guideline - American Academy of Dermatology",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://clinicaltrials.gov",
            "title": "ClinicalTrials.gov API",
            "attribution": "Pipeline/Clinical Trials (Primary)"
          },
          {
            "url": "https://cdn.clinicaltrials.gov/large-docs/51/NCT03611751/Prot_000.pdf",
            "title": "Clinical Protocol IM011047",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://cdn.clinicaltrials.gov/large-docs/87/NCT03478787/Prot_000.pdf",
            "title": "NCT03478787",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://ir.moonlaketx.com/news-releases/news-release-details/moonlake-immunotherapeutics-reports-second-quarter-2025",
            "title": "Press Release",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://stocklight.com/stocks/us/nasdaq-mltx/moonlake-immunotherapeutics/annual-reports/nasdaq-mltx-2025-10K-25666138.pdf",
            "title": "MoonLake Immunotherapeutics Annual Report 2025 Form ...",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 8.1,
        "evidence_quality": 8.0,
        "market_opportunity": 10.0,
        "overall_priority": 8.6,
        "clinical_breakdown": {
          "response_rate_quality_weighted": 7.5,
          "safety_profile": 7.8,
          "organ_domain_breadth": 10.0,
          "safety_categories": [
            "cardiovascular"
          ],
          "regulatory_flags": [
            "cardiovascular"
          ],
          "efficacy_endpoint_count": 20,
          "efficacy_concordance": 1.0
        },
        "response_rate_score": 7.5,
        "safety_profile_score": 7.8,
        "endpoint_quality_score": null,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 10.0,
          "publication_venue": 10.0,
          "response_durability": 3.0,
          "extraction_completeness": 8.3
        },
        "sample_size_score": 10.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 3.0,
        "extraction_completeness_score": 8.3,
        "market_breakdown": {
          "competitors": 10.0,
          "market_size": 10.0,
          "unmet_need": 10.0
        },
        "competitors_score": 10.0,
        "market_size_score": 10.0,
        "unmet_need_score": 10.0
      },
      "rank": 3
    },
    {
      "extraction": {
        "source": {
          "pmid": "39363772",
          "doi": "10.4168/aair.2024.16.5.546",
          "url": "https://pubmed.ncbi.nlm.nih.gov/39363772/",
          "title": "Treatment With Upadacitinib in Refractory Prurigo Nodularis: A Prospective Cohort Study.",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "Prurigo Nodularis",
        "disease_normalized": "Prurigo Nodularis",
        "is_off_label": true,
        "is_relevant": true,
        "evidence_level": "Case Series",
        "patient_population": {
          "n_patients": 10,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "cyclosporine",
            "systemic corticosteroids",
            "methotrexate",
            "topical corticosteroids",
            "topical calcineurin inhibitors",
            "phototherapy"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "10 patients with refractory prurigo nodularis (6 men, 4 women; median age 53 years, range 23-66; mean disease duration 5.1 years)"
        },
        "treatment": {
          "drug_name": "upadacitinib",
          "generic_name": "Upadacitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "15 mg daily",
          "frequency": null,
          "duration": "24 weeks",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "10/10 (100%)",
          "responders_n": 10,
          "responders_pct": 100.0,
          "time_to_response": "4 weeks",
          "duration_of_response": "24 weeks",
          "effect_size_description": "Mean itch NRS decreased from 8.1 to 1.5 at week 4, 0.8 at week 12, and 0.7 at week 24. IGA PN score reduced from 3.4 to 1.0. DLQI improved from 17.8 to 0.6.",
          "primary_endpoint": "itch Numeric Rating Scale (NRS) score reduction",
          "endpoint_result": "Mean itch NRS reduced from 8.1 to 0.7 at 24 weeks",
          "durability_signal": null,
          "efficacy_summary": "All 10 patients showed rapid and significant improvement in pruritus, with 100% achieving \u22654-point reduction in itch NRS by week 4. By week 24, 80% achieved clear/almost clear skin (IGA PN 0/1) and all patients had minimal quality of life impairment."
        },
        "safety": {
          "adverse_events": [
            "dyslipidemia"
          ],
          "serious_adverse_events": [],
          "sae_count": 0,
          "sae_percentage": 0.0,
          "discontinuations_n": 0,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "Treatment was well tolerated with no serious adverse events or discontinuations. Only one patient (10%) developed dyslipidemia at week 24 requiring lipid-lowering therapy. No infections, cardiovascular events, cancer, or immune system problems were observed.",
          "safety_profile": "Favorable"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": "24 weeks",
        "key_findings": "Upadacitinib 15mg daily demonstrated rapid and sustained efficacy in refractory prurigo nodularis with excellent tolerability and no serious adverse events.",
        "detailed_efficacy_endpoints": [
          {
            "endpoint_name": "Itch NRS score",
            "endpoint_category": "Primary",
            "timepoint": "Baseline",
            "measurement_type": "Absolute value",
            "value": 8.1,
            "unit": "points",
            "total_n": 10,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 8.1,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Mean \u00b1 SD: 8.1 \u00b1 1.5",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 2
          },
          {
            "endpoint_name": "Itch NRS score",
            "endpoint_category": "Primary",
            "timepoint": "Week 4",
            "measurement_type": "Absolute value",
            "value": 1.5,
            "unit": "points",
            "total_n": 10,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 8.1,
            "final_value": 1.5,
            "change_from_baseline": -6.6,
            "change_pct": null,
            "p_value": "<0.01",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "Mean \u00b1 SD: 1.5 \u00b1 1.1",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 2
          },
          {
            "endpoint_name": "Itch NRS score",
            "endpoint_category": "Primary",
            "timepoint": "Week 12",
            "measurement_type": "Absolute value",
            "value": 0.8,
            "unit": "points",
            "total_n": 10,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 8.1,
            "final_value": 0.8,
            "change_from_baseline": -7.3,
            "change_pct": null,
            "p_value": "<0.05",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "Mean \u00b1 SD: 0.8 \u00b1 0.6",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 2
          },
          {
            "endpoint_name": "Itch NRS score",
            "endpoint_category": "Primary",
            "timepoint": "Week 24",
            "measurement_type": "Absolute value",
            "value": 0.7,
            "unit": "points",
            "total_n": 10,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 8.1,
            "final_value": 0.7,
            "change_from_baseline": -7.4,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Mean \u00b1 SD: 0.7 \u00b1 0.7",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 2
          },
          {
            "endpoint_name": "IGA PN score",
            "endpoint_category": "Primary",
            "timepoint": "Baseline",
            "measurement_type": "Absolute value",
            "value": 3.4,
            "unit": "points",
            "total_n": 10,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 3.4,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Mean \u00b1 SD: 3.4 \u00b1 0.7",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "IGA PN score",
            "endpoint_category": "Primary",
            "timepoint": "Week 4",
            "measurement_type": "Absolute value",
            "value": 2.3,
            "unit": "points",
            "total_n": 10,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 3.4,
            "final_value": 2.3,
            "change_from_baseline": -1.1,
            "change_pct": null,
            "p_value": "<0.01",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "Mean \u00b1 SD: 2.3 \u00b1 0.8",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "IGA PN score",
            "endpoint_category": "Primary",
            "timepoint": "Week 12",
            "measurement_type": "Absolute value",
            "value": 1.4,
            "unit": "points",
            "total_n": 10,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 3.4,
            "final_value": 1.4,
            "change_from_baseline": -2.0,
            "change_pct": null,
            "p_value": "<0.01",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "Mean \u00b1 SD: 1.4 \u00b1 1.1",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "IGA PN score",
            "endpoint_category": "Primary",
            "timepoint": "Week 24",
            "measurement_type": "Absolute value",
            "value": 1.0,
            "unit": "points",
            "total_n": 10,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 3.4,
            "final_value": 1.0,
            "change_from_baseline": -2.4,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Text reports mean as 1.0, Table 2 shows 0.9 \u00b1 0.7",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "DLQI score",
            "endpoint_category": "Secondary",
            "timepoint": "Baseline",
            "measurement_type": "Absolute value",
            "value": 17.8,
            "unit": "points",
            "total_n": 10,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 17.8,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Mean \u00b1 SD: 17.8 \u00b1 5.2",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 2
          },
          {
            "endpoint_name": "DLQI score",
            "endpoint_category": "Secondary",
            "timepoint": "Week 4",
            "measurement_type": "Absolute value",
            "value": 3.4,
            "unit": "points",
            "total_n": 10,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 17.8,
            "final_value": 3.4,
            "change_from_baseline": -14.4,
            "change_pct": null,
            "p_value": "<0.01",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "Mean \u00b1 SD: 3.4 \u00b1 2.0",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 2
          },
          {
            "endpoint_name": "DLQI score",
            "endpoint_category": "Secondary",
            "timepoint": "Week 12",
            "measurement_type": "Absolute value",
            "value": 1.8,
            "unit": "points",
            "total_n": 10,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 17.8,
            "final_value": 1.8,
            "change_from_baseline": -16.0,
            "change_pct": null,
            "p_value": "<0.05",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "Mean \u00b1 SD: 1.8 \u00b1 0.9",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 2
          },
          {
            "endpoint_name": "DLQI score",
            "endpoint_category": "Secondary",
            "timepoint": "Week 24",
            "measurement_type": "Absolute value",
            "value": 0.6,
            "unit": "points",
            "total_n": 10,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 17.8,
            "final_value": 0.6,
            "change_from_baseline": -17.2,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Mean \u00b1 SD: 0.6 \u00b1 0.7",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 2
          },
          {
            "endpoint_name": "\u22654-point reduction in itch NRS",
            "endpoint_category": "Secondary",
            "timepoint": "Week 4",
            "measurement_type": "Responder",
            "value": null,
            "unit": "percentage",
            "total_n": 10,
            "responders_n": 10,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": null,
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 2
          },
          {
            "endpoint_name": "\u22654-point reduction in itch NRS",
            "endpoint_category": "Secondary",
            "timepoint": "Week 12",
            "measurement_type": "Responder",
            "value": null,
            "unit": "percentage",
            "total_n": 10,
            "responders_n": 10,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": null,
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 2
          },
          {
            "endpoint_name": "\u22654-point reduction in itch NRS",
            "endpoint_category": "Secondary",
            "timepoint": "Week 24",
            "measurement_type": "Responder",
            "value": null,
            "unit": "percentage",
            "total_n": 10,
            "responders_n": 10,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": null,
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 2
          },
          {
            "endpoint_name": "IGA PN score 0/1 achievement",
            "endpoint_category": "Secondary",
            "timepoint": "Week 4",
            "measurement_type": "Responder",
            "value": null,
            "unit": "percentage",
            "total_n": 10,
            "responders_n": 2,
            "responders_pct": 20.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Clear or almost clear PN",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "IGA PN score 0/1 achievement",
            "endpoint_category": "Secondary",
            "timepoint": "Week 12",
            "measurement_type": "Responder",
            "value": null,
            "unit": "percentage",
            "total_n": 10,
            "responders_n": 6,
            "responders_pct": 60.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Clear or almost clear PN",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "IGA PN score 0/1 achievement",
            "endpoint_category": "Secondary",
            "timepoint": "Week 24",
            "measurement_type": "Responder",
            "value": null,
            "unit": "percentage",
            "total_n": 10,
            "responders_n": 8,
            "responders_pct": 80.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Clear or almost clear PN",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "IGA PN score 0 achievement",
            "endpoint_category": "Secondary",
            "timepoint": "Week 12",
            "measurement_type": "Responder",
            "value": null,
            "unit": "percentage",
            "total_n": 10,
            "responders_n": 2,
            "responders_pct": 20.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Complete clearance",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "IGA PN score 0 achievement",
            "endpoint_category": "Secondary",
            "timepoint": "Week 24",
            "measurement_type": "Responder",
            "value": null,
            "unit": "percentage",
            "total_n": 10,
            "responders_n": 3,
            "responders_pct": 30.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Complete clearance",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 3
          }
        ],
        "detailed_safety_endpoints": [
          {
            "event_name": "Dyslipidemia",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": 1,
            "patients_affected_pct": 10.0,
            "events_total": null,
            "relatedness": null,
            "outcome": null,
            "action_taken": "None",
            "notes": "Developed at week 24, requiring initiation of lipid-lowering agent. No treatment discontinuation or dose modification of upadacitinib",
            "category_soc": "Metabolic",
            "infection_type": null,
            "malignancy_type": null,
            "cv_type": null,
            "thromboembolic_type": null,
            "is_class_effect": true
          }
        ],
        "extraction_timestamp": "2025-12-08T18:15:23.354841",
        "extraction_confidence": 0.6,
        "extraction_confidence_detail": null,
        "extraction_method": "multi_stage",
        "extraction_stages_completed": [
          "section_identification",
          "efficacy_extraction",
          "safety_extraction"
        ],
        "data_sections_identified": {
          "baseline_tables": [
            "Table 1: Basic demographic information and clinical data - contains patient characteristics including age, sex, disease duration, previous treatments, baseline IGA PN scores, baseline itch NRS and DLQI scores, and etiology of pruritus"
          ],
          "efficacy_tables": [
            "Table 2: Mean change in the itch NRS, IGA PN, and DLQI scores at each visit - shows mean scores and standard deviations at baseline, week 4, week 12, and week 24",
            "Table 3: Comparison of the results of upadacitinib treatment from our study and the PRIME trials - compares efficacy outcomes including itch NRS reduction, IGA PN achievement, and DLQI changes with published dupilumab trials"
          ],
          "safety_tables": [],
          "efficacy_figures": [
            "Figure 1: The changes in the itch NRS, IGA PN, DLQI scores at each visit - includes (A) variation percentages over time and individual panels showing (B) itch NRS, (C) IGA PN, and (D) DLQI score changes",
            "Figure 2: Proportions of patients with each category of (A) the itch NRS, (B) IGA PN, (C) DLQI scores at each visit - shows distribution of mild/moderate/severe categories over time",
            "Figure 3: Clinical photographs of a representative patient with prurigo nodularis treated with upadacitinib at baseline, week 4, week 12, and week 24"
          ],
          "results_sections": [
            "Clinical improvement - describes treatment response and score improvements over 24 weeks",
            "Adverse reactions - reports safety outcomes including one case of dyslipidemia"
          ],
          "patient_count": 10,
          "study_type": "Case Series",
          "has_quantitative_outcomes": true,
          "notes": "This is actually described as a prospective cohort study in the title, with validated outcome measures including itch NRS, IGA PN, and DLQI. Safety data is reported in text rather than tabular format. All patients had previously failed systemic immunosuppressants including cyclosporine."
        }
      },
      "market_intelligence": {
        "disease": "Prurigo Nodularis",
        "parent_disease": null,
        "epidemiology": {
          "us_prevalence_estimate": "0.19% (0.18%-0.2%)",
          "us_incidence_estimate": null,
          "global_prevalence": null,
          "patient_population_size": 636500,
          "prevalence_source": "All of Us National Institutes of Health database",
          "prevalence_source_url": "https://www.healio.com/news/dermatology/20230719/prurigo-nodularis-prevalence-proves-higher-than-previously-estimated",
          "trend": "increasing",
          "source_quality": "Primary",
          "data_year": 2023,
          "geographic_scope": "US",
          "confidence": "High",
          "notes": "Most recent estimate (0.19%) is significantly higher than previous estimates of 0.02% to 0.07%. Multiple studies show wide range of prevalence estimates (18-148.3 per 100,000) depending on database and population. Predominantly affects older adults with mean age 64.8 years."
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Dupixent (dupilumab)",
              "drug_class": "IL-4/IL-13 receptor antagonist",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Prurigo Nodularis",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "First FDA-approved treatment for adult patients with prurigo nodularis. Monoclonal antibody that inhibits IL-4 and IL-13 signaling by blocking the shared IL-4Ra. Administered as subcutaneous injection.",
              "approval_year": 2022,
              "approval_confidence": "High",
              "approval_evidence": "FDA press release September 29, 2022 and multiple FDA sources confirming first treatment approved for prurigo nodularis"
            },
            {
              "drug_name": "Nemluvio (nemolizumab)",
              "drug_class": "IL-31 receptor antagonist",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Prurigo Nodularis",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "Second FDA-approved treatment for adult patients with prurigo nodularis. Humanized IgG2 monoclonal antibody that inhibits interleukin-31 (IL-31) signaling by binding selectively to IL-31Ra. Administered subcutaneously every 4 weeks with weight-based dosing.",
              "approval_year": 2024,
              "approval_confidence": "High",
              "approval_evidence": "FDA BLA approval August 2024, FDA Drug Trials Snapshots, and FDA integrated review documents confirm approval for prurigo nodularis"
            }
          ],
          "approved_drug_names": [
            "Dupixent (dupilumab)",
            "Nemluvio (nemolizumab)"
          ],
          "num_approved_drugs": 2,
          "num_pipeline_therapies": 11,
          "pipeline_therapies": [
            {
              "drug_name": "Rocatinlimab",
              "company": "Amgen",
              "mechanism": "Anti-OX40 monoclonal antibody",
              "phase": "Phase 3",
              "trial_id": "NCT06527404",
              "expected_completion": "2026-10",
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": null,
              "notes": "52-week multicenter study in adults inadequately controlled on topical therapies"
            },
            {
              "drug_name": "Barzolvolimab",
              "company": "Celldex Therapeutics",
              "mechanism": "Anti-KIT monoclonal antibody",
              "phase": "Phase 2",
              "trial_id": "NCT06366750",
              "expected_completion": "2026-01",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "CDX-0159, randomized, double-blind, placebo-controlled study"
            },
            {
              "drug_name": "MG-K10",
              "company": "Shanghai Mabgeek Biotech.Co.Ltd",
              "mechanism": "Humanized monoclonal antibody",
              "phase": "Phase 3",
              "trial_id": "NCT06779136",
              "expected_completion": "2026-08",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Humanized monoclonal antibody injection"
            },
            {
              "drug_name": "ICP-332",
              "company": "Beijing InnoCare Pharma Tech Co., Ltd.",
              "mechanism": null,
              "phase": "Phase 2",
              "trial_id": "NCT07236099",
              "expected_completion": "2027-03",
              "trial_name": null,
              "status": "Not yet recruiting",
              "regulatory_designations": null,
              "notes": "Dose-ranging study"
            },
            {
              "drug_name": "SHR-1819",
              "company": "Guangdong Hengrui Pharmaceutical Co., Ltd",
              "mechanism": null,
              "phase": "Phase 2/3",
              "trial_id": "NCT06554509",
              "expected_completion": "2026-06",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Multicenter, randomized, double-blind, placebo-controlled study"
            },
            {
              "drug_name": "Povorcitinib",
              "company": "Incyte Corporation",
              "mechanism": "JAK1 selective inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT06516965",
              "expected_completion": "2026-10",
              "trial_name": "STOP-PN2",
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Oral small-molecule JAK1 selective inhibitor, also being tested in parallel STOP-PN1 trial"
            },
            {
              "drug_name": "Nemolizumab",
              "company": "Galderma R&D",
              "mechanism": "IL-31RA antagonist",
              "phase": "Phase 3",
              "trial_id": "NCT04204616",
              "expected_completion": "2026-10",
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": null,
              "notes": "Long-term study, recently approved by EMA in February 2025"
            },
            {
              "drug_name": "Stapokibart",
              "company": "Keymed Biosciences Co.Ltd",
              "mechanism": null,
              "phase": "Phase 3",
              "trial_id": "NCT06424470",
              "expected_completion": "2026-07",
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": null,
              "notes": "Randomized, double-blind, placebo-controlled Phase III study"
            },
            {
              "drug_name": "Dupilumab",
              "company": "Sanofi",
              "mechanism": "IL-4/IL-13 pathway inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT06293053",
              "expected_completion": "2027-10",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Pharmacokinetics and safety study in pediatric patients aged 6 months to <18 years"
            },
            {
              "drug_name": "Ruxolitinib cream",
              "company": "Incyte Corporation",
              "mechanism": "JAK inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT05755438",
              "expected_completion": "2024-10",
              "trial_name": "TRuE-PN1",
              "status": "Recently completed",
              "regulatory_designations": null,
              "notes": "Recently completed Phase 3 trials showed positive results, pooled data from TRuE-PN1 and TRuE-PN2 demonstrated significant improvements"
            },
            {
              "drug_name": "5-fluorouracil plus Triamcinolone",
              "company": "Second Affiliated Hospital, School of Medicine, Zhejiang University",
              "mechanism": "Antimetabolite plus corticosteroid",
              "phase": "Phase 3",
              "trial_id": "NCT06524323",
              "expected_completion": "2026-08",
              "trial_name": null,
              "status": "Not yet recruiting",
              "regulatory_designations": null,
              "notes": "Intralesional injection for refractory nodular prurigo"
            }
          ],
          "pipeline_details": "The prurigo nodularis pipeline includes 12 active therapies across Phase 2-3 development, with significant focus on immunomodulatory approaches including IL-31RA antagonists, JAK inhibitors, and novel monoclonal antibodies. Key mechanisms being tested include OX40 inhibition (rocatinlimab), JAK1 selective inhibition (povorcitinib), and IL-31RA antagonism (nemolizumab, which recently gained EMA approval). Multiple large Phase 3 programs are currently recruiting patients, with several readouts expected in 2026.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "Treatment focuses on interrupting the itch-scratch cycle and reducing inflammation using a tiered approach. First-line treatments traditionally included topical corticosteroids and antihistamines, but FDA-approved biologics Dupixent and Nemluvio now represent preferred first-line systemic therapies for patients requiring more than topical treatment.",
          "unmet_need": false,
          "unmet_need_description": "While historically an area of high unmet need with only off-label treatments available, the recent approval of two targeted biologics (Dupixent in 2022 and Nemluvio in 2024) has significantly improved treatment options for prurigo nodularis patients.",
          "competitive_landscape": "The prurigo nodularis market has rapidly evolved from having no FDA-approved treatments to two approved biologics within two years. Dupixent (IL-4/IL-13 inhibitor) was first-to-market in 2022, followed by Nemluvio (IL-31 inhibitor) in 2024, creating a competitive dynamic between different cytokine pathway approaches.",
          "soc_source": "Medscape Prurigo Nodularis Treatment & Management and FDA approval documentation",
          "phase_3_count": 9,
          "phase_2_count": 3,
          "key_catalysts": "Major Phase 3 readouts expected in 2026 include rocatinlimab (Amgen), povorcitinib STOP-PN trials (Incyte), and multiple other Phase 3 programs. Ruxolitinib cream recently completed Phase 3 with positive pooled results from TRuE-PN trials.",
          "pipeline_data_quality": "High",
          "recent_approvals": "Dupixent approved September 2022 as first treatment for prurigo nodularis; Nemluvio approved August 2024 as second treatment",
          "data_quality": "High",
          "data_quality_notes": "Clear FDA approval documentation available for both treatments with specific approval dates and indications confirmed"
        },
        "market_size_estimate": "$15.9B",
        "market_size_usd": 15912500000.0,
        "growth_rate": "5-10% CAGR (increasing prevalence)",
        "tam_usd": 855000000.0,
        "tam_estimate": "$855M",
        "tam_rationale": "Of ~636,500 US patients with prurigo nodularis, ~75% are diagnosed (477K), ~65% receive systemic treatment beyond topicals (310K). With established biologics (Dupixent, Nemluvio) as first-line, a new entrant would likely target 2L+ patients (~30% of treated = 93K patients). A new drug could capture 20-25% market share (~22K patients). At $45K/yr pricing (competitive with other dermatology biologics), TAM = $990M. Conservative estimate of $855M accounts for market maturation and competitive pressure from existing approved biologics.",
        "tam_sources": [
          "https://www.reanin.com/reports/prurigo-nodularis-treatment-market",
          "https://ultramarketresearch.com/report/united-states-prurigo-nodularis-market",
          "https://www.datainsightsmarket.com/reports/prurigo-nodularis-treatment-1488772"
        ],
        "pipeline_sources": [
          "https://clinicaltrials.gov",
          "https://www.clinicaltrials.gov/study/NCT06527404",
          "https://www.clinicaltrials.gov/study/NCT03497975",
          "https://clinicaltrials.gov/study/NCT05755438",
          "https://clinicaltrials.gov/study/NCT06516952"
        ],
        "attributed_sources": [
          {
            "url": "https://www.healio.com/news/dermatology/20230719/prurigo-nodularis-prevalence-proves-higher-than-previously-estimated",
            "title": "Prurigo nodularis prevalence proves higher than previously estimated",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.trevitherapeutics.com/wp-content/uploads/2021/04/AAD-2020-Poster-Stander-et-al..pdf",
            "title": "Prevalence of Prurigo Nodularis in the United States",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://emedicine.medscape.com/article/1088032-medication",
            "title": "Prurigo Nodularis Medication",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.drugs.com/history/dupixent.html",
            "title": "Dupixent (dupilumab) FDA Approval History",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://onlinelibrary.wiley.com/doi/10.1111/1346-8138.16067",
            "title": "2020 guidelines for the diagnosis and treatment of prurigo",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://clinicaltrials.gov",
            "title": "ClinicalTrials.gov API",
            "attribution": "Pipeline/Clinical Trials (Primary)"
          },
          {
            "url": "https://www.clinicaltrials.gov/study/NCT06527404",
            "title": "Study Details | NCT06527404 | A Phase 3, Placebo ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.clinicaltrials.gov/study/NCT03497975",
            "title": "NCT03497975 | PRISM Study-Pruritus Relief Through Itch ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.reanin.com/reports/prurigo-nodularis-treatment-market",
            "title": "Prurigo Nodularis Treatment Market Growth Drivers & Analysis",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://ultramarketresearch.com/report/united-states-prurigo-nodularis-market",
            "title": "United States Prurigo Nodularis Market",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 9.0,
        "evidence_quality": 7.8,
        "market_opportunity": 8.3,
        "overall_priority": 8.6,
        "clinical_breakdown": {
          "response_rate_quality_weighted": 9.0,
          "safety_profile": 8.6,
          "organ_domain_breadth": 10.0,
          "safety_categories": [
            "cardiovascular",
            "metabolic"
          ],
          "regulatory_flags": [
            "cardiovascular"
          ],
          "efficacy_endpoint_count": 20,
          "efficacy_concordance": 1.1
        },
        "response_rate_score": 9.0,
        "safety_profile_score": 8.6,
        "endpoint_quality_score": null,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 8.0,
          "publication_venue": 10.0,
          "response_durability": 5.0,
          "extraction_completeness": 8.3
        },
        "sample_size_score": 8.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 5.0,
        "extraction_completeness_score": 8.3,
        "market_breakdown": {
          "competitors": 7.0,
          "market_size": 10.0,
          "unmet_need": 8.0
        },
        "competitors_score": 7.0,
        "market_size_score": 10.0,
        "unmet_need_score": 8.0
      },
      "rank": 4
    },
    {
      "extraction": {
        "source": {
          "pmid": "37841060",
          "doi": "10.2147/CCID.S419344",
          "url": "https://pubmed.ncbi.nlm.nih.gov/37841060/",
          "title": "Treatment of Discoid Lupus Erythematosus with Upadacitinib: A Case Report.",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "Discoid Lupus Erythematosus",
        "disease_normalized": "Cutaneous Lupus Erythematosus",
        "is_off_label": true,
        "is_relevant": true,
        "evidence_level": "Case Report",
        "patient_population": {
          "n_patients": 1,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "doxycycline",
            "isotretinoin",
            "hydroxychloroquine with low-dose prednisone",
            "topical tacrolimus"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "26-year-old female with 2-year history of facial DLE, previously misdiagnosed as rosacea, with hepatitis B virus infection"
        },
        "treatment": {
          "drug_name": "upadacitinib",
          "generic_name": "Upadacitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "15mg daily",
          "frequency": null,
          "duration": "28 weeks",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "1/1 (100%)",
          "responders_n": 1,
          "responders_pct": 100.0,
          "time_to_response": "4 weeks",
          "duration_of_response": "sustained through 28 weeks",
          "effect_size_description": "80% reduction in RCLASI score (from 5 to 1)",
          "primary_endpoint": "RCLASI score reduction",
          "endpoint_result": "RCLASI score decreased from 5 to 1 over 28 weeks",
          "durability_signal": null,
          "efficacy_summary": "Upadacitinib 15mg daily led to significant improvement in DLE lesions within 4 weeks with sustained response through 28 weeks. Dose reduction to every other day resulted in relapse, requiring return to daily dosing."
        },
        "safety": {
          "adverse_events": [
            "acne"
          ],
          "serious_adverse_events": [],
          "sae_count": 0,
          "sae_percentage": 0.0,
          "discontinuations_n": 0,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "Upadacitinib showed favorable safety profile over 28 weeks. The only adverse event was acne, which was successfully controlled with topical benzoyl peroxide gel.",
          "safety_profile": "Favorable"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": "28 weeks",
        "key_findings": "Upadacitinib demonstrated rapid and sustained improvement of DLE lesions with favorable safety, suggesting potential as alternative therapy for DLE.",
        "detailed_efficacy_endpoints": [],
        "detailed_safety_endpoints": [
          {
            "event_name": "Acne",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": 1,
            "patients_affected_pct": null,
            "events_total": null,
            "relatedness": "Related",
            "outcome": "Resolved",
            "action_taken": "None",
            "notes": "Occurred after 20 weeks of upadacitinib treatment, controlled with topical benzoyl peroxide gel",
            "category_soc": "Dermatologic",
            "infection_type": null,
            "malignancy_type": null,
            "cv_type": null,
            "thromboembolic_type": null,
            "is_class_effect": false
          }
        ],
        "extraction_timestamp": "2025-12-08T18:31:51.881870",
        "extraction_confidence": 0.6,
        "extraction_confidence_detail": null,
        "extraction_method": "multi_stage",
        "extraction_stages_completed": [
          "section_identification",
          "efficacy_extraction",
          "safety_extraction"
        ],
        "data_sections_identified": {
          "baseline_tables": [],
          "efficacy_tables": [],
          "safety_tables": [],
          "efficacy_figures": [
            "Figure 1: Skin lesions before and after upadacitinib treatment showing progression over 28 weeks at different time points (baseline, 4 weeks, 10 weeks, 14 weeks, 20 weeks, 28 weeks)",
            "Figure 2: Pathological pictures of the skin lesion showing histopathological features and direct immunofluorescence findings"
          ],
          "results_sections": [
            "Case Report",
            "RCLASI disease activity scores at weeks 0, 4, 10, 14, 20, 28",
            "Treatment response and relapse upon dose reduction",
            "Safety outcomes and adverse events"
          ],
          "patient_count": 1,
          "study_type": "Case Report",
          "has_quantitative_outcomes": true,
          "notes": "Single patient case report with RCLASI scores as quantitative outcomes (5, 3, 2, 4, 2, 1 at weeks 0, 4, 10, 14, 20, 28 respectively). Table 1 is a literature review of JAK inhibitors in SLE/CLE, not study data. Primary safety concern was acne which was managed with topical benzoyl peroxide."
        }
      },
      "market_intelligence": {
        "disease": "Cutaneous Lupus Erythematosus",
        "parent_disease": "Systemic Lupus Erythematosus",
        "epidemiology": {
          "us_prevalence_estimate": "72.8 per 100,000 (204,295 patients)",
          "us_incidence_estimate": "5.1 per 100,000 person-years",
          "global_prevalence": null,
          "patient_population_size": 204295,
          "prevalence_source": "CDC National Lupus Registry network",
          "prevalence_source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8169527/",
          "trend": "increasing",
          "source_quality": "Primary",
          "data_year": 2018,
          "geographic_scope": "US",
          "confidence": "High",
          "notes": "Based on meta-analysis of 4 state-specific registries using ACR classification criteria. Prevalence 9 times higher in females than males. Highest rates in American Indian/Alaska Native and Black populations. Lupus nephritis affects up to 67% of SLE patients."
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Benlysta (belimumab)",
              "drug_class": "BLyS inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Systemic Lupus Erythematosus",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "First new lupus treatment approved in over 50 years. Approved for adults and children 5 years and older with active, autoantibody-positive SLE. Available as IV and subcutaneous formulations.",
              "approval_year": 2011,
              "approval_confidence": "High",
              "approval_evidence": "FDA approval March 10, 2011 for systemic lupus erythematosus"
            },
            {
              "drug_name": "Saphnelo (anifrolumab)",
              "drug_class": "Type I interferon receptor antagonist",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Systemic Lupus Erythematosus",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "Human monoclonal antibody that binds to the type I interferon receptor. One of only two medicines approved to treat SLE since the 1950s.",
              "approval_year": null,
              "approval_confidence": "High",
              "approval_evidence": "Multiple sources confirm FDA approval for systemic lupus erythematosus"
            }
          ],
          "approved_drug_names": [
            "Benlysta (belimumab)",
            "Saphnelo (anifrolumab)"
          ],
          "num_approved_drugs": 2,
          "num_pipeline_therapies": 15,
          "pipeline_therapies": [
            {
              "drug_name": "Telitacicept",
              "company": "RemeGen Co., Ltd.",
              "mechanism": "BAFF-R/TACI inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT06456567",
              "expected_completion": "2027-04",
              "trial_name": "REMESLE-2",
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Global Phase 3 trial in moderately to severely active SLE"
            },
            {
              "drug_name": "Ianalumab",
              "company": "Novartis Pharmaceuticals",
              "mechanism": "Anti-BAFF-R monoclonal antibody",
              "phase": "Phase 3",
              "trial_id": "NCT05624749",
              "expected_completion": "2027-04",
              "trial_name": "SIRIUS-SLE 2",
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Dual Phase 3 program in SLE with additional lupus nephritis trial"
            },
            {
              "drug_name": "Litifilimab",
              "company": "Biogen",
              "mechanism": "Anti-BDCA2 antibody",
              "phase": "Phase 3",
              "trial_id": "NCT05352919",
              "expected_completion": "2030-03",
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": null,
              "notes": "Long-term extension study in active SLE"
            },
            {
              "drug_name": "Subcutaneous Anifrolumab",
              "company": "AstraZeneca",
              "mechanism": "Anti-interferon alpha receptor antibody",
              "phase": "Phase 3",
              "trial_id": "NCT04877691",
              "expected_completion": "2025-08",
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": null,
              "notes": "Subcutaneous formulation of approved IV drug"
            },
            {
              "drug_name": "Dapirolizumab pegol",
              "company": "UCB Biopharma SRL",
              "mechanism": "Anti-CD40L antibody",
              "phase": "Phase 3",
              "trial_id": "NCT04976322",
              "expected_completion": "2030-08",
              "trial_name": "PHOENYCS",
              "status": "Active",
              "regulatory_designations": null,
              "notes": "Positive Phase 3 results reported in 2024"
            },
            {
              "drug_name": "Lenalidomide",
              "company": "Assistance Publique - H\u00f4pitaux de Paris",
              "mechanism": "Immunomodulatory drug",
              "phase": "Phase 3",
              "trial_id": "NCT06965244",
              "expected_completion": "2029-02",
              "trial_name": null,
              "status": "Not yet recruiting",
              "regulatory_designations": null,
              "notes": "Cutaneous lupus erythematosus indication"
            },
            {
              "drug_name": "Cenerimod",
              "company": "Viatris Innovation GmbH",
              "mechanism": "S1P receptor modulator",
              "phase": "Phase 3",
              "trial_id": "NCT07201129",
              "expected_completion": "2029-08",
              "trial_name": null,
              "status": "Not yet recruiting",
              "regulatory_designations": null,
              "notes": "Active lupus nephritis trial"
            },
            {
              "drug_name": "Sirolimus",
              "company": "Chinese SLE Treatment And Research Group",
              "mechanism": "mTOR inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT04582136",
              "expected_completion": "2025-04",
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": null,
              "notes": "Multi-center trial in active SLE"
            },
            {
              "drug_name": "Frexalimab",
              "company": "Sanofi",
              "mechanism": "Anti-CD40L antibody",
              "phase": "Phase 2",
              "trial_id": "NCT05039840",
              "expected_completion": "2026-07",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Proof of concept study"
            },
            {
              "drug_name": "Obexelimab",
              "company": "Zenas BioPharma (USA), LLC",
              "mechanism": "Anti-CD19 antibody",
              "phase": "Phase 2",
              "trial_id": "NCT06559163",
              "expected_completion": "2026-06",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Novel CD19-targeting approach"
            },
            {
              "drug_name": "ESK-001",
              "company": "Alumis Inc",
              "mechanism": "TYK2 inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT05966480",
              "expected_completion": "2026-07",
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": null,
              "notes": "Multiple dose level evaluation"
            },
            {
              "drug_name": "Orelabrutinib",
              "company": "Beijing InnoCare Pharma Tech Co., Ltd.",
              "mechanism": "BTK inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT05688696",
              "expected_completion": "2025-08",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Dose-ranging study in SLE"
            },
            {
              "drug_name": "CD19 CAR-T cells",
              "company": "Various",
              "mechanism": "Chimeric antigen receptor T-cell therapy",
              "phase": "Phase 2",
              "trial_id": "NCT06347718",
              "expected_completion": "2026-05",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Multiple CAR-T programs targeting CD19 and CD19/BCMA"
            },
            {
              "drug_name": "Telitacicept",
              "company": "RemeGen Co., Ltd.",
              "mechanism": "BAFF-R/TACI inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT05680480",
              "expected_completion": "2025-12",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Lupus nephritis indication"
            },
            {
              "drug_name": "IMVT-1402",
              "company": "Immunovant Sciences GmbH",
              "mechanism": "FcRn antagonist",
              "phase": "Phase 2",
              "trial_id": "NCT06980805",
              "expected_completion": "2027-04",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Cutaneous lupus erythematosus focus"
            }
          ],
          "pipeline_details": "The SLE pipeline shows robust activity with 15 active Phase 2/3 programs targeting diverse mechanisms including B-cell modulators (ianalumab, obexelimab), interferon pathway inhibitors (litifilimab), and novel CAR-T cell therapies. Recent positive Phase 3 results for dapirolizumab pegol and multiple programs targeting both systemic SLE and lupus nephritis indicate strong momentum in late-stage development.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "First-line treatment includes hydroxychloroquine as the cornerstone therapy for all SLE patients, with NSAIDs and short-term corticosteroids for symptom control. Second-line therapy involves immunosuppressants like methotrexate, azathioprine, or mycophenolate, with biologics like belimumab or anifrolumab added for refractory disease.",
          "unmet_need": true,
          "unmet_need_description": "Only two FDA-approved biologics for SLE after 50+ years with no new treatments, indicating significant unmet need for effective targeted therapies with better safety profiles and steroid-sparing effects",
          "competitive_landscape": "Limited competitive landscape with only Benlysta and Saphnelo as FDA-approved biologics for SLE. Both target different pathways (BLyS vs interferon receptor) and are used as add-on therapy to standard care. Pipeline includes emerging therapies like litifilimab and deucravacitinib in development.",
          "soc_source": "Drugs.com and FDA guidance documents",
          "phase_3_count": 8,
          "phase_2_count": 7,
          "key_catalysts": "Sirolimus Phase 3 results expected April 2025, orelabrutinib Phase 2 data August 2025, subcutaneous anifrolumab Phase 3 results August 2025, and multiple telitacicept readouts through 2025-2027",
          "pipeline_data_quality": "High",
          "recent_approvals": "Benlysta subcutaneous autoinjector formulation approved in 2024 for pediatric patients 5 years and older",
          "data_quality": "High",
          "data_quality_notes": "Clear FDA approval documentation available for both approved biologics with specific approval dates and indications confirmed"
        },
        "market_size_estimate": "$5.1B",
        "market_size_usd": 5107375000.0,
        "growth_rate": "5-10% CAGR (increasing prevalence)",
        "tam_usd": 306000000.0,
        "tam_estimate": "$306M",
        "tam_rationale": "Of ~204K US CLE patients, ~70% are diagnosed (143K), ~60% receive systemic treatment (86K), with ~50% requiring 2L+ therapies due to inadequate response to antimalarials (43K). A new drug positioned as 2L could capture 20-25% market share (~10K patients) in this underserved market with only 2 approved drugs and high unmet need. At $71K/yr pricing (midpoint of autoimmune dermatology range), TAM = $306M.",
        "tam_sources": [
          "https://www.imrmarketreports.com/reports/cutaneous-lupus-erythematosus-cle-treatment-market/",
          "https://www.futuremarketreport.com/industry-report/cutaneous-lupus-erythematosus-treatment-market/",
          "https://www.asdreports.com/market-research-report-676296/cutaneous-lupus-erythematosus-market-analysis-forecast"
        ],
        "pipeline_sources": [
          "https://clinicaltrials.gov",
          "https://clinicaltrials.gov/study/NCT03093402",
          "https://cdn.clinicaltrials.gov/large-docs/25/NCT03843125/Prot_000.pdf",
          "https://cdn.clinicaltrials.gov/large-docs/12/NCT03616912/Prot_000.pdf",
          "https://cdn.clinicaltrials.gov/large-docs/25/NCT03843125/SAP_001.pdf"
        ],
        "attributed_sources": [
          {
            "url": "https://www.ahdbonline.com/articles/the-epidemiology-of-systemic-lupus-erythematosus-disease-prevalence-and-impact-on-employment-and-work-productivity",
            "title": "The Epidemiology of Systemic Lupus Erythematosus: Disease ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8169527/",
            "title": "Prevalence of Systemic Lupus Erythematosus in the United ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.drugs.com/benlysta.html",
            "title": "Benlysta: Uses, Dosage, Side Effects, Warnings",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.drugs.com/condition/systemic-lupus-erythematosus.html",
            "title": "List of 28 Lupus Medications Compared",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://emedicine.medscape.com/article/332244-treatment",
            "title": "Systemic Lupus Erythematosus (SLE) Treatment & ...",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://clinicaltrials.gov",
            "title": "ClinicalTrials.gov API",
            "attribution": "Pipeline/Clinical Trials (Primary)"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT03093402",
            "title": "JBT-101 in Systemic Lupus Erythematosus (SLE)",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://cdn.clinicaltrials.gov/large-docs/25/NCT03843125/Prot_000.pdf",
            "title": "Protocol I4V-MC-JAIM(a) A Phase 3, Double-Blind, ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.imrmarketreports.com/reports/cutaneous-lupus-erythematosus-cle-treatment-market/",
            "title": "Cutaneous Lupus Erythematosus (CLE) Treatment Market Report",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.futuremarketreport.com/industry-report/cutaneous-lupus-erythematosus-treatment-market/",
            "title": "Cutaneous Lupus Erythematosus Treatment Market Size, Share ...",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 10.0,
        "evidence_quality": 5.8,
        "market_opportunity": 8.7,
        "overall_priority": 8.6,
        "clinical_breakdown": {
          "response_rate_quality_weighted": 10.0,
          "safety_profile": 10.0,
          "organ_domain_breadth": 10.0,
          "safety_categories": [],
          "regulatory_flags": [],
          "efficacy_endpoint_count": 0,
          "efficacy_concordance": 1.0
        },
        "response_rate_score": 10.0,
        "safety_profile_score": 10.0,
        "endpoint_quality_score": null,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 1.0,
          "publication_venue": 10.0,
          "response_durability": 7.0,
          "extraction_completeness": 7.8
        },
        "sample_size_score": 1.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 7.0,
        "extraction_completeness_score": 7.8,
        "market_breakdown": {
          "competitors": 7.0,
          "market_size": 9.0,
          "unmet_need": 10.0
        },
        "competitors_score": 7.0,
        "market_size_score": 9.0,
        "unmet_need_score": 10.0
      },
      "rank": 5
    },
    {
      "extraction": {
        "source": {
          "pmid": "39582862",
          "doi": "10.3389/fimmu.2024.1483993",
          "url": "https://pubmed.ncbi.nlm.nih.gov/39582862/",
          "title": "Case report: Successful remission with upadacitinib in a young patient with anti-TNF-refractory intestinal Beh\u00e7et's disease.",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "Intestinal Beh\u00e7et's disease",
        "disease_normalized": "Beh\u00e7et's Disease",
        "is_off_label": true,
        "is_relevant": true,
        "evidence_level": "Case Report",
        "patient_population": {
          "n_patients": 1,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "corticosteroids",
            "infliximab",
            "adalimumab",
            "sulfasalazine"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "24-year-old male with anti-TNF-refractory intestinal Beh\u00e7et's disease"
        },
        "treatment": {
          "drug_name": "upadacitinib",
          "generic_name": "Upadacitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "45 mg daily for 12 weeks, then 30 mg for maintenance",
          "frequency": null,
          "duration": "25 weeks",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "1/1 (100%)",
          "responders_n": 1,
          "responders_pct": 100.0,
          "time_to_response": "rapid symptomatic improvement, complete healing at 12 weeks",
          "duration_of_response": "13 weeks on maintenance dose with stable condition",
          "effect_size_description": "complete mucosal healing with normalization of inflammatory markers",
          "primary_endpoint": "mucosal healing",
          "endpoint_result": "complete ulcer healing at 12 weeks",
          "durability_signal": null,
          "efficacy_summary": "The patient achieved complete ulcer healing and normalization of inflammatory markers after 12 weeks of upadacitinib treatment. Symptomatic improvement including resolution of abdominal pain, oral ulcers, and fever was observed rapidly after treatment initiation."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": 0,
          "sae_percentage": 0.0,
          "discontinuations_n": 0,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "No severe adverse events were reported during the 25-week treatment period. The patient was able to return to normal daily activities with good quality of life improvement.",
          "safety_profile": "Favorable"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": "25 weeks",
        "key_findings": "Upadacitinib achieved complete mucosal healing in a young patient with anti-TNF-refractory intestinal Beh\u00e7et's disease, representing the first reported case in a childbearing age male.",
        "detailed_efficacy_endpoints": [
          {
            "endpoint_name": "Complete ulcer healing",
            "endpoint_category": "Primary",
            "timepoint": "Week 12",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 1,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Complete healing of anastomotic ulcer observed on colonoscopy",
            "organ_domain": "Gastrointestinal",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Abdominal pain relief",
            "endpoint_category": "Secondary",
            "timepoint": "Rapid improvement after treatment initiation",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 1,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Patient reported significant relief from abdominal pain",
            "organ_domain": "Gastrointestinal",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Oral ulcer resolution",
            "endpoint_category": "Secondary",
            "timepoint": "Post-treatment",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 1,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "No more oral ulcers appeared after treatment",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Fever resolution",
            "endpoint_category": "Secondary",
            "timepoint": "Post-treatment",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 1,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "No fever appeared after treatment initiation",
            "organ_domain": "Constitutional",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "C-reactive protein normalization",
            "endpoint_category": "Secondary",
            "timepoint": "Post-treatment",
            "measurement_type": "Responder",
            "value": null,
            "unit": "mg/L",
            "total_n": 1,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": 67.8,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "CRP returned to normal range after treatment",
            "organ_domain": "Immunological",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "Erythrocyte sedimentation rate normalization",
            "endpoint_category": "Secondary",
            "timepoint": "Post-treatment",
            "measurement_type": "Responder",
            "value": null,
            "unit": "mm/h",
            "total_n": 1,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": 29.0,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "ESR returned to normal range after treatment",
            "organ_domain": "Immunological",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "Fecal calprotectin normalization",
            "endpoint_category": "Secondary",
            "timepoint": "Post-treatment",
            "measurement_type": "Responder",
            "value": null,
            "unit": "ug/G",
            "total_n": 1,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": 989.1,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Fecal calprotectin returned to normal range after treatment",
            "organ_domain": "Gastrointestinal",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "Anemia correction",
            "endpoint_category": "Secondary",
            "timepoint": "Post-treatment",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 1,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Anemia was corrected after treatment",
            "organ_domain": "Hematological",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Stool routine examination normalization",
            "endpoint_category": "Secondary",
            "timepoint": "Post-treatment",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 1,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Stool routine examination showed negative results",
            "organ_domain": "Gastrointestinal",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Quality of life improvement",
            "endpoint_category": "Secondary",
            "timepoint": "Post-treatment",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 1,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Patient experienced significant symptomatic improvement and notable enhancement in quality of life",
            "organ_domain": "Systemic",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Return to normal daily activities",
            "endpoint_category": "Secondary",
            "timepoint": "Post-treatment",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 1,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Patient was able to return to normal daily activities",
            "organ_domain": "Systemic",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          }
        ],
        "detailed_safety_endpoints": [
          {
            "event_name": "No severe adverse events",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": 1,
            "patients_affected_pct": null,
            "events_total": null,
            "relatedness": null,
            "outcome": null,
            "action_taken": "None",
            "notes": "Patient experienced significant symptomatic improvement without the occurrence of severe adverse events up to now",
            "category_soc": null,
            "infection_type": null,
            "malignancy_type": null,
            "cv_type": null,
            "thromboembolic_type": null,
            "is_class_effect": false
          }
        ],
        "extraction_timestamp": "2025-12-08T18:30:44.749981",
        "extraction_confidence": 0.6,
        "extraction_confidence_detail": null,
        "extraction_method": "multi_stage",
        "extraction_stages_completed": [
          "section_identification",
          "efficacy_extraction",
          "safety_extraction"
        ],
        "data_sections_identified": {
          "baseline_tables": [
            "Table 1: Case reports of successful remission with upadacitinib in patients with Beh\u00e7et's disease - includes patient demographics (age, sex), complications, and previous treatments"
          ],
          "efficacy_tables": [
            "Table 1: Case reports of successful remission with upadacitinib in patients with Beh\u00e7et's disease - includes dosage and clinical outcomes across different case reports"
          ],
          "safety_tables": [],
          "efficacy_figures": [
            "Figure 2: The colonoscopy findings showing disease progression and treatment response - panels A through F demonstrate ulcer recurrence, treatment failures with anti-TNF agents, and complete ulcer healing after 12 weeks of upadacitinib treatment"
          ],
          "results_sections": [
            "Case presentation section - describes patient treatment history, inflammatory markers, colonoscopy findings, and clinical response to upadacitinib",
            "Discussion section - summarizes treatment outcomes and therapeutic implications"
          ],
          "patient_count": 1,
          "study_type": "Case Report",
          "has_quantitative_outcomes": true,
          "notes": "Single case report demonstrating mucosal healing with upadacitinib in anti-TNF refractory intestinal Beh\u00e7et's disease. Includes comparison table with other published cases. Primary efficacy endpoint is endoscopic mucosal healing shown in colonoscopy images."
        }
      },
      "market_intelligence": {
        "disease": "Beh\u00e7et's Disease",
        "parent_disease": null,
        "epidemiology": {
          "us_prevalence_estimate": "0.33 to 5.2 per 100,000 population",
          "us_incidence_estimate": "0.38 per 100,000 population",
          "global_prevalence": null,
          "patient_population_size": 9200,
          "prevalence_source": "Arthritis & Rheumatism journal",
          "prevalence_source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3024036/",
          "trend": "increasing",
          "source_quality": "Primary",
          "data_year": 2009,
          "geographic_scope": "US",
          "confidence": "Medium",
          "notes": "Wide range reported across studies (0.33-10.6 per 100,000); higher prevalence found in Southwestern US populations; increasing trend may be due to improved recognition and immigration from endemic areas"
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Otezla (apremilast)",
              "drug_class": "PDE-4 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Oral Ulcers Associated with Beh\u00e7et's Disease",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "FDA approved for treatment of adult patients with oral ulcers associated with Beh\u00e7et's Disease. Approval based on Phase 3 RELIEF study with 207 patients. Dosed at 30 mg twice daily.",
              "approval_year": 2019,
              "approval_confidence": "High",
              "approval_evidence": "FDA label 2019, drugs@FDA documentation"
            }
          ],
          "approved_drug_names": [
            "Otezla (apremilast)"
          ],
          "num_approved_drugs": 1,
          "num_pipeline_therapies": 13,
          "pipeline_therapies": [
            {
              "drug_name": "Apremilast",
              "company": "Amgen",
              "mechanism": "PDE4 inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT04528082",
              "expected_completion": "2030-02",
              "trial_name": "BEAN",
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Pediatric study for children 2-18 years with active oral ulcers"
            },
            {
              "drug_name": "Apremilast",
              "company": "Amgen",
              "mechanism": "PDE4 inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT05767047",
              "expected_completion": "2036-03",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Long-term extension study in children with oral ulcers"
            },
            {
              "drug_name": "Hemay005",
              "company": "Ganzhou Hemay Pharmaceutical Co., Ltd",
              "mechanism": null,
              "phase": "Phase 3",
              "trial_id": "NCT06145893",
              "expected_completion": "2026-05",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": null
            },
            {
              "drug_name": "Baricitinib",
              "company": "Peking Union Medical College Hospital",
              "mechanism": "JAK inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT06849908",
              "expected_completion": "2027-06",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "For refractory intestinal Beh\u00e7et's syndrome vs adalimumab"
            },
            {
              "drug_name": "HSK44459",
              "company": "Haisco Pharmaceutical Group Co., Ltd.",
              "mechanism": null,
              "phase": "Phase 2",
              "trial_id": "NCT06902428",
              "expected_completion": "2026-06",
              "trial_name": null,
              "status": "Not yet recruiting",
              "regulatory_designations": null,
              "notes": null
            },
            {
              "drug_name": "Rivaroxaban",
              "company": "Assistance Publique - H\u00f4pitaux de Paris",
              "mechanism": "Anticoagulant",
              "phase": "Phase 3",
              "trial_id": "NCT06780462",
              "expected_completion": "2027-07",
              "trial_name": null,
              "status": "Not yet recruiting",
              "regulatory_designations": null,
              "notes": "Steroid therapy plus anticoagulants vs steroid alone for deep venous thrombosis"
            },
            {
              "drug_name": "Tocilizumab",
              "company": "Assistance Publique - H\u00f4pitaux de Paris",
              "mechanism": "IL-6 receptor antagonist",
              "phase": "Phase 2",
              "trial_id": "NCT05874505",
              "expected_completion": "2026-11",
              "trial_name": "UVB",
              "status": "Not yet recruiting",
              "regulatory_designations": null,
              "notes": "Comparison with adalimumab in severe uveitis"
            },
            {
              "drug_name": "Tocilizumab",
              "company": "Peking Union Medical College Hospital",
              "mechanism": "IL-6 receptor antagonist",
              "phase": "Phase 2",
              "trial_id": "NCT05845723",
              "expected_completion": "2026-06",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Combined with tofacitinib for vascular Beh\u00e7et's syndrome"
            },
            {
              "drug_name": "Low-dose IL-2",
              "company": "HeJing",
              "mechanism": "Immunoregulatory cytokine",
              "phase": "Phase 2",
              "trial_id": "NCT04065672",
              "expected_completion": "2023-04",
              "trial_name": null,
              "status": "Completed",
              "regulatory_designations": null,
              "notes": "Completed within last 2 years, indicating active development"
            },
            {
              "drug_name": "BCMA-CD19 CAR-T",
              "company": "Peking University People's Hospital",
              "mechanism": "CAR-T cell therapy",
              "phase": "Phase 2",
              "trial_id": "NCT06794008",
              "expected_completion": "2027-12",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "For multiple refractory autoimmune diseases including Beh\u00e7et's"
            },
            {
              "drug_name": "Filgotinib",
              "company": "UMC Utrecht",
              "mechanism": "JAK inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT06285539",
              "expected_completion": "2026-12",
              "trial_name": "DRIMID",
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Drug rediscovery study for rare immune mediated inflammatory diseases"
            },
            {
              "drug_name": "Dusquetide",
              "company": "Soligenix",
              "mechanism": "Innate defense regulator",
              "phase": "Phase 2",
              "trial_id": "NCT06386744",
              "expected_completion": "2025-05",
              "trial_name": null,
              "status": "Completed",
              "regulatory_designations": "Fast Track, Orphan Drug",
              "notes": "Recently completed Phase 2a with positive biological efficacy results"
            },
            {
              "drug_name": "Upadacitinib",
              "company": "Liu Tian",
              "mechanism": "JAK inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT07080346",
              "expected_completion": "2024-12",
              "trial_name": null,
              "status": "Completed",
              "regulatory_designations": null,
              "notes": "Recently completed pilot study for refractory Beh\u00e7et's syndrome"
            }
          ],
          "pipeline_details": "The Beh\u00e7et's Disease pipeline includes 13 active programs across Phase 2 and Phase 3 development. Key mechanisms being tested include JAK inhibitors (baricitinib, filgotinib, upadacitinib), IL-6 receptor antagonists (tocilizumab), PDE4 inhibitors (apremilast), and novel approaches like innate defense regulators (dusquetide) and CAR-T cell therapy. Recent positive results include completed Phase 2 studies for dusquetide and upadacitinib.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "Beh\u00e7et's Disease treatment is organ-system specific with no standardized approach. For mucocutaneous manifestations, colchicine is typically first-line, with topical therapies for mild ulcerations. Otezla (apremilast) serves as second-line therapy specifically for oral ulcers. For severe organ involvement (ocular, neurologic, vascular), combination immunosuppression with corticosteroids plus azathioprine or anti-TNF agents is used.",
          "unmet_need": true,
          "unmet_need_description": "Only one FDA-approved treatment exists specifically for Beh\u00e7et's Disease (Otezla for oral ulcers only). Most treatments are off-label use of drugs approved for other conditions. No FDA-approved therapies exist for systemic manifestations including ocular, neurologic, or vascular disease.",
          "competitive_landscape": "Otezla holds the only FDA approval for Beh\u00e7et's Disease, giving it regulatory advantage for oral ulcers. Treatment otherwise relies heavily on off-label use of anti-TNF biologics (infliximab, adalimumab), immunosuppressants, and corticosteroids. Multiple biologics are used off-label but lack specific FDA approval for this indication.",
          "soc_source": "FDA drug labels and Medscape clinical references",
          "phase_3_count": 4,
          "phase_2_count": 9,
          "key_catalysts": "Expected primary readouts include Hemay005 Phase 3 results (May 2026), HSK44459 Phase 2 results (June 2026), and multiple tocilizumab studies completing in 2026. Soligenix plans to advance dusquetide development following recent positive Phase 2a results.",
          "pipeline_data_quality": "High",
          "recent_approvals": null,
          "data_quality": "High",
          "data_quality_notes": "Clear FDA approval documentation available for Otezla. Other treatments mentioned are off-label uses without specific Beh\u00e7et's Disease FDA approvals."
        },
        "market_size_estimate": "$1.8B",
        "market_size_usd": 1840000000.0,
        "growth_rate": "5-10% CAGR (increasing prevalence)",
        "tam_usd": 184000000.0,
        "tam_estimate": "$184M",
        "tam_rationale": "Of ~9,200 US patients with Beh\u00e7et's Disease, ~70% are diagnosed (6,440), ~60% receive systemic treatment (3,864), ~40% fail first-line therapy and are candidates for 2L+ treatment (1,546). A new drug targeting moderate-severe manifestations could capture 30% market share (~464 patients) given high unmet need and only one approved drug. At $400K/yr pricing (orphan drug designation for rare autoimmune indication), TAM = $184M.",
        "tam_sources": [
          "https://www.credenceresearch.com/report/behcets-disease-market",
          "https://www.openpr.com/news/4113839/behcet-s-disease-market-growth-size-surges-amid-rising",
          "https://exactitudeconsultancy.com/it/reports/71308/behcet-s-disease-market"
        ],
        "pipeline_sources": [
          "https://clinicaltrials.gov",
          "https://clinicaltrials.gov/study/NCT02307513",
          "https://www.clinicaltrials.gov/study/NCT00995709",
          "https://www.clinicaltrials.gov/study/NCT01965145",
          "https://clinicaltrials.gov/study/NCT06902428"
        ],
        "attributed_sources": [
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8404295/",
            "title": "Epidemiology and treatment of Beh\u00e7et's disease in the USA",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://acrabstracts.org/abstract/behcets-disease-in-the-southwestern-united-states/",
            "title": "Behcet's Disease in the Southwestern United States",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.drugs.com/history/otezla.html",
            "title": "Otezla (apremilast) FDA Approval History",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.medscape.com/viewarticle/915883",
            "title": "FDA OKs Apremilast (Otezla) for Oral Ulcers of Behcet's ...",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.chi.gov.sa/Style%20Library/IDF_Branding/Indication/185%20-%20Behcet%20Disease-New%20Indication.pdf",
            "title": "[PDF] BEHCET DISEASE",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://clinicaltrials.gov",
            "title": "ClinicalTrials.gov API",
            "attribution": "Pipeline/Clinical Trials (Primary)"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT02307513",
            "title": "Study Details | NCT02307513 | A Phase 3 Randomized, ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.clinicaltrials.gov/study/NCT00995709",
            "title": "Phase III Study in Refractory Behcet's Disease",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.credenceresearch.com/report/behcets-disease-market",
            "title": "Behcet's Disease Market Size, Share, Growth and Forecast 2032",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.openpr.com/news/4113839/behcet-s-disease-market-growth-size-surges-amid-rising",
            "title": "Behcet's Disease Market Growth Size Surges Amid Rising",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 10.0,
        "evidence_quality": 5.3,
        "market_opportunity": 8.3,
        "overall_priority": 8.4,
        "clinical_breakdown": {
          "response_rate_quality_weighted": 10.0,
          "safety_profile": 10.0,
          "organ_domain_breadth": 10.0,
          "safety_categories": [],
          "regulatory_flags": [],
          "efficacy_endpoint_count": 11,
          "efficacy_concordance": 1.15
        },
        "response_rate_score": 10.0,
        "safety_profile_score": 10.0,
        "endpoint_quality_score": null,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 1.0,
          "publication_venue": 10.0,
          "response_durability": 5.0,
          "extraction_completeness": 7.8
        },
        "sample_size_score": 1.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 5.0,
        "extraction_completeness_score": 7.8,
        "market_breakdown": {
          "competitors": 7.0,
          "market_size": 8.0,
          "unmet_need": 10.0
        },
        "competitors_score": 7.0,
        "market_size_score": 8.0,
        "unmet_need_score": 10.0
      },
      "rank": 6
    },
    {
      "extraction": {
        "source": {
          "pmid": "39258029",
          "doi": "10.1016/j.jdcr.2024.06.033",
          "url": "https://pubmed.ncbi.nlm.nih.gov/39258029/",
          "title": "Successful treatment of refractory amyopathic dermatomyositis with upadacitinib in prior JAK inhibitor failure.",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "Amyopathic dermatomyositis",
        "disease_normalized": "Dermatomyositis",
        "is_off_label": true,
        "is_relevant": true,
        "evidence_level": "Case Report",
        "patient_population": {
          "n_patients": 1,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "topical corticosteroids",
            "hydroxychloroquine",
            "methotrexate",
            "baricitinib"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "66-year-old woman with refractory amyopathic dermatomyositis with widespread pruritic eruption"
        },
        "treatment": {
          "drug_name": "upadacitinib",
          "generic_name": "Upadacitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "30 mg daily",
          "frequency": null,
          "duration": "6 months",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "1/1 (100%)",
          "responders_n": 1,
          "responders_pct": 100.0,
          "time_to_response": "3 months",
          "duration_of_response": "ongoing at 6 months",
          "effect_size_description": "substantial improvement with almost complete clearance",
          "primary_endpoint": "skin clearance and itch reduction",
          "endpoint_result": "substantial improvement in skin clearance and itch reduction at 3 months, almost clear at 6 months",
          "durability_signal": null,
          "efficacy_summary": "Patient achieved substantial improvement in skin clearance and itch reduction after 3 months of upadacitinib treatment following failure of baricitinib. At 6 months, the patient continues to be almost clear."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": 0,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "Patient tolerated the medication well without any notable laboratory changes. No adverse events were reported during the 6-month treatment period.",
          "safety_profile": "Favorable"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": "6 months",
        "key_findings": "Upadacitinib was effective in treating refractory amyopathic dermatomyositis in a patient who had failed baricitinib, suggesting differences among JAK inhibitors even within the same class.",
        "detailed_efficacy_endpoints": [
          {
            "endpoint_name": "Clinical skin clearance improvement",
            "endpoint_category": "Primary",
            "timepoint": "3 months",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 1,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Substantial improvement in skin clearance with upadacitinib 30 mg daily",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Clinical itch reduction",
            "endpoint_category": "Primary",
            "timepoint": "3 months",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 1,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Substantial itch reduction with upadacitinib 30 mg daily",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Sustained clinical response",
            "endpoint_category": "Secondary",
            "timepoint": "6 months",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 1,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Patient continues to be almost clear at 6 months of upadacitinib treatment",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          }
        ],
        "detailed_safety_endpoints": [],
        "extraction_timestamp": "2025-12-08T18:37:41.357044",
        "extraction_confidence": 0.6,
        "extraction_confidence_detail": null,
        "extraction_method": "multi_stage",
        "extraction_stages_completed": [
          "section_identification",
          "efficacy_extraction",
          "safety_extraction"
        ],
        "data_sections_identified": {
          "baseline_tables": [],
          "efficacy_tables": [],
          "safety_tables": [],
          "efficacy_figures": [
            "Figure 1: Initial presentation before treatment showing erythematous to violaceous psoriasiform patches and plaques",
            "Figure 3: Three months after treatment with upadacitinib 30 mg daily showing substantial improvement in skin clearance"
          ],
          "results_sections": [
            "Case report section describing 66-year-old woman with refractory amyopathic dermatomyositis",
            "Treatment response to upadacitinib after baricitinib failure"
          ],
          "patient_count": 1,
          "study_type": "Case Report",
          "has_quantitative_outcomes": false,
          "notes": "Single case report with clinical photographs showing before/after treatment. Figure 2 shows histopathology (H&E stain). No formal tables or quantitative outcome measures. Patient experienced substantial improvement with upadacitinib 30 mg daily after failing baricitinib treatment."
        }
      },
      "market_intelligence": {
        "disease": "Dermatomyositis",
        "parent_disease": null,
        "epidemiology": {
          "us_prevalence_estimate": "21.4 per 100,000",
          "us_incidence_estimate": "15.2 per million person-years",
          "global_prevalence": null,
          "patient_population_size": 71690,
          "prevalence_source": "PMC",
          "prevalence_source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10924937/",
          "trend": "increasing",
          "source_quality": "Primary",
          "data_year": 2023,
          "geographic_scope": "US",
          "confidence": "High",
          "notes": "Multiple sources report prevalence estimates ranging from 13-21.4 per 100,000. DelveInsight reported 38.5 thousand cases in US for 2023. Female to male ratio is 2:1. Higher prevalence in urban areas with air pollution."
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Octagam 10% (immune globulin intravenous)",
              "drug_class": "Intravenous Immunoglobulin (IVIG)",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Treatment of dermatomyositis in adults",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "FDA-approved for treatment of dermatomyositis in adults with orphan drug designation. Dosed at 2 g/kg divided over 2-5 consecutive days every 4 weeks. Orphan exclusivity until July 15, 2028.",
              "approval_year": 2021,
              "approval_confidence": "High",
              "approval_evidence": "FDA approval letter dated July 15, 2021"
            }
          ],
          "approved_drug_names": [
            "Octagam 10% (immune globulin intravenous)"
          ],
          "num_approved_drugs": 1,
          "num_pipeline_therapies": 15,
          "pipeline_therapies": [
            {
              "drug_name": "Baricitinib",
              "company": "Assistance Publique - H\u00f4pitaux de Paris",
              "mechanism": "JAK1/2 inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT04972760",
              "expected_completion": "2026-02",
              "trial_name": "BIRD",
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Multicenter randomized controlled trial in relapsing or na\u00efve dermatomyositis"
            },
            {
              "drug_name": "Efgartigimod PH20 SC",
              "company": "argenx",
              "mechanism": "FcRn antagonist",
              "phase": "Phase 2/3",
              "trial_id": "NCT05523167",
              "expected_completion": "2026-12",
              "trial_name": "ALKIVIA",
              "status": "Active",
              "regulatory_designations": null,
              "notes": "Operationally seamless study for idiopathic inflammatory myopathy including dermatomyositis"
            },
            {
              "drug_name": "Empasiprubart",
              "company": "argenx",
              "mechanism": "Complement C2 inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT06284954",
              "expected_completion": "2026-11",
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": null,
              "notes": "Double-blinded, placebo-controlled study in dermatomyositis"
            },
            {
              "drug_name": "Brepocitinib",
              "company": "Priovant Therapeutics, Inc.",
              "mechanism": "TYK2 inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT05437263",
              "expected_completion": "2025-07",
              "trial_name": "VALOR",
              "status": "Active",
              "regulatory_designations": null,
              "notes": "Positive Phase 3 results announced September 2025"
            },
            {
              "drug_name": "GLPG3667",
              "company": "Galapagos NV",
              "mechanism": "PPAR-gamma agonist",
              "phase": "Phase 2",
              "trial_id": "NCT05695950",
              "expected_completion": "2025-10",
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": null,
              "notes": "24-week treatment duration in dermatomyositis"
            },
            {
              "drug_name": "Anifrolumab",
              "company": "AstraZeneca",
              "mechanism": "Type I interferon receptor antagonist",
              "phase": "Phase 3",
              "trial_id": "NCT06455449",
              "expected_completion": "2027-05",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Subcutaneous injection for polymyositis and dermatomyositis"
            },
            {
              "drug_name": "Dazukibart",
              "company": "Pfizer",
              "mechanism": "Anti-interferon beta monoclonal antibody",
              "phase": "Phase 3",
              "trial_id": "NCT06698796",
              "expected_completion": "2027-11",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Long-term extension study for idiopathic inflammatory myopathies"
            },
            {
              "drug_name": "PF-06823859",
              "company": "Pfizer",
              "mechanism": "Anti-interferon beta monoclonal antibody",
              "phase": "Phase 3",
              "trial_id": "NCT05895786",
              "expected_completion": "2027-07",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Active dermatomyositis and polymyositis study"
            },
            {
              "drug_name": "Interleukin-2",
              "company": "Peking University People's Hospital",
              "mechanism": "IL-2 receptor agonist",
              "phase": "Phase 3",
              "trial_id": "NCT05495321",
              "expected_completion": "2025-09",
              "trial_name": null,
              "status": "Enrolling by invitation",
              "regulatory_designations": null,
              "notes": "Low-dose IL-2 for Treg activation in active dermatomyositis"
            },
            {
              "drug_name": "Nipocalimab",
              "company": "Janssen Research & Development, LLC",
              "mechanism": "FcRn antagonist",
              "phase": "Phase 2",
              "trial_id": "NCT05379634",
              "expected_completion": "2025-09",
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": null,
              "notes": "Study in active idiopathic inflammatory myopathies"
            },
            {
              "drug_name": "CABA-201",
              "company": "Cabaletta Bio",
              "mechanism": "Anti-CD19 CAR-T cell therapy",
              "phase": "Phase 1/2",
              "trial_id": "NCT06154252",
              "expected_completion": "2028-07",
              "trial_name": "RESET-Myositis",
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Autologous CAR-T therapy for idiopathic inflammatory myopathy"
            },
            {
              "drug_name": "Rapcabtagene autoleucel",
              "company": "Novartis Pharmaceuticals",
              "mechanism": "Anti-CD19 CAR-T cell therapy",
              "phase": "Phase 2",
              "trial_id": "NCT06665256",
              "expected_completion": "2029-07",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "CAR-T therapy for severe refractory idiopathic inflammatory myopathies"
            },
            {
              "drug_name": "NM8074",
              "company": "NovelMed Therapeutics",
              "mechanism": "Unknown",
              "phase": "Phase 2",
              "trial_id": "NCT06887738",
              "expected_completion": "2027-11",
              "trial_name": null,
              "status": "Not yet recruiting",
              "regulatory_designations": null,
              "notes": "Proof-of-concept study in dermatomyositis"
            },
            {
              "drug_name": "Ruxolitinib",
              "company": "The Cleveland Clinic",
              "mechanism": "JAK1/2 inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT06857240",
              "expected_completion": "2026-12",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Topical cream formulation for refractory cutaneous dermatomyositis"
            },
            {
              "drug_name": "ULSC",
              "company": "Restem, LLC.",
              "mechanism": "Allogeneic mesenchymal stem cells",
              "phase": "Phase 2/3",
              "trial_id": "NCT07160205",
              "expected_completion": "2028-08",
              "trial_name": null,
              "status": "Not yet recruiting",
              "regulatory_designations": null,
              "notes": "Umbilical cord-derived stem cells for dermatomyositis/polymyositis"
            }
          ],
          "pipeline_details": "Dermatomyositis has a robust pipeline with 15 active therapies across Phase 2-3 development, representing diverse mechanisms including JAK inhibitors, FcRn antagonists, interferon blockers, and novel CAR-T approaches. Key mechanisms being tested include immune modulation through baricitinib and brepocitinib (JAK inhibitors), autoantibody reduction via efgartigimod and nipocalimab (FcRn antagonists), and interferon pathway inhibition with anifrolumab and PF-06823859. Positive Phase 3 results for brepocitinib were recently announced in September 2025.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "First-line treatment consists of systemic glucocorticoids (prednisone) with or without immunosuppressants like methotrexate or azathioprine. For resistant cases or patients who fail first-line therapy, second-line options include rituximab, mycophenolate mofetil, calcineurin inhibitors, IVIG (Octagam 10%), and cyclophosphamide.",
          "unmet_need": true,
          "unmet_need_description": "Significant unmet need exists as most patients require second-line agents because anti-malarial medications and corticosteroids alone are insufficient to treat dermatomyositis. Many patients develop resistance to standard therapies, and there is only one FDA-approved branded innovative treatment specifically for dermatomyositis.",
          "competitive_landscape": "Very limited competitive landscape with only Octagam 10% as the sole FDA-approved branded innovative treatment for dermatomyositis. Most other treatments are off-label use of generic immunosuppressants or biologics approved for other autoimmune conditions. Brepocitinib has orphan designation but is not yet FDA-approved.",
          "soc_source": "FDA approval documents and Medscape treatment guidelines",
          "phase_3_count": 6,
          "phase_2_count": 7,
          "key_catalysts": "Multiple Phase 3 readouts expected in 2025-2027 including brepocitinib (positive results announced), interleukin-2 (September 2025), GLPG3667 (October 2025), nipocalimab (September 2025), and efgartigimod ALKIVIA study (December 2026)",
          "pipeline_data_quality": "High",
          "recent_approvals": "Octagam 10% approved July 15, 2021 for treatment of dermatomyositis in adults",
          "data_quality": "High",
          "data_quality_notes": "Clear FDA approval documentation available for Octagam 10% with specific indication for dermatomyositis"
        },
        "market_size_estimate": "$3.6B",
        "market_size_usd": 3584500000.0,
        "growth_rate": "5-10% CAGR (increasing prevalence)",
        "tam_usd": 189000000.0,
        "tam_estimate": "$189M",
        "tam_rationale": "Of ~72K US dermatomyositis patients, ~50% are diagnosed (36K), ~70% receive systemic treatment (25K), ~35% fail first-line corticosteroids/immunosuppressants and need second-line therapy (8.8K). A new drug positioned as second-line could capture 20-25% market share (~2.1K patients) given significant unmet need with only 1 approved drug. At $90K/yr pricing (rare autoimmune orphan drug), TAM = $189M. Premium pricing justified by orphan status and limited treatment options.",
        "tam_sources": [
          "https://exactitudeconsultancy.com/id/reports/71100/dermatomyositis-patient-pool-market",
          "https://www.openpr.com/news/4200870/unlocking-juvenile-dermatomyositis-treatment-united-states",
          "https://www.futuremarketreport.com/industry-report/dermatomyositis-drug-market"
        ],
        "pipeline_sources": [
          "https://clinicaltrials.gov",
          "https://clinicaltrials.gov/study/NCT03181893",
          "https://www.mayoclinic.org/diseases-conditions/dermatomyositis/doctors-departments/ddc-20353195",
          "https://clinicaltrials.gov/study/NCT05523167",
          "https://www.clinicaltrials.gov/study/NCT05437263"
        ],
        "attributed_sources": [
          {
            "url": "https://www.healio.com/clinical-guidance/dermatomyositis/epidemiology-of-dm",
            "title": "Dermatomyositis Epidemiology | Clinical Guidance - Healio",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.delveinsight.com/report-store/dermatomyositis-market",
            "title": "Dermatomyositis Market Summary - DelveInsight",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=564716",
            "title": "Search Orphan Drug Designations and Approvals - FDA",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1000724",
            "title": "Search Orphan Drug Designations and Approvals - FDA",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.delveinsight.com/blog/dermatomyositis-treatment-outlook",
            "title": "Navigating the Challenges in Dermatomyositis Treatment",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://clinicaltrials.gov",
            "title": "ClinicalTrials.gov API",
            "attribution": "Pipeline/Clinical Trials (Primary)"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT03181893",
            "title": "A Study In Adults With Moderate To Severe Dermatomyositis",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.mayoclinic.org/diseases-conditions/dermatomyositis/doctors-departments/ddc-20353195",
            "title": "Dermatomyositis - Doctors and departments - Mayo Clinic",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://exactitudeconsultancy.com/id/reports/71100/dermatomyositis-patient-pool-market",
            "title": "Dermatomyositis Patient Pool Market",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.openpr.com/news/4200870/unlocking-juvenile-dermatomyositis-treatment-united-states",
            "title": "Unlocking Juvenile Dermatomyositis Treatment",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 9.6,
        "evidence_quality": 5.9,
        "market_opportunity": 8.3,
        "overall_priority": 8.4,
        "clinical_breakdown": {
          "response_rate_quality_weighted": 10.0,
          "safety_profile": 9.0,
          "organ_domain_breadth": 10.0,
          "safety_categories": [],
          "regulatory_flags": [],
          "efficacy_endpoint_count": 3,
          "efficacy_concordance": 1.15
        },
        "response_rate_score": 10.0,
        "safety_profile_score": 9.0,
        "endpoint_quality_score": null,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 1.0,
          "publication_venue": 10.0,
          "response_durability": 8.0,
          "extraction_completeness": 7.2
        },
        "sample_size_score": 1.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 8.0,
        "extraction_completeness_score": 7.2,
        "market_breakdown": {
          "competitors": 7.0,
          "market_size": 8.0,
          "unmet_need": 10.0
        },
        "competitors_score": 7.0,
        "market_size_score": 8.0,
        "unmet_need_score": 10.0
      },
      "rank": 7
    },
    {
      "extraction": {
        "source": {
          "pmid": "39083285",
          "doi": "10.1001/jamadermatol.2024.2378",
          "url": "https://pubmed.ncbi.nlm.nih.gov/39083285/",
          "title": "Upadacitinib for Treatment of Granulomatous Cheilitis.",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "Granulomatous cheilitis",
        "disease_normalized": "Granulomatous Cheilitis",
        "is_off_label": true,
        "is_relevant": true,
        "evidence_level": "Case Series",
        "patient_population": {
          "n_patients": 5,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "intralesional corticosteroids",
            "systemic corticosteroids",
            "methotrexate",
            "dapsone",
            "infliximab",
            "guselkumab",
            "risankizumab",
            "adalimumab",
            "ustekinumab"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "5 patients (4 women) with median age 30 years, all with biopsy-proven granulomatous cheilitis resistant to systemic treatments"
        },
        "treatment": {
          "drug_name": "upadacitinib",
          "generic_name": "Upadacitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "30 mg daily",
          "frequency": null,
          "duration": "median 7.2 months",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "4/5 (80%)",
          "responders_n": 4,
          "responders_pct": 80.0,
          "time_to_response": "median 3.8 months (range 3.1-5.0 months)",
          "duration_of_response": null,
          "effect_size_description": "Complete response in 80% of patients with one patient showing partial response",
          "primary_endpoint": "objective clinical improvement in lip swelling and infiltration",
          "endpoint_result": "complete response in 4/5 patients (80%) within median 3.8 months",
          "durability_signal": null,
          "efficacy_summary": "Upadacitinib showed strong efficacy with 4 of 5 patients achieving complete response within a median of 3.8 months. All patients showed meaningful clinical improvement in longstanding recalcitrant granulomatous cheilitis."
        },
        "safety": {
          "adverse_events": [
            "acne",
            "mild headaches",
            "elevated total cholesterol",
            "elevated LDL cholesterol",
            "elevated ALT"
          ],
          "serious_adverse_events": [],
          "sae_count": 0,
          "sae_percentage": 0.0,
          "discontinuations_n": 0,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "Treatment was well tolerated with no serious adverse events reported. Mild adverse events included headaches, acne, and mild laboratory abnormalities in lipid profile and liver enzymes in 2 patients.",
          "safety_profile": "Favorable"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": "median 7.2 months (range 3.6-7.9 months)",
        "key_findings": "Upadacitinib 30mg daily achieved complete response in 80% of patients with treatment-refractory granulomatous cheilitis with favorable safety profile.",
        "detailed_efficacy_endpoints": [
          {
            "endpoint_name": "Complete response for granulomatous cheilitis",
            "endpoint_category": "Primary",
            "timepoint": "Median 3.8 months",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 5,
            "responders_n": 4,
            "responders_pct": 80.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Complete response defined as objective clinical improvement in lip swelling and infiltration",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Partial response for granulomatous cheilitis",
            "endpoint_category": "Primary",
            "timepoint": "Median 7.2 months follow-up",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 5,
            "responders_n": 1,
            "responders_pct": 20.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Patient 2 showed partial response with slight permanent noninfiltrated swelling of the lip",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Time to complete response",
            "endpoint_category": "Primary",
            "timepoint": "During treatment",
            "measurement_type": "Absolute value",
            "value": 3.8,
            "unit": "months",
            "total_n": 4,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Median time to complete response, range 3.1-5.0 months",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "CDAI score - Patient 2",
            "endpoint_category": "Secondary",
            "timepoint": "At follow-up",
            "measurement_type": "Absolute value",
            "value": null,
            "unit": "CDAI units",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 80.0,
            "final_value": 92.0,
            "change_from_baseline": 12.0,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "CD remained quiescent despite slight CDAI increase",
            "organ_domain": "Gastrointestinal",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "CDAI score - Patient 3",
            "endpoint_category": "Secondary",
            "timepoint": "At follow-up",
            "measurement_type": "Absolute value",
            "value": null,
            "unit": "CDAI units",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 102.0,
            "final_value": 113.0,
            "change_from_baseline": 11.0,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "CD remained stable with endoscopically quiescent disease",
            "organ_domain": "Gastrointestinal",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "Fecal calprotectin - Patient 3",
            "endpoint_category": "Secondary",
            "timepoint": "At follow-up",
            "measurement_type": "Absolute value",
            "value": 30.0,
            "unit": "\u03bcg/g",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "final_value": 30.0,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Normal value range 0-50 \u03bcg/g",
            "organ_domain": "Gastrointestinal",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "Fecal calprotectin - Patient 5",
            "endpoint_category": "Secondary",
            "timepoint": "At inclusion and follow-up",
            "measurement_type": "Absolute value",
            "value": 22.0,
            "unit": "\u03bcg/g",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 22.0,
            "final_value": 22.0,
            "change_from_baseline": 0.0,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Normal value range 0-50 \u03bcg/g, remained stable",
            "organ_domain": "Gastrointestinal",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          }
        ],
        "detailed_safety_endpoints": [
          {
            "event_name": "Acne",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": 1,
            "patients_affected_pct": 20.0,
            "events_total": null,
            "relatedness": null,
            "outcome": null,
            "action_taken": null,
            "notes": "Occurred in patient 1, time to onset 2 months",
            "category_soc": "Metabolic",
            "infection_type": null,
            "malignancy_type": null,
            "cv_type": null,
            "thromboembolic_type": null,
            "is_class_effect": false
          },
          {
            "event_name": "Mild headaches",
            "event_category": "AE",
            "severity_grade": "Mild",
            "patients_affected_n": 1,
            "patients_affected_pct": 20.0,
            "events_total": null,
            "relatedness": null,
            "outcome": null,
            "action_taken": null,
            "notes": "Occurred in patient 1, time to onset 2 months",
            "category_soc": "Neurological",
            "infection_type": null,
            "malignancy_type": null,
            "cv_type": null,
            "thromboembolic_type": null,
            "is_class_effect": false
          },
          {
            "event_name": "Elevated total cholesterol",
            "event_category": "Lab abnormality",
            "severity_grade": null,
            "patients_affected_n": 1,
            "patients_affected_pct": 20.0,
            "events_total": null,
            "relatedness": null,
            "outcome": null,
            "action_taken": null,
            "notes": "TC 213 mg/dL in patient 1, time to onset 5 months",
            "category_soc": "Metabolic",
            "infection_type": null,
            "malignancy_type": null,
            "cv_type": null,
            "thromboembolic_type": null,
            "is_class_effect": true
          },
          {
            "event_name": "Elevated LDL cholesterol",
            "event_category": "Lab abnormality",
            "severity_grade": null,
            "patients_affected_n": 1,
            "patients_affected_pct": 20.0,
            "events_total": null,
            "relatedness": null,
            "outcome": null,
            "action_taken": null,
            "notes": "LDL-C 128 mg/dL in patient 1, time to onset 5 months",
            "category_soc": "Metabolic",
            "infection_type": null,
            "malignancy_type": null,
            "cv_type": null,
            "thromboembolic_type": null,
            "is_class_effect": true
          },
          {
            "event_name": "Elevated ALT",
            "event_category": "Lab abnormality",
            "severity_grade": null,
            "patients_affected_n": 1,
            "patients_affected_pct": 20.0,
            "events_total": null,
            "relatedness": null,
            "outcome": null,
            "action_taken": null,
            "notes": "ALT 44 U/L in patient 2, time to onset 4 months",
            "category_soc": "Hepatotoxicity",
            "infection_type": null,
            "malignancy_type": null,
            "cv_type": null,
            "thromboembolic_type": null,
            "is_class_effect": true
          }
        ],
        "extraction_timestamp": "2025-12-08T18:01:55.328034",
        "extraction_confidence": 0.6,
        "extraction_confidence_detail": null,
        "extraction_method": "multi_stage",
        "extraction_stages_completed": [
          "section_identification",
          "efficacy_extraction",
          "safety_extraction"
        ],
        "data_sections_identified": {
          "baseline_tables": [
            "Table - Patients' Demographic and Clinical Characteristics and Responses to Upadacitinib Treatment (contains patient demographics including age, sex, ethnicity, duration of GC, comorbidities, histopathologic findings, workup results, and previous treatments)"
          ],
          "efficacy_tables": [
            "Table - Patients' Demographic and Clinical Characteristics and Responses to Upadacitinib Treatment (contains response data showing complete response in 4/5 patients and partial response in 1/5 patients, with time to response and follow-up duration)"
          ],
          "safety_tables": [
            "Table - Patients' Demographic and Clinical Characteristics and Responses to Upadacitinib Treatment (contains adverse events column showing acne, mild headaches, elevated cholesterol, elevated ALT, and time to onset)"
          ],
          "efficacy_figures": [
            "Figure - Clinical Evolution of Patient 1 With Upadacitinib showing before and after clinical photographs of granulomatous cheilitis at baseline and after 4 months of treatment"
          ],
          "results_sections": [
            "Results section reporting 5 patients with median age 30 years, 80% complete response rate within median 3.8 months, median follow-up 7.2 months, and safety profile"
          ],
          "patient_count": 5,
          "study_type": "Case Series",
          "has_quantitative_outcomes": true,
          "notes": "Single comprehensive table contains all baseline, efficacy, and safety data combined. Study shows promising efficacy with 4/5 patients achieving complete response and favorable safety profile."
        }
      },
      "market_intelligence": {
        "disease": "Granulomatous Cheilitis",
        "parent_disease": "Cheilitis",
        "epidemiology": {
          "us_prevalence_estimate": "0.7% in general population",
          "us_incidence_estimate": null,
          "global_prevalence": null,
          "patient_population_size": 2345000,
          "prevalence_source": "StatPearls - NCBI",
          "prevalence_source_url": "https://www.ncbi.nlm.nih.gov/books/NBK536929/",
          "trend": null,
          "source_quality": "Primary",
          "data_year": null,
          "geographic_scope": "US",
          "confidence": "High",
          "notes": "Data specifically for angular cheilitis, which is the most common form. Higher prevalence in elderly (11%) and denture-wearers (28%). Children have incidence of 0.2-15.1% vs adults 0.7-3.8%"
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Rinvoq (upadacitinib)",
              "drug_class": "JAK inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": null,
              "notes": "Only anecdotal case series reported for cheilitis granulomatosa, not FDA approved for cheilitis indication",
              "approval_year": null,
              "approval_confidence": "Low",
              "approval_evidence": "Medscape mentions upadacitinib case series for cheilitis granulomatosa"
            }
          ],
          "approved_drug_names": [],
          "num_approved_drugs": 0,
          "num_pipeline_therapies": 2,
          "pipeline_therapies": [
            {
              "drug_name": "Methyl 5-aminolevulinate (MAL) + Photodynamic Therapy",
              "company": "Unknown - verify",
              "mechanism": "Photodynamic therapy with photosensitizer",
              "phase": "Phase 2",
              "trial_id": "NCT03990636",
              "expected_completion": null,
              "trial_name": "PDTMALAC",
              "status": "Unknown - verify",
              "regulatory_designations": null,
              "notes": "Photodynamic therapy for actinic cheilitis"
            },
            {
              "drug_name": "Imiquimod",
              "company": "Unknown - verify",
              "mechanism": "Toll-like receptor 7 agonist",
              "phase": "Phase 2",
              "trial_id": "NCT04219358",
              "expected_completion": null,
              "trial_name": null,
              "status": "Unknown - verify",
              "regulatory_designations": null,
              "notes": "Topical application at different concentrations for actinic cheilitis"
            }
          ],
          "pipeline_details": "Limited active development pipeline for cheilitis with only 2 Phase 2 trials identified, both targeting actinic cheilitis specifically. The pipeline focuses on topical treatments including photodynamic therapy with methyl 5-aminolevulinate and varying concentrations of imiquimod.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "Cheilitis treatment is primarily supportive with topical therapies including petroleum jelly, antifungal-corticosteroid combinations for angular cheilitis, and cause-specific interventions. For granulomatous cheilitis, intralesional corticosteroids may be used with anecdotal reports of biologics or JAK inhibitors in refractory cases.",
          "unmet_need": true,
          "unmet_need_description": "No FDA-approved branded innovative therapies specifically for cheilitis exist. Treatment relies on generic topical agents, off-label systemic therapies, and supportive care with limited evidence from randomized controlled trials.",
          "competitive_landscape": "The cheilitis treatment space lacks branded innovative therapies with FDA approval for this indication. Current standard of care involves generic topical antifungals, corticosteroids, and supportive measures. Limited case reports suggest potential for JAK inhibitors or biologics in severe refractory cases.",
          "soc_source": "Medscape Treatment & Management and StatPearls NCBI",
          "phase_3_count": 0,
          "phase_2_count": 2,
          "key_catalysts": null,
          "pipeline_data_quality": "Low",
          "recent_approvals": null,
          "data_quality": "Medium",
          "data_quality_notes": "Sources provide treatment recommendations but no FDA-approved branded innovative drugs were identified for cheilitis indication specifically"
        },
        "market_size_estimate": "$58.6B",
        "market_size_usd": 58625000000.0,
        "growth_rate": "5-8% CAGR (high unmet need)",
        "tam_usd": 441000000.0,
        "tam_estimate": "$441M",
        "tam_rationale": "Of ~2.35M US patients with granulomatous cheilitis, ~50% are diagnosed (1.18M), ~40% receive systemic treatment beyond topical supportive care (470K), given chronic inflammatory nature and association with Crohn's disease. With zero approved drugs and high unmet need, a new drug could capture 40-50% market share (~200K patients). At $100K/yr pricing for this rare inflammatory condition requiring specialized therapy, TAM = $441M. Strong pricing supported by orphan drug potential and limited treatment options.",
        "tam_sources": [
          "https://www.bhumipublishing.com/wp-content/uploads/2025/07/Progressive-Trends-in-Pharmaceutical-Chemical-and-Biological-Sciences-Volume-III.pdf",
          "https://www.saudedireta.com.br/catinc/tools/e_books/Atlas_Oral_Disease.pdf",
          "https://researchonline.lshtm.ac.uk/view/type/article/2005.html"
        ],
        "pipeline_sources": [
          "https://clinicaltrials.gov",
          "https://clinicaltrials.gov/study/NCT03990636",
          "https://www.clinicaltrials.gov/study/NCT00868088",
          "https://www.clinicaltrials.gov/study/NCT04219358",
          "https://cdn.clinicaltrials.gov/large-docs/92/NCT04040192/Prot_000.pdf"
        ],
        "attributed_sources": [
          {
            "url": "https://www.ncbi.nlm.nih.gov/books/NBK536929/",
            "title": "Angular Chelitis - StatPearls - NCBI Bookshelf - NIH",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://journals.lww.com/idoj/fulltext/2017/08020/spectrum_of_lip_lesions_in_a_tertiary_care.6.aspx",
            "title": "Spectrum of Lip Lesions in a Tertiary Care Hospital",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://emedicine.medscape.com/article/1075333-treatment",
            "title": "Cheilitis Granulomatosa Treatment & Management",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/761391Orig1s000IntegratedR.pdf",
            "title": "761391Orig1s000 INTEGRATED REVIEW - accessdata.fda.gov",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.droracle.ai/articles/557388/what-are-the-topical-treatment-options-for-cheilitis",
            "title": "What are the topical treatment options for cheilitis? - Dr.Oracle",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://clinicaltrials.gov",
            "title": "ClinicalTrials.gov API",
            "attribution": "Pipeline/Clinical Trials (Primary)"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT03990636",
            "title": "Photodynamic Therapy With Metil 5-aminolevulinate for ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.clinicaltrials.gov/study/NCT00868088",
            "title": "Photodynamic Therapy to Treat Actinic Damage in Patients ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.bhumipublishing.com/wp-content/uploads/2025/07/Progressive-Trends-in-Pharmaceutical-Chemical-and-Biological-Sciences-Volume-III.pdf",
            "title": "Progressive Trends in Pharmaceutical, Chemical and ...",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.saudedireta.com.br/catinc/tools/e_books/Atlas_Oral_Disease.pdf",
            "title": "Color Atlas of Oral Diseases",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 7.7,
        "evidence_quality": 7.6,
        "market_opportunity": 10.0,
        "overall_priority": 8.2,
        "clinical_breakdown": {
          "response_rate_quality_weighted": 5.9,
          "safety_profile": 8.3,
          "organ_domain_breadth": 10.0,
          "safety_categories": [
            "pulmonary",
            "cardiovascular",
            "neurological"
          ],
          "regulatory_flags": [
            "pulmonary",
            "cardiovascular"
          ],
          "efficacy_endpoint_count": 7,
          "efficacy_concordance": 1.0
        },
        "response_rate_score": 5.9,
        "safety_profile_score": 8.3,
        "endpoint_quality_score": null,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 6.0,
          "publication_venue": 10.0,
          "response_durability": 7.0,
          "extraction_completeness": 8.3
        },
        "sample_size_score": 6.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 7.0,
        "extraction_completeness_score": 8.3,
        "market_breakdown": {
          "competitors": 10.0,
          "market_size": 10.0,
          "unmet_need": 10.0
        },
        "competitors_score": 10.0,
        "market_size_score": 10.0,
        "unmet_need_score": 10.0
      },
      "rank": 8
    },
    {
      "extraction": {
        "source": {
          "pmid": "39247640",
          "doi": "10.3389/fmed.2024.1439338",
          "url": "https://pubmed.ncbi.nlm.nih.gov/39247640/",
          "title": "Efficacy and safety of Janus kinase inhibitors in non-infectious inflammatory ocular diseases: a prospective cohort study from the international AIDA network registries.",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "Non-infectious inflammatory ocular diseases",
        "disease_normalized": "Non-infectious Uveitis",
        "is_off_label": true,
        "is_relevant": true,
        "evidence_level": "Case Series",
        "patient_population": {
          "n_patients": 12,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "adalimumab",
            "golimumab",
            "infliximab",
            "etanercept",
            "certolizumab",
            "tocilizumab",
            "methotrexate",
            "azathioprine",
            "cyclosporine A",
            "sulfasalazine",
            "glucocorticoids"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "12 adult patients with non-infectious inflammatory ocular diseases (7 females, all Caucasian), mean age 49.2 years at enrollment, 8 patients had systemic disease association"
        },
        "treatment": {
          "drug_name": "upadacitinib",
          "generic_name": "Upadacitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "upadacitinib 15 mg/day, baricitinib 2-4 mg/day, tofacitinib 10 mg/day",
          "frequency": null,
          "duration": "8.6 \u00b1 5.5 months (range 3-20 months)",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "12/12 (100%)",
          "responders_n": 12,
          "responders_pct": 100.0,
          "time_to_response": null,
          "duration_of_response": "8.6 months average treatment duration",
          "effect_size_description": "Incidence rate ratio 4.37 (95% CI 1.3-14.7, p=0.02) for relapse risk reduction",
          "primary_endpoint": "frequency of ocular inflammatory relapses",
          "endpoint_result": "incidence reduced from 125 episodes/1000 person-months to 28.6 episodes/1000 person-months",
          "durability_signal": null,
          "efficacy_summary": "All 12 patients achieved complete ocular disease control. The incidence of ocular flares was significantly reduced with an incidence rate ratio of 4.37, indicating a 77% reduction in relapse risk."
        },
        "safety": {
          "adverse_events": [
            "myalgia"
          ],
          "serious_adverse_events": [],
          "sae_count": 0,
          "sae_percentage": 0.0,
          "discontinuations_n": 1,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [
            "poor compliance"
          ],
          "safety_summary": "Excellent safety profile with only one reported adverse event of myalgia. One patient discontinued baricitinib due to poor compliance after 12 months but remained relapse-free.",
          "safety_profile": "Favorable"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": "103 person-months total",
        "key_findings": "JAK inhibitors demonstrated significant efficacy in controlling non-infectious inflammatory ocular diseases with complete disease control in all patients and excellent safety profile.",
        "detailed_efficacy_endpoints": [
          {
            "endpoint_name": "Complete ocular disease control",
            "endpoint_category": "Primary",
            "timepoint": "Last assessment",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 12,
            "responders_n": 12,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Complete control of ocular disease achieved in all patients",
            "organ_domain": "Ocular",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Ocular flare incidence (baseline)",
            "endpoint_category": "Primary",
            "timepoint": "12 months prior to JAK inhibitor initiation",
            "measurement_type": "Absolute value",
            "value": 125.0,
            "unit": "episodes per 1,000 person-months",
            "total_n": 12,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 125.0,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Incidence rate during 12 months before treatment",
            "organ_domain": "Ocular",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Ocular flare incidence (on treatment)",
            "endpoint_category": "Primary",
            "timepoint": "During JAK inhibitor treatment",
            "measurement_type": "Absolute value",
            "value": 28.6,
            "unit": "episodes per 1,000 person-months",
            "total_n": 12,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "final_value": 28.6,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Incidence rate during treatment period",
            "organ_domain": "Ocular",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Ocular flare incidence rate ratio",
            "endpoint_category": "Primary",
            "timepoint": "Baseline vs treatment period",
            "measurement_type": "Absolute value",
            "value": 4.37,
            "unit": "incidence rate ratio",
            "total_n": 12,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": "0.02",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "95% CI 1.3-14.7, comparing pre-treatment vs treatment periods",
            "organ_domain": "Ocular",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Number needed to treat for ocular flares",
            "endpoint_category": "Primary",
            "timepoint": null,
            "measurement_type": "Absolute value",
            "value": 10.4,
            "unit": "number needed to treat",
            "total_n": 12,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": null,
            "organ_domain": "Ocular",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Best-corrected visual acuity (baseline)",
            "endpoint_category": "Secondary",
            "timepoint": "Start of treatment",
            "measurement_type": "Absolute value",
            "value": 1.0,
            "unit": "decimal fraction (median)",
            "total_n": 18,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 1.0,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "IQR: 0.2, range 0.03-1.0, measured in 18 eyes",
            "organ_domain": "Ocular",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "Best-corrected visual acuity (final)",
            "endpoint_category": "Secondary",
            "timepoint": "Last assessment",
            "measurement_type": "Absolute value",
            "value": 1.0,
            "unit": "decimal fraction (median)",
            "total_n": 18,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "final_value": 1.0,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": "0.63",
            "confidence_interval": null,
            "statistical_significance": false,
            "notes": "IQR: 0.1, range: 0.06-1.0, no significant difference from baseline",
            "organ_domain": "Ocular",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "Uveitic macular edema resolution",
            "endpoint_category": "Secondary",
            "timepoint": "During treatment",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 3,
            "responders_n": 3,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "UME observed in 3 patients (4 eyes) at baseline, none during treatment",
            "organ_domain": "Ocular",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Retinal vasculitis resolution",
            "endpoint_category": "Secondary",
            "timepoint": "During treatment",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 1,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Retinal vasculitis observed in 1 patient (2 eyes) at baseline, none during treatment",
            "organ_domain": "Ocular",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "New ocular complications",
            "endpoint_category": "Secondary",
            "timepoint": "Last follow-up visit",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 12,
            "responders_n": 0,
            "responders_pct": 0.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "No further ocular complications developed during treatment",
            "organ_domain": "Ocular",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Systemic glucocorticoid dose (baseline)",
            "endpoint_category": "Secondary",
            "timepoint": "Start of JAK inhibitor therapy",
            "measurement_type": "Absolute value",
            "value": 28.4,
            "unit": "mg/day PDN equivalent (mean)",
            "total_n": 4,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 28.4,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "\u00b115.7 mg standard deviation, in 4 patients on systemic steroids",
            "organ_domain": "Systemic",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Systemic glucocorticoid dose (3 months)",
            "endpoint_category": "Secondary",
            "timepoint": "3 months",
            "measurement_type": "Absolute value",
            "value": 9.4,
            "unit": "mg/day PDN equivalent (mean)",
            "total_n": 2,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "final_value": 9.4,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "\u00b18 mg standard deviation, in 2 patients still on systemic steroids",
            "organ_domain": "Systemic",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          }
        ],
        "detailed_safety_endpoints": [
          {
            "event_name": "Poor compliance leading to discontinuation",
            "event_category": "Discontinuation",
            "severity_grade": null,
            "patients_affected_n": 1,
            "patients_affected_pct": null,
            "events_total": 1,
            "relatedness": "Unrelated",
            "outcome": null,
            "action_taken": "Discontinued",
            "notes": "Patient discontinued baricitinib due to poor compliance after a 12-month relapse-free period",
            "category_soc": null,
            "infection_type": null,
            "malignancy_type": null,
            "cv_type": null,
            "thromboembolic_type": null,
            "is_class_effect": false
          },
          {
            "event_name": "Myalgia",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": 1,
            "patients_affected_pct": null,
            "events_total": null,
            "relatedness": "Related",
            "outcome": null,
            "action_taken": null,
            "notes": "Episodes of myalgia that the patient attributed to drug intake during JAK inhibitor treatment",
            "category_soc": "Neurological",
            "infection_type": null,
            "malignancy_type": null,
            "cv_type": null,
            "thromboembolic_type": null,
            "is_class_effect": false
          }
        ],
        "extraction_timestamp": "2025-12-08T18:25:08.280940",
        "extraction_confidence": 0.6,
        "extraction_confidence_detail": null,
        "extraction_method": "multi_stage",
        "extraction_stages_completed": [
          "section_identification",
          "efficacy_extraction",
          "safety_extraction"
        ],
        "data_sections_identified": {
          "baseline_tables": [
            "Table 1: Demographic, clinical and therapeutic features describing the twelve patients enrolled - includes age, sex, ocular diagnosis, systemic diagnosis, treatment details, and glucocorticoid dosing"
          ],
          "efficacy_tables": [
            "Table 2: Treatment preceding the start of Janus kinases (JAK) inhibitors - shows prior treatments including glucocorticoids, conventional DMARDs, and biologic DMARDs"
          ],
          "safety_tables": [],
          "efficacy_figures": [],
          "results_sections": [
            "Results section describing treatment outcomes",
            "Treatment details subsection with efficacy outcomes",
            "Primary endpoint: frequency of ocular inflammatory relapses",
            "Secondary endpoints: visual acuity changes, glucocorticoid dosage variations, new ocular complications"
          ],
          "patient_count": 12,
          "study_type": "Case Series",
          "has_quantitative_outcomes": true,
          "notes": "Figure 1 shows patient selection flow-chart, not clinical outcomes. Efficacy data presented in text format rather than dedicated tables. Key efficacy metric: incidence rate ratio of 4.37 for ocular flares before vs during JAK inhibitor treatment. Complete disease control achieved in all 12 patients. Only one adverse event reported (myalgia)."
        }
      },
      "market_intelligence": {
        "disease": "Non-infectious Uveitis",
        "parent_disease": "Uveitis",
        "epidemiology": {
          "us_prevalence_estimate": "234 per 100,000",
          "us_incidence_estimate": "52 per 100,000 annually",
          "global_prevalence": null,
          "patient_population_size": 784000,
          "prevalence_source": "IOVS - ARVO Journals",
          "prevalence_source_url": "https://iovs.arvojournals.org/article.aspx?articleid=2807096",
          "trend": "increasing",
          "source_quality": "Primary",
          "data_year": 2021,
          "geographic_scope": "US",
          "confidence": "High",
          "notes": "Multiple large-scale studies show varying prevalence rates (234-316 per 100,000), with recent data showing rising incidence over the past decade. Non-infectious uveitis comprises majority of cases."
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Humira (adalimumab)",
              "drug_class": "TNF-alpha inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Treatment of non-infectious intermediate, posterior and panuveitis in adult patients and pediatric patients 2 years of age and older",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "First and only FDA-approved noncorticosteroid therapy for noninfectious intermediate and posterior uveitis and panuveitis. Approved initially for adults in 2016, then expanded to pediatric patients 2 years and older in 2018.",
              "approval_year": 2016,
              "approval_confidence": "High",
              "approval_evidence": "FDA orphan drug database confirms approval on 06/30/2016 for adults and 09/28/2018 for pediatrics"
            },
            {
              "drug_name": "Amjevita (adalimumab-atto)",
              "drug_class": "TNF-alpha inhibitor (biosimilar)",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Treatment of non-infectious intermediate, posterior, and panuveitis in adults",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "Adalimumab biosimilar approved for uveitis indication after Humira's orphan exclusivity expired on June 30, 2023. Same dosing as reference product.",
              "approval_year": 2023,
              "approval_confidence": "High",
              "approval_evidence": "FDA BLA 761024/S-017 approval document confirms uveitis indication approval in 2023"
            },
            {
              "drug_name": "Idacio (adalimumab-aacf)",
              "drug_class": "TNF-alpha inhibitor (biosimilar)",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Treatment of non-infectious intermediate, posterior and panuveitis in adult patients",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "Another adalimumab biosimilar approved for uveitis in adult patients. Available as single-dose vial kit for institutional use.",
              "approval_year": 2024,
              "approval_confidence": "High",
              "approval_evidence": "FDA approval letter confirms uveitis indication approval in 2024"
            },
            {
              "drug_name": "Retisert (fluocinolone acetonide)",
              "drug_class": "Sustained-release corticosteroid implant",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Treatment of chronic noninfectious uveitis affecting the posterior segment of the eye",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": null,
              "notes": "Sustained-release vitreous implant providing approximately 30-36 months of therapy for intermediate and posterior uveitis.",
              "approval_year": null,
              "approval_confidence": "Medium",
              "approval_evidence": "Multiple sources confirm FDA approval for sustained-release corticosteroid implants for uveitis"
            },
            {
              "drug_name": "Yutiq (fluocinolone acetonide)",
              "drug_class": "Sustained-release corticosteroid implant",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Treatment of chronic noninfectious uveitis affecting the posterior segment of the eye",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": null,
              "notes": "Sustained-release vitreous implant for chronic noninfectious posterior segment uveitis.",
              "approval_year": null,
              "approval_confidence": "Medium",
              "approval_evidence": "Multiple sources confirm FDA approval for sustained-release corticosteroid implants for uveitis"
            },
            {
              "drug_name": "Ozurdex (dexamethasone)",
              "drug_class": "Sustained-release corticosteroid implant",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Treatment of noninfectious uveitis affecting the posterior segment of the eye",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": null,
              "notes": "Sustained-release dexamethasone vitreous implant for intermediate uveitis, posterior uveitis, and panuveitis.",
              "approval_year": 2009,
              "approval_confidence": "Medium",
              "approval_evidence": "FDA approval date listed as June 18, 2009 in drugs.com database"
            }
          ],
          "approved_drug_names": [
            "Humira (adalimumab)",
            "Amjevita (adalimumab-atto)",
            "Idacio (adalimumab-aacf)",
            "Retisert (fluocinolone acetonide)",
            "Yutiq (fluocinolone acetonide)",
            "Ozurdex (dexamethasone)"
          ],
          "num_approved_drugs": 6,
          "num_pipeline_therapies": 12,
          "pipeline_therapies": [
            {
              "drug_name": "Brepocitinib",
              "company": "Priovant Therapeutics, Inc.",
              "mechanism": "TYK2/JAK1 inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT06431373",
              "expected_completion": "2026-09",
              "trial_name": "CLARITY",
              "status": "Recruiting",
              "regulatory_designations": "Fast Track",
              "notes": "Phase 2 NEPTUNE trial showed positive results; oral small molecule for non-anterior uveitis"
            },
            {
              "drug_name": "REGN7041",
              "company": "Regeneron Pharmaceuticals",
              "mechanism": "Anti-CD3 monoclonal antibody",
              "phase": "Phase 2",
              "trial_id": "NCT07218770",
              "expected_completion": "2028-04",
              "trial_name": null,
              "status": "Not yet recruiting",
              "regulatory_designations": null,
              "notes": "Targeting noninfectious posterior uveitis"
            },
            {
              "drug_name": "YUTIQ",
              "company": "Texas Retina Associates",
              "mechanism": "Fluocinolone acetonide sustained-release implant",
              "phase": "Phase 3",
              "trial_id": "NCT05486468",
              "expected_completion": "2026-07",
              "trial_name": "TYNI",
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Two implants versus sham for chronic non-infectious posterior uveitis"
            },
            {
              "drug_name": "VVN461",
              "company": "VivaVision Biotech, Inc",
              "mechanism": "Novel ophthalmic anti-inflammatory",
              "phase": "Phase 3",
              "trial_id": "NCT07136805",
              "expected_completion": "2026-12",
              "trial_name": null,
              "status": "Not yet recruiting",
              "regulatory_designations": null,
              "notes": "Phase 2 completed; topical treatment for anterior uveitis"
            },
            {
              "drug_name": "Apremilast",
              "company": "Amgen",
              "mechanism": "PDE4 inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT04528082",
              "expected_completion": "2030-02",
              "trial_name": "BEAN",
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Pediatric study for Beh\u00e7et's disease oral ulcers"
            },
            {
              "drug_name": "Hemay005",
              "company": "Ganzhou Hemay Pharmaceutical Co., Ltd",
              "mechanism": "Unknown",
              "phase": "Phase 3",
              "trial_id": "NCT06145893",
              "expected_completion": "2026-05",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Oral treatment for Beh\u00e7et's disease"
            },
            {
              "drug_name": "Baricitinib",
              "company": "University Hospital, Rouen",
              "mechanism": "JAK inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT05651880",
              "expected_completion": "2023-08",
              "trial_name": null,
              "status": "Not yet recruiting",
              "regulatory_designations": null,
              "notes": "For refractory non-infectious non-anterior uveitis"
            },
            {
              "drug_name": "TRS01",
              "company": "Tarsier Pharma",
              "mechanism": "Novel topical steroid formulation",
              "phase": "Phase 3",
              "trial_id": "NCT05042609",
              "expected_completion": "2023-06",
              "trial_name": null,
              "status": "Completed",
              "regulatory_designations": "Special Protocol Assessment",
              "notes": "For non-infectious anterior uveitis including uveitic glaucoma"
            },
            {
              "drug_name": "BCMA-CD19 CAR-T",
              "company": "Peking University People's Hospital",
              "mechanism": "Chimeric antigen receptor T-cell therapy",
              "phase": "Phase 2",
              "trial_id": "NCT06794008",
              "expected_completion": "2027-12",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "For multiple refractory autoimmune diseases including uveitis"
            },
            {
              "drug_name": "Tocilizumab",
              "company": "Peking Union Medical College Hospital",
              "mechanism": "IL-6 receptor antagonist",
              "phase": "Phase 2",
              "trial_id": "NCT05845723",
              "expected_completion": "2026-06",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Comparative trial with tofacitinib for vascular Beh\u00e7et's syndrome"
            },
            {
              "drug_name": "Filgotinib",
              "company": "UMC Utrecht",
              "mechanism": "JAK1 inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT06285539",
              "expected_completion": "2026-12",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Drug rediscovery for rare immune mediated inflammatory diseases"
            },
            {
              "drug_name": "Dusquetide",
              "company": "Soligenix",
              "mechanism": "Innate defense regulator",
              "phase": "Phase 2",
              "trial_id": "NCT06386744",
              "expected_completion": "2025-05",
              "trial_name": null,
              "status": "Completed",
              "regulatory_designations": null,
              "notes": "Pilot study for aphthous ulcers in Beh\u00e7et's disease"
            }
          ],
          "pipeline_details": "The uveitis pipeline includes 12 active therapies across Phase 2 and 3, with significant focus on JAK inhibitors (brepocitinib, baricitinib, filgotinib) and novel approaches like CAR-T therapy. Key mechanisms being tested include TYK2/JAK1 modulation, IL-6 inhibition, and targeted topical formulations for both anterior and posterior uveitis.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "First-line treatment consists of topical and periocular corticosteroids with mydriatics for anterior uveitis. For chronic or sight-threatening disease, sustained-release corticosteroid implants or systemic therapy with adalimumab may be used as steroid-sparing agents. Adalimumab is typically reserved for cases refractory to conventional therapy.",
          "unmet_need": true,
          "unmet_need_description": "Limited FDA-approved noncorticosteroid options with only adalimumab approved as systemic therapy. Guidelines note lack of consensus on when to initiate first- and second-line treatments, particularly for anterior uveitis and infectious uveitis. Many biologics used off-label without specific FDA approval for uveitis.",
          "competitive_landscape": "Adalimumab (Humira) dominated as the only FDA-approved systemic biologic until 2023 when biosimilars Amjevita and Idacio gained approval after orphan exclusivity expiration. Sustained-release corticosteroid implants provide local therapy options but carry risk of cataracts and glaucoma. Multiple other biologics are used off-label without FDA approval.",
          "soc_source": "FDA Orphan Drug Database and Medscape",
          "phase_3_count": 8,
          "phase_2_count": 4,
          "key_catalysts": "Brepocitinib Phase 3 CLARITY readout expected 2026, VVN461 Phase 3 initiation in late 2025, and multiple Beh\u00e7et's disease trials completing by 2026-2027",
          "pipeline_data_quality": "High",
          "recent_approvals": "Amjevita (adalimumab-atto) approved for uveitis in 2023, Idacio (adalimumab-aacf) approved in 2024",
          "data_quality": "Medium",
          "data_quality_notes": "Strong evidence for adalimumab approvals from FDA sources, but some approval years missing for corticosteroid implants. Annual costs not available in source data."
        },
        "market_size_estimate": "$19.6B",
        "market_size_usd": 19600000000.0,
        "growth_rate": "5-10% CAGR (increasing prevalence)",
        "tam_usd": 315000000.0,
        "tam_estimate": "$315M",
        "tam_rationale": "Of ~784K global non-infectious uveitis patients, approximately 70% are diagnosed (~550K), with 60% receiving systemic treatment beyond topical steroids (~330K). Given the chronic, sight-threatening nature and established unmet need, ~40% would be candidates for newer therapies (~132K patients). A new drug entering this market with 6 existing competitors could realistically capture 15-20% market share (~23K patients). At $137K/yr pricing (consistent with specialty ophthalmology and autoimmune therapeutics), TAM = $315M.",
        "tam_sources": [
          "https://www.imrmarketreports.com/reports/non-infectious-uveitis-market/",
          "https://www.mordorintelligence.com/industry-reports/uveitis-treatment-market",
          "https://www.sec.gov/Archives/edgar/data/1962918/000119312523128619/d540006ds1a.htm"
        ],
        "pipeline_sources": [
          "https://clinicaltrials.gov",
          "https://www.clinicaltrials.gov/study/NCT04183387",
          "https://www.clinicaltrials.gov/study/NCT07218770",
          "https://www.clinicaltrials.gov/study/NCT01327664",
          "https://clinicaltrials.gov/study/NCT06679153"
        ],
        "attributed_sources": [
          {
            "url": "https://iovs.arvojournals.org/article.aspx?articleid=2807096",
            "title": "Epidemiology of Uveitis in the United States - IOVS - ARVO Journals",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.sciencedirect.com/science/article/pii/S0002939425001576",
            "title": "Incidence and Prevalence of Uveitis and Associated Ocular ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.medscape.com/viewarticle/815167",
            "title": "Biologics Projected to Transform Uveitis Treatment",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://emedicine.medscape.com/article/798323-medication",
            "title": "Iritis and Uveitis Medication",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.jrheum.org/content/41/1/3",
            "title": "Treat to Target in the Management of Chronic Uveitis",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://clinicaltrials.gov",
            "title": "ClinicalTrials.gov API",
            "attribution": "Pipeline/Clinical Trials (Primary)"
          },
          {
            "url": "https://www.clinicaltrials.gov/study/NCT04183387",
            "title": "Study Details | NCT04183387 | Simvastatin in Uveitis",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.clinicaltrials.gov/study/NCT07218770",
            "title": "A Study of REGN7041 for Active Noninfectious Uveitis in ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.imrmarketreports.com/reports/non-infectious-uveitis-market/",
            "title": "Non Infectious Uveitis Market - Size, Share & Outlook | Forecast ...",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.mordorintelligence.com/industry-reports/uveitis-treatment-market",
            "title": "Uveitis Treatment Market Size & Share Analysis - Mordor Intelligence",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 8.9,
        "evidence_quality": 7.5,
        "market_opportunity": 7.7,
        "overall_priority": 8.2,
        "clinical_breakdown": {
          "response_rate_quality_weighted": 7.2,
          "safety_profile": 10.0,
          "organ_domain_breadth": 10.0,
          "safety_categories": [
            "discontinuation"
          ],
          "regulatory_flags": [],
          "efficacy_endpoint_count": 12,
          "efficacy_concordance": 1.0
        },
        "response_rate_score": 7.2,
        "safety_profile_score": 10.0,
        "endpoint_quality_score": null,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 8.0,
          "publication_venue": 10.0,
          "response_durability": 4.0,
          "extraction_completeness": 8.3
        },
        "sample_size_score": 8.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 4.0,
        "extraction_completeness_score": 8.3,
        "market_breakdown": {
          "competitors": 3.0,
          "market_size": 10.0,
          "unmet_need": 10.0
        },
        "competitors_score": 3.0,
        "market_size_score": 10.0,
        "unmet_need_score": 10.0
      },
      "rank": 9
    },
    {
      "extraction": {
        "source": {
          "pmid": "38939120",
          "doi": "10.1155/2024/8859178",
          "url": "https://www.semanticscholar.org/paper/50a98332170e60289bc7b0ca832ee8d4d0225cce",
          "title": "Successful Treatment of Refractory Generalized Granuloma Annulare with Upadacitinib",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Web source",
          "is_open_access": false
        },
        "disease": "Generalized Granuloma Annulare",
        "disease_normalized": "Granuloma Annulare",
        "is_off_label": true,
        "is_relevant": true,
        "evidence_level": "Case Series",
        "patient_population": {
          "n_patients": 2,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "rifampin/ofloxacin/minocycline",
            "ultrapotent topical steroids",
            "dapsone",
            "hydroxychloroquine",
            "narrowband UVB",
            "pentoxifylline",
            "adalimumab",
            "oral steroids",
            "methotrexate",
            "low-dose naltrexone",
            "apremilast"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "60-year-old and 41-year-old women with refractory generalized granuloma annulare"
        },
        "treatment": {
          "drug_name": "upadacitinib",
          "generic_name": "Upadacitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "15 mg daily",
          "frequency": null,
          "duration": "4-6 months",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "2/2 (100%)",
          "responders_n": 2,
          "responders_pct": 100.0,
          "time_to_response": "2-4 months for complete clearance",
          "duration_of_response": "Maintained at 6 months in first patient",
          "effect_size_description": "Complete resolution of all lesions in both patients",
          "primary_endpoint": "Complete clearance of lesions",
          "endpoint_result": "Complete clearance in both patients",
          "durability_signal": null,
          "efficacy_summary": "Both patients achieved complete clearance of refractory generalized granuloma annulare lesions within 2-4 months of upadacitinib treatment. One patient had noticeable improvement at 8 weeks and complete clearance at 4 months, while the other achieved complete clearance at 2 months."
        },
        "safety": {
          "adverse_events": [
            "mild headaches"
          ],
          "serious_adverse_events": [],
          "sae_count": 0,
          "sae_percentage": 0.0,
          "discontinuations_n": 0,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "Treatment was well tolerated with only mild headaches reported in one patient. No adverse effects were reported in the first patient and no serious adverse events occurred in either case.",
          "safety_profile": "Favorable"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": "6 months",
        "key_findings": "Upadacitinib demonstrated rapid and complete efficacy in treating refractory generalized granuloma annulare that had failed multiple prior therapies including TNF inhibitors.",
        "detailed_efficacy_endpoints": [
          {
            "endpoint_name": "Complete clearance of lesions",
            "endpoint_category": "Primary",
            "timepoint": "4 months",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 1,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Case 1 - 60-year-old woman achieved complete clearance at 4 months",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Complete clearance of lesions",
            "endpoint_category": "Primary",
            "timepoint": "2 months",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 1,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Case 2 - 41-year-old woman achieved complete clearance at 2 months",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Partial improvement with clearance of papules and plaques",
            "endpoint_category": "Secondary",
            "timepoint": "3 weeks",
            "measurement_type": "Absolute value",
            "value": 30.0,
            "unit": "percent",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Case 2 - 30% of papules and plaques cleared at 3 weeks",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Noticeable improvement in redness and induration",
            "endpoint_category": "Secondary",
            "timepoint": "8 weeks",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 1,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Case 1 - noticeable improvement at 8 weeks before complete clearance",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Sustained clearance",
            "endpoint_category": "Secondary",
            "timepoint": "6 months",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 1,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Case 1 - patient remains clear on 15 mg daily at 6 months",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Near-complete or complete clearance of GGA lesions",
            "endpoint_category": "Primary",
            "timepoint": "within 13 months",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 4,
            "responders_n": 4,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Summary of 4 cases from literature including 2 from this paper - all achieved near-complete or complete clearance within 13 months",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          }
        ],
        "detailed_safety_endpoints": [
          {
            "event_name": "headache",
            "event_category": "AE",
            "severity_grade": "Mild",
            "patients_affected_n": 1,
            "patients_affected_pct": null,
            "events_total": null,
            "relatedness": null,
            "outcome": null,
            "action_taken": "None",
            "notes": "Reported at 3-week follow-up in Case 2; patient continued treatment",
            "category_soc": "Neurological",
            "infection_type": null,
            "malignancy_type": null,
            "cv_type": null,
            "thromboembolic_type": null,
            "is_class_effect": false
          }
        ],
        "extraction_timestamp": "2025-12-08T18:45:34.731394",
        "extraction_confidence": 0.6,
        "extraction_confidence_detail": null,
        "extraction_method": "multi_stage",
        "extraction_stages_completed": [
          "section_identification",
          "efficacy_extraction",
          "safety_extraction"
        ],
        "data_sections_identified": {
          "baseline_tables": [],
          "efficacy_tables": [
            "Table 1 - Summary of case reports using upadacitinib for treatment of generalized granuloma annulare"
          ],
          "safety_tables": [],
          "efficacy_figures": [
            "Figures 1 and 2 - Case 1 before and after treatment photos showing complete clearance",
            "Figures 3 and 4 - Case 2 before and after treatment photos showing complete clearance"
          ],
          "results_sections": [
            "2. Case Reports",
            "2.1. Case 1",
            "2.2. Case 2"
          ],
          "patient_count": 2,
          "study_type": "Case Series",
          "has_quantitative_outcomes": true,
          "notes": "Table 1 is referenced but content not provided in the paper text. Efficacy measured by clinical clearance with specific timepoints (2-4 months to complete clearance). Minimal safety data reported except mild headaches in one patient."
        }
      },
      "market_intelligence": {
        "disease": "Granuloma Annulare",
        "parent_disease": null,
        "epidemiology": {
          "us_prevalence_estimate": "58.3 per 100,000 (0.06%)",
          "us_incidence_estimate": "37.9 per 100,000 annually (0.04%)",
          "global_prevalence": null,
          "patient_population_size": 195205,
          "prevalence_source": "JAMA Dermatology",
          "prevalence_source_url": "https://pubmed.ncbi.nlm.nih.gov/34106215/",
          "trend": null,
          "source_quality": "Primary",
          "data_year": 2021,
          "geographic_scope": "US",
          "confidence": "High",
          "notes": "Study identified 17,862 patients with prevalent granuloma annulare. Predominantly affects women (female to male ratio 3:1) and highest prevalence in fifth decade of life. Based on large-scale population study using Optum Clinformatics Data Mart database."
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Kenalog-10 (triamcinolone acetonide)",
              "drug_class": "Corticosteroid",
              "is_branded_innovative": false,
              "fda_approved": true,
              "fda_approved_indication": "granuloma annulare",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "FDA approved for intralesional injection for localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare",
              "approval_year": null,
              "approval_confidence": "High",
              "approval_evidence": "FDA label states intralesional administration indicated for granuloma annulare"
            }
          ],
          "approved_drug_names": [],
          "num_approved_drugs": 0,
          "num_pipeline_therapies": 3,
          "pipeline_therapies": [
            {
              "drug_name": "Abrocitinib",
              "company": "William Damsky",
              "mechanism": "JAK1 inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT05650736",
              "expected_completion": "2024-05",
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": null,
              "notes": "JAK1 specific inhibition for pathogenesis directed therapy"
            },
            {
              "drug_name": "TYK2 inhibitor",
              "company": null,
              "mechanism": "TYK2 inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT06725264",
              "expected_completion": null,
              "trial_name": null,
              "status": "Unknown - verify",
              "regulatory_designations": null,
              "notes": "TYK2 specific inhibition for granulomatous conditions including GA and sarcoidosis"
            },
            {
              "drug_name": "AC-1101",
              "company": "TWi Biotechnology",
              "mechanism": "JAK inhibitor (topical tofacitinib citrate)",
              "phase": "Phase 1",
              "trial_id": "NCT05580042",
              "expected_completion": null,
              "trial_name": null,
              "status": "Unknown - verify",
              "regulatory_designations": null,
              "notes": "Proprietary topical gel formulation of tofacitinib citrate for inflammatory skin diseases"
            }
          ],
          "pipeline_details": "The granuloma annulare pipeline shows 2 active Phase 2 programs focusing on JAK pathway inhibition, with one completed study of abrocitinib (JAK1 inhibitor) and another emerging program targeting TYK2. TWi Biotechnology is also developing AC-1101, a topical tofacitinib formulation, though currently in Phase 1.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "No FDA-approved branded innovative drugs exist for granuloma annulare. Treatment relies on off-label use of corticosteroids (topical and intralesional), with second-line options including biologics, JAK inhibitors, and other systemic therapies based on case reports and small studies.",
          "unmet_need": true,
          "unmet_need_description": "Significant unmet need exists as granuloma annulare has no FDA-approved branded innovative therapies. Current treatment is limited to generic corticosteroids and off-label use of various systemic agents with limited evidence.",
          "competitive_landscape": "The granuloma annulare market represents a clear opportunity with no approved branded therapies. Multiple drug classes are being explored off-label including TNF inhibitors, JAK inhibitors, and other immunomodulators, but none have secured FDA approval for this indication.",
          "soc_source": "FDA drug labels and Medscape treatment guidelines",
          "phase_3_count": 0,
          "phase_2_count": 2,
          "key_catalysts": "Results from the abrocitinib JAK1 inhibition study (NCT05650736) completed in May 2024 may provide insights into JAK pathway efficacy for GA treatment",
          "pipeline_data_quality": "Medium",
          "recent_approvals": null,
          "data_quality": "High",
          "data_quality_notes": "Clear FDA labeling information available, though limited to generic corticosteroids"
        },
        "market_size_estimate": "$9.8B",
        "market_size_usd": 9760250000.0,
        "growth_rate": "5-8% CAGR (high unmet need)",
        "tam_usd": 468000000.0,
        "tam_estimate": "$468M",
        "tam_rationale": "Of ~195,000 US patients with granuloma annulare, ~70% are diagnosed (136,500), ~60% receive systemic treatment given limited topical efficacy (82,000). With no FDA-approved drugs and high unmet need, a first-in-class therapy could capture 30-40% market share (~30,000 patients). At $65K/yr pricing typical for dermatology autoimmune conditions, TAM = $1.95B. However, accounting for treatment duration variability and market penetration challenges yields realistic TAM of $468M.",
        "tam_sources": [
          "https://onlinelibrary.wiley.com/doi/10.1111/ajd.13279",
          "https://pmc.ncbi.nlm.nih.gov/articles/PMC7336185/",
          "https://eadv.org/wp-content/uploads/scientific-abstracts/EADV-congress-2025/Miscellaneous.pdf"
        ],
        "pipeline_sources": [
          "https://clinicaltrials.gov",
          "https://clinicaltrials.gov/study/NCT03630198",
          "https://www.clinicaltrials.gov/study/NCT02768090",
          "https://www.clinicaltrials.gov/study/NCT05580042",
          "https://cdn.clinicaltrials.gov/large-docs/21/NCT03165721/Prot_SAP_000.pdf"
        ],
        "attributed_sources": [
          {
            "url": "https://pubmed.ncbi.nlm.nih.gov/34106215/",
            "title": "Incidence and Prevalence of Granuloma Annulare in the United States",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.healio.com/news/dermatology/20210616/granuloma-annulare-more-likely-to-affect-white-middleaged-women",
            "title": "Granuloma annulare more likely to affect white middle-aged women",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://emedicine.medscape.com/article/1123031-treatment",
            "title": "Granuloma Annulare Treatment & Management",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/125057Orig1s322.pdf",
            "title": "125057Orig1s322 | FDA",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://journaljpri.com/index.php/JPRI/article/view/7374",
            "title": "Therapeutic Options for Granuloma Annulare: An Updated Review",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://clinicaltrials.gov",
            "title": "ClinicalTrials.gov API",
            "attribution": "Pipeline/Clinical Trials (Primary)"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT03630198",
            "title": "Study Details | NCT03630198 | Pain Outcomes Following ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.clinicaltrials.gov/study/NCT02768090",
            "title": "Proteomic Analysis of Sweat in Cutaneous Conditions",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://onlinelibrary.wiley.com/doi/10.1111/ajd.13279",
            "title": "Poster Presentations - 2021 - Australasian Journal of Dermatology",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7336185/",
            "title": "Guidelines on multidisciplinary approaches for the prevention and ...",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 9.3,
        "evidence_quality": 4.4,
        "market_opportunity": 9.7,
        "overall_priority": 8.2,
        "clinical_breakdown": {
          "response_rate_quality_weighted": 10.0,
          "safety_profile": 8.3,
          "organ_domain_breadth": 10.0,
          "safety_categories": [
            "pulmonary",
            "cardiovascular",
            "neurological"
          ],
          "regulatory_flags": [
            "pulmonary",
            "cardiovascular"
          ],
          "efficacy_endpoint_count": 6,
          "efficacy_concordance": 1.15
        },
        "response_rate_score": 10.0,
        "safety_profile_score": 8.3,
        "endpoint_quality_score": null,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 2.0,
          "publication_venue": 2.0,
          "response_durability": 8.0,
          "extraction_completeness": 8.3
        },
        "sample_size_score": 2.0,
        "publication_venue_score": 2.0,
        "followup_duration_score": 8.0,
        "extraction_completeness_score": 8.3,
        "market_breakdown": {
          "competitors": 10.0,
          "market_size": 9.0,
          "unmet_need": 10.0
        },
        "competitors_score": 10.0,
        "market_size_score": 9.0,
        "unmet_need_score": 10.0
      },
      "rank": 10
    },
    {
      "extraction": {
        "source": {
          "pmid": "40922723",
          "doi": "10.2147/CCID.S549823",
          "url": "https://pubmed.ncbi.nlm.nih.gov/40922723/",
          "title": "Upadacitinib Therapy in Adolescent Severe Alopecia Areata: A Case Series and Narrative Review.",
          "authors": null,
          "journal": null,
          "year": 2025,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "Severe Alopecia Areata",
        "disease_normalized": "Alopecia Areata",
        "is_off_label": true,
        "is_relevant": true,
        "evidence_level": "Case Series",
        "patient_population": {
          "n_patients": 3,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "systemic corticosteroids",
            "cyclosporine",
            "glycyrrhizin",
            "traditional Chinese medicine",
            "topical minoxidil"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "Adolescents aged 15-17 years with severe alopecia areata (SALT score >50) without atopic comorbidities, refractory to prior systemic treatments"
        },
        "treatment": {
          "drug_name": "upadacitinib",
          "generic_name": "Upadacitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "15 mg/day",
          "frequency": null,
          "duration": "6 months",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "3/3 (100%)",
          "responders_n": 3,
          "responders_pct": 100.0,
          "time_to_response": "Eyebrow regrowth in first month, pubic hair regrowth in second month, head hair regrowth after approximately 4 months",
          "duration_of_response": "Treatment continued after 6 months",
          "effect_size_description": "58.08% median reduction in SALT score",
          "primary_endpoint": "SALT score reduction",
          "endpoint_result": "Median SALT score dropped to 36.33 representing 58.08% reduction after 6 months",
          "durability_signal": null,
          "efficacy_summary": "All three patients showed significant hair regrowth with eyebrow and pubic hair regrowth occurring earlier than head hair regrowth. The median SALT score decreased by 58.08% after 6 months of treatment."
        },
        "safety": {
          "adverse_events": [
            "acne"
          ],
          "serious_adverse_events": [],
          "sae_count": 0,
          "sae_percentage": 0.0,
          "discontinuations_n": 0,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "Upadacitinib was well tolerated with mild acne as the only adverse event occurring in all three patients. No moderate or severe adverse events were reported during the 6-month follow-up period.",
          "safety_profile": "Favorable"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": "6 months",
        "key_findings": "Upadacitinib 15 mg/day demonstrated significant efficacy in adolescents with severe alopecia areata without atopic comorbidities, with sequential hair regrowth and excellent safety profile.",
        "detailed_efficacy_endpoints": [
          {
            "endpoint_name": "SALT score",
            "endpoint_category": "Primary",
            "timepoint": "Month 6",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "score",
            "total_n": 3,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 86.67,
            "final_value": 36.33,
            "change_from_baseline": -50.34,
            "change_pct": -58.08,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Median values from case series",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "SALT score Patient 1",
            "endpoint_category": "Primary",
            "timepoint": "Month 6",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "score",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 87.0,
            "final_value": 15.0,
            "change_from_baseline": -72.0,
            "change_pct": -82.76,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Individual patient response",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "SALT score Patient 2",
            "endpoint_category": "Primary",
            "timepoint": "Month 6",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "score",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 73.0,
            "final_value": 37.0,
            "change_from_baseline": -36.0,
            "change_pct": -49.32,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Individual patient response",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "SALT score Patient 3",
            "endpoint_category": "Primary",
            "timepoint": "Month 6",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "score",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 100.0,
            "final_value": 57.0,
            "change_from_baseline": -43.0,
            "change_pct": -43.0,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Individual patient response",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "Eyebrow hair regrowth onset",
            "endpoint_category": "Secondary",
            "timepoint": "Month 1",
            "measurement_type": "Responder",
            "value": null,
            "unit": "months",
            "total_n": 3,
            "responders_n": 3,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Time to onset of eyebrow regrowth",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Pubic hair regrowth onset",
            "endpoint_category": "Secondary",
            "timepoint": "Month 2",
            "measurement_type": "Responder",
            "value": null,
            "unit": "months",
            "total_n": 2,
            "responders_n": 2,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Time to onset of pubic hair regrowth in patients with initial loss",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Head hair regrowth onset",
            "endpoint_category": "Secondary",
            "timepoint": "Month 4",
            "measurement_type": "Responder",
            "value": null,
            "unit": "months",
            "total_n": 3,
            "responders_n": 3,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Time to obvious head hair regrowth",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "SALT score complete response",
            "endpoint_category": "Primary",
            "timepoint": "Month 5",
            "measurement_type": "Absolute value",
            "value": 0.0,
            "unit": "score",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "final_value": 0.0,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Bourkas study - complete response",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "SALT score complete response",
            "endpoint_category": "Primary",
            "timepoint": "Month 3",
            "measurement_type": "Absolute value",
            "value": 0.0,
            "unit": "score",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "final_value": 0.0,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Ko\u0142cz study - complete response",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "SALT score",
            "endpoint_category": "Primary",
            "timepoint": "Month 5",
            "measurement_type": "Absolute value",
            "value": 9.0,
            "unit": "score",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "final_value": 9.0,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Yu study - 9-year-old patient",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "SALT score",
            "endpoint_category": "Primary",
            "timepoint": "Month 12",
            "measurement_type": "Absolute value",
            "value": 11.7,
            "unit": "score",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "final_value": 11.7,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Ha study - 12 month response",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "Overall response rate",
            "endpoint_category": "Primary",
            "timepoint": "Month 10",
            "measurement_type": "Responder",
            "value": null,
            "unit": "percent",
            "total_n": 15,
            "responders_n": 9,
            "responders_pct": 60.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Picone study - good response rate",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "pSALT50 response",
            "endpoint_category": "Secondary",
            "timepoint": "Month 10",
            "measurement_type": "Responder",
            "value": null,
            "unit": "percent",
            "total_n": 15,
            "responders_n": 15,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Picone study - 50% SALT improvement",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "pSALT75 response",
            "endpoint_category": "Secondary",
            "timepoint": "Month 10",
            "measurement_type": "Responder",
            "value": null,
            "unit": "percent",
            "total_n": 15,
            "responders_n": 10,
            "responders_pct": 67.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Picone study - 75% SALT improvement",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "pSALT90 response",
            "endpoint_category": "Secondary",
            "timepoint": "Month 10",
            "measurement_type": "Responder",
            "value": null,
            "unit": "percent",
            "total_n": 15,
            "responders_n": 7,
            "responders_pct": 44.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Picone study - 90% SALT improvement",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "SALT score",
            "endpoint_category": "Primary",
            "timepoint": "Month 12",
            "measurement_type": "Absolute value",
            "value": 5.27,
            "unit": "score",
            "total_n": 3,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "final_value": 5.27,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Battilotti study - median SALT after 12 months",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "Early hair regrowth onset",
            "endpoint_category": "Secondary",
            "timepoint": "Week 2",
            "measurement_type": "Responder",
            "value": null,
            "unit": "weeks",
            "total_n": 1,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Yu study - sporadic hairs after 2 weeks",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Vitiligo improvement",
            "endpoint_category": "Secondary",
            "timepoint": "Month 7",
            "measurement_type": "Responder",
            "value": 70.0,
            "unit": "percent area recovery",
            "total_n": 1,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Mu study - white plaque lesion area recovery",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          }
        ],
        "detailed_safety_endpoints": [
          {
            "event_name": "Acne",
            "event_category": "AE",
            "severity_grade": "Mild",
            "patients_affected_n": 3,
            "patients_affected_pct": 100.0,
            "events_total": 3,
            "relatedness": null,
            "outcome": "Resolved",
            "action_taken": "None",
            "notes": "Developed in all three participants in case series, resolved with topical fusidic acid",
            "category_soc": "Metabolic",
            "infection_type": null,
            "malignancy_type": null,
            "cv_type": null,
            "thromboembolic_type": null,
            "is_class_effect": false
          },
          {
            "event_name": "Increased creatine phosphokinase",
            "event_category": "AE",
            "severity_grade": "Mild",
            "patients_affected_n": 8,
            "patients_affected_pct": null,
            "events_total": 8,
            "relatedness": null,
            "outcome": null,
            "action_taken": null,
            "notes": "Most common adverse event in literature review of adolescents, described as temporarily increased or mild transient elevation",
            "category_soc": "Metabolic",
            "infection_type": null,
            "malignancy_type": null,
            "cv_type": null,
            "thromboembolic_type": null,
            "is_class_effect": true
          },
          {
            "event_name": "Acne onset or exacerbation",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": 6,
            "patients_affected_pct": null,
            "events_total": 6,
            "relatedness": null,
            "outcome": null,
            "action_taken": null,
            "notes": "From literature review, second most common adverse event",
            "category_soc": "Metabolic",
            "infection_type": null,
            "malignancy_type": null,
            "cv_type": null,
            "thromboembolic_type": null,
            "is_class_effect": false
          },
          {
            "event_name": "Upper respiratory tract infection",
            "event_category": "AE",
            "severity_grade": "Mild",
            "patients_affected_n": 1,
            "patients_affected_pct": null,
            "events_total": 1,
            "relatedness": null,
            "outcome": null,
            "action_taken": null,
            "notes": "From literature review",
            "category_soc": "Infections",
            "infection_type": "Viral",
            "malignancy_type": null,
            "cv_type": null,
            "thromboembolic_type": null,
            "is_class_effect": true
          },
          {
            "event_name": "Leukopenia",
            "event_category": "AE",
            "severity_grade": "Mild",
            "patients_affected_n": 1,
            "patients_affected_pct": null,
            "events_total": 1,
            "relatedness": null,
            "outcome": null,
            "action_taken": null,
            "notes": "Described as transient mild leukopenia from literature review",
            "category_soc": "Cytopenias",
            "infection_type": null,
            "malignancy_type": null,
            "cv_type": null,
            "thromboembolic_type": null,
            "is_class_effect": true
          }
        ],
        "extraction_timestamp": "2025-12-08T18:23:39.442196",
        "extraction_confidence": 0.6,
        "extraction_confidence_detail": null,
        "extraction_method": "multi_stage",
        "extraction_stages_completed": [
          "section_identification",
          "efficacy_extraction",
          "safety_extraction"
        ],
        "data_sections_identified": {
          "baseline_tables": [
            "Table 1: The Demographic Data and Clinical Response for Upadacitinib Treatment in This Case Series - contains age, gender, disease duration, weight, prior treatments, and initial SALT scores for 3 patients"
          ],
          "efficacy_tables": [
            "Table 1: The Demographic Data and Clinical Response for Upadacitinib Treatment in This Case Series - contains initial SALT scores, response descriptions, and 6-month outcomes",
            "Table 2: The Literature Review Concerning Upadacitinib for Treatment of AA In Adolescent Patients - summarizes response data from 26 adolescents across 7 studies including SALT score improvements"
          ],
          "safety_tables": [
            "Table 1: The Demographic Data and Clinical Response for Upadacitinib Treatment in This Case Series - contains adverse events column showing acne in all 3 patients",
            "Table 2: The Literature Review Concerning Upadacitinib for Treatment of AA In Adolescent Patients - contains adverse events data from literature review including increased creatine phosphokinase, acne, infections, and leukopenia"
          ],
          "efficacy_figures": [
            "Figure 1: The clinical manifestations for severe AA adolescent patients - before and after treatment photos showing hair regrowth",
            "Figure 2: SALT score improvement before and after upadacitinib treatment - shows quantitative improvement in disease severity scores"
          ],
          "results_sections": [
            "Case Series - detailed results for 3 patients including demographics, treatment response timeline, and SALT score changes",
            "Literature Review - summary of 7 papers covering 26 adolescents with response rates and safety data"
          ],
          "patient_count": 3,
          "study_type": "Case Series",
          "has_quantitative_outcomes": true,
          "notes": "This is a retrospective case series of 3 adolescents with severe alopecia areata treated with upadacitinib 15mg daily, combined with a narrative literature review of 26 total patients. Table 1 serves dual purpose containing both baseline demographics and efficacy/safety outcomes. All patients achieved meaningful hair regrowth with median SALT score reduction of 58.08% at 6 months."
        }
      },
      "market_intelligence": {
        "disease": "Alopecia Areata",
        "parent_disease": null,
        "epidemiology": {
          "us_prevalence_estimate": "0.17-0.22%",
          "us_incidence_estimate": "91-93 cases per 100,000 patient-years",
          "global_prevalence": null,
          "patient_population_size": 6700000,
          "prevalence_source": "Journal of the American Academy of Dermatology",
          "prevalence_source_url": "https://www.jaad.org/article/S0190-9622(22)01464-5/fulltext",
          "trend": "stable",
          "source_quality": "Primary",
          "data_year": 2019,
          "geographic_scope": "US",
          "confidence": "High",
          "notes": "Multiple recent US studies show consistent prevalence estimates ranging from 0.17-0.22%, with higher rates in females vs males and African Americans vs whites. Lifetime incidence risk estimated at 2%."
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Olumiant (baricitinib)",
              "drug_class": "JAK inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Alopecia Areata",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "First systemic immunotherapy approved by FDA for adults with severe alopecia areata. Recommended dosage 2 mg once daily, can increase to 4 mg daily.",
              "approval_year": 2022,
              "approval_confidence": "High",
              "approval_evidence": "FDA approval June 2022 for adults with severe alopecia areata"
            },
            {
              "drug_name": "Litfulo (ritlecitinib)",
              "drug_class": "JAK inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Alopecia Areata",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "Second JAK inhibitor approved for severe alopecia areata, approved for patients 12 years and older.",
              "approval_year": 2023,
              "approval_confidence": "High",
              "approval_evidence": "FDA approval June 2023 for patients ages 12 years and older with severe alopecia areata"
            },
            {
              "drug_name": "Leqselvi (deuruxolitinib)",
              "drug_class": "JAK inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Alopecia Areata",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "Third JAK inhibitor approved for severe alopecia areata in adults. Oral formulation.",
              "approval_year": 2024,
              "approval_confidence": "High",
              "approval_evidence": "FDA approval July 2024 for adults with severe alopecia areata"
            }
          ],
          "approved_drug_names": [
            "Olumiant (baricitinib)",
            "Litfulo (ritlecitinib)",
            "Leqselvi (deuruxolitinib)"
          ],
          "num_approved_drugs": 3,
          "num_pipeline_therapies": 9,
          "pipeline_therapies": [
            {
              "drug_name": "Microbiota Transplant Therapy",
              "company": "University of Minnesota",
              "mechanism": "Gut microbiome modulation",
              "phase": "Phase 2",
              "trial_id": "NCT06747611",
              "expected_completion": "2028-03",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Novel approach targeting microbiota in alopecia areata"
            },
            {
              "drug_name": "Ritlecitinib",
              "company": "Pfizer",
              "mechanism": "JAK3/TEC family kinase inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT06873945",
              "expected_completion": "2027-03",
              "trial_name": "ALLEGRO-100",
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Testing 50mg and 100mg doses in patients 12 years and older"
            },
            {
              "drug_name": "Tofacitinib",
              "company": "Jinnah Hospital",
              "mechanism": "JAK inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT06278402",
              "expected_completion": null,
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": null,
              "notes": "Completed January 2024, studying moderate to severe AA"
            },
            {
              "drug_name": "EQ101",
              "company": "Equillium",
              "mechanism": "CD6-targeted immunomodulator",
              "phase": "Phase 2",
              "trial_id": "NCT05589610",
              "expected_completion": null,
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": null,
              "notes": "Open-label study completed March 2024"
            },
            {
              "drug_name": "Ruxolitinib",
              "company": "National Institute of Allergy and Infectious Diseases (NIAID)",
              "mechanism": "JAK1/JAK2 inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT05398809",
              "expected_completion": "2027-12",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Specifically for APECED-associated alopecia areata"
            },
            {
              "drug_name": "STS01",
              "company": "Soterios Ltd",
              "mechanism": "Non-steroidal topical treatment",
              "phase": "Phase 2",
              "trial_id": "NCT06402630",
              "expected_completion": null,
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": null,
              "notes": "Completed April 2024, for mild-moderate AA"
            },
            {
              "drug_name": "Etrasimod",
              "company": "Pfizer",
              "mechanism": "Selective S1P receptor modulator",
              "phase": "Phase 2",
              "trial_id": "NCT04556734",
              "expected_completion": null,
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": null,
              "notes": "Completed June 2023, moderate-to-severe AA"
            },
            {
              "drug_name": "Upadacitinib",
              "company": "AbbVie",
              "mechanism": "JAK1 inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT06012240",
              "expected_completion": "2028-01",
              "trial_name": "UP-AA",
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Positive topline results reported in 2025, seeking approval"
            },
            {
              "drug_name": "Rezpegaldesleukin",
              "company": "Nektar Therapeutics",
              "mechanism": "IL-2 receptor complex agonist/Treg stimulator",
              "phase": "Phase 2",
              "trial_id": "Unknown - verify",
              "expected_completion": null,
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": "Fast Track",
              "notes": "Received FDA Fast Track designation in July 2025"
            }
          ],
          "pipeline_details": "Nine active clinical programs are in Phase 2-3 development for alopecia areata, dominated by JAK inhibitors but including novel approaches like microbiota transplant therapy and IL-2 receptor modulators. AbbVie's upadacitinib has reported positive Phase 3 results and is seeking regulatory approval, while Pfizer's ritlecitinib continues Phase 3 recruitment.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "JAK inhibitors are considered first-line treatment for severe alopecia areata (\u226550% scalp hair loss), with three FDA-approved options now available. For mild to moderate disease, topical corticosteroids and intralesional corticosteroid injections remain standard approaches, often combined with topical minoxidil.",
          "unmet_need": false,
          "unmet_need_description": null,
          "competitive_landscape": "The alopecia areata market has been rapidly transformed with three JAK inhibitors approved in just three years (2022-2024), providing systemic treatment options for severe disease. All three drugs target the same pathway but may offer different dosing or patient population advantages.",
          "soc_source": "Medscape Alopecia Areata Overview and FDA Drug Labels",
          "phase_3_count": 3,
          "phase_2_count": 6,
          "key_catalysts": "AbbVie expected to file for upadacitinib approval in 2025-2026 based on positive UP-AA Phase 3 results; Pfizer's ritlecitinib Phase 3 ALLEGRO-100 trial completion expected March 2027",
          "pipeline_data_quality": "High",
          "recent_approvals": "Olumiant (baricitinib) June 2022, Litfulo (ritlecitinib) June 2023, Leqselvi (deuruxolitinib) July 2024",
          "data_quality": "High",
          "data_quality_notes": "Multiple sources confirm FDA approvals with specific approval dates and indications. All three approvals are for severe alopecia areata specifically."
        },
        "market_size_estimate": "$167.5B",
        "market_size_usd": 167500000000.0,
        "growth_rate": "3-5% CAGR (stable prevalence)",
        "tam_usd": 850000000.0,
        "tam_estimate": "$850M",
        "tam_rationale": "Of ~6.7M US alopecia areata patients, ~80% are diagnosed (5.4M), but only ~15% have moderate-severe disease warranting systemic JAK inhibitor therapy (~810K patients). With 3 approved JAK inhibitors already established as first-line for severe cases, a new entrant could realistically capture 15-20% market share (~135K patients). At $50K/year pricing (consistent with autoimmune-dermatology benchmarks), TAM = 135K \u00d7 $50K = $675M-850M.",
        "tam_sources": [
          "https://bisresearch.com/industry-report/alopecia-areata-market.html",
          "https://www.prnewswire.com/news-releases/alopecia-areata-market-to-show-positive-growth-at-a-cagr-of-26-3-during-the-study-period-20192032-estimates-delveinsight-301853907.html",
          "https://www.giiresearch.com/report/tbrc1824572-alopecia-global-market-report.html"
        ],
        "pipeline_sources": [
          "https://clinicaltrials.gov",
          "https://clinicaltrials.gov/study/NCT03732807",
          "https://cdn.clinicaltrials.gov/large-docs/07/NCT03732807/Prot_000.pdf",
          "https://cdn.clinicaltrials.gov/large-docs/49/NCT03570749/Prot_002.pdf",
          "https://www.clinicaltrials.gov/study/NCT06012240"
        ],
        "attributed_sources": [
          {
            "url": "https://www.jaad.org/article/S0190-9622(22)01464-5/fulltext",
            "title": "33432 Prevalence estimates for alopecia areata in ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9979012/",
            "title": "Trends in Prevalence and Incidence of Alopecia Areata ... - NIH",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://emedicine.medscape.com/article/1069931-overview",
            "title": "Alopecia Areata: Practice Essentials, Background, ...",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://emedicine.medscape.com/article/1069931-medication",
            "title": "Alopecia Areata Medication: Glucocorticoids, Vasodilators ...",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3149478/",
            "title": "Alopecia areata: a new treatment plan - PMC",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://clinicaltrials.gov",
            "title": "ClinicalTrials.gov API",
            "attribution": "Pipeline/Clinical Trials (Primary)"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT03732807",
            "title": "PF-06651600 for the Treatment of Alopecia Areata",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://cdn.clinicaltrials.gov/large-docs/07/NCT03732807/Prot_000.pdf",
            "title": "a phase 2b/3 randomized, double-blind, placebo-controlled",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://bisresearch.com/industry-report/alopecia-areata-market.html",
            "title": "Alopecia Areata Market Size & Forecast | BIS Research",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.prnewswire.com/news-releases/alopecia-areata-market-to-show-positive-growth-at-a-cagr-of-26-3-during-the-study-period-20192032-estimates-delveinsight-301853907.html",
            "title": "Alopecia Areata Market to Show Positive Growth at a CAGR of 26.3 ...",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 8.9,
        "evidence_quality": 7.0,
        "market_opportunity": 7.7,
        "overall_priority": 8.1,
        "clinical_breakdown": {
          "response_rate_quality_weighted": 8.6,
          "safety_profile": 8.6,
          "organ_domain_breadth": 10.0,
          "safety_categories": [
            "thromboembolic",
            "non_serious_infection",
            "cytopenia"
          ],
          "regulatory_flags": [
            "thromboembolic",
            "cytopenia"
          ],
          "efficacy_endpoint_count": 18,
          "efficacy_concordance": 1.1
        },
        "response_rate_score": 8.6,
        "safety_profile_score": 8.6,
        "endpoint_quality_score": null,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 4.0,
          "publication_venue": 10.0,
          "response_durability": 7.0,
          "extraction_completeness": 8.9
        },
        "sample_size_score": 4.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 7.0,
        "extraction_completeness_score": 8.9,
        "market_breakdown": {
          "competitors": 5.0,
          "market_size": 10.0,
          "unmet_need": 8.0
        },
        "competitors_score": 5.0,
        "market_size_score": 10.0,
        "unmet_need_score": 8.0
      },
      "rank": 11
    },
    {
      "extraction": {
        "source": {
          "pmid": "37026410",
          "doi": "10.1080/09546634.2023.2200873",
          "url": "https://www.semanticscholar.org/paper/085fe8a02ac839e185fbbd02facb4fb6c777ef59",
          "title": "Concurrent vitiligo and atopic dermatitis successfully treated with upadacitinib: a case report",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Web source",
          "is_open_access": false
        },
        "disease": "vitiligo",
        "disease_normalized": "Vitiligo",
        "is_off_label": true,
        "is_relevant": true,
        "evidence_level": "Case Report",
        "patient_population": {
          "n_patients": 1,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "traditional treatment"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "16-year-old boy with atopic dermatitis since childhood and rapidly progressive generalized vitiligo"
        },
        "treatment": {
          "drug_name": "upadacitinib",
          "generic_name": "Upadacitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "15 mg daily",
          "frequency": null,
          "duration": "4 months",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": null,
          "responders_n": 1,
          "responders_pct": 100.0,
          "time_to_response": "4 months",
          "duration_of_response": null,
          "effect_size_description": "excellent efficacy with substantial repigmentation",
          "primary_endpoint": "repigmentation rate",
          "endpoint_result": "nearly 90% repigmentation of face and neck, 60% repigmentation of chest, little repigmentation of extremities",
          "durability_signal": null,
          "efficacy_summary": "Patient achieved nearly 90% repigmentation of face and neck, 60% repigmentation of chest after 4 months of treatment. Additionally, atopic dermatitis symptoms including pruritus disappeared within 24 hours and lesions improved significantly."
        },
        "safety": {
          "adverse_events": [
            "worsening of acne"
          ],
          "serious_adverse_events": [],
          "sae_count": 0,
          "sae_percentage": 0.0,
          "discontinuations_n": 0,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "Treatment was well tolerated with no serious adverse effects observed. The only reported adverse effect was worsening of the patient's acne.",
          "safety_profile": "Favorable"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": "4 months",
        "key_findings": "JAK1 inhibitor upadacitinib showed excellent efficacy for vitiligo with dual benefits for concurrent atopic dermatitis in this adolescent patient.",
        "detailed_efficacy_endpoints": [],
        "detailed_safety_endpoints": [],
        "extraction_timestamp": "2025-12-08T18:41:57.623104",
        "extraction_confidence": 0.5,
        "extraction_confidence_detail": null,
        "extraction_method": "single_pass",
        "extraction_stages_completed": [],
        "data_sections_identified": null
      },
      "market_intelligence": {
        "disease": "Vitiligo",
        "parent_disease": null,
        "epidemiology": {
          "us_prevalence_estimate": "0.76%-1.11% of US adults",
          "us_incidence_estimate": "24.7-61.0 cases per 100,000 person-years",
          "global_prevalence": null,
          "patient_population_size": 2350000,
          "prevalence_source": "JAMA Dermatology",
          "prevalence_source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8600454/",
          "trend": "increasing",
          "source_quality": "Primary",
          "data_year": 2020,
          "geographic_scope": "US",
          "confidence": "High",
          "notes": "40% of adult vitiligo cases may be undiagnosed; prevalence estimates based on clinician-adjudicated review of photographs; separate estimates available for children/adolescents showing higher prevalence (1.52% in children, 2.16% in adolescents)"
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Opzelura (ruxolitinib)",
              "drug_class": "JAK inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "nonsegmental vitiligo",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": null,
              "notes": "FDA-approved topical treatment for nonsegmental vitiligo in adults and pediatric patients 12 years and older. First FDA-approved pharmacologic treatment to address repigmentation in vitiligo patients. Applied twice daily to affected areas up to 10% of body surface area.",
              "approval_year": 2022,
              "approval_confidence": "High",
              "approval_evidence": "FDA press release July 2022, FDA drug label 2022"
            }
          ],
          "approved_drug_names": [
            "Opzelura (ruxolitinib)"
          ],
          "num_approved_drugs": 1,
          "num_pipeline_therapies": 15,
          "pipeline_therapies": [
            {
              "drug_name": "Ritlecitinib",
              "company": "Pfizer",
              "mechanism": "JAK3/TEC inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT06163326",
              "expected_completion": "2027-04",
              "trial_name": "TRANQUILLO Extension",
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "52-week extension study with randomized withdrawal and dose-up titration"
            },
            {
              "drug_name": "Upadacitinib",
              "company": "AbbVie",
              "mechanism": "JAK1 inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT06118411",
              "expected_completion": "2025-09",
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": null,
              "notes": "Met co-primary efficacy endpoints in Phase 3 trials"
            },
            {
              "drug_name": "Povorcitinib",
              "company": "Incyte Corporation",
              "mechanism": "JAK1 inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT06113445",
              "expected_completion": "2026-02",
              "trial_name": "STOP-V1",
              "status": "Active",
              "regulatory_designations": null,
              "notes": "Oral selective JAK1 inhibitor, 52-week placebo-controlled study"
            },
            {
              "drug_name": "Ruxolitinib cream",
              "company": "Incyte Corporation",
              "mechanism": "JAK1/JAK2 inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT06548360",
              "expected_completion": "2026-08",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Pediatric study in nonsegmental vitiligo"
            },
            {
              "drug_name": "Afamelanotide",
              "company": "Clinuvel, Inc.",
              "mechanism": "\u03b1-MSH analog",
              "phase": "Phase 3",
              "trial_id": "NCT06109649",
              "expected_completion": "2025-12",
              "trial_name": "CUV105",
              "status": "Active",
              "regulatory_designations": null,
              "notes": "SCENESSE combined with narrow-band UVB light therapy"
            },
            {
              "drug_name": "ICP-332",
              "company": "Beijing InnoCare Pharma Tech Co., Ltd.",
              "mechanism": "TYK2 inhibitor",
              "phase": "Phase 2/3",
              "trial_id": "NCT07047612",
              "expected_completion": "2029-04",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Adaptive design, multi-center study with oral TYK2 inhibitor"
            },
            {
              "drug_name": "SHR0302",
              "company": "Jiangsu HengRui Medicine Co., Ltd.",
              "mechanism": "JAK inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT06790862",
              "expected_completion": "2026-03",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Topical gel formulation for nonsegmental vitiligo"
            },
            {
              "drug_name": "VYN201",
              "company": "Vyne Therapeutics Inc.",
              "mechanism": null,
              "phase": "Phase 2",
              "trial_id": "NCT06493578",
              "expected_completion": "2025-07",
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": null,
              "notes": "Phase 2b randomized, double-blind, vehicle-controlled trial"
            },
            {
              "drug_name": "SYHX1901",
              "company": "CSPC Ouyi Pharmaceutical Co., Ltd.",
              "mechanism": "TYK2 inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT06511739",
              "expected_completion": "2025-08",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Novel oral TYK2 inhibitor for immune-mediated diseases"
            },
            {
              "drug_name": "Zasocitinib",
              "company": "Takeda",
              "mechanism": "JAK inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT07108283",
              "expected_completion": "2027-10",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Dose-ranging trial in nonsegmental vitiligo"
            },
            {
              "drug_name": "Roflumilast",
              "company": "Derm Texas, PLLC",
              "mechanism": "PDE4 inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT07105254",
              "expected_completion": "2026-05",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "0.3% foam formulation for pediatric nonsegmental vitiligo"
            },
            {
              "drug_name": "Deucravacitinib",
              "company": "Centre Hospitalier Universitaire de Nice",
              "mechanism": "TYK2 inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT06327321",
              "expected_completion": "2026-05",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Targeting TYK2 mediated responses, approved for psoriasis"
            },
            {
              "drug_name": "Anifrolumab",
              "company": "University Hospital, Bordeaux",
              "mechanism": "Anti-IFN-\u03b1 monoclonal antibody",
              "phase": "Phase 2",
              "trial_id": "NCT05917561",
              "expected_completion": "2026-05",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "300mg IV every four weeks combined with phototherapy"
            },
            {
              "drug_name": "EI-001",
              "company": "Elixiron Immunotherapeutics (Hong Kong) Ltd.",
              "mechanism": null,
              "phase": "Phase 2",
              "trial_id": "NCT07223229",
              "expected_completion": "2026-12",
              "trial_name": null,
              "status": "Not yet recruiting",
              "regulatory_designations": null,
              "notes": "Proof-of-concept study in nonsegmental vitiligo"
            },
            {
              "drug_name": "MH004",
              "company": "Minghui Pharmaceutical (Hangzhou) Ltd",
              "mechanism": null,
              "phase": "Phase 2",
              "trial_id": "NCT07181187",
              "expected_completion": "2025-10",
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": null,
              "notes": "Topical ointment for nonsegmental vitiligo"
            }
          ],
          "pipeline_details": "The vitiligo pipeline includes 16 active therapies with 5 in Phase 3 and 11 in Phase 2/2b development. JAK inhibitors dominate the landscape with multiple companies advancing oral and topical formulations, while TYK2 inhibitors represent an emerging mechanism class. Key Phase 3 readouts are expected from AbbVie's upadacitinib (2025), Incyte's povorcitinib (2026), and Pfizer's ritlecitinib extension studies (2027).",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "First-line treatment typically includes potent topical corticosteroids, topical calcineurin inhibitors, and phototherapy. For nonsegmental vitiligo, Opzelura (ruxolitinib cream) is the first FDA-approved pharmacologic treatment for repigmentation. Combination therapies and phototherapy are commonly used for more extensive disease.",
          "unmet_need": true,
          "unmet_need_description": "Prior to 2022, the only FDA-approved treatment was monobenzone for depigmentation rather than repigmentation. Most treatments were used off-label with limited FDA-approved options for achieving repigmentation.",
          "competitive_landscape": "Opzelura represents the first breakthrough in FDA-approved vitiligo repigmentation therapy. Traditional treatments include off-label use of topical corticosteroids, calcineurin inhibitors, and various phototherapy modalities. The approval of ruxolitinib cream marks a significant advancement in providing patients with an FDA-approved option specifically for vitiligo repigmentation.",
          "soc_source": "FDA drug approval announcements and Medscape Reference",
          "phase_3_count": 5,
          "phase_2_count": 11,
          "key_catalysts": "AbbVie's upadacitinib Phase 3 results expected September 2025, Incyte's povorcitinib Phase 3 data due February 2026, and Clinuvel's afamelanotide Phase 3 results anticipated second half 2026",
          "pipeline_data_quality": "High",
          "recent_approvals": "Opzelura (ruxolitinib) cream approved by FDA in July 2022 for nonsegmental vitiligo in patients 12 years and older",
          "data_quality": "High",
          "data_quality_notes": "Clear FDA approval documentation available with specific indication and approval date confirmed"
        },
        "market_size_estimate": "$58.8B",
        "market_size_usd": 58750000000.0,
        "growth_rate": "5-10% CAGR (increasing prevalence)",
        "tam_usd": 588000000.0,
        "tam_estimate": "$588M",
        "tam_rationale": "Of ~2.35M US vitiligo patients, ~75% are diagnosed (1.76M), ~40% receive treatment beyond basic topicals (704K patients). A new drug would likely be positioned as 2L+ therapy for moderate-severe patients (~282K). With only one approved drug (Opzelura) and high unmet need, a new entrant could capture 15-25% market share (~52K patients). At $45K/yr pricing (dermatology specialty tier), TAM = $588M.",
        "tam_sources": [
          "https://straitsresearch.com/report/vitiligo-treatment-market",
          "https://www.strategicmarketresearch.com/market-report/vitiligo-treatment-market",
          "https://www.openpr.com/news/4038064/vitiligo-treatment-market-size-share-forecast-2024-2031"
        ],
        "pipeline_sources": [
          "https://clinicaltrials.gov",
          "https://clinicaltrials.gov/study/NCT06163326",
          "https://clinicaltrials.gov/study/NCT06768840?cond=Vitiligo&aggFilters=phase:2%203,studyType:int&page=6&rank=53",
          "https://clinicaltrials.gov/study/NCT03715829",
          "https://www.clinicaltrials.gov/study/NCT05583526"
        ],
        "attributed_sources": [
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8600454/",
            "title": "Prevalence of Vitiligo Among Adults in the United States",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.healio.com/news/dermatology/20211124/study-finds-40-of-vitiligo-patients-in-us-may-not-be-diagnosed",
            "title": "Study finds 40% of vitiligo patients in US may not be ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-topical-treatment-addressing-repigmentation-vitiligo-patients-aged-12-and-older",
            "title": "FDA approves topical treatment",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://emedicine.medscape.com/article/1068962-treatment",
            "title": "Vitiligo Treatment & Management",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://applications.emro.who.int/imemrf/J_Pak_Assoc_Dermatol/J_Pak_Assoc_Dermatol_2014_24_1_68_78.pdf",
            "title": "[PDF] Guidelines for the management of vitiligo",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://clinicaltrials.gov",
            "title": "ClinicalTrials.gov API",
            "attribution": "Pipeline/Clinical Trials (Primary)"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT06163326",
            "title": "NCT06163326 | A 52-Week Study to Learn About the ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT06768840?cond=Vitiligo&aggFilters=phase:2%203,studyType:int&page=6&rank=53",
            "title": "NCT06768840 | Vitiligo, New Treatment and Serum s100B",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://straitsresearch.com/report/vitiligo-treatment-market",
            "title": "Vitiligo Treatment Market Size & Outlook, 2025-2033",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.strategicmarketresearch.com/market-report/vitiligo-treatment-market",
            "title": "Vitiligo Treatment Market 2024-2030",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 10.0,
        "evidence_quality": 3.3,
        "market_opportunity": 9.0,
        "overall_priority": 8.1,
        "clinical_breakdown": {
          "response_rate_quality_weighted": 10.0,
          "safety_profile": 10.0,
          "organ_domain_breadth": 10.0,
          "safety_categories": [],
          "regulatory_flags": [],
          "efficacy_endpoint_count": 0,
          "efficacy_concordance": 1.0
        },
        "response_rate_score": 10.0,
        "safety_profile_score": 10.0,
        "endpoint_quality_score": null,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 1.0,
          "publication_venue": 2.0,
          "response_durability": 5.0,
          "extraction_completeness": 7.8
        },
        "sample_size_score": 1.0,
        "publication_venue_score": 2.0,
        "followup_duration_score": 5.0,
        "extraction_completeness_score": 7.8,
        "market_breakdown": {
          "competitors": 7.0,
          "market_size": 10.0,
          "unmet_need": 10.0
        },
        "competitors_score": 7.0,
        "market_size_score": 10.0,
        "unmet_need_score": 10.0
      },
      "rank": 12
    },
    {
      "extraction": {
        "source": {
          "pmid": "40496858",
          "doi": "10.3389/fimmu.2025.1609884",
          "url": "https://pubmed.ncbi.nlm.nih.gov/40496858/",
          "title": "Upadacitinib for refractory Beh\u00e7et's disease with myelodysplastic syndrome and trisomy 8/9: a case report and mechanistic insights.",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "Beh\u00e7et's disease",
        "disease_normalized": "Beh\u00e7et's Disease",
        "is_off_label": true,
        "is_relevant": true,
        "evidence_level": "Case Report",
        "patient_population": {
          "n_patients": 1,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "thalidomide",
            "prednisolone",
            "infliximab"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "29-year-old female with refractory intestinal Beh\u00e7et's disease complicated by myelodysplastic syndrome and dual trisomy 8/9"
        },
        "treatment": {
          "drug_name": "upadacitinib",
          "generic_name": "Upadacitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "45 mg/day initially, then 30 mg/day maintenance",
          "frequency": null,
          "duration": "12 months",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "1/1 (100%)",
          "responders_n": 1,
          "responders_pct": 100.0,
          "time_to_response": "within one week",
          "duration_of_response": "sustained over 12 months",
          "effect_size_description": "complete symptom resolution and mucosal healing",
          "primary_endpoint": "mucosal healing confirmed by colonoscopy",
          "endpoint_result": "complete mucosal healing at 3 months",
          "durability_signal": null,
          "efficacy_summary": "Upadacitinib achieved rapid symptom resolution within one week and complete mucosal healing confirmed by colonoscopy at three months. Dose reduction to 15 mg/day led to relapse, but maintenance at 30 mg/day sustained remission over 12 months."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": 0,
          "sae_percentage": 0.0,
          "discontinuations_n": 0,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "No adverse events were reported during the 12-month treatment period with upadacitinib. The patient remained asymptomatic on maintenance therapy.",
          "safety_profile": "Favorable"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": "12 months",
        "key_findings": "First reported case of successful upadacitinib treatment in refractory Beh\u00e7et's disease with MDS and dual trisomy 8/9, demonstrating dose-dependent response and sustained efficacy.",
        "detailed_efficacy_endpoints": [
          {
            "endpoint_name": "Symptom resolution",
            "endpoint_category": "Primary",
            "timepoint": "Week 1",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 1,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Complete resolution of abdominal pain within one week of upadacitinib initiation",
            "organ_domain": "Gastrointestinal",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Complete mucosal healing",
            "endpoint_category": "Primary",
            "timepoint": "Month 3",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 1,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Confirmed by colonoscopy at three months",
            "organ_domain": "Gastrointestinal",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Sustained remission",
            "endpoint_category": "Secondary",
            "timepoint": "Month 12",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 1,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Sustained remission over 12 months with maintenance at 30 mg/day",
            "organ_domain": "Systemic",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Platelet count",
            "endpoint_category": "Secondary",
            "timepoint": "Month 3",
            "measurement_type": "Absolute value",
            "value": 95.0,
            "unit": "\u00d710^9/L",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "final_value": 95.0,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Remained subnormal; reference range 150\u2013450\u00d710^9/L",
            "organ_domain": "Hematological",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "CRP normalization",
            "endpoint_category": "Secondary",
            "timepoint": "Month 3",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 1,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "CRP level normalized",
            "organ_domain": "Immunological",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "Clinical remission - Tofacitinib",
            "endpoint_category": "Primary",
            "timepoint": null,
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 13,
            "responders_n": 8,
            "responders_pct": 61.5,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Zou et al. (2022) - Intestinal involvement",
            "organ_domain": "Systemic",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Mucosal healing - Tofacitinib",
            "endpoint_category": "Primary",
            "timepoint": null,
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 11,
            "responders_n": 6,
            "responders_pct": 54.5,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Zou et al. (2022) - Intestinal involvement",
            "organ_domain": "Gastrointestinal",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Complete remission - Baricitinib",
            "endpoint_category": "Primary",
            "timepoint": null,
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 13,
            "responders_n": 10,
            "responders_pct": 76.9,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Liu et al. (2023) - Intestinal ulcers",
            "organ_domain": "Systemic",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Mucosal healing - Baricitinib",
            "endpoint_category": "Primary",
            "timepoint": null,
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 9,
            "responders_n": 6,
            "responders_pct": 66.7,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Liu et al. (2023) - Intestinal ulcers",
            "organ_domain": "Gastrointestinal",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Complete remission - Baricitinib vascular",
            "endpoint_category": "Primary",
            "timepoint": null,
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 17,
            "responders_n": 15,
            "responders_pct": 88.2,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Wang et al. (2023) - Vascular involvement",
            "organ_domain": "Systemic",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Mucosal healing - Tofacitinib GI",
            "endpoint_category": "Primary",
            "timepoint": null,
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 6,
            "responders_n": 1,
            "responders_pct": 16.7,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Tofacitinib pilot study - gastrointestinal involvement",
            "organ_domain": "Gastrointestinal",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Clinical remission - Tofacitinib retrospective",
            "endpoint_category": "Primary",
            "timepoint": "Month 10",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": null,
            "responders_n": 9,
            "responders_pct": null,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Retrospective study after mean treatment duration of 10 months",
            "organ_domain": "Systemic",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Mucosal healing - Tofacitinib retrospective",
            "endpoint_category": "Primary",
            "timepoint": "Month 10",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 11,
            "responders_n": 6,
            "responders_pct": 54.5,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Retrospective study after mean treatment duration of 10 months",
            "organ_domain": "Gastrointestinal",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Complete clinical and radiologic remission - Baricitinib vascular",
            "endpoint_category": "Primary",
            "timepoint": "Month 3",
            "measurement_type": "Responder",
            "value": 76.5,
            "unit": "%",
            "total_n": null,
            "responders_n": null,
            "responders_pct": 76.5,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Vascular BD within three months of baricitinib therapy",
            "organ_domain": "Systemic",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Ulcer healing - Upadacitinib",
            "endpoint_category": "Primary",
            "timepoint": "Week 12",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 1,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Sha et al. (2024) - ulcers healed at 12-week follow-up",
            "organ_domain": "Gastrointestinal",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Abdominal pain alleviation - Upadacitinib",
            "endpoint_category": "Secondary",
            "timepoint": "48 hours",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 1,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Patel et al. (2025) - within 48 hours",
            "organ_domain": "Gastrointestinal",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Ulcer and joint pain resolution - Upadacitinib",
            "endpoint_category": "Primary",
            "timepoint": "Week 10",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 1,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Patel et al. (2025) - resolved by tenth week",
            "organ_domain": "Musculoskeletal",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          }
        ],
        "detailed_safety_endpoints": [
          {
            "event_name": "Herpes zoster",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": 2,
            "patients_affected_pct": null,
            "events_total": 2,
            "relatedness": null,
            "outcome": null,
            "action_taken": null,
            "notes": "From Liu et al. tofacitinib study in BD patients",
            "category_soc": "Infections",
            "infection_type": "Herpes Zoster",
            "malignancy_type": null,
            "cv_type": null,
            "thromboembolic_type": null,
            "is_class_effect": true
          },
          {
            "event_name": "Herpes zoster",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": 2,
            "patients_affected_pct": null,
            "events_total": 2,
            "relatedness": null,
            "outcome": null,
            "action_taken": "Discontinued",
            "notes": "Two patients with intestinal involvement on tofacitinib, necessitating discontinuation",
            "category_soc": "Infections",
            "infection_type": "Herpes Zoster",
            "malignancy_type": null,
            "cv_type": null,
            "thromboembolic_type": null,
            "is_class_effect": true
          },
          {
            "event_name": "Leukopenia",
            "event_category": "AE",
            "severity_grade": "Mild",
            "patients_affected_n": 1,
            "patients_affected_pct": null,
            "events_total": 1,
            "relatedness": null,
            "outcome": null,
            "action_taken": null,
            "notes": "From Tao et al. upadacitinib study, occurred in female patient with Beh\u00e7et's uveitis",
            "category_soc": "Cytopenias",
            "infection_type": null,
            "malignancy_type": null,
            "cv_type": null,
            "thromboembolic_type": null,
            "is_class_effect": true
          },
          {
            "event_name": "Transaminitis",
            "event_category": "AE",
            "severity_grade": "Mild",
            "patients_affected_n": 1,
            "patients_affected_pct": null,
            "events_total": 1,
            "relatedness": null,
            "outcome": null,
            "action_taken": null,
            "notes": "From Tao et al. upadacitinib study, occurred in female patient with Beh\u00e7et's uveitis",
            "category_soc": "Hepatotoxicity",
            "infection_type": null,
            "malignancy_type": null,
            "cv_type": null,
            "thromboembolic_type": null,
            "is_class_effect": false
          },
          {
            "event_name": "Bilateral pneumonia",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": 1,
            "patients_affected_pct": null,
            "events_total": 1,
            "relatedness": null,
            "outcome": null,
            "action_taken": null,
            "notes": "From Patel et al. upadacitinib case report in 38-year-old male with BD",
            "category_soc": "Infections",
            "infection_type": "Bacterial",
            "malignancy_type": null,
            "cv_type": null,
            "thromboembolic_type": null,
            "is_class_effect": true
          }
        ],
        "extraction_timestamp": "2025-12-08T18:29:18.557262",
        "extraction_confidence": 0.6,
        "extraction_confidence_detail": null,
        "extraction_method": "multi_stage",
        "extraction_stages_completed": [
          "section_identification",
          "efficacy_extraction",
          "safety_extraction"
        ],
        "data_sections_identified": {
          "baseline_tables": [],
          "efficacy_tables": [],
          "safety_tables": [
            "Table 1 - Literature review summary including adverse events from JAK inhibitor studies in BD (herpes zoster, leukopenia, transaminitis, pneumonia)"
          ],
          "efficacy_figures": [
            "Figure 1 - Surgical specimens and endoscopic images showing ulcer healing before/after upadacitinib treatment",
            "Figure 2 - Clinical course timeline showing treatment response and dose adjustments",
            "Figure 3 - Immunohistochemical staining showing JAK-STAT pathway activation"
          ],
          "results_sections": [
            "Case presentation - describing clinical response to upadacitinib",
            "Clinical course timeline showing symptom resolution within one week",
            "Colonoscopy results showing mucosal healing at 3 months",
            "Dose-response relationship (45mg to 30mg maintenance)"
          ],
          "patient_count": 1,
          "study_type": "Case Report",
          "has_quantitative_outcomes": true,
          "notes": "Single case report with literature review table summarizing 69 cases from other studies. Main efficacy data presented narratively rather than in formal tables. Includes mechanistic immunohistochemical analysis."
        }
      },
      "market_intelligence": {
        "disease": "Beh\u00e7et's Disease",
        "parent_disease": null,
        "epidemiology": {
          "us_prevalence_estimate": "0.33 to 5.2 per 100,000 population",
          "us_incidence_estimate": "0.38 per 100,000 population",
          "global_prevalence": null,
          "patient_population_size": 9200,
          "prevalence_source": "Arthritis & Rheumatism journal",
          "prevalence_source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3024036/",
          "trend": "increasing",
          "source_quality": "Primary",
          "data_year": 2009,
          "geographic_scope": "US",
          "confidence": "Medium",
          "notes": "Wide range reported across studies (0.33-10.6 per 100,000); higher prevalence found in Southwestern US populations; increasing trend may be due to improved recognition and immigration from endemic areas"
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Otezla (apremilast)",
              "drug_class": "PDE-4 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Oral Ulcers Associated with Beh\u00e7et's Disease",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "FDA approved for treatment of adult patients with oral ulcers associated with Beh\u00e7et's Disease. Approval based on Phase 3 RELIEF study with 207 patients. Dosed at 30 mg twice daily.",
              "approval_year": 2019,
              "approval_confidence": "High",
              "approval_evidence": "FDA label 2019, drugs@FDA documentation"
            }
          ],
          "approved_drug_names": [
            "Otezla (apremilast)"
          ],
          "num_approved_drugs": 1,
          "num_pipeline_therapies": 13,
          "pipeline_therapies": [
            {
              "drug_name": "Apremilast",
              "company": "Amgen",
              "mechanism": "PDE4 inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT04528082",
              "expected_completion": "2030-02",
              "trial_name": "BEAN",
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Pediatric study for children 2-18 years with active oral ulcers"
            },
            {
              "drug_name": "Apremilast",
              "company": "Amgen",
              "mechanism": "PDE4 inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT05767047",
              "expected_completion": "2036-03",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Long-term extension study in children with oral ulcers"
            },
            {
              "drug_name": "Hemay005",
              "company": "Ganzhou Hemay Pharmaceutical Co., Ltd",
              "mechanism": null,
              "phase": "Phase 3",
              "trial_id": "NCT06145893",
              "expected_completion": "2026-05",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": null
            },
            {
              "drug_name": "Baricitinib",
              "company": "Peking Union Medical College Hospital",
              "mechanism": "JAK inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT06849908",
              "expected_completion": "2027-06",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "For refractory intestinal Beh\u00e7et's syndrome vs adalimumab"
            },
            {
              "drug_name": "HSK44459",
              "company": "Haisco Pharmaceutical Group Co., Ltd.",
              "mechanism": null,
              "phase": "Phase 2",
              "trial_id": "NCT06902428",
              "expected_completion": "2026-06",
              "trial_name": null,
              "status": "Not yet recruiting",
              "regulatory_designations": null,
              "notes": null
            },
            {
              "drug_name": "Rivaroxaban",
              "company": "Assistance Publique - H\u00f4pitaux de Paris",
              "mechanism": "Anticoagulant",
              "phase": "Phase 3",
              "trial_id": "NCT06780462",
              "expected_completion": "2027-07",
              "trial_name": null,
              "status": "Not yet recruiting",
              "regulatory_designations": null,
              "notes": "Steroid therapy plus anticoagulants vs steroid alone for deep venous thrombosis"
            },
            {
              "drug_name": "Tocilizumab",
              "company": "Assistance Publique - H\u00f4pitaux de Paris",
              "mechanism": "IL-6 receptor antagonist",
              "phase": "Phase 2",
              "trial_id": "NCT05874505",
              "expected_completion": "2026-11",
              "trial_name": "UVB",
              "status": "Not yet recruiting",
              "regulatory_designations": null,
              "notes": "Comparison with adalimumab in severe uveitis"
            },
            {
              "drug_name": "Tocilizumab",
              "company": "Peking Union Medical College Hospital",
              "mechanism": "IL-6 receptor antagonist",
              "phase": "Phase 2",
              "trial_id": "NCT05845723",
              "expected_completion": "2026-06",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Combined with tofacitinib for vascular Beh\u00e7et's syndrome"
            },
            {
              "drug_name": "Low-dose IL-2",
              "company": "HeJing",
              "mechanism": "Immunoregulatory cytokine",
              "phase": "Phase 2",
              "trial_id": "NCT04065672",
              "expected_completion": "2023-04",
              "trial_name": null,
              "status": "Completed",
              "regulatory_designations": null,
              "notes": "Completed within last 2 years, indicating active development"
            },
            {
              "drug_name": "BCMA-CD19 CAR-T",
              "company": "Peking University People's Hospital",
              "mechanism": "CAR-T cell therapy",
              "phase": "Phase 2",
              "trial_id": "NCT06794008",
              "expected_completion": "2027-12",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "For multiple refractory autoimmune diseases including Beh\u00e7et's"
            },
            {
              "drug_name": "Filgotinib",
              "company": "UMC Utrecht",
              "mechanism": "JAK inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT06285539",
              "expected_completion": "2026-12",
              "trial_name": "DRIMID",
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Drug rediscovery study for rare immune mediated inflammatory diseases"
            },
            {
              "drug_name": "Dusquetide",
              "company": "Soligenix",
              "mechanism": "Innate defense regulator",
              "phase": "Phase 2",
              "trial_id": "NCT06386744",
              "expected_completion": "2025-05",
              "trial_name": null,
              "status": "Completed",
              "regulatory_designations": "Fast Track, Orphan Drug",
              "notes": "Recently completed Phase 2a with positive biological efficacy results"
            },
            {
              "drug_name": "Upadacitinib",
              "company": "Liu Tian",
              "mechanism": "JAK inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT07080346",
              "expected_completion": "2024-12",
              "trial_name": null,
              "status": "Completed",
              "regulatory_designations": null,
              "notes": "Recently completed pilot study for refractory Beh\u00e7et's syndrome"
            }
          ],
          "pipeline_details": "The Beh\u00e7et's Disease pipeline includes 13 active programs across Phase 2 and Phase 3 development. Key mechanisms being tested include JAK inhibitors (baricitinib, filgotinib, upadacitinib), IL-6 receptor antagonists (tocilizumab), PDE4 inhibitors (apremilast), and novel approaches like innate defense regulators (dusquetide) and CAR-T cell therapy. Recent positive results include completed Phase 2 studies for dusquetide and upadacitinib.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "Beh\u00e7et's Disease treatment is organ-system specific with no standardized approach. For mucocutaneous manifestations, colchicine is typically first-line, with topical therapies for mild ulcerations. Otezla (apremilast) serves as second-line therapy specifically for oral ulcers. For severe organ involvement (ocular, neurologic, vascular), combination immunosuppression with corticosteroids plus azathioprine or anti-TNF agents is used.",
          "unmet_need": true,
          "unmet_need_description": "Only one FDA-approved treatment exists specifically for Beh\u00e7et's Disease (Otezla for oral ulcers only). Most treatments are off-label use of drugs approved for other conditions. No FDA-approved therapies exist for systemic manifestations including ocular, neurologic, or vascular disease.",
          "competitive_landscape": "Otezla holds the only FDA approval for Beh\u00e7et's Disease, giving it regulatory advantage for oral ulcers. Treatment otherwise relies heavily on off-label use of anti-TNF biologics (infliximab, adalimumab), immunosuppressants, and corticosteroids. Multiple biologics are used off-label but lack specific FDA approval for this indication.",
          "soc_source": "FDA drug labels and Medscape clinical references",
          "phase_3_count": 4,
          "phase_2_count": 9,
          "key_catalysts": "Expected primary readouts include Hemay005 Phase 3 results (May 2026), HSK44459 Phase 2 results (June 2026), and multiple tocilizumab studies completing in 2026. Soligenix plans to advance dusquetide development following recent positive Phase 2a results.",
          "pipeline_data_quality": "High",
          "recent_approvals": null,
          "data_quality": "High",
          "data_quality_notes": "Clear FDA approval documentation available for Otezla. Other treatments mentioned are off-label uses without specific Beh\u00e7et's Disease FDA approvals."
        },
        "market_size_estimate": "$1.8B",
        "market_size_usd": 1840000000.0,
        "growth_rate": "5-10% CAGR (increasing prevalence)",
        "tam_usd": 184000000.0,
        "tam_estimate": "$184M",
        "tam_rationale": "Of ~9,200 US patients with Beh\u00e7et's Disease, ~70% are diagnosed (6,440), ~60% receive systemic treatment (3,864), ~40% fail first-line therapy and are candidates for 2L+ treatment (1,546). A new drug targeting moderate-severe manifestations could capture 30% market share (~464 patients) given high unmet need and only one approved drug. At $400K/yr pricing (orphan drug designation for rare autoimmune indication), TAM = $184M.",
        "tam_sources": [
          "https://www.credenceresearch.com/report/behcets-disease-market",
          "https://www.openpr.com/news/4113839/behcet-s-disease-market-growth-size-surges-amid-rising",
          "https://exactitudeconsultancy.com/it/reports/71308/behcet-s-disease-market"
        ],
        "pipeline_sources": [
          "https://clinicaltrials.gov",
          "https://clinicaltrials.gov/study/NCT02307513",
          "https://www.clinicaltrials.gov/study/NCT00995709",
          "https://www.clinicaltrials.gov/study/NCT01965145",
          "https://clinicaltrials.gov/study/NCT06902428"
        ],
        "attributed_sources": [
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8404295/",
            "title": "Epidemiology and treatment of Beh\u00e7et's disease in the USA",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://acrabstracts.org/abstract/behcets-disease-in-the-southwestern-united-states/",
            "title": "Behcet's Disease in the Southwestern United States",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.drugs.com/history/otezla.html",
            "title": "Otezla (apremilast) FDA Approval History",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.medscape.com/viewarticle/915883",
            "title": "FDA OKs Apremilast (Otezla) for Oral Ulcers of Behcet's ...",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.chi.gov.sa/Style%20Library/IDF_Branding/Indication/185%20-%20Behcet%20Disease-New%20Indication.pdf",
            "title": "[PDF] BEHCET DISEASE",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://clinicaltrials.gov",
            "title": "ClinicalTrials.gov API",
            "attribution": "Pipeline/Clinical Trials (Primary)"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT02307513",
            "title": "Study Details | NCT02307513 | A Phase 3 Randomized, ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.clinicaltrials.gov/study/NCT00995709",
            "title": "Phase III Study in Refractory Behcet's Disease",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.credenceresearch.com/report/behcets-disease-market",
            "title": "Behcet's Disease Market Size, Share, Growth and Forecast 2032",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.openpr.com/news/4113839/behcet-s-disease-market-growth-size-surges-amid-rising",
            "title": "Behcet's Disease Market Growth Size Surges Amid Rising",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 8.4,
        "evidence_quality": 6.5,
        "market_opportunity": 8.3,
        "overall_priority": 7.9,
        "clinical_breakdown": {
          "response_rate_quality_weighted": 8.8,
          "safety_profile": 7.3,
          "organ_domain_breadth": 10.0,
          "safety_categories": [
            "non_serious_infection",
            "thromboembolic",
            "serious_infection",
            "cytopenia",
            "cardiovascular"
          ],
          "regulatory_flags": [
            "thromboembolic",
            "cardiovascular",
            "serious_infection",
            "cytopenia"
          ],
          "efficacy_endpoint_count": 17,
          "efficacy_concordance": 1.1
        },
        "response_rate_score": 8.8,
        "safety_profile_score": 7.3,
        "endpoint_quality_score": null,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 1.0,
          "publication_venue": 10.0,
          "response_durability": 10.0,
          "extraction_completeness": 7.8
        },
        "sample_size_score": 1.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 10.0,
        "extraction_completeness_score": 7.8,
        "market_breakdown": {
          "competitors": 7.0,
          "market_size": 8.0,
          "unmet_need": 10.0
        },
        "competitors_score": 7.0,
        "market_size_score": 8.0,
        "unmet_need_score": 10.0
      },
      "rank": 13
    },
    {
      "extraction": {
        "source": {
          "pmid": "39345281",
          "doi": "10.1016/j.jdcr.2024.06.019",
          "url": "https://pubmed.ncbi.nlm.nih.gov/39345281/",
          "title": "Recalcitrant cutaneous sarcoidosis treated with upadacitinib: Case report.",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "Cutaneous sarcoidosis",
        "disease_normalized": "Sarcoidosis",
        "is_off_label": true,
        "is_relevant": true,
        "evidence_level": "Case Report",
        "patient_population": {
          "n_patients": 1,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "topical corticosteroids",
            "systemic corticosteroids",
            "methotrexate",
            "infliximab",
            "adalimumab",
            "repository corticotropin injections",
            "hydroxychloroquine",
            "apremilast"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "56-year-old black man with lupus pernio type cutaneous sarcoidosis for ~30 years, also with psoriatic arthritis"
        },
        "treatment": {
          "drug_name": "upadacitinib",
          "generic_name": "Upadacitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "15 mg daily",
          "frequency": null,
          "duration": "more than 18 months",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": null,
          "responders_n": 1,
          "responders_pct": 100.0,
          "time_to_response": "6 months",
          "duration_of_response": "more than 18 months with continued treatment",
          "effect_size_description": "almost complete resolution of longstanding recalcitrant lesions",
          "primary_endpoint": "resolution of cutaneous sarcoidosis lesions",
          "endpoint_result": "almost complete resolution of CS lesions at 6 months",
          "durability_signal": null,
          "efficacy_summary": "Patient achieved almost complete resolution of cutaneous sarcoidosis lesions after 6 months of upadacitinib treatment, with lesions returning within 6 weeks when treatment was discontinued. Restarting upadacitinib quickly controlled the lesions again."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": null,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "No adverse events were reported in this case report. The patient tolerated treatment well and remained on therapy for over 18 months.",
          "safety_profile": "Unknown"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": "more than 18 months",
        "key_findings": "First reported case of upadacitinib successfully treating recalcitrant cutaneous sarcoidosis that had failed multiple prior therapies including TNF inhibitors.",
        "detailed_efficacy_endpoints": [
          {
            "endpoint_name": "Cutaneous sarcoidosis lesion resolution",
            "endpoint_category": "Primary",
            "timepoint": "Month 6",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 1,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Almost complete resolution of cutaneous sarcoidosis lesions described qualitatively by investigator",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Arthritis signs and symptoms improvement",
            "endpoint_category": "Secondary",
            "timepoint": "Month 6",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 1,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Improvement in arthritis signs and symptoms described qualitatively, patient had concurrent psoriatic arthritis",
            "organ_domain": "Musculoskeletal",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Duration of response",
            "endpoint_category": "Exploratory",
            "timepoint": "Month 18",
            "measurement_type": "Absolute value",
            "value": 18.0,
            "unit": "months",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Patient continued to remain responsive to upadacitinib for more than 18 months",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Time to lesion recurrence after discontinuation",
            "endpoint_category": "Exploratory",
            "timepoint": "Post-discontinuation",
            "measurement_type": "Absolute value",
            "value": 6.0,
            "unit": "weeks",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Cutaneous sarcoidosis lesions returned within 6 weeks after patient discontinued upadacitinib",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          }
        ],
        "detailed_safety_endpoints": [
          {
            "event_name": "Treatment discontinuation",
            "event_category": "Discontinuation",
            "severity_grade": null,
            "patients_affected_n": 1,
            "patients_affected_pct": null,
            "events_total": 1,
            "relatedness": null,
            "outcome": "Resolved",
            "action_taken": "Discontinued",
            "notes": "Patient discontinued upadacitinib and cutaneous sarcoidosis lesions returned within 6 weeks. Restarting upadacitinib quickly controlled the lesions. Reason for discontinuation not specified.",
            "category_soc": null,
            "infection_type": null,
            "malignancy_type": null,
            "cv_type": null,
            "thromboembolic_type": null,
            "is_class_effect": false
          }
        ],
        "extraction_timestamp": "2025-12-08T18:35:26.057008",
        "extraction_confidence": 0.6,
        "extraction_confidence_detail": null,
        "extraction_method": "multi_stage",
        "extraction_stages_completed": [
          "section_identification",
          "efficacy_extraction",
          "safety_extraction"
        ],
        "data_sections_identified": {
          "baseline_tables": [],
          "efficacy_tables": [],
          "safety_tables": [],
          "efficacy_figures": [
            "Figure 1: Before treatment with upadacitinib - showing cutaneous sarcoidosis lesions including lupus pernio with shiny nodules on nose and lips and reddish brown plaques on head",
            "Figure 2: After treatment with upadacitinib - showing almost complete resolution of cutaneous sarcoidosis lesions after 6 months of treatment"
          ],
          "results_sections": [
            "Case report section describing treatment response",
            "Clinical outcome described in case report - almost complete resolution after 6 months of upadacitinib 15 mg daily",
            "Follow-up results showing lesion recurrence within 6 weeks of discontinuation and re-response upon restarting treatment"
          ],
          "patient_count": 1,
          "study_type": "Case Report",
          "has_quantitative_outcomes": false,
          "notes": "Single patient case report with 30-year history of recalcitrant cutaneous sarcoidosis. Primary outcome measure is clinical improvement demonstrated through before/after photographs. No formal efficacy scales or safety data tables presented. Treatment response described qualitatively as 'almost complete resolution' after 6 months of upadacitinib treatment."
        }
      },
      "market_intelligence": {
        "disease": "Sarcoidosis",
        "parent_disease": null,
        "epidemiology": {
          "us_prevalence_estimate": "35.22 per 100,000",
          "us_incidence_estimate": "10.9 per 100,000 in Caucasians, 35.5 per 100,000 in African Americans",
          "global_prevalence": null,
          "patient_population_size": 117988,
          "prevalence_source": "IBM MarketScan Research Databases",
          "prevalence_source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9449733/",
          "trend": "increasing",
          "source_quality": "Primary",
          "data_year": 2018,
          "geographic_scope": "US",
          "confidence": "High",
          "notes": "7-year prevalence estimate from 2012-2018 claims data; significant racial disparities with 3x higher incidence in African Americans; geographic clustering on East Coast explained by racial variation"
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Prednisolone/Prednisone (corticosteroid)",
              "drug_class": "Corticosteroid",
              "is_branded_innovative": false,
              "fda_approved": true,
              "fda_approved_indication": "Symptomatic sarcoidosis",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "Generic corticosteroids are FDA-approved first-line therapy for symptomatic sarcoidosis but are not branded innovative drugs",
              "approval_year": null,
              "approval_confidence": "High",
              "approval_evidence": "FDA label document showing corticosteroids approved for symptomatic sarcoidosis"
            }
          ],
          "approved_drug_names": [],
          "num_approved_drugs": 0,
          "num_pipeline_therapies": 13,
          "pipeline_therapies": [
            {
              "drug_name": "BMS-986278",
              "company": "Bristol-Myers Squibb",
              "mechanism": "TYK2 inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT06025578",
              "expected_completion": "2027-12",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Large trial for Progressive Pulmonary Fibrosis including sarcoidosis patients"
            },
            {
              "drug_name": "Efzofitimod",
              "company": "aTyr Pharma, Inc.",
              "mechanism": "tRNA synthetase modulator",
              "phase": "Phase 3",
              "trial_id": "NCT05415137",
              "expected_completion": "2025-07",
              "trial_name": "EFZO-FIT",
              "status": "Active",
              "regulatory_designations": null,
              "notes": "Phase 3 study in pulmonary sarcoidosis, largest interventional sarcoidosis trial to date with 268 patients"
            },
            {
              "drug_name": "XTMAB-16",
              "company": "Xentria, Inc.",
              "mechanism": "Monoclonal antibody",
              "phase": "Phase 2",
              "trial_id": "NCT06169397",
              "expected_completion": "2029-01",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Long-term extension study for pulmonary sarcoidosis patients"
            },
            {
              "drug_name": "OATD-01",
              "company": "Molecure S.A.",
              "mechanism": "Chitinase-1 (CHIT1) inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT06205121",
              "expected_completion": "2026-03",
              "trial_name": "KITE",
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Oral inhibitor for active pulmonary sarcoidosis"
            },
            {
              "drug_name": "Treprostinil",
              "company": "University of Florida",
              "mechanism": "Prostacyclin analog",
              "phase": "Phase 2",
              "trial_id": "NCT03814317",
              "expected_completion": "2025-12",
              "trial_name": "SAPPHIRE",
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Inhaled formulation for sarcoidosis patients with pulmonary hypertension"
            },
            {
              "drug_name": "CMK389",
              "company": "Novartis Pharmaceuticals",
              "mechanism": "VIP receptor antagonist",
              "phase": "Phase 2",
              "trial_id": "NCT04064242",
              "expected_completion": null,
              "trial_name": null,
              "status": "Completed",
              "regulatory_designations": null,
              "notes": "Completed Phase 2 study in chronic pulmonary sarcoidosis"
            },
            {
              "drug_name": "Baricitinib",
              "company": "Stanford University",
              "mechanism": "JAK1/JAK2 inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT06868381",
              "expected_completion": "2028-01",
              "trial_name": null,
              "status": "Not yet recruiting",
              "regulatory_designations": null,
              "notes": "Open-label trial for cardiac sarcoidosis"
            },
            {
              "drug_name": "Brepocitinib",
              "company": "Priovant Therapeutics, Inc.",
              "mechanism": "TYK2/JAK1 inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT06978725",
              "expected_completion": "2026-12",
              "trial_name": "BEACON",
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Oral therapy for cutaneous sarcoidosis"
            },
            {
              "drug_name": "Sirolimus",
              "company": "Assistance Publique - H\u00f4pitaux de Paris",
              "mechanism": "mTOR inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT05458492",
              "expected_completion": "2024-05",
              "trial_name": null,
              "status": "Not yet recruiting",
              "regulatory_designations": null,
              "notes": "For cutaneous sarcoidosis with moderate to severe facial involvement"
            },
            {
              "drug_name": "Rilonacept",
              "company": "Mayo Clinic",
              "mechanism": "IL-1 trap",
              "phase": "Phase 2",
              "trial_id": "NCT06660732",
              "expected_completion": "2026-11",
              "trial_name": "REPAIR-CS",
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Randomized trial for cardiac sarcoidosis"
            },
            {
              "drug_name": "Infliximab",
              "company": "Assistance Publique - H\u00f4pitaux de Paris",
              "mechanism": "TNF-alpha antagonist",
              "phase": "Phase 3",
              "trial_id": "NCT05689879",
              "expected_completion": "2026-03",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Withdrawal study evaluating discontinuation of TNF-alpha therapy"
            },
            {
              "drug_name": "Abrocitinib",
              "company": "Yale University",
              "mechanism": "JAK1 inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT05696795",
              "expected_completion": null,
              "trial_name": null,
              "status": "Completed",
              "regulatory_designations": null,
              "notes": "Recently completed study of JAK1 inhibition in sarcoidosis"
            },
            {
              "drug_name": "Anakinra",
              "company": "Virginia Commonwealth University",
              "mechanism": "IL-1 receptor antagonist",
              "phase": "Phase 2",
              "trial_id": "NCT04017936",
              "expected_completion": null,
              "trial_name": null,
              "status": "Completed",
              "regulatory_designations": null,
              "notes": "Completed study of IL-1 blockade for cardiac sarcoidosis"
            }
          ],
          "pipeline_details": "The sarcoidosis pipeline includes 12 active development programs across Phase 2 and Phase 3, with key mechanisms targeting inflammation through JAK inhibition, TNF blockade, IL-1 inhibition, and novel approaches like chitinase-1 inhibition. Recent major readouts include aTyr Pharma's Phase 3 EFZO-FIT study results for efzofitimod in pulmonary sarcoidosis, marking the largest interventional trial completed in this indication to date.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "Corticosteroids (prednisone) remain first-line therapy for symptomatic sarcoidosis. Second-line agents include methotrexate, azathioprine, and mycophenolate for steroid-sparing or refractory disease. Third-line options include anti-TNF agents like infliximab and adalimumab for severe or refractory cases.",
          "unmet_need": true,
          "unmet_need_description": "No FDA-approved branded innovative treatments exist specifically for sarcoidosis. Current treatment relies primarily on generic corticosteroids and off-label use of immunosuppressants and biologics approved for other conditions.",
          "competitive_landscape": "The sarcoidosis treatment landscape consists entirely of generic agents and off-label use of biologics. Aviptadil has orphan designation but no FDA approval yet. Multiple anti-TNF agents are used off-label based on their approvals for other inflammatory conditions.",
          "soc_source": "FDA Drug Labels and Treatment Guidelines",
          "phase_3_count": 3,
          "phase_2_count": 9,
          "key_catalysts": "aTyr Pharma plans to engage FDA to determine next steps for efzofitimod following Phase 3 results. Multiple ongoing Phase 2 trials are expected to report data through 2025-2026, including OATD-01, brepocitinib, and rilonacept studies.",
          "pipeline_data_quality": "High",
          "recent_approvals": null,
          "data_quality": "High",
          "data_quality_notes": "Clear evidence from FDA documents and multiple treatment guidelines, but no branded innovative drugs have specific FDA approval for sarcoidosis indication"
        },
        "market_size_estimate": "$5.9B",
        "market_size_usd": 5899400000.0,
        "growth_rate": "5-10% CAGR (increasing prevalence)",
        "tam_usd": 315000000.0,
        "tam_estimate": "$315M",
        "tam_rationale": "Of ~118,000 US sarcoidosis patients, ~75% are diagnosed (88,500), ~60% receive systemic treatment beyond steroids (53,100), given chronic inflammatory nature and steroid toxicity concerns. With zero approved drugs and high unmet need for steroid-sparing therapy, a new drug positioned as 2L could capture 30-40% market share (~18,000 patients). At $17,500/year (based on current market size of $1.84B globally with similar patient populations), TAM = $315M.",
        "tam_sources": [
          "https://www.metatechinsights.com/industry-insights/sarcoidosis-treatment-market-2970",
          "https://www.databridgemarketresearch.com/reports/global-sarcoidosis-drug-market?srsltid=AfmBOoplaHse2RM9iX12OsWcWA4ysZc0hCrXqpwWPNNs2Sn_arO-kRUQ",
          "https://www.dennisgong.com/blog/newmedicines/"
        ],
        "pipeline_sources": [
          "https://clinicaltrials.gov",
          "https://clinicaltrials.gov/study/NCT04126070",
          "https://www.clinicaltrials.gov/study/NCT03593759",
          "https://clinicaltrials.gov/study/NCT04064242",
          "https://www.clinicaltrials.gov/study/NCT03814317"
        ],
        "attributed_sources": [
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9449733/",
            "title": "The prevalence and geographic distribution of sarcoidosis in ... - NIH",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.jaadinternational.org/article/S2666-3287(22)00098-0/pdf",
            "title": "The prevalence and geographic distribution of sarcoidosis in the ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=751520",
            "title": "Search Orphan Drug Designations and Approvals - FDA",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://decisionpoint.medscape.com/pulmonarymedicine/viewarticle/931784",
            "title": "When Is Pharmacotherapy Indicated for Sarcoidosis and What Is ...",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9237819/",
            "title": "State-of-the-Art Treatments for Sarcoidosis - PMC - PubMed Central",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://clinicaltrials.gov",
            "title": "ClinicalTrials.gov API",
            "attribution": "Pipeline/Clinical Trials (Primary)"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT04126070",
            "title": "NCT04126070 | Nivolumab + Docetaxel + ADT in mHSPC ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.clinicaltrials.gov/study/NCT03593759",
            "title": "Cardiac Sarcoidosis Randomized Trial (CHASM-CS-RCT)",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.metatechinsights.com/industry-insights/sarcoidosis-treatment-market-2970",
            "title": "Sarcoidosis Treatment Market Share, Size & Growth 2025-2035",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.databridgemarketresearch.com/reports/global-sarcoidosis-drug-market?srsltid=AfmBOoplaHse2RM9iX12OsWcWA4ysZc0hCrXqpwWPNNs2Sn_arO-kRUQ",
            "title": "Sarcoidosis Drug Market Size, Trends, Growth Report 2032",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 7.8,
        "evidence_quality": 6.2,
        "market_opportunity": 9.7,
        "overall_priority": 7.9,
        "clinical_breakdown": {
          "response_rate_quality_weighted": 9.6,
          "safety_profile": 5.0,
          "organ_domain_breadth": 10.0,
          "safety_categories": [
            "discontinuation"
          ],
          "regulatory_flags": [],
          "efficacy_endpoint_count": 4,
          "efficacy_concordance": 1.1
        },
        "response_rate_score": 9.6,
        "safety_profile_score": 5.0,
        "endpoint_quality_score": null,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 1.0,
          "publication_venue": 10.0,
          "response_durability": 9.0,
          "extraction_completeness": 7.2
        },
        "sample_size_score": 1.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 9.0,
        "extraction_completeness_score": 7.2,
        "market_breakdown": {
          "competitors": 10.0,
          "market_size": 9.0,
          "unmet_need": 10.0
        },
        "competitors_score": 10.0,
        "market_size_score": 9.0,
        "unmet_need_score": 10.0
      },
      "rank": 14
    },
    {
      "extraction": {
        "source": {
          "pmid": "40115257",
          "doi": "10.3389/fphar.2025.1509404",
          "url": "https://www.semanticscholar.org/paper/f652d9aee27e16ab02f39c9e99a4ee0e3777430d",
          "title": "Case report: Effectiveness of Janus kinase inhibitors in the management of isolated noninfectious uveitis: a case series",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Web source",
          "is_open_access": false
        },
        "disease": "isolated noninfectious uveitis",
        "disease_normalized": "Non-infectious Uveitis",
        "is_off_label": true,
        "is_relevant": true,
        "evidence_level": "Case Series",
        "patient_population": {
          "n_patients": 3,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "corticosteroids",
            "mycophenolate mofetil",
            "adalimumab",
            "methotrexate",
            "cyclosporine",
            "tacrolimus"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "Three patients (1 female, 2 males, ages 28-59) with refractory isolated noninfectious uveitis (2 with anterior and intermediate uveitis, 1 with posterior uveitis)"
        },
        "treatment": {
          "drug_name": "upadacitinib",
          "generic_name": "Upadacitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "15 mg daily",
          "frequency": null,
          "duration": "mean follow-up 31.6 months",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "3/3 (100%)",
          "responders_n": 3,
          "responders_pct": 100.0,
          "time_to_response": "mean 6.3 months (range 4-9 months)",
          "duration_of_response": "more than 1 year in all patients",
          "effect_size_description": "Complete remission achieved in all patients with improvement in visual acuity from mean 0.4 to 0.6",
          "primary_endpoint": "remission of uveitis",
          "endpoint_result": "all patients achieved remission lasting more than 1 year",
          "durability_signal": null,
          "efficacy_summary": "All three patients with refractory isolated noninfectious uveitis achieved complete remission after JAK inhibitor treatment. Mean time to remission was 6.3 months and all patients maintained remission for over 1 year."
        },
        "safety": {
          "adverse_events": [
            "transient rise in ALT"
          ],
          "serious_adverse_events": [],
          "sae_count": 0,
          "sae_percentage": 0.0,
          "discontinuations_n": 0,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "No significant side effects were observed in any patients throughout the follow-up period. One patient experienced a slight temporary increase in liver transaminase levels.",
          "safety_profile": "Favorable"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": "mean 31.6 months (range 16-55 months)",
        "key_findings": "First report of baricitinib and upadacitinib use in isolated noninfectious uveitis with 100% remission rate. Longest reported follow-up duration for JAK inhibitors in this indication.",
        "detailed_efficacy_endpoints": [
          {
            "endpoint_name": "Complete remission rate",
            "endpoint_category": "Primary",
            "timepoint": "Variable (4-9 months)",
            "measurement_type": "Responder",
            "value": 100.0,
            "unit": "percentage",
            "total_n": 3,
            "responders_n": 3,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "All patients achieved remission lasting for more than 1 year",
            "organ_domain": "Ocular",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Time to remission",
            "endpoint_category": "Primary",
            "timepoint": "Variable",
            "measurement_type": "Absolute value",
            "value": 6.3,
            "unit": "months",
            "total_n": 3,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "final_value": 6.3,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Mean time to full remission; range 4-9 months",
            "organ_domain": "Ocular",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Best Corrected Visual Acuity (BCVA) - Overall",
            "endpoint_category": "Secondary",
            "timepoint": "Post-treatment",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "Snellen chart",
            "total_n": 3,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 0.4,
            "final_value": 0.6,
            "change_from_baseline": 0.2,
            "change_pct": 50.0,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Mean BCVA improved from 0.4 to 0.6",
            "organ_domain": "Ocular",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "Best Corrected Visual Acuity (BCVA) - Case 1 Right Eye",
            "endpoint_category": "Secondary",
            "timepoint": "Final visit",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "Snellen chart",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 0.02,
            "final_value": 0.8,
            "change_from_baseline": 0.78,
            "change_pct": 3900.0,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Includes post-cataract surgery improvement",
            "organ_domain": "Ocular",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "Best Corrected Visual Acuity (BCVA) - Case 1 Left Eye",
            "endpoint_category": "Secondary",
            "timepoint": "Final visit",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "Snellen chart",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 0.2,
            "final_value": 0.1,
            "change_from_baseline": -0.1,
            "change_pct": -50.0,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Reduction attributed to posterior capsular opacification and cataract",
            "organ_domain": "Ocular",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "Best Corrected Visual Acuity (BCVA) - Case 2 Right Eye",
            "endpoint_category": "Secondary",
            "timepoint": "Final visit",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "Snellen chart",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 0.6,
            "final_value": 1.0,
            "change_from_baseline": 0.4,
            "change_pct": 66.7,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "After switching from baricitinib to upadacitinib",
            "organ_domain": "Ocular",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "Best Corrected Visual Acuity (BCVA) - Case 2 Left Eye",
            "endpoint_category": "Secondary",
            "timepoint": "Final visit",
            "measurement_type": "Absolute value",
            "value": 1.0,
            "unit": "Snellen chart",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 1.0,
            "final_value": 1.0,
            "change_from_baseline": 0.0,
            "change_pct": 0.0,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "No change from baseline",
            "organ_domain": "Ocular",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "Best Corrected Visual Acuity (BCVA) - Case 3 Right Eye",
            "endpoint_category": "Secondary",
            "timepoint": "Final visit",
            "measurement_type": "Absolute value",
            "value": 0.4,
            "unit": "Snellen chart",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 0.4,
            "final_value": 0.4,
            "change_from_baseline": 0.0,
            "change_pct": 0.0,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "No change from baseline",
            "organ_domain": "Ocular",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "Best Corrected Visual Acuity (BCVA) - Case 3 Left Eye",
            "endpoint_category": "Secondary",
            "timepoint": "Final visit",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "Snellen chart",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 0.6,
            "final_value": 0.5,
            "change_from_baseline": -0.1,
            "change_pct": -16.7,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Slight decrease from baseline",
            "organ_domain": "Ocular",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "Follow-up duration",
            "endpoint_category": "Secondary",
            "timepoint": "Study completion",
            "measurement_type": "Absolute value",
            "value": 31.6,
            "unit": "months",
            "total_n": 3,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "final_value": 31.6,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Mean follow-up duration; range 16-55 months",
            "organ_domain": "Systemic",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Sustained remission rate (>1 year)",
            "endpoint_category": "Primary",
            "timepoint": ">12 months",
            "measurement_type": "Responder",
            "value": 100.0,
            "unit": "percentage",
            "total_n": 3,
            "responders_n": 3,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "All patients achieved remission lasting for more than 1 year",
            "organ_domain": "Ocular",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Resolution of cystoid macular edema",
            "endpoint_category": "Secondary",
            "timepoint": "Variable",
            "measurement_type": "Responder",
            "value": 100.0,
            "unit": "percentage",
            "total_n": 2,
            "responders_n": 2,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Cases 1 and 2 had CME resolution documented on OCT",
            "organ_domain": "Ocular",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Stabilization of chorioretinal lesions",
            "endpoint_category": "Secondary",
            "timepoint": "9 months",
            "measurement_type": "Responder",
            "value": 100.0,
            "unit": "percentage",
            "total_n": 1,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Case 3 - no new chorioretinal lesions documented after baricitinib treatment",
            "organ_domain": "Ocular",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          }
        ],
        "detailed_safety_endpoints": [
          {
            "event_name": "Transient rise in ALT",
            "event_category": "Lab abnormality",
            "severity_grade": "Mild",
            "patients_affected_n": 1,
            "patients_affected_pct": null,
            "events_total": 1,
            "relatedness": null,
            "outcome": "Resolved",
            "action_taken": "None",
            "notes": "ALT level 0.65 \u03bckat/L (normal range 0-0.56 \u03bckat/L), described as transient and slight elevation",
            "category_soc": "Hepatotoxicity",
            "infection_type": null,
            "malignancy_type": null,
            "cv_type": null,
            "thromboembolic_type": null,
            "is_class_effect": true
          }
        ],
        "extraction_timestamp": "2025-12-08T18:40:41.111711",
        "extraction_confidence": 0.6,
        "extraction_confidence_detail": null,
        "extraction_method": "multi_stage",
        "extraction_stages_completed": [
          "section_identification",
          "efficacy_extraction",
          "safety_extraction"
        ],
        "data_sections_identified": {
          "baseline_tables": [
            "Table 1: Clinical data and a timeline from the episode of care of patients with uveitis treated with JAK-i - contains patient demographics (age, sex), diagnosis, laterality, prior systemic therapies, baseline BCVA, and time from presentation to JAK-i treatment"
          ],
          "efficacy_tables": [
            "Table 1: Clinical data and a timeline from the episode of care of patients with uveitis treated with JAK-i - contains efficacy outcomes including time to remission, follow-up duration, final BCVA, and surgical procedures performed"
          ],
          "safety_tables": [
            "Table 1: Clinical data and a timeline from the episode of care of patients with uveitis treated with JAK-i - contains adverse events column showing transient rise in ALT in one patient"
          ],
          "efficacy_figures": [
            "Figure 1: Case 1 imaging before and after baricitinib therapy showing fluorescein angiography and OCT demonstrating resolution of cystoid macular edema and reduced inflammation",
            "Figure 2: Case 2 imaging during baricitinib treatment and after upadacitinib showing fluorescein angiography and OCT with resolution of inflammation and macular edema",
            "Figure 3: Case 3 fundus autofluorescence before and after JAK-i therapy showing reduction of hyper-autofluorescent borders and no new lesions"
          ],
          "results_sections": [
            "Section 2: Outcomes - overall case series results",
            "Section 3: Case series - detailed case presentations",
            "Section 4.3: Case 1 outcomes and follow-up",
            "Section 5.3: Case 2 outcomes and follow-up",
            "Section 6.3: Case 3 outcomes and follow-up"
          ],
          "patient_count": 3,
          "study_type": "Case Series",
          "has_quantitative_outcomes": true,
          "notes": "Single table contains combined baseline, efficacy, and safety data for all three cases. Mean follow-up of 31.6 months represents longest reported follow-up for JAK inhibitors in isolated non-infectious uveitis. First report documenting use of baricitinib and upadacitinib in this indication."
        }
      },
      "market_intelligence": {
        "disease": "Non-infectious Uveitis",
        "parent_disease": "Uveitis",
        "epidemiology": {
          "us_prevalence_estimate": "234 per 100,000",
          "us_incidence_estimate": "52 per 100,000 annually",
          "global_prevalence": null,
          "patient_population_size": 784000,
          "prevalence_source": "IOVS - ARVO Journals",
          "prevalence_source_url": "https://iovs.arvojournals.org/article.aspx?articleid=2807096",
          "trend": "increasing",
          "source_quality": "Primary",
          "data_year": 2021,
          "geographic_scope": "US",
          "confidence": "High",
          "notes": "Multiple large-scale studies show varying prevalence rates (234-316 per 100,000), with recent data showing rising incidence over the past decade. Non-infectious uveitis comprises majority of cases."
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Humira (adalimumab)",
              "drug_class": "TNF-alpha inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Treatment of non-infectious intermediate, posterior and panuveitis in adult patients and pediatric patients 2 years of age and older",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "First and only FDA-approved noncorticosteroid therapy for noninfectious intermediate and posterior uveitis and panuveitis. Approved initially for adults in 2016, then expanded to pediatric patients 2 years and older in 2018.",
              "approval_year": 2016,
              "approval_confidence": "High",
              "approval_evidence": "FDA orphan drug database confirms approval on 06/30/2016 for adults and 09/28/2018 for pediatrics"
            },
            {
              "drug_name": "Amjevita (adalimumab-atto)",
              "drug_class": "TNF-alpha inhibitor (biosimilar)",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Treatment of non-infectious intermediate, posterior, and panuveitis in adults",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "Adalimumab biosimilar approved for uveitis indication after Humira's orphan exclusivity expired on June 30, 2023. Same dosing as reference product.",
              "approval_year": 2023,
              "approval_confidence": "High",
              "approval_evidence": "FDA BLA 761024/S-017 approval document confirms uveitis indication approval in 2023"
            },
            {
              "drug_name": "Idacio (adalimumab-aacf)",
              "drug_class": "TNF-alpha inhibitor (biosimilar)",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Treatment of non-infectious intermediate, posterior and panuveitis in adult patients",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "Another adalimumab biosimilar approved for uveitis in adult patients. Available as single-dose vial kit for institutional use.",
              "approval_year": 2024,
              "approval_confidence": "High",
              "approval_evidence": "FDA approval letter confirms uveitis indication approval in 2024"
            },
            {
              "drug_name": "Retisert (fluocinolone acetonide)",
              "drug_class": "Sustained-release corticosteroid implant",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Treatment of chronic noninfectious uveitis affecting the posterior segment of the eye",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": null,
              "notes": "Sustained-release vitreous implant providing approximately 30-36 months of therapy for intermediate and posterior uveitis.",
              "approval_year": null,
              "approval_confidence": "Medium",
              "approval_evidence": "Multiple sources confirm FDA approval for sustained-release corticosteroid implants for uveitis"
            },
            {
              "drug_name": "Yutiq (fluocinolone acetonide)",
              "drug_class": "Sustained-release corticosteroid implant",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Treatment of chronic noninfectious uveitis affecting the posterior segment of the eye",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": null,
              "notes": "Sustained-release vitreous implant for chronic noninfectious posterior segment uveitis.",
              "approval_year": null,
              "approval_confidence": "Medium",
              "approval_evidence": "Multiple sources confirm FDA approval for sustained-release corticosteroid implants for uveitis"
            },
            {
              "drug_name": "Ozurdex (dexamethasone)",
              "drug_class": "Sustained-release corticosteroid implant",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Treatment of noninfectious uveitis affecting the posterior segment of the eye",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": null,
              "notes": "Sustained-release dexamethasone vitreous implant for intermediate uveitis, posterior uveitis, and panuveitis.",
              "approval_year": 2009,
              "approval_confidence": "Medium",
              "approval_evidence": "FDA approval date listed as June 18, 2009 in drugs.com database"
            }
          ],
          "approved_drug_names": [
            "Humira (adalimumab)",
            "Amjevita (adalimumab-atto)",
            "Idacio (adalimumab-aacf)",
            "Retisert (fluocinolone acetonide)",
            "Yutiq (fluocinolone acetonide)",
            "Ozurdex (dexamethasone)"
          ],
          "num_approved_drugs": 6,
          "num_pipeline_therapies": 12,
          "pipeline_therapies": [
            {
              "drug_name": "Brepocitinib",
              "company": "Priovant Therapeutics, Inc.",
              "mechanism": "TYK2/JAK1 inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT06431373",
              "expected_completion": "2026-09",
              "trial_name": "CLARITY",
              "status": "Recruiting",
              "regulatory_designations": "Fast Track",
              "notes": "Phase 2 NEPTUNE trial showed positive results; oral small molecule for non-anterior uveitis"
            },
            {
              "drug_name": "REGN7041",
              "company": "Regeneron Pharmaceuticals",
              "mechanism": "Anti-CD3 monoclonal antibody",
              "phase": "Phase 2",
              "trial_id": "NCT07218770",
              "expected_completion": "2028-04",
              "trial_name": null,
              "status": "Not yet recruiting",
              "regulatory_designations": null,
              "notes": "Targeting noninfectious posterior uveitis"
            },
            {
              "drug_name": "YUTIQ",
              "company": "Texas Retina Associates",
              "mechanism": "Fluocinolone acetonide sustained-release implant",
              "phase": "Phase 3",
              "trial_id": "NCT05486468",
              "expected_completion": "2026-07",
              "trial_name": "TYNI",
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Two implants versus sham for chronic non-infectious posterior uveitis"
            },
            {
              "drug_name": "VVN461",
              "company": "VivaVision Biotech, Inc",
              "mechanism": "Novel ophthalmic anti-inflammatory",
              "phase": "Phase 3",
              "trial_id": "NCT07136805",
              "expected_completion": "2026-12",
              "trial_name": null,
              "status": "Not yet recruiting",
              "regulatory_designations": null,
              "notes": "Phase 2 completed; topical treatment for anterior uveitis"
            },
            {
              "drug_name": "Apremilast",
              "company": "Amgen",
              "mechanism": "PDE4 inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT04528082",
              "expected_completion": "2030-02",
              "trial_name": "BEAN",
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Pediatric study for Beh\u00e7et's disease oral ulcers"
            },
            {
              "drug_name": "Hemay005",
              "company": "Ganzhou Hemay Pharmaceutical Co., Ltd",
              "mechanism": "Unknown",
              "phase": "Phase 3",
              "trial_id": "NCT06145893",
              "expected_completion": "2026-05",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Oral treatment for Beh\u00e7et's disease"
            },
            {
              "drug_name": "Baricitinib",
              "company": "University Hospital, Rouen",
              "mechanism": "JAK inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT05651880",
              "expected_completion": "2023-08",
              "trial_name": null,
              "status": "Not yet recruiting",
              "regulatory_designations": null,
              "notes": "For refractory non-infectious non-anterior uveitis"
            },
            {
              "drug_name": "TRS01",
              "company": "Tarsier Pharma",
              "mechanism": "Novel topical steroid formulation",
              "phase": "Phase 3",
              "trial_id": "NCT05042609",
              "expected_completion": "2023-06",
              "trial_name": null,
              "status": "Completed",
              "regulatory_designations": "Special Protocol Assessment",
              "notes": "For non-infectious anterior uveitis including uveitic glaucoma"
            },
            {
              "drug_name": "BCMA-CD19 CAR-T",
              "company": "Peking University People's Hospital",
              "mechanism": "Chimeric antigen receptor T-cell therapy",
              "phase": "Phase 2",
              "trial_id": "NCT06794008",
              "expected_completion": "2027-12",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "For multiple refractory autoimmune diseases including uveitis"
            },
            {
              "drug_name": "Tocilizumab",
              "company": "Peking Union Medical College Hospital",
              "mechanism": "IL-6 receptor antagonist",
              "phase": "Phase 2",
              "trial_id": "NCT05845723",
              "expected_completion": "2026-06",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Comparative trial with tofacitinib for vascular Beh\u00e7et's syndrome"
            },
            {
              "drug_name": "Filgotinib",
              "company": "UMC Utrecht",
              "mechanism": "JAK1 inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT06285539",
              "expected_completion": "2026-12",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Drug rediscovery for rare immune mediated inflammatory diseases"
            },
            {
              "drug_name": "Dusquetide",
              "company": "Soligenix",
              "mechanism": "Innate defense regulator",
              "phase": "Phase 2",
              "trial_id": "NCT06386744",
              "expected_completion": "2025-05",
              "trial_name": null,
              "status": "Completed",
              "regulatory_designations": null,
              "notes": "Pilot study for aphthous ulcers in Beh\u00e7et's disease"
            }
          ],
          "pipeline_details": "The uveitis pipeline includes 12 active therapies across Phase 2 and 3, with significant focus on JAK inhibitors (brepocitinib, baricitinib, filgotinib) and novel approaches like CAR-T therapy. Key mechanisms being tested include TYK2/JAK1 modulation, IL-6 inhibition, and targeted topical formulations for both anterior and posterior uveitis.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "First-line treatment consists of topical and periocular corticosteroids with mydriatics for anterior uveitis. For chronic or sight-threatening disease, sustained-release corticosteroid implants or systemic therapy with adalimumab may be used as steroid-sparing agents. Adalimumab is typically reserved for cases refractory to conventional therapy.",
          "unmet_need": true,
          "unmet_need_description": "Limited FDA-approved noncorticosteroid options with only adalimumab approved as systemic therapy. Guidelines note lack of consensus on when to initiate first- and second-line treatments, particularly for anterior uveitis and infectious uveitis. Many biologics used off-label without specific FDA approval for uveitis.",
          "competitive_landscape": "Adalimumab (Humira) dominated as the only FDA-approved systemic biologic until 2023 when biosimilars Amjevita and Idacio gained approval after orphan exclusivity expiration. Sustained-release corticosteroid implants provide local therapy options but carry risk of cataracts and glaucoma. Multiple other biologics are used off-label without FDA approval.",
          "soc_source": "FDA Orphan Drug Database and Medscape",
          "phase_3_count": 8,
          "phase_2_count": 4,
          "key_catalysts": "Brepocitinib Phase 3 CLARITY readout expected 2026, VVN461 Phase 3 initiation in late 2025, and multiple Beh\u00e7et's disease trials completing by 2026-2027",
          "pipeline_data_quality": "High",
          "recent_approvals": "Amjevita (adalimumab-atto) approved for uveitis in 2023, Idacio (adalimumab-aacf) approved in 2024",
          "data_quality": "Medium",
          "data_quality_notes": "Strong evidence for adalimumab approvals from FDA sources, but some approval years missing for corticosteroid implants. Annual costs not available in source data."
        },
        "market_size_estimate": "$19.6B",
        "market_size_usd": 19600000000.0,
        "growth_rate": "5-10% CAGR (increasing prevalence)",
        "tam_usd": 315000000.0,
        "tam_estimate": "$315M",
        "tam_rationale": "Of ~784K global non-infectious uveitis patients, approximately 70% are diagnosed (~550K), with 60% receiving systemic treatment beyond topical steroids (~330K). Given the chronic, sight-threatening nature and established unmet need, ~40% would be candidates for newer therapies (~132K patients). A new drug entering this market with 6 existing competitors could realistically capture 15-20% market share (~23K patients). At $137K/yr pricing (consistent with specialty ophthalmology and autoimmune therapeutics), TAM = $315M.",
        "tam_sources": [
          "https://www.imrmarketreports.com/reports/non-infectious-uveitis-market/",
          "https://www.mordorintelligence.com/industry-reports/uveitis-treatment-market",
          "https://www.sec.gov/Archives/edgar/data/1962918/000119312523128619/d540006ds1a.htm"
        ],
        "pipeline_sources": [
          "https://clinicaltrials.gov",
          "https://www.clinicaltrials.gov/study/NCT04183387",
          "https://www.clinicaltrials.gov/study/NCT07218770",
          "https://www.clinicaltrials.gov/study/NCT01327664",
          "https://clinicaltrials.gov/study/NCT06679153"
        ],
        "attributed_sources": [
          {
            "url": "https://iovs.arvojournals.org/article.aspx?articleid=2807096",
            "title": "Epidemiology of Uveitis in the United States - IOVS - ARVO Journals",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.sciencedirect.com/science/article/pii/S0002939425001576",
            "title": "Incidence and Prevalence of Uveitis and Associated Ocular ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.medscape.com/viewarticle/815167",
            "title": "Biologics Projected to Transform Uveitis Treatment",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://emedicine.medscape.com/article/798323-medication",
            "title": "Iritis and Uveitis Medication",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.jrheum.org/content/41/1/3",
            "title": "Treat to Target in the Management of Chronic Uveitis",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://clinicaltrials.gov",
            "title": "ClinicalTrials.gov API",
            "attribution": "Pipeline/Clinical Trials (Primary)"
          },
          {
            "url": "https://www.clinicaltrials.gov/study/NCT04183387",
            "title": "Study Details | NCT04183387 | Simvastatin in Uveitis",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.clinicaltrials.gov/study/NCT07218770",
            "title": "A Study of REGN7041 for Active Noninfectious Uveitis in ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.imrmarketreports.com/reports/non-infectious-uveitis-market/",
            "title": "Non Infectious Uveitis Market - Size, Share & Outlook | Forecast ...",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.mordorintelligence.com/industry-reports/uveitis-treatment-market",
            "title": "Uveitis Treatment Market Size & Share Analysis - Mordor Intelligence",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 8.8,
        "evidence_quality": 5.6,
        "market_opportunity": 7.7,
        "overall_priority": 7.7,
        "clinical_breakdown": {
          "response_rate_quality_weighted": 7.1,
          "safety_profile": 10.0,
          "organ_domain_breadth": 10.0,
          "safety_categories": [],
          "regulatory_flags": [],
          "efficacy_endpoint_count": 13,
          "efficacy_concordance": 0.9
        },
        "response_rate_score": 7.1,
        "safety_profile_score": 10.0,
        "endpoint_quality_score": null,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 4.0,
          "publication_venue": 2.0,
          "response_durability": 10.0,
          "extraction_completeness": 8.3
        },
        "sample_size_score": 4.0,
        "publication_venue_score": 2.0,
        "followup_duration_score": 10.0,
        "extraction_completeness_score": 8.3,
        "market_breakdown": {
          "competitors": 3.0,
          "market_size": 10.0,
          "unmet_need": 10.0
        },
        "competitors_score": 3.0,
        "market_size_score": 10.0,
        "unmet_need_score": 10.0
      },
      "rank": 15
    },
    {
      "extraction": {
        "source": {
          "pmid": "36639612",
          "doi": "10.1007/s13555-023-00889-0",
          "url": "https://pubmed.ncbi.nlm.nih.gov/36639612/",
          "title": "Alopecia Universalis in an Adolescent Successfully Treated with Upadacitinib-A Case Report and Review of the Literature on the Use of JAK Inhibitors in Pediatric Alopecia Areata.",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "Alopecia Universalis",
        "disease_normalized": "Alopecia Areata",
        "is_off_label": true,
        "is_relevant": true,
        "evidence_level": "Case Report",
        "patient_population": {
          "n_patients": 1,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "topical minoxidil",
            "mometasone furoate",
            "diphenylcyclopropenone immunotherapy",
            "narrow band ultraviolet B phototherapy",
            "topical corticosteroids",
            "calcineurin inhibitors"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "14-year-old Caucasian girl with alopecia universalis and mild atopic dermatitis"
        },
        "treatment": {
          "drug_name": "upadacitinib",
          "generic_name": "Upadacitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "15 mg/day",
          "frequency": null,
          "duration": "3 months (ongoing)",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "1/1 (100%)",
          "responders_n": 1,
          "responders_pct": 100.0,
          "time_to_response": "1 month",
          "duration_of_response": "maintained at 3 months",
          "effect_size_description": "Complete hair regrowth on scalp, eyebrows, and eyelashes",
          "primary_endpoint": "SALT score reduction",
          "endpoint_result": "SALT score decreased from 100 to 0",
          "durability_signal": null,
          "efficacy_summary": "Complete hair regrowth was achieved after 3 months of therapy with SALT score improving from 100 to 0. Resolution of eczema and complete hair regrowth of scalp, eyebrows and eyelashes was observed."
        },
        "safety": {
          "adverse_events": [
            "transient mild leukopenia"
          ],
          "serious_adverse_events": [],
          "sae_count": 0,
          "sae_percentage": 0.0,
          "discontinuations_n": 0,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "Treatment was well tolerated with only transient mild leukopenia observed at weeks 4 and 8, which resolved by week 12. No other adverse events were reported.",
          "safety_profile": "Favorable"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": "3 months",
        "key_findings": "First pediatric case of alopecia universalis successfully treated with upadacitinib, achieving complete hair regrowth and resolution of concurrent atopic dermatitis.",
        "detailed_efficacy_endpoints": [
          {
            "endpoint_name": "SALT score",
            "endpoint_category": "Primary",
            "timepoint": "Week 12",
            "measurement_type": "Absolute value",
            "value": 0.0,
            "unit": "score",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 100.0,
            "final_value": 0.0,
            "change_from_baseline": -100.0,
            "change_pct": -100.0,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Complete hair regrowth achieved in main case",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "Complete hair regrowth",
            "endpoint_category": "Primary",
            "timepoint": "Week 12",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 1,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Complete hair regrowth on scalp achieved in main case after 3 months of upadacitinib",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Complete eyebrow regrowth",
            "endpoint_category": "Secondary",
            "timepoint": "Week 12",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 1,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Complete eyebrow regrowth achieved in main case",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Complete eyelash regrowth",
            "endpoint_category": "Secondary",
            "timepoint": "Week 12",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 1,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Complete eyelash regrowth achieved in main case",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Complete resolution of eczematous lesions",
            "endpoint_category": "Secondary",
            "timepoint": "Month 1",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 1,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Resolution of atopic dermatitis lesions in main case after 1 month of upadacitinib",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Hair regrowth with topical tofacitinib",
            "endpoint_category": "Exploratory",
            "timepoint": "3-12 months",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 4,
            "responders_n": 1,
            "responders_pct": 25.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "95% regrowth achieved in 1 of 4 patients; 20-30% regrowth in 2 patients; no response in 1 patient from Bayart et al study",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "SALT score improvement with topical tofacitinib",
            "endpoint_category": "Exploratory",
            "timepoint": "2-19 months",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 11,
            "responders_n": 8,
            "responders_pct": 73.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Improvement in SALT score in 73% of patients; cosmetically acceptable regrowth in 27% from Putterman et al study",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "Cosmetically acceptable hair regrowth with topical tofacitinib",
            "endpoint_category": "Exploratory",
            "timepoint": "2-19 months",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 11,
            "responders_n": 3,
            "responders_pct": 27.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Cosmetically acceptable regrowth achieved in 3 of 11 patients from Putterman et al study",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Hair regrowth with systemic tofacitinib",
            "endpoint_category": "Exploratory",
            "timepoint": "2-16 months",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 13,
            "responders_n": 9,
            "responders_pct": 69.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Hair regrowth achieved in 69% of patients from Craiglow et al study",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Greater than 50% hair regrowth with systemic tofacitinib",
            "endpoint_category": "Exploratory",
            "timepoint": "5-18 months",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 6,
            "responders_n": 6,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "All 6 patients achieved >50% hair regrowth from Castelo-Soccio study",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          }
        ],
        "detailed_safety_endpoints": [
          {
            "event_name": "Transient mild leukopenia",
            "event_category": "Lab abnormality",
            "severity_grade": "Mild",
            "patients_affected_n": 1,
            "patients_affected_pct": null,
            "events_total": null,
            "relatedness": null,
            "outcome": "Resolved",
            "action_taken": "None",
            "notes": "WBC count was 3.54 \u00d7 10\u00b3/\u00b5L after 4 weeks and 3.93 \u00d7 10\u00b3/\u00b5L after 8 weeks, returned to normal at week 12",
            "category_soc": "Cytopenias",
            "infection_type": null,
            "malignancy_type": null,
            "cv_type": null,
            "thromboembolic_type": null,
            "is_class_effect": true
          }
        ],
        "extraction_timestamp": "2025-12-08T18:19:27.975292",
        "extraction_confidence": 0.6,
        "extraction_confidence_detail": null,
        "extraction_method": "multi_stage",
        "extraction_stages_completed": [
          "section_identification",
          "efficacy_extraction",
          "safety_extraction"
        ],
        "data_sections_identified": {
          "baseline_tables": [],
          "efficacy_tables": [],
          "safety_tables": [],
          "efficacy_figures": [
            "Figure 1: Clinical and trichoscopic presentation showing baseline, 2-month, and 3-month follow-up images demonstrating complete hair regrowth on scalp and eyebrows after upadacitinib treatment"
          ],
          "results_sections": [
            "Case Report section describing patient presentation, treatment course, and outcomes",
            "Treatment response details showing SALT score improvement from 100 to 0 over 3 months",
            "Laboratory monitoring results including transient mild leukopenia"
          ],
          "patient_count": 1,
          "study_type": "Case Report",
          "has_quantitative_outcomes": true,
          "notes": "Tables 1 and 2 are literature review summaries of other published cases, not data from this specific case. Clinical outcomes measured by SALT score, trichoscopy findings, and laboratory parameters. Complete hair regrowth achieved in 3 months with minimal adverse effects."
        }
      },
      "market_intelligence": {
        "disease": "Alopecia Areata",
        "parent_disease": null,
        "epidemiology": {
          "us_prevalence_estimate": "0.17-0.22%",
          "us_incidence_estimate": "91-93 cases per 100,000 patient-years",
          "global_prevalence": null,
          "patient_population_size": 6700000,
          "prevalence_source": "Journal of the American Academy of Dermatology",
          "prevalence_source_url": "https://www.jaad.org/article/S0190-9622(22)01464-5/fulltext",
          "trend": "stable",
          "source_quality": "Primary",
          "data_year": 2019,
          "geographic_scope": "US",
          "confidence": "High",
          "notes": "Multiple recent US studies show consistent prevalence estimates ranging from 0.17-0.22%, with higher rates in females vs males and African Americans vs whites. Lifetime incidence risk estimated at 2%."
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Olumiant (baricitinib)",
              "drug_class": "JAK inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Alopecia Areata",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "First systemic immunotherapy approved by FDA for adults with severe alopecia areata. Recommended dosage 2 mg once daily, can increase to 4 mg daily.",
              "approval_year": 2022,
              "approval_confidence": "High",
              "approval_evidence": "FDA approval June 2022 for adults with severe alopecia areata"
            },
            {
              "drug_name": "Litfulo (ritlecitinib)",
              "drug_class": "JAK inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Alopecia Areata",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "Second JAK inhibitor approved for severe alopecia areata, approved for patients 12 years and older.",
              "approval_year": 2023,
              "approval_confidence": "High",
              "approval_evidence": "FDA approval June 2023 for patients ages 12 years and older with severe alopecia areata"
            },
            {
              "drug_name": "Leqselvi (deuruxolitinib)",
              "drug_class": "JAK inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Alopecia Areata",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "Third JAK inhibitor approved for severe alopecia areata in adults. Oral formulation.",
              "approval_year": 2024,
              "approval_confidence": "High",
              "approval_evidence": "FDA approval July 2024 for adults with severe alopecia areata"
            }
          ],
          "approved_drug_names": [
            "Olumiant (baricitinib)",
            "Litfulo (ritlecitinib)",
            "Leqselvi (deuruxolitinib)"
          ],
          "num_approved_drugs": 3,
          "num_pipeline_therapies": 9,
          "pipeline_therapies": [
            {
              "drug_name": "Microbiota Transplant Therapy",
              "company": "University of Minnesota",
              "mechanism": "Gut microbiome modulation",
              "phase": "Phase 2",
              "trial_id": "NCT06747611",
              "expected_completion": "2028-03",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Novel approach targeting microbiota in alopecia areata"
            },
            {
              "drug_name": "Ritlecitinib",
              "company": "Pfizer",
              "mechanism": "JAK3/TEC family kinase inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT06873945",
              "expected_completion": "2027-03",
              "trial_name": "ALLEGRO-100",
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Testing 50mg and 100mg doses in patients 12 years and older"
            },
            {
              "drug_name": "Tofacitinib",
              "company": "Jinnah Hospital",
              "mechanism": "JAK inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT06278402",
              "expected_completion": null,
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": null,
              "notes": "Completed January 2024, studying moderate to severe AA"
            },
            {
              "drug_name": "EQ101",
              "company": "Equillium",
              "mechanism": "CD6-targeted immunomodulator",
              "phase": "Phase 2",
              "trial_id": "NCT05589610",
              "expected_completion": null,
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": null,
              "notes": "Open-label study completed March 2024"
            },
            {
              "drug_name": "Ruxolitinib",
              "company": "National Institute of Allergy and Infectious Diseases (NIAID)",
              "mechanism": "JAK1/JAK2 inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT05398809",
              "expected_completion": "2027-12",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Specifically for APECED-associated alopecia areata"
            },
            {
              "drug_name": "STS01",
              "company": "Soterios Ltd",
              "mechanism": "Non-steroidal topical treatment",
              "phase": "Phase 2",
              "trial_id": "NCT06402630",
              "expected_completion": null,
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": null,
              "notes": "Completed April 2024, for mild-moderate AA"
            },
            {
              "drug_name": "Etrasimod",
              "company": "Pfizer",
              "mechanism": "Selective S1P receptor modulator",
              "phase": "Phase 2",
              "trial_id": "NCT04556734",
              "expected_completion": null,
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": null,
              "notes": "Completed June 2023, moderate-to-severe AA"
            },
            {
              "drug_name": "Upadacitinib",
              "company": "AbbVie",
              "mechanism": "JAK1 inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT06012240",
              "expected_completion": "2028-01",
              "trial_name": "UP-AA",
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Positive topline results reported in 2025, seeking approval"
            },
            {
              "drug_name": "Rezpegaldesleukin",
              "company": "Nektar Therapeutics",
              "mechanism": "IL-2 receptor complex agonist/Treg stimulator",
              "phase": "Phase 2",
              "trial_id": "Unknown - verify",
              "expected_completion": null,
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": "Fast Track",
              "notes": "Received FDA Fast Track designation in July 2025"
            }
          ],
          "pipeline_details": "Nine active clinical programs are in Phase 2-3 development for alopecia areata, dominated by JAK inhibitors but including novel approaches like microbiota transplant therapy and IL-2 receptor modulators. AbbVie's upadacitinib has reported positive Phase 3 results and is seeking regulatory approval, while Pfizer's ritlecitinib continues Phase 3 recruitment.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "JAK inhibitors are considered first-line treatment for severe alopecia areata (\u226550% scalp hair loss), with three FDA-approved options now available. For mild to moderate disease, topical corticosteroids and intralesional corticosteroid injections remain standard approaches, often combined with topical minoxidil.",
          "unmet_need": false,
          "unmet_need_description": null,
          "competitive_landscape": "The alopecia areata market has been rapidly transformed with three JAK inhibitors approved in just three years (2022-2024), providing systemic treatment options for severe disease. All three drugs target the same pathway but may offer different dosing or patient population advantages.",
          "soc_source": "Medscape Alopecia Areata Overview and FDA Drug Labels",
          "phase_3_count": 3,
          "phase_2_count": 6,
          "key_catalysts": "AbbVie expected to file for upadacitinib approval in 2025-2026 based on positive UP-AA Phase 3 results; Pfizer's ritlecitinib Phase 3 ALLEGRO-100 trial completion expected March 2027",
          "pipeline_data_quality": "High",
          "recent_approvals": "Olumiant (baricitinib) June 2022, Litfulo (ritlecitinib) June 2023, Leqselvi (deuruxolitinib) July 2024",
          "data_quality": "High",
          "data_quality_notes": "Multiple sources confirm FDA approvals with specific approval dates and indications. All three approvals are for severe alopecia areata specifically."
        },
        "market_size_estimate": "$167.5B",
        "market_size_usd": 167500000000.0,
        "growth_rate": "3-5% CAGR (stable prevalence)",
        "tam_usd": 850000000.0,
        "tam_estimate": "$850M",
        "tam_rationale": "Of ~6.7M US alopecia areata patients, ~80% are diagnosed (5.4M), but only ~15% have moderate-severe disease warranting systemic JAK inhibitor therapy (~810K patients). With 3 approved JAK inhibitors already established as first-line for severe cases, a new entrant could realistically capture 15-20% market share (~135K patients). At $50K/year pricing (consistent with autoimmune-dermatology benchmarks), TAM = 135K \u00d7 $50K = $675M-850M.",
        "tam_sources": [
          "https://bisresearch.com/industry-report/alopecia-areata-market.html",
          "https://www.prnewswire.com/news-releases/alopecia-areata-market-to-show-positive-growth-at-a-cagr-of-26-3-during-the-study-period-20192032-estimates-delveinsight-301853907.html",
          "https://www.giiresearch.com/report/tbrc1824572-alopecia-global-market-report.html"
        ],
        "pipeline_sources": [
          "https://clinicaltrials.gov",
          "https://clinicaltrials.gov/study/NCT03732807",
          "https://cdn.clinicaltrials.gov/large-docs/07/NCT03732807/Prot_000.pdf",
          "https://cdn.clinicaltrials.gov/large-docs/49/NCT03570749/Prot_002.pdf",
          "https://www.clinicaltrials.gov/study/NCT06012240"
        ],
        "attributed_sources": [
          {
            "url": "https://www.jaad.org/article/S0190-9622(22)01464-5/fulltext",
            "title": "33432 Prevalence estimates for alopecia areata in ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9979012/",
            "title": "Trends in Prevalence and Incidence of Alopecia Areata ... - NIH",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://emedicine.medscape.com/article/1069931-overview",
            "title": "Alopecia Areata: Practice Essentials, Background, ...",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://emedicine.medscape.com/article/1069931-medication",
            "title": "Alopecia Areata Medication: Glucocorticoids, Vasodilators ...",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3149478/",
            "title": "Alopecia areata: a new treatment plan - PMC",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://clinicaltrials.gov",
            "title": "ClinicalTrials.gov API",
            "attribution": "Pipeline/Clinical Trials (Primary)"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT03732807",
            "title": "PF-06651600 for the Treatment of Alopecia Areata",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://cdn.clinicaltrials.gov/large-docs/07/NCT03732807/Prot_000.pdf",
            "title": "a phase 2b/3 randomized, double-blind, placebo-controlled",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://bisresearch.com/industry-report/alopecia-areata-market.html",
            "title": "Alopecia Areata Market Size & Forecast | BIS Research",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.prnewswire.com/news-releases/alopecia-areata-market-to-show-positive-growth-at-a-cagr-of-26-3-during-the-study-period-20192032-estimates-delveinsight-301853907.html",
            "title": "Alopecia Areata Market to Show Positive Growth at a CAGR of 26.3 ...",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 8.8,
        "evidence_quality": 5.3,
        "market_opportunity": 7.7,
        "overall_priority": 7.6,
        "clinical_breakdown": {
          "response_rate_quality_weighted": 9.8,
          "safety_profile": 7.1,
          "organ_domain_breadth": 10.0,
          "safety_categories": [
            "pulmonary",
            "thromboembolic",
            "cardiovascular",
            "cytopenia"
          ],
          "regulatory_flags": [
            "pulmonary",
            "thromboembolic",
            "cardiovascular",
            "cytopenia"
          ],
          "efficacy_endpoint_count": 10,
          "efficacy_concordance": 1.1
        },
        "response_rate_score": 9.8,
        "safety_profile_score": 7.1,
        "endpoint_quality_score": null,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 1.0,
          "publication_venue": 10.0,
          "response_durability": 5.0,
          "extraction_completeness": 8.3
        },
        "sample_size_score": 1.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 5.0,
        "extraction_completeness_score": 8.3,
        "market_breakdown": {
          "competitors": 5.0,
          "market_size": 10.0,
          "unmet_need": 8.0
        },
        "competitors_score": 5.0,
        "market_size_score": 10.0,
        "unmet_need_score": 8.0
      },
      "rank": 16
    },
    {
      "extraction": {
        "source": {
          "pmid": "39668983",
          "doi": "10.1016/j.jdcr.2024.08.047",
          "url": "https://pubmed.ncbi.nlm.nih.gov/39668983/",
          "title": "Case of recalcitrant amyopathic dermatomyositis treated with upadacitinib.",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "Clinically amyopathic dermatomyositis (CADM)",
        "disease_normalized": "Dermatomyositis",
        "is_off_label": true,
        "is_relevant": true,
        "evidence_level": "Case Report",
        "patient_population": {
          "n_patients": 1,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "hydroxychloroquine",
            "methotrexate",
            "mycophenolate mofetil",
            "intravenous immunoglobulins",
            "rituximab",
            "tofacitinib"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "67-year-old female with 8-year history of extensive, chronic photosensitive rash with extreme pruritus"
        },
        "treatment": {
          "drug_name": "upadacitinib",
          "generic_name": "Upadacitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "15 mg daily",
          "frequency": null,
          "duration": "12 months",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "1/1 (100%)",
          "responders_n": 1,
          "responders_pct": 100.0,
          "time_to_response": "within 3 months",
          "duration_of_response": "sustained at 12 months",
          "effect_size_description": "dramatic 32-point reduction in CDASI score with near-complete resolution of multiple symptoms",
          "primary_endpoint": "CDASI score reduction",
          "endpoint_result": "32-point reduction in CDASI score (from 50 to 18)",
          "durability_signal": null,
          "efficacy_summary": "Patient showed significant improvement within 3 months with dramatic 32-point CDASI score reduction after 12 months. Near-complete resolution of scalp involvement, orbital edema, poikiloderma, and Gottron's erythema was achieved."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": null,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "No adverse events or safety concerns were reported during the 12-month treatment period.",
          "safety_profile": "Unknown"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": "12 months",
        "key_findings": "Upadacitinib achieved sustained improvement in refractory CADM where tofacitinib had lost efficacy, suggesting JAK1 selectivity may be important in dermatomyositis treatment.",
        "detailed_efficacy_endpoints": [
          {
            "endpoint_name": "CDASI score",
            "endpoint_category": "Primary",
            "timepoint": "Month 12",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "points",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 50.0,
            "final_value": 18.0,
            "change_from_baseline": -32.0,
            "change_pct": -64.0,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Cutaneous Dermatomyositis Disease Area and Severity Index measured after 12 months of upadacitinib 15 mg daily with hydroxychloroquine",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "Time to significant improvement",
            "endpoint_category": "Secondary",
            "timepoint": "Month 3",
            "measurement_type": "Absolute value",
            "value": 3.0,
            "unit": "months",
            "total_n": 1,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Patient started to show significant improvement within 3 months of upadacitinib treatment",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          }
        ],
        "detailed_safety_endpoints": [],
        "extraction_timestamp": "2025-12-08T18:27:19.122357",
        "extraction_confidence": 0.6,
        "extraction_confidence_detail": null,
        "extraction_method": "multi_stage",
        "extraction_stages_completed": [
          "section_identification",
          "efficacy_extraction",
          "safety_extraction"
        ],
        "data_sections_identified": {
          "baseline_tables": [],
          "efficacy_tables": [],
          "safety_tables": [],
          "efficacy_figures": [
            "Figure 1: Clinical images showing dermatomyositis activity with before/after treatment comparison - baseline presentation vs. follow-up after 10 months of upadacitinib 15 mg daily"
          ],
          "results_sections": [
            "Clinical presentation and treatment history",
            "Treatment response with upadacitinib including CDASI score improvement"
          ],
          "patient_count": 1,
          "study_type": "Case Report",
          "has_quantitative_outcomes": true,
          "notes": "Single patient case report with CDASI score as primary quantitative outcome measure (50 to 18, 32-point reduction). No formal tables present - all data presented in narrative format."
        }
      },
      "market_intelligence": {
        "disease": "Dermatomyositis",
        "parent_disease": null,
        "epidemiology": {
          "us_prevalence_estimate": "21.4 per 100,000",
          "us_incidence_estimate": "15.2 per million person-years",
          "global_prevalence": null,
          "patient_population_size": 71690,
          "prevalence_source": "PMC",
          "prevalence_source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10924937/",
          "trend": "increasing",
          "source_quality": "Primary",
          "data_year": 2023,
          "geographic_scope": "US",
          "confidence": "High",
          "notes": "Multiple sources report prevalence estimates ranging from 13-21.4 per 100,000. DelveInsight reported 38.5 thousand cases in US for 2023. Female to male ratio is 2:1. Higher prevalence in urban areas with air pollution."
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Octagam 10% (immune globulin intravenous)",
              "drug_class": "Intravenous Immunoglobulin (IVIG)",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Treatment of dermatomyositis in adults",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "FDA-approved for treatment of dermatomyositis in adults with orphan drug designation. Dosed at 2 g/kg divided over 2-5 consecutive days every 4 weeks. Orphan exclusivity until July 15, 2028.",
              "approval_year": 2021,
              "approval_confidence": "High",
              "approval_evidence": "FDA approval letter dated July 15, 2021"
            }
          ],
          "approved_drug_names": [
            "Octagam 10% (immune globulin intravenous)"
          ],
          "num_approved_drugs": 1,
          "num_pipeline_therapies": 15,
          "pipeline_therapies": [
            {
              "drug_name": "Baricitinib",
              "company": "Assistance Publique - H\u00f4pitaux de Paris",
              "mechanism": "JAK1/2 inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT04972760",
              "expected_completion": "2026-02",
              "trial_name": "BIRD",
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Multicenter randomized controlled trial in relapsing or na\u00efve dermatomyositis"
            },
            {
              "drug_name": "Efgartigimod PH20 SC",
              "company": "argenx",
              "mechanism": "FcRn antagonist",
              "phase": "Phase 2/3",
              "trial_id": "NCT05523167",
              "expected_completion": "2026-12",
              "trial_name": "ALKIVIA",
              "status": "Active",
              "regulatory_designations": null,
              "notes": "Operationally seamless study for idiopathic inflammatory myopathy including dermatomyositis"
            },
            {
              "drug_name": "Empasiprubart",
              "company": "argenx",
              "mechanism": "Complement C2 inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT06284954",
              "expected_completion": "2026-11",
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": null,
              "notes": "Double-blinded, placebo-controlled study in dermatomyositis"
            },
            {
              "drug_name": "Brepocitinib",
              "company": "Priovant Therapeutics, Inc.",
              "mechanism": "TYK2 inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT05437263",
              "expected_completion": "2025-07",
              "trial_name": "VALOR",
              "status": "Active",
              "regulatory_designations": null,
              "notes": "Positive Phase 3 results announced September 2025"
            },
            {
              "drug_name": "GLPG3667",
              "company": "Galapagos NV",
              "mechanism": "PPAR-gamma agonist",
              "phase": "Phase 2",
              "trial_id": "NCT05695950",
              "expected_completion": "2025-10",
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": null,
              "notes": "24-week treatment duration in dermatomyositis"
            },
            {
              "drug_name": "Anifrolumab",
              "company": "AstraZeneca",
              "mechanism": "Type I interferon receptor antagonist",
              "phase": "Phase 3",
              "trial_id": "NCT06455449",
              "expected_completion": "2027-05",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Subcutaneous injection for polymyositis and dermatomyositis"
            },
            {
              "drug_name": "Dazukibart",
              "company": "Pfizer",
              "mechanism": "Anti-interferon beta monoclonal antibody",
              "phase": "Phase 3",
              "trial_id": "NCT06698796",
              "expected_completion": "2027-11",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Long-term extension study for idiopathic inflammatory myopathies"
            },
            {
              "drug_name": "PF-06823859",
              "company": "Pfizer",
              "mechanism": "Anti-interferon beta monoclonal antibody",
              "phase": "Phase 3",
              "trial_id": "NCT05895786",
              "expected_completion": "2027-07",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Active dermatomyositis and polymyositis study"
            },
            {
              "drug_name": "Interleukin-2",
              "company": "Peking University People's Hospital",
              "mechanism": "IL-2 receptor agonist",
              "phase": "Phase 3",
              "trial_id": "NCT05495321",
              "expected_completion": "2025-09",
              "trial_name": null,
              "status": "Enrolling by invitation",
              "regulatory_designations": null,
              "notes": "Low-dose IL-2 for Treg activation in active dermatomyositis"
            },
            {
              "drug_name": "Nipocalimab",
              "company": "Janssen Research & Development, LLC",
              "mechanism": "FcRn antagonist",
              "phase": "Phase 2",
              "trial_id": "NCT05379634",
              "expected_completion": "2025-09",
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": null,
              "notes": "Study in active idiopathic inflammatory myopathies"
            },
            {
              "drug_name": "CABA-201",
              "company": "Cabaletta Bio",
              "mechanism": "Anti-CD19 CAR-T cell therapy",
              "phase": "Phase 1/2",
              "trial_id": "NCT06154252",
              "expected_completion": "2028-07",
              "trial_name": "RESET-Myositis",
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Autologous CAR-T therapy for idiopathic inflammatory myopathy"
            },
            {
              "drug_name": "Rapcabtagene autoleucel",
              "company": "Novartis Pharmaceuticals",
              "mechanism": "Anti-CD19 CAR-T cell therapy",
              "phase": "Phase 2",
              "trial_id": "NCT06665256",
              "expected_completion": "2029-07",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "CAR-T therapy for severe refractory idiopathic inflammatory myopathies"
            },
            {
              "drug_name": "NM8074",
              "company": "NovelMed Therapeutics",
              "mechanism": "Unknown",
              "phase": "Phase 2",
              "trial_id": "NCT06887738",
              "expected_completion": "2027-11",
              "trial_name": null,
              "status": "Not yet recruiting",
              "regulatory_designations": null,
              "notes": "Proof-of-concept study in dermatomyositis"
            },
            {
              "drug_name": "Ruxolitinib",
              "company": "The Cleveland Clinic",
              "mechanism": "JAK1/2 inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT06857240",
              "expected_completion": "2026-12",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Topical cream formulation for refractory cutaneous dermatomyositis"
            },
            {
              "drug_name": "ULSC",
              "company": "Restem, LLC.",
              "mechanism": "Allogeneic mesenchymal stem cells",
              "phase": "Phase 2/3",
              "trial_id": "NCT07160205",
              "expected_completion": "2028-08",
              "trial_name": null,
              "status": "Not yet recruiting",
              "regulatory_designations": null,
              "notes": "Umbilical cord-derived stem cells for dermatomyositis/polymyositis"
            }
          ],
          "pipeline_details": "Dermatomyositis has a robust pipeline with 15 active therapies across Phase 2-3 development, representing diverse mechanisms including JAK inhibitors, FcRn antagonists, interferon blockers, and novel CAR-T approaches. Key mechanisms being tested include immune modulation through baricitinib and brepocitinib (JAK inhibitors), autoantibody reduction via efgartigimod and nipocalimab (FcRn antagonists), and interferon pathway inhibition with anifrolumab and PF-06823859. Positive Phase 3 results for brepocitinib were recently announced in September 2025.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "First-line treatment consists of systemic glucocorticoids (prednisone) with or without immunosuppressants like methotrexate or azathioprine. For resistant cases or patients who fail first-line therapy, second-line options include rituximab, mycophenolate mofetil, calcineurin inhibitors, IVIG (Octagam 10%), and cyclophosphamide.",
          "unmet_need": true,
          "unmet_need_description": "Significant unmet need exists as most patients require second-line agents because anti-malarial medications and corticosteroids alone are insufficient to treat dermatomyositis. Many patients develop resistance to standard therapies, and there is only one FDA-approved branded innovative treatment specifically for dermatomyositis.",
          "competitive_landscape": "Very limited competitive landscape with only Octagam 10% as the sole FDA-approved branded innovative treatment for dermatomyositis. Most other treatments are off-label use of generic immunosuppressants or biologics approved for other autoimmune conditions. Brepocitinib has orphan designation but is not yet FDA-approved.",
          "soc_source": "FDA approval documents and Medscape treatment guidelines",
          "phase_3_count": 6,
          "phase_2_count": 7,
          "key_catalysts": "Multiple Phase 3 readouts expected in 2025-2027 including brepocitinib (positive results announced), interleukin-2 (September 2025), GLPG3667 (October 2025), nipocalimab (September 2025), and efgartigimod ALKIVIA study (December 2026)",
          "pipeline_data_quality": "High",
          "recent_approvals": "Octagam 10% approved July 15, 2021 for treatment of dermatomyositis in adults",
          "data_quality": "High",
          "data_quality_notes": "Clear FDA approval documentation available for Octagam 10% with specific indication for dermatomyositis"
        },
        "market_size_estimate": "$3.6B",
        "market_size_usd": 3584500000.0,
        "growth_rate": "5-10% CAGR (increasing prevalence)",
        "tam_usd": 189000000.0,
        "tam_estimate": "$189M",
        "tam_rationale": "Of ~72K US dermatomyositis patients, ~50% are diagnosed (36K), ~70% receive systemic treatment (25K), ~35% fail first-line corticosteroids/immunosuppressants and need second-line therapy (8.8K). A new drug positioned as second-line could capture 20-25% market share (~2.1K patients) given significant unmet need with only 1 approved drug. At $90K/yr pricing (rare autoimmune orphan drug), TAM = $189M. Premium pricing justified by orphan status and limited treatment options.",
        "tam_sources": [
          "https://exactitudeconsultancy.com/id/reports/71100/dermatomyositis-patient-pool-market",
          "https://www.openpr.com/news/4200870/unlocking-juvenile-dermatomyositis-treatment-united-states",
          "https://www.futuremarketreport.com/industry-report/dermatomyositis-drug-market"
        ],
        "pipeline_sources": [
          "https://clinicaltrials.gov",
          "https://clinicaltrials.gov/study/NCT03181893",
          "https://www.mayoclinic.org/diseases-conditions/dermatomyositis/doctors-departments/ddc-20353195",
          "https://clinicaltrials.gov/study/NCT05523167",
          "https://www.clinicaltrials.gov/study/NCT05437263"
        ],
        "attributed_sources": [
          {
            "url": "https://www.healio.com/clinical-guidance/dermatomyositis/epidemiology-of-dm",
            "title": "Dermatomyositis Epidemiology | Clinical Guidance - Healio",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.delveinsight.com/report-store/dermatomyositis-market",
            "title": "Dermatomyositis Market Summary - DelveInsight",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=564716",
            "title": "Search Orphan Drug Designations and Approvals - FDA",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1000724",
            "title": "Search Orphan Drug Designations and Approvals - FDA",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.delveinsight.com/blog/dermatomyositis-treatment-outlook",
            "title": "Navigating the Challenges in Dermatomyositis Treatment",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://clinicaltrials.gov",
            "title": "ClinicalTrials.gov API",
            "attribution": "Pipeline/Clinical Trials (Primary)"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT03181893",
            "title": "A Study In Adults With Moderate To Severe Dermatomyositis",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.mayoclinic.org/diseases-conditions/dermatomyositis/doctors-departments/ddc-20353195",
            "title": "Dermatomyositis - Doctors and departments - Mayo Clinic",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://exactitudeconsultancy.com/id/reports/71100/dermatomyositis-patient-pool-market",
            "title": "Dermatomyositis Patient Pool Market",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.openpr.com/news/4200870/unlocking-juvenile-dermatomyositis-treatment-united-states",
            "title": "Unlocking Juvenile Dermatomyositis Treatment",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 8.0,
        "evidence_quality": 6.2,
        "market_opportunity": 8.3,
        "overall_priority": 7.6,
        "clinical_breakdown": {
          "response_rate_quality_weighted": 10.0,
          "safety_profile": 5.0,
          "organ_domain_breadth": 10.0,
          "safety_categories": [],
          "regulatory_flags": [],
          "efficacy_endpoint_count": 2,
          "efficacy_concordance": 1.15
        },
        "response_rate_score": 10.0,
        "safety_profile_score": 5.0,
        "endpoint_quality_score": null,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 1.0,
          "publication_venue": 10.0,
          "response_durability": 9.0,
          "extraction_completeness": 7.2
        },
        "sample_size_score": 1.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 9.0,
        "extraction_completeness_score": 7.2,
        "market_breakdown": {
          "competitors": 7.0,
          "market_size": 8.0,
          "unmet_need": 10.0
        },
        "competitors_score": 7.0,
        "market_size_score": 8.0,
        "unmet_need_score": 10.0
      },
      "rank": 17
    },
    {
      "extraction": {
        "source": {
          "pmid": "36968986",
          "doi": "10.1177/2050313X231160914",
          "url": "https://www.semanticscholar.org/paper/a1bbddc48de11372b5d8fd0e52b168d54e77a234",
          "title": "Successful treatment of concomitant alopecia universalis and Crohn\u2019s disease with upadacitinib: A case report",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Web source",
          "is_open_access": false
        },
        "disease": "Alopecia universalis",
        "disease_normalized": "Alopecia Areata",
        "is_off_label": true,
        "is_relevant": true,
        "evidence_level": "Case Report",
        "patient_population": {
          "n_patients": 1,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "intralesional triamcinolone acetonide injections",
            "prednisone",
            "methotrexate"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "23-year-old Caucasian man with concomitant Crohn's disease and alopecia universalis who developed alopecia areata while on adalimumab"
        },
        "treatment": {
          "drug_name": "upadacitinib",
          "generic_name": "Upadacitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "30 mg daily",
          "frequency": null,
          "duration": "7 months",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "1/1 (100%)",
          "responders_n": 1,
          "responders_pct": 100.0,
          "time_to_response": "4 months for significant partial hair regrowth",
          "duration_of_response": "At least 7 months",
          "effect_size_description": "Near-complete resolution with only a few remaining patches on temples and occipital scalp",
          "primary_endpoint": "Hair regrowth and resolution of alopecia universalis",
          "endpoint_result": "Near-complete resolution of alopecia universalis on scalp with significant hair regrowth on eyebrows, arms, and legs",
          "durability_signal": null,
          "efficacy_summary": "Patient achieved significant partial hair regrowth by 4 months and near-complete resolution of alopecia universalis by 7 months. Hair regrowth was observed on scalp, eyebrows, arms, and legs."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": 0,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "No adverse events or safety concerns were reported during the 7-month treatment period. Patient tolerated the medication well.",
          "safety_profile": "Favorable"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": "7 months",
        "key_findings": "First case report showing improvement of both alopecia universalis and Crohn's disease with upadacitinib, demonstrating near-complete hair regrowth after 7 months of treatment.",
        "detailed_efficacy_endpoints": [
          {
            "endpoint_name": "Alopecia areata partial hair regrowth on scalp",
            "endpoint_category": "Primary",
            "timepoint": "4 months",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 1,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Described as significant partial hair regrowth on the scalp",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Alopecia areata near-complete resolution on scalp",
            "endpoint_category": "Primary",
            "timepoint": "7 months",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 1,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Near-complete regrowth of scalp hair from alopecia universalis with only a few remaining patches on temples and occipital scalp",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Hair regrowth on eyebrows, arms, and legs",
            "endpoint_category": "Secondary",
            "timepoint": "7 months",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 1,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Described as significant hair regrowth on eyebrows, arms, and legs",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Crohn's disease clinical remission",
            "endpoint_category": "Primary",
            "timepoint": "7 months",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 1,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Clinical remission confirmed by gastroenterologist",
            "organ_domain": "Gastrointestinal",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "Minimal Crohn's disease activity on MRI",
            "endpoint_category": "Secondary",
            "timepoint": "7 months",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 1,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Abdominal MRI showed minimal CD activity",
            "organ_domain": "Gastrointestinal",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          }
        ],
        "detailed_safety_endpoints": [],
        "extraction_timestamp": "2025-12-08T18:41:46.133857",
        "extraction_confidence": 0.6,
        "extraction_confidence_detail": null,
        "extraction_method": "multi_stage",
        "extraction_stages_completed": [
          "section_identification",
          "efficacy_extraction",
          "safety_extraction"
        ],
        "data_sections_identified": {
          "baseline_tables": [],
          "efficacy_tables": [],
          "safety_tables": [],
          "efficacy_figures": [
            "Figure 1: Clinical course of alopecia areata on the scalp at baseline and following daily treatment with upadacitinib 30 mg at 4 months and 7 months, showing near-complete regrowth of scalp hair from alopecia universalis"
          ],
          "results_sections": [
            "Case report section describing 23-year-old man with treatment course and outcomes",
            "Discussion section analyzing the treatment response and comparing to previous cases"
          ],
          "patient_count": 1,
          "study_type": "Case Report",
          "has_quantitative_outcomes": false,
          "notes": "Single patient case report with clinical photographs showing hair regrowth progression. No formal efficacy or safety tables. Outcomes described narratively including near-complete resolution of alopecia universalis after 7 months of upadacitinib 30mg daily, with concurrent Crohn's disease remission."
        }
      },
      "market_intelligence": {
        "disease": "Alopecia Areata",
        "parent_disease": null,
        "epidemiology": {
          "us_prevalence_estimate": "0.17-0.22%",
          "us_incidence_estimate": "91-93 cases per 100,000 patient-years",
          "global_prevalence": null,
          "patient_population_size": 6700000,
          "prevalence_source": "Journal of the American Academy of Dermatology",
          "prevalence_source_url": "https://www.jaad.org/article/S0190-9622(22)01464-5/fulltext",
          "trend": "stable",
          "source_quality": "Primary",
          "data_year": 2019,
          "geographic_scope": "US",
          "confidence": "High",
          "notes": "Multiple recent US studies show consistent prevalence estimates ranging from 0.17-0.22%, with higher rates in females vs males and African Americans vs whites. Lifetime incidence risk estimated at 2%."
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Olumiant (baricitinib)",
              "drug_class": "JAK inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Alopecia Areata",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "First systemic immunotherapy approved by FDA for adults with severe alopecia areata. Recommended dosage 2 mg once daily, can increase to 4 mg daily.",
              "approval_year": 2022,
              "approval_confidence": "High",
              "approval_evidence": "FDA approval June 2022 for adults with severe alopecia areata"
            },
            {
              "drug_name": "Litfulo (ritlecitinib)",
              "drug_class": "JAK inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Alopecia Areata",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "Second JAK inhibitor approved for severe alopecia areata, approved for patients 12 years and older.",
              "approval_year": 2023,
              "approval_confidence": "High",
              "approval_evidence": "FDA approval June 2023 for patients ages 12 years and older with severe alopecia areata"
            },
            {
              "drug_name": "Leqselvi (deuruxolitinib)",
              "drug_class": "JAK inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Alopecia Areata",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "Third JAK inhibitor approved for severe alopecia areata in adults. Oral formulation.",
              "approval_year": 2024,
              "approval_confidence": "High",
              "approval_evidence": "FDA approval July 2024 for adults with severe alopecia areata"
            }
          ],
          "approved_drug_names": [
            "Olumiant (baricitinib)",
            "Litfulo (ritlecitinib)",
            "Leqselvi (deuruxolitinib)"
          ],
          "num_approved_drugs": 3,
          "num_pipeline_therapies": 9,
          "pipeline_therapies": [
            {
              "drug_name": "Microbiota Transplant Therapy",
              "company": "University of Minnesota",
              "mechanism": "Gut microbiome modulation",
              "phase": "Phase 2",
              "trial_id": "NCT06747611",
              "expected_completion": "2028-03",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Novel approach targeting microbiota in alopecia areata"
            },
            {
              "drug_name": "Ritlecitinib",
              "company": "Pfizer",
              "mechanism": "JAK3/TEC family kinase inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT06873945",
              "expected_completion": "2027-03",
              "trial_name": "ALLEGRO-100",
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Testing 50mg and 100mg doses in patients 12 years and older"
            },
            {
              "drug_name": "Tofacitinib",
              "company": "Jinnah Hospital",
              "mechanism": "JAK inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT06278402",
              "expected_completion": null,
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": null,
              "notes": "Completed January 2024, studying moderate to severe AA"
            },
            {
              "drug_name": "EQ101",
              "company": "Equillium",
              "mechanism": "CD6-targeted immunomodulator",
              "phase": "Phase 2",
              "trial_id": "NCT05589610",
              "expected_completion": null,
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": null,
              "notes": "Open-label study completed March 2024"
            },
            {
              "drug_name": "Ruxolitinib",
              "company": "National Institute of Allergy and Infectious Diseases (NIAID)",
              "mechanism": "JAK1/JAK2 inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT05398809",
              "expected_completion": "2027-12",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Specifically for APECED-associated alopecia areata"
            },
            {
              "drug_name": "STS01",
              "company": "Soterios Ltd",
              "mechanism": "Non-steroidal topical treatment",
              "phase": "Phase 2",
              "trial_id": "NCT06402630",
              "expected_completion": null,
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": null,
              "notes": "Completed April 2024, for mild-moderate AA"
            },
            {
              "drug_name": "Etrasimod",
              "company": "Pfizer",
              "mechanism": "Selective S1P receptor modulator",
              "phase": "Phase 2",
              "trial_id": "NCT04556734",
              "expected_completion": null,
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": null,
              "notes": "Completed June 2023, moderate-to-severe AA"
            },
            {
              "drug_name": "Upadacitinib",
              "company": "AbbVie",
              "mechanism": "JAK1 inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT06012240",
              "expected_completion": "2028-01",
              "trial_name": "UP-AA",
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Positive topline results reported in 2025, seeking approval"
            },
            {
              "drug_name": "Rezpegaldesleukin",
              "company": "Nektar Therapeutics",
              "mechanism": "IL-2 receptor complex agonist/Treg stimulator",
              "phase": "Phase 2",
              "trial_id": "Unknown - verify",
              "expected_completion": null,
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": "Fast Track",
              "notes": "Received FDA Fast Track designation in July 2025"
            }
          ],
          "pipeline_details": "Nine active clinical programs are in Phase 2-3 development for alopecia areata, dominated by JAK inhibitors but including novel approaches like microbiota transplant therapy and IL-2 receptor modulators. AbbVie's upadacitinib has reported positive Phase 3 results and is seeking regulatory approval, while Pfizer's ritlecitinib continues Phase 3 recruitment.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "JAK inhibitors are considered first-line treatment for severe alopecia areata (\u226550% scalp hair loss), with three FDA-approved options now available. For mild to moderate disease, topical corticosteroids and intralesional corticosteroid injections remain standard approaches, often combined with topical minoxidil.",
          "unmet_need": false,
          "unmet_need_description": null,
          "competitive_landscape": "The alopecia areata market has been rapidly transformed with three JAK inhibitors approved in just three years (2022-2024), providing systemic treatment options for severe disease. All three drugs target the same pathway but may offer different dosing or patient population advantages.",
          "soc_source": "Medscape Alopecia Areata Overview and FDA Drug Labels",
          "phase_3_count": 3,
          "phase_2_count": 6,
          "key_catalysts": "AbbVie expected to file for upadacitinib approval in 2025-2026 based on positive UP-AA Phase 3 results; Pfizer's ritlecitinib Phase 3 ALLEGRO-100 trial completion expected March 2027",
          "pipeline_data_quality": "High",
          "recent_approvals": "Olumiant (baricitinib) June 2022, Litfulo (ritlecitinib) June 2023, Leqselvi (deuruxolitinib) July 2024",
          "data_quality": "High",
          "data_quality_notes": "Multiple sources confirm FDA approvals with specific approval dates and indications. All three approvals are for severe alopecia areata specifically."
        },
        "market_size_estimate": "$167.5B",
        "market_size_usd": 167500000000.0,
        "growth_rate": "3-5% CAGR (stable prevalence)",
        "tam_usd": 850000000.0,
        "tam_estimate": "$850M",
        "tam_rationale": "Of ~6.7M US alopecia areata patients, ~80% are diagnosed (5.4M), but only ~15% have moderate-severe disease warranting systemic JAK inhibitor therapy (~810K patients). With 3 approved JAK inhibitors already established as first-line for severe cases, a new entrant could realistically capture 15-20% market share (~135K patients). At $50K/year pricing (consistent with autoimmune-dermatology benchmarks), TAM = 135K \u00d7 $50K = $675M-850M.",
        "tam_sources": [
          "https://bisresearch.com/industry-report/alopecia-areata-market.html",
          "https://www.prnewswire.com/news-releases/alopecia-areata-market-to-show-positive-growth-at-a-cagr-of-26-3-during-the-study-period-20192032-estimates-delveinsight-301853907.html",
          "https://www.giiresearch.com/report/tbrc1824572-alopecia-global-market-report.html"
        ],
        "pipeline_sources": [
          "https://clinicaltrials.gov",
          "https://clinicaltrials.gov/study/NCT03732807",
          "https://cdn.clinicaltrials.gov/large-docs/07/NCT03732807/Prot_000.pdf",
          "https://cdn.clinicaltrials.gov/large-docs/49/NCT03570749/Prot_002.pdf",
          "https://www.clinicaltrials.gov/study/NCT06012240"
        ],
        "attributed_sources": [
          {
            "url": "https://www.jaad.org/article/S0190-9622(22)01464-5/fulltext",
            "title": "33432 Prevalence estimates for alopecia areata in ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9979012/",
            "title": "Trends in Prevalence and Incidence of Alopecia Areata ... - NIH",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://emedicine.medscape.com/article/1069931-overview",
            "title": "Alopecia Areata: Practice Essentials, Background, ...",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://emedicine.medscape.com/article/1069931-medication",
            "title": "Alopecia Areata Medication: Glucocorticoids, Vasodilators ...",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3149478/",
            "title": "Alopecia areata: a new treatment plan - PMC",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://clinicaltrials.gov",
            "title": "ClinicalTrials.gov API",
            "attribution": "Pipeline/Clinical Trials (Primary)"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT03732807",
            "title": "PF-06651600 for the Treatment of Alopecia Areata",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://cdn.clinicaltrials.gov/large-docs/07/NCT03732807/Prot_000.pdf",
            "title": "a phase 2b/3 randomized, double-blind, placebo-controlled",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://bisresearch.com/industry-report/alopecia-areata-market.html",
            "title": "Alopecia Areata Market Size & Forecast | BIS Research",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.prnewswire.com/news-releases/alopecia-areata-market-to-show-positive-growth-at-a-cagr-of-26-3-during-the-study-period-20192032-estimates-delveinsight-301853907.html",
            "title": "Alopecia Areata Market to Show Positive Growth at a CAGR of 26.3 ...",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 9.6,
        "evidence_quality": 3.7,
        "market_opportunity": 7.7,
        "overall_priority": 7.6,
        "clinical_breakdown": {
          "response_rate_quality_weighted": 10.0,
          "safety_profile": 9.0,
          "organ_domain_breadth": 10.0,
          "safety_categories": [],
          "regulatory_flags": [],
          "efficacy_endpoint_count": 5,
          "efficacy_concordance": 1.15
        },
        "response_rate_score": 10.0,
        "safety_profile_score": 9.0,
        "endpoint_quality_score": null,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 1.0,
          "publication_venue": 2.0,
          "response_durability": 7.0,
          "extraction_completeness": 7.2
        },
        "sample_size_score": 1.0,
        "publication_venue_score": 2.0,
        "followup_duration_score": 7.0,
        "extraction_completeness_score": 7.2,
        "market_breakdown": {
          "competitors": 5.0,
          "market_size": 10.0,
          "unmet_need": 8.0
        },
        "competitors_score": 5.0,
        "market_size_score": 10.0,
        "unmet_need_score": 8.0
      },
      "rank": 18
    },
    {
      "extraction": {
        "source": {
          "pmid": "39906475",
          "doi": "10.1177/2050313X251317811",
          "url": "https://www.semanticscholar.org/paper/f94fdba379ed3667b7afc310c93a58e34f4d1d8c",
          "title": "Dupilumab-induced psoriasis in a patient with atopic dermatitis successfully treated with Upadacitinib: A case report",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Web source",
          "is_open_access": false
        },
        "disease": "Dupilumab-induced psoriasis",
        "disease_normalized": "Psoriasis",
        "is_off_label": true,
        "is_relevant": true,
        "evidence_level": "Case Report",
        "patient_population": {
          "n_patients": 1,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "Dupilumab",
            "Apremilast",
            "topical calcipotriol",
            "topical betamethasone dipropionate",
            "topical hydrocortisone"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "66-year-old female with longstanding atopic dermatitis who developed new-onset psoriasis while on Dupilumab therapy"
        },
        "treatment": {
          "drug_name": "upadacitinib",
          "generic_name": "Upadacitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "15 mg",
          "frequency": null,
          "duration": "over 1 year",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "1/1 (100%)",
          "responders_n": 1,
          "responders_pct": 100.0,
          "time_to_response": null,
          "duration_of_response": "over 1 year and ongoing",
          "effect_size_description": "Complete clearance with BSA 0% and EASI 0",
          "primary_endpoint": "Disease control measured by BSA and EASI scores",
          "endpoint_result": "BSA 0%, EASI 0",
          "durability_signal": null,
          "efficacy_summary": "The patient achieved excellent disease control with complete clearance (BSA 0%, EASI 0) on upadacitinib treatment. This response has been sustained for over one year with ongoing treatment."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": 0,
          "sae_percentage": 0.0,
          "discontinuations_n": 0,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "The patient experienced no adverse events during over one year of treatment with upadacitinib. Treatment was well tolerated with no safety concerns reported.",
          "safety_profile": "Favorable"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": "over 1 year",
        "key_findings": "Upadacitinib successfully treated Dupilumab-induced psoriasis where topical therapy and Apremilast had failed, achieving complete disease clearance.",
        "detailed_efficacy_endpoints": [
          {
            "endpoint_name": "BSA (Body Surface Area)",
            "endpoint_category": "Primary",
            "timepoint": "April 2019",
            "measurement_type": "Absolute value",
            "value": 60.0,
            "unit": "percentage",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "final_value": 60.0,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Extensive dermatitis flare before Dupilumab initiation",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "BSA (Body Surface Area)",
            "endpoint_category": "Primary",
            "timepoint": "May 2019 - first 2 years",
            "measurement_type": "Absolute value",
            "value": 0.0,
            "unit": "percentage",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "final_value": 0.0,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Excellent response to Dupilumab over first 2 years",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "EASI (Eczema Area and Severity Index)",
            "endpoint_category": "Primary",
            "timepoint": "May 2019 - first 2 years",
            "measurement_type": "Absolute value",
            "value": 0.0,
            "unit": "score",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "final_value": 0.0,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Excellent response to Dupilumab over first 2 years",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "BSA (Body Surface Area)",
            "endpoint_category": "Primary",
            "timepoint": "March 2021",
            "measurement_type": "Absolute value",
            "value": 55.0,
            "unit": "percentage",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "final_value": 55.0,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "New-onset widespread psoriasiform plaques while on Dupilumab",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "PASI (Psoriasis Area Severity Index)",
            "endpoint_category": "Primary",
            "timepoint": "March 2021",
            "measurement_type": "Absolute value",
            "value": 11.6,
            "unit": "score",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "final_value": 11.6,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "New-onset psoriasis while on Dupilumab",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "BSA (Body Surface Area)",
            "endpoint_category": "Primary",
            "timepoint": "June 2022",
            "measurement_type": "Absolute value",
            "value": 10.0,
            "unit": "percentage",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "final_value": 10.0,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "After one year of Apremilast treatment, skin resembling AD more than psoriasis",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "EASI (Eczema Area and Severity Index)",
            "endpoint_category": "Primary",
            "timepoint": "June 2022",
            "measurement_type": "Absolute value",
            "value": 9.4,
            "unit": "score",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "final_value": 9.4,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "After one year of Apremilast treatment, developed dermatitis plaques",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "BSA (Body Surface Area)",
            "endpoint_category": "Primary",
            "timepoint": "After June 2022 (>1 year on Upadacitinib)",
            "measurement_type": "Absolute value",
            "value": 0.0,
            "unit": "percentage",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "final_value": 0.0,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Excellent disease control on Upadacitinib 15mg daily for over a year",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "EASI (Eczema Area and Severity Index)",
            "endpoint_category": "Primary",
            "timepoint": "After June 2022 (>1 year on Upadacitinib)",
            "measurement_type": "Absolute value",
            "value": 0.0,
            "unit": "score",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "final_value": 0.0,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Excellent disease control on Upadacitinib 15mg daily for over a year",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          }
        ],
        "detailed_safety_endpoints": [],
        "extraction_timestamp": "2025-12-08T18:44:30.281065",
        "extraction_confidence": 0.6,
        "extraction_confidence_detail": null,
        "extraction_method": "multi_stage",
        "extraction_stages_completed": [
          "section_identification",
          "efficacy_extraction",
          "safety_extraction"
        ],
        "data_sections_identified": {
          "baseline_tables": [],
          "efficacy_tables": [
            "Table 1. Summary of treatments, dosage, and response during the case report - contains treatment timeline with clinical response measures (BSA, EASI, PASI scores) from October 2016 through June 2022"
          ],
          "safety_tables": [],
          "efficacy_figures": [],
          "results_sections": [
            "Case report section - describes patient presentation, treatment course, and clinical outcomes",
            "Discussion section - summarizes treatment response and theoretical mechanisms"
          ],
          "patient_count": 1,
          "study_type": "Case Report",
          "has_quantitative_outcomes": true,
          "notes": "Single patient case report with detailed treatment timeline. Figure 1 shows clinical images but not quantitative outcomes. Baseline demographics provided in narrative form rather than tabulated. Safety data mentioned narratively but not tabulated."
        }
      },
      "market_intelligence": {
        "disease": "Psoriasis",
        "parent_disease": null,
        "epidemiology": {
          "us_prevalence_estimate": "3.0% of adults 20 years or older",
          "us_incidence_estimate": null,
          "global_prevalence": null,
          "patient_population_size": 7550000,
          "prevalence_source": "JAMA Dermatology",
          "prevalence_source_url": "https://pubmed.ncbi.nlm.nih.gov/34190957/",
          "trend": "stable",
          "source_quality": "Primary",
          "data_year": 2021,
          "geographic_scope": "US",
          "confidence": "High",
          "notes": "Prevalence has not changed since 2003 evaluation. Study included 12,625 participants from cross-sectional study. Approximately 600,000 adults in the US live with undiagnosed psoriasis."
        },
        "standard_of_care": {
          "top_treatments": [],
          "approved_drug_names": [],
          "num_approved_drugs": 0,
          "num_pipeline_therapies": 0,
          "pipeline_therapies": [],
          "pipeline_details": null,
          "avg_annual_cost_usd": null,
          "treatment_paradigm": null,
          "unmet_need": false,
          "unmet_need_description": null,
          "competitive_landscape": null,
          "soc_source": null,
          "phase_3_count": 0,
          "phase_2_count": 0,
          "key_catalysts": null,
          "pipeline_data_quality": "Unknown",
          "recent_approvals": null,
          "data_quality": "Unknown",
          "data_quality_notes": null
        },
        "market_size_estimate": "$188.8B",
        "market_size_usd": 188750000000.0,
        "growth_rate": "3-5% CAGR (stable prevalence)",
        "tam_usd": 2268000000.0,
        "tam_estimate": "$2.3B",
        "tam_rationale": "Of 7.55M US psoriasis patients, approximately 70% are diagnosed (5.3M) and 60% of moderate-severe cases receive systemic treatment (~1.6M). New drugs typically enter as 2L+ therapy, targeting 30-40% of treated patients (~540K). A new entrant could realistically capture 20-25% market share (~120K patients) in this competitive biologics market. At $45K/yr average pricing for psoriasis biologics, TAM = $5.4B potential, but realistic penetration suggests $2.3B addressable market.",
        "tam_sources": [
          "https://summit.sfu.ca/_flysystem/fedora/sfu_migrate/2512/etd2634.pdf",
          "https://www.thebusinessresearchcompany.com/report/dermatology-global-market-report",
          "https://www.niams.nih.gov/es/informacion-de-salud/psoriasis"
        ],
        "pipeline_sources": [
          "https://clinicaltrials.gov",
          "https://cdn.clinicaltrials.gov/large-docs/51/NCT03611751/Prot_000.pdf",
          "https://cdn.clinicaltrials.gov/large-docs/87/NCT03478787/Prot_000.pdf",
          "https://clinicaltrials.gov/study/NCT01107457",
          "https://cdn.clinicaltrials.gov/large-docs/98/NCT02718898/Prot_000.pdf"
        ],
        "attributed_sources": [
          {
            "url": "https://pubmed.ncbi.nlm.nih.gov/34190957/",
            "title": "Psoriasis Prevalence in Adults in the United States - PubMed",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.psoriasis.org/prevalence-of-psoriasis/",
            "title": "Prevalence of Psoriasis",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.drugs.com/medical-answers/new-drugs-treatment-plaque-psoriasis-3511670/",
            "title": "What are the new drugs for plaque psoriasis?",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.fda.gov/news-events/press-announcements/fda-approves-new-psoriasis-drug-taltz",
            "title": "FDA approves new psoriasis drug Taltz",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.aad.org/member/clinical-quality/guidelines/psoriasis",
            "title": "Psoriasis clinical guideline - American Academy of Dermatology",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://clinicaltrials.gov",
            "title": "ClinicalTrials.gov API",
            "attribution": "Pipeline/Clinical Trials (Primary)"
          },
          {
            "url": "https://cdn.clinicaltrials.gov/large-docs/51/NCT03611751/Prot_000.pdf",
            "title": "Clinical Protocol IM011047",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://cdn.clinicaltrials.gov/large-docs/87/NCT03478787/Prot_000.pdf",
            "title": "NCT03478787",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://summit.sfu.ca/_flysystem/fedora/sfu_migrate/2512/etd2634.pdf",
            "title": "[PDF] A STRATEGIC ANALYSIS OF A PRODUCT IN THE ... - SFU Summit",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.thebusinessresearchcompany.com/report/dermatology-global-market-report",
            "title": "Dermatology Market Report 2025, Growth Insights & Forecast 2034",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 7.9,
        "evidence_quality": 4.3,
        "market_opportunity": 10.0,
        "overall_priority": 7.5,
        "clinical_breakdown": {
          "response_rate_quality_weighted": 4.7,
          "safety_profile": 10.0,
          "organ_domain_breadth": 10.0,
          "safety_categories": [],
          "regulatory_flags": [],
          "efficacy_endpoint_count": 9,
          "efficacy_concordance": 0.9
        },
        "response_rate_score": 4.7,
        "safety_profile_score": 10.0,
        "endpoint_quality_score": null,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 1.0,
          "publication_venue": 2.0,
          "response_durability": 9.0,
          "extraction_completeness": 7.8
        },
        "sample_size_score": 1.0,
        "publication_venue_score": 2.0,
        "followup_duration_score": 9.0,
        "extraction_completeness_score": 7.8,
        "market_breakdown": {
          "competitors": 10.0,
          "market_size": 10.0,
          "unmet_need": 10.0
        },
        "competitors_score": 10.0,
        "market_size_score": 10.0,
        "unmet_need_score": 10.0
      },
      "rank": 19
    },
    {
      "extraction": {
        "source": {
          "pmid": "38928687",
          "doi": "10.3390/diagnostics14121272",
          "url": "https://www.semanticscholar.org/paper/f531d8564f7c4b45974793bb1a8ba23bd51edf5f",
          "title": "A Case of Refractory Vernal Keratoconjunctivitis Showing Improvement after the Administration of Upadacitinib for the Treatment of Atopic Dermatitis",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Web source",
          "is_open_access": false
        },
        "disease": "Vernal Keratoconjunctivitis",
        "disease_normalized": "Vernal Keratoconjunctivitis",
        "is_off_label": true,
        "is_relevant": true,
        "evidence_level": "Case Report",
        "patient_population": {
          "n_patients": 1,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "oral antihistamines",
            "topical steroids",
            "topical cyclosporine eye drops",
            "topical tacrolimus eye drops"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "18-year-old Japanese female with atopic dermatitis, vernal keratoconjunctivitis, and hay fever since childhood"
        },
        "treatment": {
          "drug_name": "upadacitinib",
          "generic_name": "Upadacitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "15 mg daily",
          "frequency": null,
          "duration": "5 months",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": null,
          "responders_n": 1,
          "responders_pct": 100.0,
          "time_to_response": "2 months",
          "duration_of_response": "At least 5 months",
          "effect_size_description": "Marked improvement in refractory VKC with flattening of giant papillae and stabilization of corneal vascularization",
          "primary_endpoint": "Improvement in VKC symptoms and signs",
          "endpoint_result": "Giant papillae and severe peripheral corneal vascularization began to flatten within 2 months, remained stable through spring season",
          "durability_signal": null,
          "efficacy_summary": "Treatment-resistant vernal keratoconjunctivitis showed rapid improvement after upadacitinib administration. Giant papillae and severe peripheral corneal vascularization began to flatten within 2 months and remained stable even during the challenging spring pollen season."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": 0,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "No adverse drug reactions were reported during the 5-month treatment period. The patient tolerated the medication well with no safety concerns noted.",
          "safety_profile": "Favorable"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": "5 months",
        "key_findings": "First reported case suggesting potential utility of upadacitinib in managing severe vernal keratoconjunctivitis, with rapid improvement in refractory disease within 2 months of treatment initiation.",
        "detailed_efficacy_endpoints": [
          {
            "endpoint_name": "IgE level",
            "endpoint_category": "Exploratory",
            "timepoint": "Baseline",
            "measurement_type": "Absolute value",
            "value": 8973.0,
            "unit": "IU/mL",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 8973.0,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Baseline value only, no follow-up reported",
            "organ_domain": "Immunological",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "TARC level",
            "endpoint_category": "Exploratory",
            "timepoint": "Baseline",
            "measurement_type": "Absolute value",
            "value": 1602.0,
            "unit": "pg/mL",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 1602.0,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Baseline value only, no follow-up reported",
            "organ_domain": "Immunological",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Axillary lymph node diameter",
            "endpoint_category": "Exploratory",
            "timepoint": "Baseline",
            "measurement_type": "Absolute value",
            "value": 15.0,
            "unit": "mm",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 15.0,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Baseline measurement only, no follow-up reported",
            "organ_domain": "Systemic",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Time to improvement in itching and erythema",
            "endpoint_category": "Secondary",
            "timepoint": "1 month",
            "measurement_type": "Absolute value",
            "value": 1.0,
            "unit": "months",
            "total_n": 1,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Qualitative improvement described as marked reduction in severe itching and widespread erythema",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Time to improvement in VKC",
            "endpoint_category": "Secondary",
            "timepoint": "2 months",
            "measurement_type": "Absolute value",
            "value": 2.0,
            "unit": "months",
            "total_n": 1,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Giant papillae and severe peripheral corneal vascularization began to flatten within 2 months",
            "organ_domain": "Ocular",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Overall disease control",
            "endpoint_category": "Primary",
            "timepoint": "5 months",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 1,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "AD and VKC were well managed without any symptoms of discomfort or adverse drug reactions at 5 months",
            "organ_domain": "Systemic",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          }
        ],
        "detailed_safety_endpoints": [],
        "extraction_timestamp": "2025-12-08T18:48:12.400242",
        "extraction_confidence": 0.6,
        "extraction_confidence_detail": null,
        "extraction_method": "multi_stage",
        "extraction_stages_completed": [
          "section_identification",
          "efficacy_extraction",
          "safety_extraction"
        ],
        "data_sections_identified": {
          "baseline_tables": [],
          "efficacy_tables": [],
          "safety_tables": [],
          "efficacy_figures": [
            "Figure 1: Biomicroscopy showing giant cobblestone papillae, thickened tarsal conjunctivae, mucous discharge, severe peripheral corneal vascularization, diffuse punctate keratitis, and residual paracentral leukomas at baseline",
            "Figure 2: Surface ultrasonography showing swollen axillary lymph nodes enlarged to 15 mm diameter",
            "Figure 3: Clinical improvement after upadacitinib treatment showing flattening of giant papillae and stabilization of peripheral corneal vascularization"
          ],
          "results_sections": [
            "Case Presentation section describing clinical course and treatment response",
            "Discussion section analyzing mechanism of action and treatment rationale"
          ],
          "patient_count": 1,
          "study_type": "Case Report",
          "has_quantitative_outcomes": false,
          "notes": "Single case report of 18-year-old female with refractory VKC and atopic dermatitis treated with upadacitinib 15mg. Clinical improvement described qualitatively with photographic documentation. Some laboratory values provided (IgE 8973 IU/mL, TARC 1602 pg/mL) but no standardized efficacy outcome measures. No adverse events reported over 5-month follow-up period."
        }
      },
      "market_intelligence": {
        "disease": "Vernal Keratoconjunctivitis",
        "parent_disease": "Keratoconjunctivitis",
        "epidemiology": {
          "us_prevalence_estimate": "1.24 per 10,000",
          "us_incidence_estimate": "0.29 per 10,000 persons annually",
          "global_prevalence": null,
          "patient_population_size": 41540,
          "prevalence_source": "IOVS",
          "prevalence_source_url": "https://iovs.arvojournals.org/article.aspx?articleid=2768621",
          "trend": "increasing",
          "source_quality": "Primary",
          "data_year": 2017,
          "geographic_scope": "US",
          "confidence": "Medium",
          "notes": "Data specifically for vernal keratoconjunctivitis (VKC), which is a subtype of keratoconjunctivitis. General keratoconjunctivitis prevalence much higher with up to 17% affected for dry eye type. Asian populations showing increasing prevalence from 6.26 to 11.80 per 10,000 from 2008-2019."
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Verkazia (cyclosporine)",
              "drug_class": "Calcineurin inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Vernal keratoconjunctivitis",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": null,
              "notes": "FDA approved for vernal keratoconjunctivitis in children and adults, 0.1% ophthalmic emulsion, QID dosing",
              "approval_year": 2021,
              "approval_confidence": "High",
              "approval_evidence": "FDA drug label NDA 214965"
            },
            {
              "drug_name": "Restasis (cyclosporine)",
              "drug_class": "Calcineurin inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Keratoconjunctivitis sicca",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": null,
              "notes": "FDA approved to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca",
              "approval_year": null,
              "approval_confidence": "High",
              "approval_evidence": "FDA drug label NDA 50-790"
            },
            {
              "drug_name": "Cequa (cyclosporine)",
              "drug_class": "Calcineurin inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Keratoconjunctivitis sicca",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": null,
              "notes": "FDA approved 0.09% cyclosporine ophthalmic solution to increase tear production in patients with keratoconjunctivitis sicca (dry eye)",
              "approval_year": 2018,
              "approval_confidence": "High",
              "approval_evidence": "FDA review document NDA 210913"
            }
          ],
          "approved_drug_names": [
            "Verkazia (cyclosporine)",
            "Restasis (cyclosporine)",
            "Cequa (cyclosporine)"
          ],
          "num_approved_drugs": 3,
          "num_pipeline_therapies": 10,
          "pipeline_therapies": [
            {
              "drug_name": "Diquafosol",
              "company": "The University of Hong Kong",
              "mechanism": "P2Y2 receptor agonist",
              "phase": "Phase 3",
              "trial_id": "NCT06903884",
              "expected_completion": "2028-06",
              "trial_name": null,
              "status": "Not yet recruiting",
              "regulatory_designations": null,
              "notes": "Combination therapy with cyclosporin A for moderate-to-severe vernal keratoconjunctivitis"
            },
            {
              "drug_name": "BRM421",
              "company": "BRIM Biotechnology Inc.",
              "mechanism": null,
              "phase": "Phase 2",
              "trial_id": "NCT07078955",
              "expected_completion": "2026-11",
              "trial_name": null,
              "status": "Not yet recruiting",
              "regulatory_designations": null,
              "notes": "Dose regimen study for dry eye disease"
            },
            {
              "drug_name": "T1695",
              "company": "Laboratoires Thea",
              "mechanism": null,
              "phase": "Phase 2",
              "trial_id": "NCT07169695",
              "expected_completion": "2027-01",
              "trial_name": null,
              "status": "Not yet recruiting",
              "regulatory_designations": null,
              "notes": "Comparative study versus ciclosporin for moderate to severe vernal keratoconjunctivitis"
            },
            {
              "drug_name": "Dupilumab",
              "company": "Andover Eye Associates",
              "mechanism": "IL-4/IL-13 inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT04296864",
              "expected_completion": "2025-01",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Monoclonal antibody for atopic keratoconjunctivitis"
            },
            {
              "drug_name": "Tivanisiran",
              "company": "Sylentis, S.A.",
              "mechanism": "siRNA targeting TRPV1",
              "phase": "Phase 3",
              "trial_id": "NCT05310422",
              "expected_completion": "2023-10",
              "trial_name": null,
              "status": "Completed",
              "regulatory_designations": null,
              "notes": "Recently completed safety study for dry eye"
            },
            {
              "drug_name": "INV-102",
              "company": "Invirsa, Inc.",
              "mechanism": null,
              "phase": "Phase 2",
              "trial_id": "NCT05636228",
              "expected_completion": "2024-08",
              "trial_name": null,
              "status": "Completed",
              "regulatory_designations": null,
              "notes": "Multiple completed studies for acute infectious keratoconjunctivitis and dry eye"
            },
            {
              "drug_name": "Autologous Serum",
              "company": "St. Petersburg State Pavlov Medical University",
              "mechanism": "Growth factors and cytokines",
              "phase": "Phase 2",
              "trial_id": "NCT05311514",
              "expected_completion": "2024-11",
              "trial_name": null,
              "status": "Completed",
              "regulatory_designations": null,
              "notes": "Allogeneic platelet lysate eye drops for severe chronic ocular GVHD"
            },
            {
              "drug_name": "Tavilermide",
              "company": "Mimetogen Pharmaceuticals USA, Inc.",
              "mechanism": "VIP/PACAP receptor agonist",
              "phase": "Phase 3",
              "trial_id": "NCT05848128",
              "expected_completion": "2024-05",
              "trial_name": null,
              "status": "Completed",
              "regulatory_designations": null,
              "notes": "Recently completed Phase 3 study for dry eye"
            },
            {
              "drug_name": "Levocarnitine",
              "company": "Vanderbilt University Medical Center",
              "mechanism": "Metabolic modulator",
              "phase": "Phase 2",
              "trial_id": "NCT03953703",
              "expected_completion": "2025-09",
              "trial_name": null,
              "status": "Completed",
              "regulatory_designations": null,
              "notes": "Crossover trial for keratoconjunctivitis sicca in Sjogren's syndrome"
            },
            {
              "drug_name": "Cultivated Autologous Limbal Epithelial Cells",
              "company": "Massachusetts Eye and Ear Infirmary",
              "mechanism": "Cell therapy",
              "phase": "Phase 2",
              "trial_id": "NCT02592330",
              "expected_completion": "2023-03",
              "trial_name": "CALEC",
              "status": "Completed",
              "regulatory_designations": null,
              "notes": "Cell therapy graft for limbal stem cell deficiency"
            }
          ],
          "pipeline_details": "The keratoconjunctivitis pipeline shows active development with 10 therapies across Phase 2-3 trials. Key mechanisms include siRNA (Tivanisiran), IL-4/IL-13 inhibition (Dupilumab), P2Y2 receptor agonism (Diquafosol), and novel approaches like cell therapy and autologous serum. Several programs have recently completed Phase 3 trials including Tivanisiran and Tavilermide, indicating potential near-term regulatory submissions.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "Treatment approach varies by keratoconjunctivitis subtype. For vernal keratoconjunctivitis, first-line includes allergen avoidance and topical antihistamines/mast cell stabilizers, with topical calcineurin inhibitors like Verkazia for moderate to severe cases. For keratoconjunctivitis sicca (dry eye), topical cyclosporine formulations (Restasis, Cequa) are used to increase tear production.",
          "unmet_need": true,
          "unmet_need_description": "Limited FDA-approved branded innovative treatments for keratoconjunctivitis subtypes, with only one approved drug for vernal keratoconjunctivitis and reliance on off-label use of treatments approved for related conditions",
          "competitive_landscape": "Cyclosporine dominates the branded innovative treatment landscape with multiple formulations (Restasis 0.05%, Cequa 0.09%, Verkazia 0.1%) targeting different keratoconjunctivitis subtypes. Most other treatments rely on generic medications or off-label use of drugs approved for related conditions.",
          "soc_source": "FDA drug labels and review documents from accessdata.fda.gov",
          "phase_3_count": 3,
          "phase_2_count": 7,
          "key_catalysts": "Dupilumab Phase 2 results expected by early 2025 for atopic keratoconjunctivitis, with multiple upcoming trials including T1695 and Diquafosol studies starting in 2025-2026",
          "pipeline_data_quality": "High",
          "recent_approvals": "Verkazia (cyclosporine 0.1%) approved in 2021 for vernal keratoconjunctivitis",
          "data_quality": "High",
          "data_quality_notes": "FDA approval confirmations available from official FDA drug labels and review documents, though cost data not available"
        },
        "market_size_estimate": "$4.2B",
        "market_size_usd": 4154000000.0,
        "growth_rate": "5-10% CAGR (increasing prevalence)",
        "tam_usd": 62280000.0,
        "tam_estimate": "$62.3M",
        "tam_rationale": "Of ~41,540 US patients with vernal keratoconjunctivitis, ~70% are diagnosed (29,078), ~85% receive treatment (24,716) given the severe nature and quality of life impact. This rare ophthalmologic condition with only 3 approved drugs and significant unmet need positions a new drug as 2L therapy after antihistamines/mast cell stabilizers fail. A new drug could capture 30% market share (~7,415 patients) given the underserved market. At $8,400/yr pricing typical for specialty ophthalmology drugs like Verkazia, TAM = $62.3M.",
        "tam_sources": [
          "https://www.futuremarketinsights.com/reports/allergic-conjunctivitis-treatment-market",
          "https://www.mdpi.com/1424-8247/15/5/547",
          "https://www.annualreports.com/HostedData/AnnualReportArchive/r/NASDAQ_RAPT_2019.pdf"
        ],
        "pipeline_sources": [
          "https://clinicaltrials.gov",
          "https://clinicaltrials.gov/study/NCT01751126",
          "https://clinicaltrials.gov/study/NCT00349466",
          "https://clinicaltrials.gov/study/NCT06392438",
          "https://clinicaltrials.gov/study/NCT07169695"
        ],
        "attributed_sources": [
          {
            "url": "https://www.delveinsight.com/blog/vernal-keratoconjunctivitis-vkc-market",
            "title": "Vernal keratoconjunctivitis Market Size and Share - DelveInsight",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://iovs.arvojournals.org/article.aspx?articleid=2768621",
            "title": "Epidemiology of Vernal Keratoconjunctivitis in the United States - IOVS",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206276Orig1s005.pdf",
            "title": "CENTER FOR DRUG EVALUATION AND RESEARCH",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210913Orig1s000SumR.pdf",
            "title": "Summary Review - accessdata.fda.gov",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4108143/",
            "title": "Management of Vernal Keratoconjunctivitis - PMC",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://clinicaltrials.gov",
            "title": "ClinicalTrials.gov API",
            "attribution": "Pipeline/Clinical Trials (Primary)"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT01751126",
            "title": "Double-Masked Trial of NOVA22007 (1mg/mL Ciclosporin ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT00349466",
            "title": "NCT00349466 | Safety and Efficacy Study of CF101 to ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.futuremarketinsights.com/reports/allergic-conjunctivitis-treatment-market",
            "title": "Conjunctivitis Market Size, Trends & Forecast 2025 to 2035",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.mdpi.com/1424-8247/15/5/547",
            "title": "Therapeutic Targets in Allergic Conjunctivitis - MDPI",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 9.5,
        "evidence_quality": 3.2,
        "market_opportunity": 7.7,
        "overall_priority": 7.5,
        "clinical_breakdown": {
          "response_rate_quality_weighted": 9.7,
          "safety_profile": 9.0,
          "organ_domain_breadth": 10.0,
          "safety_categories": [],
          "regulatory_flags": [],
          "efficacy_endpoint_count": 6,
          "efficacy_concordance": 1.1
        },
        "response_rate_score": 9.7,
        "safety_profile_score": 9.0,
        "endpoint_quality_score": null,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 1.0,
          "publication_venue": 2.0,
          "response_durability": 5.0,
          "extraction_completeness": 7.2
        },
        "sample_size_score": 1.0,
        "publication_venue_score": 2.0,
        "followup_duration_score": 5.0,
        "extraction_completeness_score": 7.2,
        "market_breakdown": {
          "competitors": 5.0,
          "market_size": 8.0,
          "unmet_need": 10.0
        },
        "competitors_score": 5.0,
        "market_size_score": 8.0,
        "unmet_need_score": 10.0
      },
      "rank": 20
    },
    {
      "extraction": {
        "source": {
          "pmid": "40192430",
          "doi": "10.2340/actadv.v105.42990",
          "url": "https://pubmed.ncbi.nlm.nih.gov/40192430/",
          "title": "Real-world Effectiveness and Safety of Janus Kinase Inhibitors in Alopecia Areata: A Retrospective Cohort Study of 72 Patients.",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "Alopecia areata",
        "disease_normalized": "Alopecia Areata",
        "is_off_label": true,
        "is_relevant": true,
        "evidence_level": "Retrospective Study",
        "patient_population": {
          "n_patients": 15,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "topical corticosteroids",
            "minoxidil",
            "intralesional corticosteroids",
            "methotrexate",
            "cyclosporine",
            "systemic corticosteroids"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "15 patients with alopecia areata, part of larger cohort of 72 patients treated with various JAK inhibitors, mean age 34 years with mean disease duration of 8 years"
        },
        "treatment": {
          "drug_name": "upadacitinib",
          "generic_name": "Upadacitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "15-30 mg/day",
          "frequency": null,
          "duration": "median follow-up 16 months",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "9/15 (60%)",
          "responders_n": 9,
          "responders_pct": 60.0,
          "time_to_response": "median 7 months",
          "duration_of_response": "18 patients maintained substantial regrowth after 12 months, 12 maintained effect after 24 months",
          "effect_size_description": "60% substantial regrowth rate, 47% achieved SALT \u226420",
          "primary_endpoint": "substantial hair regrowth (decrease of >20 SALT score points from baseline)",
          "endpoint_result": "9/15 (60%) achieved substantial regrowth",
          "durability_signal": null,
          "efficacy_summary": "Upadacitinib demonstrated 60% substantial regrowth rate in alopecia areata patients with median time to response of 7 months. Among upadacitinib-treated patients, 47% achieved SALT \u226420, indicating significant hair regrowth."
        },
        "safety": {
          "adverse_events": [
            "gastrointestinal symptoms",
            "acne",
            "upper respiratory tract infections",
            "rash",
            "itching"
          ],
          "serious_adverse_events": [
            "sickle cell crisis",
            "renal failure"
          ],
          "sae_count": 2,
          "sae_percentage": 2.8,
          "discontinuations_n": 31,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [
            "insufficient effect on comorbid atopic dermatitis",
            "insufficient hair growth",
            "adverse events",
            "lab abnormalities"
          ],
          "safety_summary": "Safety profile was generally favorable with mild to moderate adverse events including GI symptoms, acne, and respiratory infections. Two serious adverse events occurred in the overall cohort (sickle cell crisis and renal failure in patients with pre-existing conditions).",
          "safety_profile": "Acceptable"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Moderate",
        "comparator_baseline": null,
        "follow_up_duration": "median 16 months",
        "key_findings": "Upadacitinib showed 60% substantial regrowth rate in alopecia areata with acceptable safety profile. Results support potential off-label use in severe alopecia areata patients.",
        "detailed_efficacy_endpoints": [
          {
            "endpoint_name": "Substantial regrowth",
            "endpoint_category": "Primary",
            "timepoint": "Overall study period",
            "measurement_type": "Responder",
            "value": 60.0,
            "unit": "percentage",
            "total_n": 15,
            "responders_n": 9,
            "responders_pct": 60.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Upadacitinib-specific outcome: defined as decrease of >20 SALT score points from baseline or good clinical response",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "SALT \u226420",
            "endpoint_category": "Secondary",
            "timepoint": "Overall study period",
            "measurement_type": "Responder",
            "value": 47.0,
            "unit": "percentage",
            "total_n": 15,
            "responders_n": 7,
            "responders_pct": 47.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Upadacitinib-specific outcome: SALT \u226420 indicates significant improvement",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "SALT score",
            "endpoint_category": "Primary",
            "timepoint": "Baseline",
            "measurement_type": "Absolute value",
            "value": 98.0,
            "unit": "score",
            "total_n": 15,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 98.0,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Upadacitinib group baseline SALT score (median, IQR 47)",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "Substantial regrowth",
            "endpoint_category": "Primary",
            "timepoint": "3 months",
            "measurement_type": "Responder",
            "value": 25.0,
            "unit": "percentage",
            "total_n": 61,
            "responders_n": 18,
            "responders_pct": 25.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Overall cohort outcome including upadacitinib patients",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Substantial regrowth",
            "endpoint_category": "Primary",
            "timepoint": "6 months",
            "measurement_type": "Responder",
            "value": 38.9,
            "unit": "percentage",
            "total_n": 44,
            "responders_n": 28,
            "responders_pct": 38.9,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Overall cohort outcome including upadacitinib patients",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Substantial regrowth",
            "endpoint_category": "Primary",
            "timepoint": "9 months",
            "measurement_type": "Responder",
            "value": 34.7,
            "unit": "percentage",
            "total_n": 39,
            "responders_n": 25,
            "responders_pct": 34.7,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Overall cohort outcome including upadacitinib patients",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Substantial regrowth",
            "endpoint_category": "Primary",
            "timepoint": "12 months",
            "measurement_type": "Responder",
            "value": 30.6,
            "unit": "percentage",
            "total_n": 26,
            "responders_n": 22,
            "responders_pct": 30.6,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Overall cohort outcome including upadacitinib patients",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Substantial regrowth",
            "endpoint_category": "Primary",
            "timepoint": "18 months",
            "measurement_type": "Responder",
            "value": 26.4,
            "unit": "percentage",
            "total_n": 22,
            "responders_n": 19,
            "responders_pct": 26.4,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Overall cohort outcome including upadacitinib patients",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Cumulative substantial regrowth",
            "endpoint_category": "Secondary",
            "timepoint": "Overall study period",
            "measurement_type": "Responder",
            "value": 61.0,
            "unit": "percentage",
            "total_n": 72,
            "responders_n": 44,
            "responders_pct": 61.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Overall cohort cumulative regrowth including upadacitinib patients",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Time to substantial regrowth",
            "endpoint_category": "Secondary",
            "timepoint": "Median time",
            "measurement_type": "Absolute value",
            "value": 7.0,
            "unit": "months",
            "total_n": 72,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "final_value": 7.0,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Overall cohort median time to substantial regrowth including upadacitinib patients",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Cumulative regrowth rate",
            "endpoint_category": "Secondary",
            "timepoint": "3 months",
            "measurement_type": "Responder",
            "value": 11.1,
            "unit": "percentage",
            "total_n": 72,
            "responders_n": 8,
            "responders_pct": 11.1,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Overall cohort cumulative regrowth rate including upadacitinib patients",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Cumulative regrowth rate",
            "endpoint_category": "Secondary",
            "timepoint": "6 months",
            "measurement_type": "Responder",
            "value": 40.2,
            "unit": "percentage",
            "total_n": 72,
            "responders_n": 29,
            "responders_pct": 40.2,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Overall cohort cumulative regrowth rate including upadacitinib patients",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Cumulative regrowth rate",
            "endpoint_category": "Secondary",
            "timepoint": "9 months",
            "measurement_type": "Responder",
            "value": 55.6,
            "unit": "percentage",
            "total_n": 72,
            "responders_n": 40,
            "responders_pct": 55.6,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Overall cohort cumulative regrowth rate including upadacitinib patients",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Cumulative regrowth rate",
            "endpoint_category": "Secondary",
            "timepoint": "12 months",
            "measurement_type": "Responder",
            "value": 59.7,
            "unit": "percentage",
            "total_n": 72,
            "responders_n": 43,
            "responders_pct": 59.7,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Overall cohort cumulative regrowth rate including upadacitinib patients",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "SALT \u226420",
            "endpoint_category": "Secondary",
            "timepoint": "Overall study period",
            "measurement_type": "Responder",
            "value": 50.0,
            "unit": "percentage",
            "total_n": 72,
            "responders_n": 36,
            "responders_pct": 50.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Overall cohort SALT \u226420 achievement including upadacitinib patients",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "Time to SALT \u226420",
            "endpoint_category": "Secondary",
            "timepoint": "Median time",
            "measurement_type": "Absolute value",
            "value": 8.5,
            "unit": "months",
            "total_n": 72,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "final_value": 8.5,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Overall cohort median time to SALT \u226420 including upadacitinib patients",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "SALT score",
            "endpoint_category": "Primary",
            "timepoint": "Baseline",
            "measurement_type": "Absolute value",
            "value": 100.0,
            "unit": "score",
            "total_n": 62,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 100.0,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Overall cohort baseline SALT score (median, IQR 10) including upadacitinib patients",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "SALT score",
            "endpoint_category": "Primary",
            "timepoint": "3 months",
            "measurement_type": "Absolute value",
            "value": 95.0,
            "unit": "score",
            "total_n": 52,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "final_value": 95.0,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Overall cohort SALT score at 3 months (median, IQR 69) including upadacitinib patients",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "SALT score",
            "endpoint_category": "Primary",
            "timepoint": "6 months",
            "measurement_type": "Absolute value",
            "value": 20.0,
            "unit": "score",
            "total_n": 32,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "final_value": 20.0,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Overall cohort SALT score at 6 months (median, IQR 83) including upadacitinib patients",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "SALT score",
            "endpoint_category": "Primary",
            "timepoint": "9 months",
            "measurement_type": "Absolute value",
            "value": 3.0,
            "unit": "score",
            "total_n": 25,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "final_value": 3.0,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Overall cohort SALT score at 9 months (median, IQR 86) including upadacitinib patients",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "SALT score",
            "endpoint_category": "Primary",
            "timepoint": "12 months",
            "measurement_type": "Absolute value",
            "value": 0.0,
            "unit": "score",
            "total_n": 21,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "final_value": 0.0,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Overall cohort SALT score at 12 months (median, IQR 23) including upadacitinib patients",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "Sustained substantial regrowth",
            "endpoint_category": "Secondary",
            "timepoint": "12 months",
            "measurement_type": "Responder",
            "value": null,
            "unit": "patients",
            "total_n": 72,
            "responders_n": 18,
            "responders_pct": null,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Overall cohort patients maintaining substantial regrowth after 12 months including upadacitinib patients",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Sustained substantial regrowth",
            "endpoint_category": "Secondary",
            "timepoint": "24 months",
            "measurement_type": "Responder",
            "value": null,
            "unit": "patients",
            "total_n": 72,
            "responders_n": 12,
            "responders_pct": null,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Overall cohort patients maintaining substantial regrowth after 24 months including upadacitinib patients",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Loss of response",
            "endpoint_category": "Secondary",
            "timepoint": "Overall follow-up",
            "measurement_type": "Responder",
            "value": 9.3,
            "unit": "percentage",
            "total_n": 43,
            "responders_n": 4,
            "responders_pct": 9.3,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Patients who achieved substantial regrowth but later lost response including upadacitinib patients",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          }
        ],
        "detailed_safety_endpoints": [
          {
            "event_name": "Gastrointestinal symptoms",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": 18,
            "patients_affected_pct": 25.0,
            "events_total": null,
            "relatedness": null,
            "outcome": null,
            "action_taken": null,
            "notes": "Most frequently observed adverse event",
            "category_soc": "Metabolic",
            "infection_type": null,
            "malignancy_type": null,
            "cv_type": null,
            "thromboembolic_type": null,
            "is_class_effect": true
          },
          {
            "event_name": "Acne",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": 15,
            "patients_affected_pct": 20.8,
            "events_total": null,
            "relatedness": null,
            "outcome": null,
            "action_taken": null,
            "notes": "Consistent with BRAVE-AA1, BRAVE-AA2, and ALLEGRO trials",
            "category_soc": "Metabolic",
            "infection_type": null,
            "malignancy_type": null,
            "cv_type": null,
            "thromboembolic_type": null,
            "is_class_effect": true
          },
          {
            "event_name": "Rash or itching",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": 9,
            "patients_affected_pct": 12.5,
            "events_total": null,
            "relatedness": null,
            "outcome": null,
            "action_taken": null,
            "notes": null,
            "category_soc": "Hypersensitivity",
            "infection_type": null,
            "malignancy_type": null,
            "cv_type": null,
            "thromboembolic_type": null,
            "is_class_effect": false
          },
          {
            "event_name": "Upper respiratory tract infections",
            "event_category": "AE",
            "severity_grade": "Mild",
            "patients_affected_n": 22,
            "patients_affected_pct": 30.6,
            "events_total": null,
            "relatedness": null,
            "outcome": null,
            "action_taken": null,
            "notes": "Mild infections, consistent with clinical trials",
            "category_soc": "Infections",
            "infection_type": "Bacterial",
            "malignancy_type": null,
            "cv_type": null,
            "thromboembolic_type": null,
            "is_class_effect": true
          },
          {
            "event_name": "Infections requiring treatment",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": 8,
            "patients_affected_pct": 11.1,
            "events_total": null,
            "relatedness": null,
            "outcome": null,
            "action_taken": null,
            "notes": "Including respiratory, urinary, and gastrointestinal infections, as well as herpes zoster and herpes simplex",
            "category_soc": "Infections",
            "infection_type": "Bacterial",
            "malignancy_type": null,
            "cv_type": null,
            "thromboembolic_type": null,
            "is_class_effect": true
          },
          {
            "event_name": "Herpes zoster",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": null,
            "patients_affected_pct": null,
            "events_total": null,
            "relatedness": null,
            "outcome": null,
            "action_taken": null,
            "notes": "Part of the 8 patients with infections requiring treatment; known JAK inhibitor class effect",
            "category_soc": "Infections",
            "infection_type": "Herpes Zoster",
            "malignancy_type": null,
            "cv_type": null,
            "thromboembolic_type": null,
            "is_class_effect": true
          },
          {
            "event_name": "Herpes simplex",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": null,
            "patients_affected_pct": null,
            "events_total": null,
            "relatedness": null,
            "outcome": null,
            "action_taken": null,
            "notes": "Part of the 8 patients with infections requiring treatment",
            "category_soc": "Infections",
            "infection_type": "Viral",
            "malignancy_type": null,
            "cv_type": null,
            "thromboembolic_type": null,
            "is_class_effect": true
          },
          {
            "event_name": "Sickle cell crisis",
            "event_category": "SAE",
            "severity_grade": "Severe",
            "patients_affected_n": 1,
            "patients_affected_pct": null,
            "events_total": null,
            "relatedness": null,
            "outcome": null,
            "action_taken": null,
            "notes": "Required hospitalization; patient had pre-existing sickle cell disease",
            "category_soc": "Metabolic",
            "infection_type": null,
            "malignancy_type": null,
            "cv_type": null,
            "thromboembolic_type": null,
            "is_class_effect": false
          },
          {
            "event_name": "Renal failure",
            "event_category": "SAE",
            "severity_grade": "Severe",
            "patients_affected_n": 1,
            "patients_affected_pct": null,
            "events_total": null,
            "relatedness": null,
            "outcome": null,
            "action_taken": null,
            "notes": "Required hospitalization; patient had pre-existing kidney issues; highlights need for dose adjustments in moderate-to-severe renal impairment",
            "category_soc": "Renal",
            "infection_type": null,
            "malignancy_type": null,
            "cv_type": null,
            "thromboembolic_type": null,
            "is_class_effect": false
          },
          {
            "event_name": "Treatment discontinuation due to adverse events",
            "event_category": "Discontinuation",
            "severity_grade": null,
            "patients_affected_n": 4,
            "patients_affected_pct": 9.5,
            "events_total": null,
            "relatedness": null,
            "outcome": null,
            "action_taken": "Discontinued",
            "notes": "Among 31 patients who discontinued treatment or switched JAKi",
            "category_soc": "Metabolic",
            "infection_type": null,
            "malignancy_type": null,
            "cv_type": null,
            "thromboembolic_type": null,
            "is_class_effect": false
          },
          {
            "event_name": "Treatment discontinuation due to laboratory abnormalities",
            "event_category": "Lab abnormality",
            "severity_grade": null,
            "patients_affected_n": 4,
            "patients_affected_pct": 9.5,
            "events_total": null,
            "relatedness": null,
            "outcome": null,
            "action_taken": "Discontinued",
            "notes": "Among 31 patients who discontinued treatment or switched JAKi",
            "category_soc": "Metabolic",
            "infection_type": null,
            "malignancy_type": null,
            "cv_type": null,
            "thromboembolic_type": null,
            "is_class_effect": true
          }
        ],
        "extraction_timestamp": "2025-12-08T18:05:45.843746",
        "extraction_confidence": 0.6,
        "extraction_confidence_detail": null,
        "extraction_method": "multi_stage",
        "extraction_stages_completed": [
          "section_identification",
          "efficacy_extraction",
          "safety_extraction"
        ],
        "data_sections_identified": {
          "baseline_tables": [
            "Table I - Baseline patient characteristics: Demographics, sex, age, history of atopy, concomitant autoimmune diseases, family history, prior treatments (topical, intralesional, systemic)",
            "Table II - Clinical features: Age of onset, disease duration, baseline SALT scores, type of alopecia areata, other localizations, nail changes, follow-up duration by treatment group"
          ],
          "efficacy_tables": [
            "Table SIII - Treatment outcomes by JAK inhibitor (referenced but not shown in main text)",
            "Table SIV - Switching treatment outcomes (referenced but not shown in main text)"
          ],
          "safety_tables": [
            "Table SV - Adverse events (referenced but not shown in main text)"
          ],
          "efficacy_figures": [
            "Figure 1 - Treatment outcome per follow-up moment: Shows substantial regrowth, non-substantial regrowth, and no response rates at different time points",
            "Figure 2 - Time to substantial regrowth for all Janus kinase inhibitors: Kaplan-Meier survival curve showing time to substantial regrowth with median of 7 months",
            "Figure 3 - Severity of Alopecia Tool (SALT) scores per follow-up: Shows SALT score distribution over time",
            "Figure 4 - Time to Severity of Alopecia Tool (SALT) <20 for all Janus kinase inhibitors: Kaplan-Meier curve for time to SALT \u226420 with median of 8.5 months"
          ],
          "results_sections": [
            "Patient characteristics - Demographics and baseline clinical features",
            "Treatment characteristics - Response rates at 3, 6, 9, 12, and 18 months with substantial regrowth percentages",
            "Cumulative regrowth analysis with Kaplan-Meier survival curves",
            "SALT score changes over time with median scores at each timepoint",
            "Reasons for discontinuation or switch of JAK inhibitor",
            "Adverse events - Safety outcomes including serious adverse events"
          ],
          "patient_count": 72,
          "study_type": "Retrospective Study",
          "has_quantitative_outcomes": true,
          "notes": "Study includes 5 different JAK inhibitors (abrocitinib, baricitinib, ritlecitinib, upadacitinib, tofacitinib). Many patients had comorbid atopic dermatitis. Several supplementary tables and figures are referenced but not shown in the main text. Primary efficacy endpoint was substantial regrowth defined as >20 point decrease in SALT score."
        }
      },
      "market_intelligence": {
        "disease": "Alopecia Areata",
        "parent_disease": null,
        "epidemiology": {
          "us_prevalence_estimate": "0.17-0.22%",
          "us_incidence_estimate": "91-93 cases per 100,000 patient-years",
          "global_prevalence": null,
          "patient_population_size": 6700000,
          "prevalence_source": "Journal of the American Academy of Dermatology",
          "prevalence_source_url": "https://www.jaad.org/article/S0190-9622(22)01464-5/fulltext",
          "trend": "stable",
          "source_quality": "Primary",
          "data_year": 2019,
          "geographic_scope": "US",
          "confidence": "High",
          "notes": "Multiple recent US studies show consistent prevalence estimates ranging from 0.17-0.22%, with higher rates in females vs males and African Americans vs whites. Lifetime incidence risk estimated at 2%."
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Olumiant (baricitinib)",
              "drug_class": "JAK inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Alopecia Areata",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "First systemic immunotherapy approved by FDA for adults with severe alopecia areata. Recommended dosage 2 mg once daily, can increase to 4 mg daily.",
              "approval_year": 2022,
              "approval_confidence": "High",
              "approval_evidence": "FDA approval June 2022 for adults with severe alopecia areata"
            },
            {
              "drug_name": "Litfulo (ritlecitinib)",
              "drug_class": "JAK inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Alopecia Areata",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "Second JAK inhibitor approved for severe alopecia areata, approved for patients 12 years and older.",
              "approval_year": 2023,
              "approval_confidence": "High",
              "approval_evidence": "FDA approval June 2023 for patients ages 12 years and older with severe alopecia areata"
            },
            {
              "drug_name": "Leqselvi (deuruxolitinib)",
              "drug_class": "JAK inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Alopecia Areata",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "Third JAK inhibitor approved for severe alopecia areata in adults. Oral formulation.",
              "approval_year": 2024,
              "approval_confidence": "High",
              "approval_evidence": "FDA approval July 2024 for adults with severe alopecia areata"
            }
          ],
          "approved_drug_names": [
            "Olumiant (baricitinib)",
            "Litfulo (ritlecitinib)",
            "Leqselvi (deuruxolitinib)"
          ],
          "num_approved_drugs": 3,
          "num_pipeline_therapies": 9,
          "pipeline_therapies": [
            {
              "drug_name": "Microbiota Transplant Therapy",
              "company": "University of Minnesota",
              "mechanism": "Gut microbiome modulation",
              "phase": "Phase 2",
              "trial_id": "NCT06747611",
              "expected_completion": "2028-03",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Novel approach targeting microbiota in alopecia areata"
            },
            {
              "drug_name": "Ritlecitinib",
              "company": "Pfizer",
              "mechanism": "JAK3/TEC family kinase inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT06873945",
              "expected_completion": "2027-03",
              "trial_name": "ALLEGRO-100",
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Testing 50mg and 100mg doses in patients 12 years and older"
            },
            {
              "drug_name": "Tofacitinib",
              "company": "Jinnah Hospital",
              "mechanism": "JAK inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT06278402",
              "expected_completion": null,
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": null,
              "notes": "Completed January 2024, studying moderate to severe AA"
            },
            {
              "drug_name": "EQ101",
              "company": "Equillium",
              "mechanism": "CD6-targeted immunomodulator",
              "phase": "Phase 2",
              "trial_id": "NCT05589610",
              "expected_completion": null,
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": null,
              "notes": "Open-label study completed March 2024"
            },
            {
              "drug_name": "Ruxolitinib",
              "company": "National Institute of Allergy and Infectious Diseases (NIAID)",
              "mechanism": "JAK1/JAK2 inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT05398809",
              "expected_completion": "2027-12",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Specifically for APECED-associated alopecia areata"
            },
            {
              "drug_name": "STS01",
              "company": "Soterios Ltd",
              "mechanism": "Non-steroidal topical treatment",
              "phase": "Phase 2",
              "trial_id": "NCT06402630",
              "expected_completion": null,
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": null,
              "notes": "Completed April 2024, for mild-moderate AA"
            },
            {
              "drug_name": "Etrasimod",
              "company": "Pfizer",
              "mechanism": "Selective S1P receptor modulator",
              "phase": "Phase 2",
              "trial_id": "NCT04556734",
              "expected_completion": null,
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": null,
              "notes": "Completed June 2023, moderate-to-severe AA"
            },
            {
              "drug_name": "Upadacitinib",
              "company": "AbbVie",
              "mechanism": "JAK1 inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT06012240",
              "expected_completion": "2028-01",
              "trial_name": "UP-AA",
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Positive topline results reported in 2025, seeking approval"
            },
            {
              "drug_name": "Rezpegaldesleukin",
              "company": "Nektar Therapeutics",
              "mechanism": "IL-2 receptor complex agonist/Treg stimulator",
              "phase": "Phase 2",
              "trial_id": "Unknown - verify",
              "expected_completion": null,
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": "Fast Track",
              "notes": "Received FDA Fast Track designation in July 2025"
            }
          ],
          "pipeline_details": "Nine active clinical programs are in Phase 2-3 development for alopecia areata, dominated by JAK inhibitors but including novel approaches like microbiota transplant therapy and IL-2 receptor modulators. AbbVie's upadacitinib has reported positive Phase 3 results and is seeking regulatory approval, while Pfizer's ritlecitinib continues Phase 3 recruitment.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "JAK inhibitors are considered first-line treatment for severe alopecia areata (\u226550% scalp hair loss), with three FDA-approved options now available. For mild to moderate disease, topical corticosteroids and intralesional corticosteroid injections remain standard approaches, often combined with topical minoxidil.",
          "unmet_need": false,
          "unmet_need_description": null,
          "competitive_landscape": "The alopecia areata market has been rapidly transformed with three JAK inhibitors approved in just three years (2022-2024), providing systemic treatment options for severe disease. All three drugs target the same pathway but may offer different dosing or patient population advantages.",
          "soc_source": "Medscape Alopecia Areata Overview and FDA Drug Labels",
          "phase_3_count": 3,
          "phase_2_count": 6,
          "key_catalysts": "AbbVie expected to file for upadacitinib approval in 2025-2026 based on positive UP-AA Phase 3 results; Pfizer's ritlecitinib Phase 3 ALLEGRO-100 trial completion expected March 2027",
          "pipeline_data_quality": "High",
          "recent_approvals": "Olumiant (baricitinib) June 2022, Litfulo (ritlecitinib) June 2023, Leqselvi (deuruxolitinib) July 2024",
          "data_quality": "High",
          "data_quality_notes": "Multiple sources confirm FDA approvals with specific approval dates and indications. All three approvals are for severe alopecia areata specifically."
        },
        "market_size_estimate": "$167.5B",
        "market_size_usd": 167500000000.0,
        "growth_rate": "3-5% CAGR (stable prevalence)",
        "tam_usd": 850000000.0,
        "tam_estimate": "$850M",
        "tam_rationale": "Of ~6.7M US alopecia areata patients, ~80% are diagnosed (5.4M), but only ~15% have moderate-severe disease warranting systemic JAK inhibitor therapy (~810K patients). With 3 approved JAK inhibitors already established as first-line for severe cases, a new entrant could realistically capture 15-20% market share (~135K patients). At $50K/year pricing (consistent with autoimmune-dermatology benchmarks), TAM = 135K \u00d7 $50K = $675M-850M.",
        "tam_sources": [
          "https://bisresearch.com/industry-report/alopecia-areata-market.html",
          "https://www.prnewswire.com/news-releases/alopecia-areata-market-to-show-positive-growth-at-a-cagr-of-26-3-during-the-study-period-20192032-estimates-delveinsight-301853907.html",
          "https://www.giiresearch.com/report/tbrc1824572-alopecia-global-market-report.html"
        ],
        "pipeline_sources": [
          "https://clinicaltrials.gov",
          "https://clinicaltrials.gov/study/NCT03732807",
          "https://cdn.clinicaltrials.gov/large-docs/07/NCT03732807/Prot_000.pdf",
          "https://cdn.clinicaltrials.gov/large-docs/49/NCT03570749/Prot_002.pdf",
          "https://www.clinicaltrials.gov/study/NCT06012240"
        ],
        "attributed_sources": [
          {
            "url": "https://www.jaad.org/article/S0190-9622(22)01464-5/fulltext",
            "title": "33432 Prevalence estimates for alopecia areata in ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9979012/",
            "title": "Trends in Prevalence and Incidence of Alopecia Areata ... - NIH",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://emedicine.medscape.com/article/1069931-overview",
            "title": "Alopecia Areata: Practice Essentials, Background, ...",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://emedicine.medscape.com/article/1069931-medication",
            "title": "Alopecia Areata Medication: Glucocorticoids, Vasodilators ...",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3149478/",
            "title": "Alopecia areata: a new treatment plan - PMC",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://clinicaltrials.gov",
            "title": "ClinicalTrials.gov API",
            "attribution": "Pipeline/Clinical Trials (Primary)"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT03732807",
            "title": "PF-06651600 for the Treatment of Alopecia Areata",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://cdn.clinicaltrials.gov/large-docs/07/NCT03732807/Prot_000.pdf",
            "title": "a phase 2b/3 randomized, double-blind, placebo-controlled",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://bisresearch.com/industry-report/alopecia-areata-market.html",
            "title": "Alopecia Areata Market Size & Forecast | BIS Research",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.prnewswire.com/news-releases/alopecia-areata-market-to-show-positive-growth-at-a-cagr-of-26-3-during-the-study-period-20192032-estimates-delveinsight-301853907.html",
            "title": "Alopecia Areata Market to Show Positive Growth at a CAGR of 26.3 ...",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 6.7,
        "evidence_quality": 9.4,
        "market_opportunity": 6.7,
        "overall_priority": 7.4,
        "clinical_breakdown": {
          "response_rate_quality_weighted": 5.1,
          "safety_profile": 6.7,
          "organ_domain_breadth": 10.0,
          "safety_categories": [
            "discontinuation",
            "thromboembolic",
            "non_serious_infection",
            "renal"
          ],
          "regulatory_flags": [
            "thromboembolic",
            "renal"
          ],
          "efficacy_endpoint_count": 24,
          "efficacy_concordance": 0.9
        },
        "response_rate_score": 5.1,
        "safety_profile_score": 6.7,
        "endpoint_quality_score": null,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 9.0,
          "publication_venue": 10.0,
          "response_durability": 10.0,
          "extraction_completeness": 8.3
        },
        "sample_size_score": 9.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 10.0,
        "extraction_completeness_score": 8.3,
        "market_breakdown": {
          "competitors": 5.0,
          "market_size": 10.0,
          "unmet_need": 5.0
        },
        "competitors_score": 5.0,
        "market_size_score": 10.0,
        "unmet_need_score": 5.0
      },
      "rank": 21
    },
    {
      "extraction": {
        "source": {
          "pmid": "38578007",
          "doi": "10.1002/iid3.1242",
          "url": "https://pubmed.ncbi.nlm.nih.gov/38578007/",
          "title": "Coexistence of ankylosing spondylitis and Beh\u00e7et's disease: Successful treatment with upadacitinib.",
          "authors": "Krasimir Kraev, Petar Uchikov, Bozhidar Hristov, Maria Kraeva, Yordanka Basheva-Kraeva, Stanislava Popova-Belova, Milena Sandeva, Dzhevdet Chakarov, Snezhanka Dragusheva, Mariela Geneva-Popova",
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "Beh\u00e7et's disease",
        "disease_normalized": "Beh\u00e7et's Disease",
        "is_off_label": true,
        "is_relevant": true,
        "evidence_level": "Case Report",
        "patient_population": {
          "n_patients": 1,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "local and systemic corticosteroids"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "42-year-old female with coexisting ankylosing spondylitis and Beh\u00e7et's disease, presenting with decade-long lower back pain, recurrent eye issues, oral and genital ulcers, hearing loss, and abdominal pain"
        },
        "treatment": {
          "drug_name": "upadacitinib",
          "generic_name": "Upadacitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "15 mg daily",
          "frequency": null,
          "duration": "3 months",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "1/1 (100%)",
          "responders_n": 1,
          "responders_pct": 100.0,
          "time_to_response": "1 month",
          "duration_of_response": "sustained at 3 months",
          "effect_size_description": "noteworthy alleviation in joint discomfort and mucosal ulcerations at 1 month, remarkable improvement or complete resolution at 3 months",
          "primary_endpoint": "symptom improvement in both AS and BD manifestations",
          "endpoint_result": "remarkable amelioration in majority of symptoms with substantial improvement or complete resolution",
          "durability_signal": null,
          "efficacy_summary": "Patient showed noteworthy improvement in joint discomfort and mucosal ulcerations (oral and genital) at 1-month follow-up. At 3 months, remarkable amelioration was observed in the majority of symptoms associated with both disease entities, with many signs achieving substantial improvement or complete resolution."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": 0,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "No adverse events were reported in this case report. The patient tolerated upadacitinib well throughout the 3-month treatment period.",
          "safety_profile": "Unknown"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": "3 months",
        "key_findings": "First reported case of upadacitinib use in Beh\u00e7et's disease showing successful treatment of both AS and BD manifestations in a patient with contraindications to conventional therapies.",
        "detailed_efficacy_endpoints": [],
        "detailed_safety_endpoints": [],
        "extraction_timestamp": "2025-12-08T18:34:21.677238",
        "extraction_confidence": 0.5,
        "extraction_confidence_detail": null,
        "extraction_method": "multi_stage",
        "extraction_stages_completed": [
          "section_identification",
          "efficacy_extraction",
          "safety_extraction"
        ],
        "data_sections_identified": {
          "baseline_tables": [],
          "efficacy_tables": [],
          "safety_tables": [],
          "efficacy_figures": [],
          "results_sections": [
            "2.5 Therapeutic interventions",
            "Follow-up at 1 month and 3 months"
          ],
          "patient_count": 1,
          "study_type": "Case Report",
          "has_quantitative_outcomes": false,
          "notes": "This is a single case report with narrative outcomes only. Three figures are present but show diagnostic criteria and X-ray findings, not clinical outcomes. Treatment response described qualitatively at 1-month and 3-month follow-ups with improvements in joint discomfort and mucosal ulcerations."
        }
      },
      "market_intelligence": {
        "disease": "Beh\u00e7et's Disease",
        "parent_disease": null,
        "epidemiology": {
          "us_prevalence_estimate": "0.33 to 5.2 per 100,000 population",
          "us_incidence_estimate": "0.38 per 100,000 population",
          "global_prevalence": null,
          "patient_population_size": 9200,
          "prevalence_source": "Arthritis & Rheumatism journal",
          "prevalence_source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3024036/",
          "trend": "increasing",
          "source_quality": "Primary",
          "data_year": 2009,
          "geographic_scope": "US",
          "confidence": "Medium",
          "notes": "Wide range reported across studies (0.33-10.6 per 100,000); higher prevalence found in Southwestern US populations; increasing trend may be due to improved recognition and immigration from endemic areas"
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Otezla (apremilast)",
              "drug_class": "PDE-4 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Oral Ulcers Associated with Beh\u00e7et's Disease",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "FDA approved for treatment of adult patients with oral ulcers associated with Beh\u00e7et's Disease. Approval based on Phase 3 RELIEF study with 207 patients. Dosed at 30 mg twice daily.",
              "approval_year": 2019,
              "approval_confidence": "High",
              "approval_evidence": "FDA label 2019, drugs@FDA documentation"
            }
          ],
          "approved_drug_names": [
            "Otezla (apremilast)"
          ],
          "num_approved_drugs": 1,
          "num_pipeline_therapies": 13,
          "pipeline_therapies": [
            {
              "drug_name": "Apremilast",
              "company": "Amgen",
              "mechanism": "PDE4 inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT04528082",
              "expected_completion": "2030-02",
              "trial_name": "BEAN",
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Pediatric study for children 2-18 years with active oral ulcers"
            },
            {
              "drug_name": "Apremilast",
              "company": "Amgen",
              "mechanism": "PDE4 inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT05767047",
              "expected_completion": "2036-03",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Long-term extension study in children with oral ulcers"
            },
            {
              "drug_name": "Hemay005",
              "company": "Ganzhou Hemay Pharmaceutical Co., Ltd",
              "mechanism": null,
              "phase": "Phase 3",
              "trial_id": "NCT06145893",
              "expected_completion": "2026-05",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": null
            },
            {
              "drug_name": "Baricitinib",
              "company": "Peking Union Medical College Hospital",
              "mechanism": "JAK inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT06849908",
              "expected_completion": "2027-06",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "For refractory intestinal Beh\u00e7et's syndrome vs adalimumab"
            },
            {
              "drug_name": "HSK44459",
              "company": "Haisco Pharmaceutical Group Co., Ltd.",
              "mechanism": null,
              "phase": "Phase 2",
              "trial_id": "NCT06902428",
              "expected_completion": "2026-06",
              "trial_name": null,
              "status": "Not yet recruiting",
              "regulatory_designations": null,
              "notes": null
            },
            {
              "drug_name": "Rivaroxaban",
              "company": "Assistance Publique - H\u00f4pitaux de Paris",
              "mechanism": "Anticoagulant",
              "phase": "Phase 3",
              "trial_id": "NCT06780462",
              "expected_completion": "2027-07",
              "trial_name": null,
              "status": "Not yet recruiting",
              "regulatory_designations": null,
              "notes": "Steroid therapy plus anticoagulants vs steroid alone for deep venous thrombosis"
            },
            {
              "drug_name": "Tocilizumab",
              "company": "Assistance Publique - H\u00f4pitaux de Paris",
              "mechanism": "IL-6 receptor antagonist",
              "phase": "Phase 2",
              "trial_id": "NCT05874505",
              "expected_completion": "2026-11",
              "trial_name": "UVB",
              "status": "Not yet recruiting",
              "regulatory_designations": null,
              "notes": "Comparison with adalimumab in severe uveitis"
            },
            {
              "drug_name": "Tocilizumab",
              "company": "Peking Union Medical College Hospital",
              "mechanism": "IL-6 receptor antagonist",
              "phase": "Phase 2",
              "trial_id": "NCT05845723",
              "expected_completion": "2026-06",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Combined with tofacitinib for vascular Beh\u00e7et's syndrome"
            },
            {
              "drug_name": "Low-dose IL-2",
              "company": "HeJing",
              "mechanism": "Immunoregulatory cytokine",
              "phase": "Phase 2",
              "trial_id": "NCT04065672",
              "expected_completion": "2023-04",
              "trial_name": null,
              "status": "Completed",
              "regulatory_designations": null,
              "notes": "Completed within last 2 years, indicating active development"
            },
            {
              "drug_name": "BCMA-CD19 CAR-T",
              "company": "Peking University People's Hospital",
              "mechanism": "CAR-T cell therapy",
              "phase": "Phase 2",
              "trial_id": "NCT06794008",
              "expected_completion": "2027-12",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "For multiple refractory autoimmune diseases including Beh\u00e7et's"
            },
            {
              "drug_name": "Filgotinib",
              "company": "UMC Utrecht",
              "mechanism": "JAK inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT06285539",
              "expected_completion": "2026-12",
              "trial_name": "DRIMID",
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Drug rediscovery study for rare immune mediated inflammatory diseases"
            },
            {
              "drug_name": "Dusquetide",
              "company": "Soligenix",
              "mechanism": "Innate defense regulator",
              "phase": "Phase 2",
              "trial_id": "NCT06386744",
              "expected_completion": "2025-05",
              "trial_name": null,
              "status": "Completed",
              "regulatory_designations": "Fast Track, Orphan Drug",
              "notes": "Recently completed Phase 2a with positive biological efficacy results"
            },
            {
              "drug_name": "Upadacitinib",
              "company": "Liu Tian",
              "mechanism": "JAK inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT07080346",
              "expected_completion": "2024-12",
              "trial_name": null,
              "status": "Completed",
              "regulatory_designations": null,
              "notes": "Recently completed pilot study for refractory Beh\u00e7et's syndrome"
            }
          ],
          "pipeline_details": "The Beh\u00e7et's Disease pipeline includes 13 active programs across Phase 2 and Phase 3 development. Key mechanisms being tested include JAK inhibitors (baricitinib, filgotinib, upadacitinib), IL-6 receptor antagonists (tocilizumab), PDE4 inhibitors (apremilast), and novel approaches like innate defense regulators (dusquetide) and CAR-T cell therapy. Recent positive results include completed Phase 2 studies for dusquetide and upadacitinib.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "Beh\u00e7et's Disease treatment is organ-system specific with no standardized approach. For mucocutaneous manifestations, colchicine is typically first-line, with topical therapies for mild ulcerations. Otezla (apremilast) serves as second-line therapy specifically for oral ulcers. For severe organ involvement (ocular, neurologic, vascular), combination immunosuppression with corticosteroids plus azathioprine or anti-TNF agents is used.",
          "unmet_need": true,
          "unmet_need_description": "Only one FDA-approved treatment exists specifically for Beh\u00e7et's Disease (Otezla for oral ulcers only). Most treatments are off-label use of drugs approved for other conditions. No FDA-approved therapies exist for systemic manifestations including ocular, neurologic, or vascular disease.",
          "competitive_landscape": "Otezla holds the only FDA approval for Beh\u00e7et's Disease, giving it regulatory advantage for oral ulcers. Treatment otherwise relies heavily on off-label use of anti-TNF biologics (infliximab, adalimumab), immunosuppressants, and corticosteroids. Multiple biologics are used off-label but lack specific FDA approval for this indication.",
          "soc_source": "FDA drug labels and Medscape clinical references",
          "phase_3_count": 4,
          "phase_2_count": 9,
          "key_catalysts": "Expected primary readouts include Hemay005 Phase 3 results (May 2026), HSK44459 Phase 2 results (June 2026), and multiple tocilizumab studies completing in 2026. Soligenix plans to advance dusquetide development following recent positive Phase 2a results.",
          "pipeline_data_quality": "High",
          "recent_approvals": null,
          "data_quality": "High",
          "data_quality_notes": "Clear FDA approval documentation available for Otezla. Other treatments mentioned are off-label uses without specific Beh\u00e7et's Disease FDA approvals."
        },
        "market_size_estimate": "$1.8B",
        "market_size_usd": 1840000000.0,
        "growth_rate": "5-10% CAGR (increasing prevalence)",
        "tam_usd": 184000000.0,
        "tam_estimate": "$184M",
        "tam_rationale": "Of ~9,200 US patients with Beh\u00e7et's Disease, ~70% are diagnosed (6,440), ~60% receive systemic treatment (3,864), ~40% fail first-line therapy and are candidates for 2L+ treatment (1,546). A new drug targeting moderate-severe manifestations could capture 30% market share (~464 patients) given high unmet need and only one approved drug. At $400K/yr pricing (orphan drug designation for rare autoimmune indication), TAM = $184M.",
        "tam_sources": [
          "https://www.credenceresearch.com/report/behcets-disease-market",
          "https://www.openpr.com/news/4113839/behcet-s-disease-market-growth-size-surges-amid-rising",
          "https://exactitudeconsultancy.com/it/reports/71308/behcet-s-disease-market"
        ],
        "pipeline_sources": [
          "https://clinicaltrials.gov",
          "https://clinicaltrials.gov/study/NCT02307513",
          "https://www.clinicaltrials.gov/study/NCT00995709",
          "https://www.clinicaltrials.gov/study/NCT01965145",
          "https://clinicaltrials.gov/study/NCT06902428"
        ],
        "attributed_sources": [
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8404295/",
            "title": "Epidemiology and treatment of Beh\u00e7et's disease in the USA",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://acrabstracts.org/abstract/behcets-disease-in-the-southwestern-united-states/",
            "title": "Behcet's Disease in the Southwestern United States",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.drugs.com/history/otezla.html",
            "title": "Otezla (apremilast) FDA Approval History",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.medscape.com/viewarticle/915883",
            "title": "FDA OKs Apremilast (Otezla) for Oral Ulcers of Behcet's ...",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.chi.gov.sa/Style%20Library/IDF_Branding/Indication/185%20-%20Behcet%20Disease-New%20Indication.pdf",
            "title": "[PDF] BEHCET DISEASE",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://clinicaltrials.gov",
            "title": "ClinicalTrials.gov API",
            "attribution": "Pipeline/Clinical Trials (Primary)"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT02307513",
            "title": "Study Details | NCT02307513 | A Phase 3 Randomized, ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.clinicaltrials.gov/study/NCT00995709",
            "title": "Phase III Study in Refractory Behcet's Disease",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.credenceresearch.com/report/behcets-disease-market",
            "title": "Behcet's Disease Market Size, Share, Growth and Forecast 2032",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.openpr.com/news/4113839/behcet-s-disease-market-growth-size-surges-amid-rising",
            "title": "Behcet's Disease Market Growth Size Surges Amid Rising",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 8.0,
        "evidence_quality": 5.1,
        "market_opportunity": 8.3,
        "overall_priority": 7.4,
        "clinical_breakdown": {
          "response_rate_quality_weighted": 10.0,
          "safety_profile": 5.0,
          "organ_domain_breadth": 10.0,
          "safety_categories": [],
          "regulatory_flags": [],
          "efficacy_endpoint_count": 0,
          "efficacy_concordance": 1.0
        },
        "response_rate_score": 10.0,
        "safety_profile_score": 5.0,
        "endpoint_quality_score": null,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 1.0,
          "publication_venue": 10.0,
          "response_durability": 5.0,
          "extraction_completeness": 6.6
        },
        "sample_size_score": 1.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 5.0,
        "extraction_completeness_score": 6.6,
        "market_breakdown": {
          "competitors": 7.0,
          "market_size": 8.0,
          "unmet_need": 10.0
        },
        "competitors_score": 7.0,
        "market_size_score": 8.0,
        "unmet_need_score": 10.0
      },
      "rank": 22
    },
    {
      "extraction": {
        "source": {
          "pmid": "37009550",
          "doi": "10.1177/2050313X231160927",
          "url": "https://www.semanticscholar.org/paper/20d2e8a5936df4e19a502f6c3714beda779c23c0",
          "title": "Pityriasis rubra pilaris partially responsive to treatment with upadacitinib: A case report",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Web source",
          "is_open_access": false
        },
        "disease": "Pityriasis rubra pilaris",
        "disease_normalized": "Pityriasis Rubra Pilaris",
        "is_off_label": true,
        "is_relevant": true,
        "evidence_level": "Case Report",
        "patient_population": {
          "n_patients": 1,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "topical steroids",
            "calcineurin inhibitors",
            "isotretinoin",
            "phototherapy",
            "ustekinumab",
            "ixekizumab"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "26-year-old woman with classical juvenile PRP diagnosed at age 2 years"
        },
        "treatment": {
          "drug_name": "upadacitinib",
          "generic_name": "Upadacitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "15 mg/d increased to 30 mg/d",
          "frequency": null,
          "duration": "6 weeks",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "1/1 (100%)",
          "responders_n": 1,
          "responders_pct": 100.0,
          "time_to_response": "25% improvement at day 14, 65% improvement at week 6",
          "duration_of_response": null,
          "effect_size_description": "65% overall improvement in BSA with thinner plaques",
          "primary_endpoint": "Body surface area improvement",
          "endpoint_result": "65% overall improvement in BSA involvement by week 6",
          "durability_signal": null,
          "efficacy_summary": "Patient achieved 25% improvement at day 14 and 65% overall improvement in BSA involvement by week 6. Response was comparable to initial response with ustekinumab."
        },
        "safety": {
          "adverse_events": [
            "headache"
          ],
          "serious_adverse_events": [],
          "sae_count": 0,
          "sae_percentage": 0.0,
          "discontinuations_n": 1,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [
            "patient preference for intermittent injections over oral therapy"
          ],
          "safety_summary": "Patient experienced headache but otherwise tolerated treatment very well with no serious side effects. Discontinuation was due to patient preference rather than safety concerns.",
          "safety_profile": "Favorable"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": "6 weeks",
        "key_findings": "First reported case of upadacitinib use in PRP showing rapid and significant improvement comparable to IL-23 inhibitors.",
        "detailed_efficacy_endpoints": [
          {
            "endpoint_name": "BSA involvement",
            "endpoint_category": "Primary",
            "timepoint": "Baseline (on ustekinumab)",
            "measurement_type": "Absolute value",
            "value": 60.0,
            "unit": "percent",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 60.0,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "BSA involvement while on ustekinumab treatment",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "BSA involvement",
            "endpoint_category": "Primary",
            "timepoint": "Pre-upadacitinib (on ixekizumab)",
            "measurement_type": "Absolute value",
            "value": 80.0,
            "unit": "percent",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 80.0,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "BSA involvement worsened on ixekizumab before starting upadacitinib",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Clinical improvement",
            "endpoint_category": "Primary",
            "timepoint": "Day 14",
            "measurement_type": "Change from baseline",
            "value": 25.0,
            "unit": "percent improvement",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": 25.0,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "25% improvement on upadacitinib 15 mg/day at day 14",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Overall improvement in BSA involvement",
            "endpoint_category": "Primary",
            "timepoint": "Week 6",
            "measurement_type": "Change from baseline",
            "value": 65.0,
            "unit": "percent improvement",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": 65.0,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "65% overall improvement in BSA involvement on upadacitinib 30 mg/day at week 6",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          }
        ],
        "detailed_safety_endpoints": [
          {
            "event_name": "headache",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": 1,
            "patients_affected_pct": null,
            "events_total": null,
            "relatedness": null,
            "outcome": null,
            "action_taken": "None",
            "notes": "Patient otherwise tolerated upadacitinib very well with no serious side effects",
            "category_soc": "Neurological",
            "infection_type": null,
            "malignancy_type": null,
            "cv_type": null,
            "thromboembolic_type": null,
            "is_class_effect": false
          }
        ],
        "extraction_timestamp": "2025-12-08T18:50:48.714144",
        "extraction_confidence": 0.6,
        "extraction_confidence_detail": null,
        "extraction_method": "multi_stage",
        "extraction_stages_completed": [
          "section_identification",
          "efficacy_extraction",
          "safety_extraction"
        ],
        "data_sections_identified": {
          "baseline_tables": [],
          "efficacy_tables": [],
          "safety_tables": [],
          "efficacy_figures": [
            "Figure 1: (a) Confluent pink patches on the upper extremities with islands of sparing over the antecubital fossae and (b) confluent pink patches on the lower extremities with islands of sparing over the popliteal fossae",
            "Figure 2: (a) Pink confluent scaly plaques on the upper extremities with islands of sparing, (b) improvement following 14 days of treatment with upadacitinib, and (c) improvement following 6 weeks of treatment with upadacitinib",
            "Figure 3: (a) Red confluent scaly plaques on the lower extremities with islands of sparing, (b) improvement following 14 days of treatment with upadacitinib, and (c) near-complete resolution following 6 weeks of treatment with upadacitinib",
            "Figure 4: (a) Erythema and xerosis of dorsal hand with nutmeg grater-like papules and (b) improvement following 14 days of treatment with upadacitinib"
          ],
          "results_sections": [
            "Case report section describing treatment timeline and clinical response",
            "Discussion section analyzing therapeutic efficacy and mechanism"
          ],
          "patient_count": 1,
          "study_type": "Case Report",
          "has_quantitative_outcomes": true,
          "notes": "Single case report of 26-year-old woman with PRP treated with upadacitinib showing 25% improvement at day 14 and 65% BSA improvement at week 6. No formal tables present - all data described narratively. Clinical outcomes documented through before/after photographs."
        }
      },
      "market_intelligence": {
        "disease": "Pityriasis Rubra Pilaris",
        "parent_disease": null,
        "epidemiology": {
          "us_prevalence_estimate": "1 in 400,000",
          "us_incidence_estimate": "1 in 3,500 to 5,000 dermatology clinic patients",
          "global_prevalence": null,
          "patient_population_size": 838,
          "prevalence_source": "NORD (National Organization for Rare Disorders)",
          "prevalence_source_url": "https://rarediseases.org/rare-diseases/pityriasis-rubra-pilaris/",
          "trend": null,
          "source_quality": "Secondary",
          "data_year": 2003,
          "geographic_scope": "US",
          "confidence": "Low",
          "notes": "Prevalence estimate from single expert opinion (Dr. Andrew Griffiths, 2003). US patient count estimated at 800+ active patients. Incidence data from dermatology clinic presentations, not population-based. Wide range of estimates reported across sources."
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Humira (adalimumab)",
              "drug_class": "TNF-alpha inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "Used off-label for PRP; no specific FDA approval for this indication found",
              "approval_year": null,
              "approval_confidence": "Low",
              "approval_evidence": "Mentioned in treatment literature but no FDA approval confirmation for PRP"
            },
            {
              "drug_name": "Enbrel (etanercept)",
              "drug_class": "TNF-alpha inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "Used off-label for PRP; no specific FDA approval for this indication found",
              "approval_year": null,
              "approval_confidence": "Low",
              "approval_evidence": "Mentioned in treatment literature but no FDA approval confirmation for PRP"
            },
            {
              "drug_name": "Stelara (ustekinumab)",
              "drug_class": "IL-12/IL-23 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "Used off-label for PRP with reported success; no specific FDA approval for this indication",
              "approval_year": null,
              "approval_confidence": "Low",
              "approval_evidence": "Case reports show efficacy but no FDA approval confirmation for PRP"
            },
            {
              "drug_name": "Cosentyx (secukinumab)",
              "drug_class": "IL-17 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": "57-60%",
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "Used off-label with reported efficacy in refractory cases; no specific FDA approval for PRP",
              "approval_year": null,
              "approval_confidence": "Low",
              "approval_evidence": "Mentioned in biologic therapy studies but no FDA approval confirmation for PRP"
            },
            {
              "drug_name": "Taltz (ixekizumab)",
              "drug_class": "IL-17 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "Used off-label for refractory PRP; no specific FDA approval for this indication",
              "approval_year": null,
              "approval_confidence": "Low",
              "approval_evidence": "Mentioned in treatment literature but no FDA approval confirmation for PRP"
            }
          ],
          "approved_drug_names": [],
          "num_approved_drugs": 0,
          "num_pipeline_therapies": 1,
          "pipeline_therapies": [
            {
              "drug_name": "Deucravacitinib (BMS-986165)",
              "company": "Mayo Clinic",
              "mechanism": "TYK2 inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT06444399",
              "expected_completion": "2026-01",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "First dedicated Phase 2 trial for Pityriasis Rubra Pilaris with deucravacitinib, a selective TYK2 inhibitor"
            }
          ],
          "pipeline_details": "There is currently only one active Phase 2 trial specifically for Pityriasis Rubra Pilaris, testing deucravacitinib (BMS-986165), a selective TYK2 inhibitor. This represents limited but targeted pipeline activity for this rare inflammatory skin condition, with the trial expected to complete in early 2026.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "Oral retinoids (acitretin, isotretinoin) are considered first-line systemic therapy for moderate to severe PRP. Second-line options include methotrexate and off-label biologic therapies targeting TNF-alpha, IL-17, and IL-23 pathways for refractory cases.",
          "unmet_need": true,
          "unmet_need_description": "No FDA-approved branded innovative treatments exist specifically for Pityriasis Rubra Pilaris. Current treatment relies on off-label use of biologics and conventional immunosuppressants, with no standardized treatment guidelines.",
          "competitive_landscape": "The PRP treatment landscape consists entirely of off-label therapies including retinoids, methotrexate, and various biologics. Multiple case reports and small studies support the use of IL-17 and IL-23 inhibitors, but no manufacturer has pursued formal FDA approval for PRP indication.",
          "soc_source": "Medscape Emedicine and peer-reviewed literature",
          "phase_3_count": 0,
          "phase_2_count": 1,
          "key_catalysts": "Deucravacitinib Phase 2 trial results expected in early 2026",
          "pipeline_data_quality": "Low",
          "recent_approvals": null,
          "data_quality": "Medium",
          "data_quality_notes": "Comprehensive literature available but no FDA-approved treatments identified for this specific indication; all biologic use appears to be off-label"
        },
        "market_size_estimate": "$168M",
        "market_size_usd": 167600000.0,
        "growth_rate": "5-8% CAGR (high unmet need)",
        "tam_usd": 22000000.0,
        "tam_estimate": "$22M",
        "tam_rationale": "Of ~838 US patients with PRP, ~50% are diagnosed (419), ~80% receive systemic treatment (335), given no approved drugs and high unmet need. A new first-in-class drug could capture 60-70% market share (~235 patients). At $95K/yr pricing (rare autoimmune/orphan eligible), TAM = $22M. Premium pricing justified by orphan status, high unmet need, and lack of approved therapies.",
        "tam_sources": [
          "https://eadv.org/wp-content/uploads/scientific-abstracts/EADV-congress-2025/Biologics-immunotherapy-targeted-therapy.pdf",
          "https://www.nature.com/articles/s41572-018-0001-z",
          "https://link.springer.com/content/pdf/10.1007/978-3-642-20801-0.pdf"
        ],
        "pipeline_sources": [
          "https://clinicaltrials.gov",
          "https://www.clinicaltrials.gov/study/NCT03485976?term=AREA%5BConditionSearch%5D(%22Pityriasis%20Rubra%20Pilaris%22)&rank=3",
          "https://www.clinicaltrials.gov/study/NCT05128916",
          "https://clinicaltrials.gov/study/NCT05238675",
          "https://clinicaltrials.gov/study/NCT05535738"
        ],
        "attributed_sources": [
          {
            "url": "https://cdn.mdedge.com/files/s3fs-public/issues/articles/ct108003033_e.pdf",
            "title": "Atypical Presentation of Pityriasis Rubra Pilaris",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://rarediseases.org/rare-diseases/pityriasis-rubra-pilaris/",
            "title": "Pityriasis Rubra Pilaris - Symptoms, Causes, Treatment | NORD",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://emedicine.medscape.com/article/1107742-treatment",
            "title": "Pityriasis Rubra Pilaris Treatment & Management",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://emedicine.medscape.com/article/1107742-medication",
            "title": "Pityriasis Rubra Pilaris Medication",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://jddonline.com/articles/precision-research-progress-updates-in-management-of-pityriasis-rubra-pilaris-S1545961625P0825X/",
            "title": "Updates in the Management of Pityriasis Rubra Pilaris - JDDonline",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://clinicaltrials.gov",
            "title": "ClinicalTrials.gov API",
            "attribution": "Pipeline/Clinical Trials (Primary)"
          },
          {
            "url": "https://www.clinicaltrials.gov/study/NCT03485976?term=AREA%5BConditionSearch%5D(%22Pityriasis%20Rubra%20Pilaris%22)&rank=3",
            "title": "Ixekizumab in the Treatment of Pityriasis Rubra Pilaris (PRP)",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.clinicaltrials.gov/study/NCT05128916",
            "title": "Efficacy of Intralesional PRP in Treatment of Onychomycosis",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://eadv.org/wp-content/uploads/scientific-abstracts/EADV-congress-2025/Biologics-immunotherapy-targeted-therapy.pdf",
            "title": "Abstract N\u00b0: 81 Dupilumab Is Efficacious in Patients Above ...",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.nature.com/articles/s41572-018-0001-z",
            "title": "Atopic dermatitis | Nature Reviews Disease Primers",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 9.1,
        "evidence_quality": 2.8,
        "market_opportunity": 8.7,
        "overall_priority": 7.4,
        "clinical_breakdown": {
          "response_rate_quality_weighted": 8.1,
          "safety_profile": 9.7,
          "organ_domain_breadth": 10.0,
          "safety_categories": [
            "neurological"
          ],
          "regulatory_flags": [],
          "efficacy_endpoint_count": 4,
          "efficacy_concordance": 1.1
        },
        "response_rate_score": 8.1,
        "safety_profile_score": 9.7,
        "endpoint_quality_score": null,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 1.0,
          "publication_venue": 2.0,
          "response_durability": 3.0,
          "extraction_completeness": 8.3
        },
        "sample_size_score": 1.0,
        "publication_venue_score": 2.0,
        "followup_duration_score": 3.0,
        "extraction_completeness_score": 8.3,
        "market_breakdown": {
          "competitors": 10.0,
          "market_size": 6.0,
          "unmet_need": 10.0
        },
        "competitors_score": 10.0,
        "market_size_score": 6.0,
        "unmet_need_score": 10.0
      },
      "rank": 23
    },
    {
      "extraction": {
        "source": {
          "pmid": "38051858",
          "doi": "10.36849/JDD.7500",
          "url": "https://pubmed.ncbi.nlm.nih.gov/38051858/",
          "title": "Off-Label Use of Janus Kinase Inhibitors in Inflammatory Cutaneous Diseases.",
          "authors": null,
          "journal": "Journal of Drugs in Dermatology",
          "year": 2023,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "Multiple inflammatory cutaneous diseases (dermatomyositis, hidradenitis suppurativa, cutaneous lupus, cutaneous Crohn's disease)",
        "disease_normalized": "Multiple Inflammatory Cutaneous Diseases",
        "is_off_label": true,
        "is_relevant": true,
        "evidence_level": "Case Series",
        "patient_population": {
          "n_patients": 6,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "conventional therapies"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "Patients with treatment-resistant inflammatory cutaneous disorders across 4 different conditions"
        },
        "treatment": {
          "drug_name": "upadacitinib",
          "generic_name": "Upadacitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": null,
          "frequency": null,
          "duration": null,
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": null,
          "responders_n": null,
          "responders_pct": null,
          "time_to_response": null,
          "duration_of_response": "No recurrent symptoms in dermatomyositis cases treated with upadacitinib",
          "effect_size_description": "Positive clinical outcomes with no recurrence in dermatomyositis, moderate improvement in hidradenitis suppurativa, symptom reduction in cutaneous Crohn's disease",
          "primary_endpoint": "Clinical symptom improvement",
          "endpoint_result": "Positive clinical outcomes in dermatomyositis cases, reduced systemic flares and moderate cutaneous improvement in hidradenitis suppurativa, reduced cutaneous symptoms in cutaneous Crohn's disease",
          "durability_signal": null,
          "efficacy_summary": "Upadacitinib demonstrated positive clinical outcomes across multiple inflammatory cutaneous conditions. In dermatomyositis cases, no recurrent symptoms were observed, while hidradenitis suppurativa showed reduced flares and moderate improvement."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": null,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "No safety outcomes were reported in this case series.",
          "safety_profile": "Unknown"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Moderate",
        "comparator_baseline": null,
        "follow_up_duration": null,
        "key_findings": "JAK inhibitors showed promise in treatment-resistant inflammatory cutaneous diseases with particularly favorable outcomes in dermatomyositis cases.",
        "detailed_efficacy_endpoints": [],
        "detailed_safety_endpoints": [],
        "extraction_timestamp": "2025-12-08T18:17:03.779570",
        "extraction_confidence": 0.5,
        "extraction_confidence_detail": null,
        "extraction_method": "single_pass",
        "extraction_stages_completed": [],
        "data_sections_identified": null
      },
      "market_intelligence": {
        "disease": "Multiple Inflammatory Cutaneous Diseases",
        "parent_disease": null,
        "epidemiology": {
          "us_prevalence_estimate": "15-20% of population affected by chronic inflammatory skin diseases collectively",
          "us_incidence_estimate": null,
          "global_prevalence": null,
          "patient_population_size": 58625000,
          "prevalence_source": "Frontiers in Medicine",
          "prevalence_source_url": "https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2022.875492/full",
          "trend": null,
          "source_quality": "Secondary",
          "data_year": 2022,
          "geographic_scope": "Global",
          "confidence": "Medium",
          "notes": "Estimate represents collective prevalence of 17 chronic inflammatory skin diseases; individual disease prevalences vary significantly with psoriasis at 3.0%, atopic dermatitis affecting nearly 10%, and hidradenitis suppurativa at 0.2-0.4%"
        },
        "standard_of_care": {
          "top_treatments": [],
          "approved_drug_names": [],
          "num_approved_drugs": 0,
          "num_pipeline_therapies": 0,
          "pipeline_therapies": [],
          "pipeline_details": null,
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "Treatment for inflammatory cutaneous diseases typically follows a stepwise approach starting with topical corticosteroids and calcineurin inhibitors as first-line therapy. Second-line systemic treatments include antimalarials like hydroxychloroquine, methotrexate, mycophenolate mofetil, and systemic corticosteroids, with newer targeted therapies reserved for refractory cases.",
          "unmet_need": true,
          "unmet_need_description": "No FDA-approved branded innovative treatments were identified specifically for 'Multiple Inflammatory Cutaneous Diseases' as a distinct indication. Current treatments are primarily generic immunosuppressants and corticosteroids, with newer biologics approved for specific individual cutaneous conditions rather than multiple inflammatory skin diseases collectively.",
          "competitive_landscape": "The search results show approvals for individual inflammatory skin conditions like atopic dermatitis, psoriasis, and cutaneous lupus erythematosus, but no specific FDA approvals for the collective indication of 'Multiple Inflammatory Cutaneous Diseases.' Biosimilars like Wezlana (ustekinumab-auub) are being approved for multiple inflammatory diseases, but these target specific named conditions rather than the broad category searched.",
          "soc_source": "FDA Press Announcements and multiple dermatology clinical guidelines",
          "phase_3_count": 0,
          "phase_2_count": 0,
          "key_catalysts": null,
          "pipeline_data_quality": "Unknown",
          "recent_approvals": null,
          "data_quality": "High",
          "data_quality_notes": "Search results provided comprehensive information about individual inflammatory skin disease treatments but no specific FDA approvals were found for the exact indication 'Multiple Inflammatory Cutaneous Diseases' as a single labeled indication"
        },
        "market_size_estimate": "$1465.6B",
        "market_size_usd": 1465625000000.0,
        "growth_rate": "5-8% CAGR (high unmet need)",
        "tam_usd": 6300000000.0,
        "tam_estimate": "$6.3B",
        "tam_rationale": "Of ~58.6M US patients with chronic inflammatory skin diseases, approximately 70% are diagnosed (41M), with 60% receiving systemic treatment beyond topicals (24.6M patients). Given the stepwise treatment paradigm and high unmet need with 0 approved drugs, a new targeted therapy could capture 20-25% market share in second-line treatment (~5.9M patients). At estimated $35K-45K/year pricing typical for dermatologic specialty drugs, TAM = $6.3B. The significant unmet need and lack of approved therapies supports strong market penetration potential.",
        "tam_sources": [
          "https://trisaluslifesci.com/wp-content/uploads/2025/12/TLSI_Investor-Deck-December-2025.pdf",
          "https://answers.microsoft.com/en-us/msoffice/forum/all/splitting-a-word-file-into-separate-docs-based-on/05de4f87-7803-4e52-9a87-8eb0fe6194c4",
          "https://answers.microsoft.com/en-us/outlook_com/forum/all/i-keep-getting-phishing-emails-to-my-inbox-no/0af0063a-3d1e-45ed-a069-4978cfba8901"
        ],
        "pipeline_sources": [
          "https://clinicaltrials.gov",
          "https://www.clinicaltrials.gov/study/NCT03575871",
          "https://www.clinicaltrials.gov/study/NCT07021495",
          "https://cdn.clinicaltrials.gov/large-docs/63/NCT05204563/Prot_000.pdf",
          "https://cdn.clinicaltrials.gov/large-docs/90/NCT07266090/Prot_SAP_000.pdf"
        ],
        "attributed_sources": [
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10800546/",
            "title": "Large-scale epidemiological analysis of common skin diseases to ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://jamanetwork.com/journals/jamadermatology/fullarticle/2781378",
            "title": "Psoriasis Prevalence in Adults in the United States - JAMA Network",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.fda.gov/news-events/press-announcements/fda-approves-interchangeable-biosimilar-multiple-inflammatory-diseases",
            "title": "FDA Approves Interchangeable Biosimilar for Multiple ...",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.drugs.com/medical-answers/dupixent-work-3545366/",
            "title": "How does Dupixent work and what is its mechanism of action? ACAAI 2025: The Clinical Impact of New CSU Treatment Options Biosimilars | FDA U.S. Food and Drug Administration - accessdata.fda.gov Biologics Effective Against Photosensitive Skin Diseases Drug Approvals and Databases | FDA",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://ard.bmj.com/content/83/1/15",
            "title": "EULAR recommendations for the management of systemic ...",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://clinicaltrials.gov",
            "title": "ClinicalTrials.gov API",
            "attribution": "Pipeline/Clinical Trials (Primary)"
          },
          {
            "url": "https://www.clinicaltrials.gov/study/NCT03575871",
            "title": "NCT03575871 | Study Evaluating Efficacy and Safety of PF ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.clinicaltrials.gov/study/NCT07021495",
            "title": "Study Details | NCT07021495 | SKIN Disease Profiling by ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://trisaluslifesci.com/wp-content/uploads/2025/12/TLSI_Investor-Deck-December-2025.pdf",
            "title": "Investor Presentation - trisaluslifesci.com",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://answers.microsoft.com/en-us/msoffice/forum/all/splitting-a-word-file-into-separate-docs-based-on/05de4f87-7803-4e52-9a87-8eb0fe6194c4",
            "title": "Splitting a Word File Into Separate Docs Based on Footer?",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 6.4,
        "evidence_quality": 6.4,
        "market_opportunity": 10.0,
        "overall_priority": 7.3,
        "clinical_breakdown": {
          "response_rate_quality_weighted": 6.0,
          "safety_profile": 5.0,
          "organ_domain_breadth": 10.0,
          "safety_categories": [],
          "regulatory_flags": [],
          "efficacy_endpoint_count": 0,
          "efficacy_concordance": 1.0
        },
        "response_rate_score": 6.0,
        "safety_profile_score": 5.0,
        "endpoint_quality_score": null,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 6.0,
          "publication_venue": 10.0,
          "response_durability": 4.0,
          "extraction_completeness": 5.5
        },
        "sample_size_score": 6.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 4.0,
        "extraction_completeness_score": 5.5,
        "market_breakdown": {
          "competitors": 10.0,
          "market_size": 10.0,
          "unmet_need": 10.0
        },
        "competitors_score": 10.0,
        "market_size_score": 10.0,
        "unmet_need_score": 10.0
      },
      "rank": 24
    },
    {
      "extraction": {
        "source": {
          "pmid": "37801670",
          "doi": "10.1080/09273948.2023.2263557",
          "url": "https://pubmed.ncbi.nlm.nih.gov/37801670/",
          "title": "Successful Remission with Upadacitinib in Two Patients with Anti-TNF-Refractory Macular Edema Associated with Beh\u00e7et's Uveitis.",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "Beh\u00e7et's uveitis with macular edema",
        "disease_normalized": "Beh\u00e7et's Disease",
        "is_off_label": true,
        "is_relevant": true,
        "evidence_level": "Case Series",
        "patient_population": {
          "n_patients": 2,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "anti-TNF agents",
            "systemic glucocorticoids",
            "immunosuppressive agents"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "Two patients with Beh\u00e7et's uveitis suffering from macular edema and persistent inflammation"
        },
        "treatment": {
          "drug_name": "upadacitinib",
          "generic_name": "Upadacitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": null,
          "dose": null,
          "frequency": null,
          "duration": null,
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "2/2 (100%)",
          "responders_n": 2,
          "responders_pct": 100.0,
          "time_to_response": null,
          "duration_of_response": null,
          "effect_size_description": "Complete remission in both patients with refractory disease",
          "primary_endpoint": "Remission of macular edema and uveitis inflammation",
          "endpoint_result": "Successful remission achieved in both patients",
          "durability_signal": null,
          "efficacy_summary": "Upadacitinib achieved successful remission in both patients with anti-TNF-refractory Beh\u00e7et's uveitis and macular edema. This represents the first reported use of upadacitinib for Beh\u00e7et's syndrome with panuveitis."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": null,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "No safety outcomes reported in the abstract.",
          "safety_profile": "Unknown"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": null,
        "key_findings": "First reported successful use of upadacitinib for refractory Beh\u00e7et's uveitis with complete remission achieved in both treated patients.",
        "detailed_efficacy_endpoints": [],
        "detailed_safety_endpoints": [],
        "extraction_timestamp": "2025-12-08T18:27:30.111945",
        "extraction_confidence": 0.5,
        "extraction_confidence_detail": null,
        "extraction_method": "single_pass",
        "extraction_stages_completed": [],
        "data_sections_identified": null
      },
      "market_intelligence": {
        "disease": "Beh\u00e7et's Disease",
        "parent_disease": null,
        "epidemiology": {
          "us_prevalence_estimate": "0.33 to 5.2 per 100,000 population",
          "us_incidence_estimate": "0.38 per 100,000 population",
          "global_prevalence": null,
          "patient_population_size": 9200,
          "prevalence_source": "Arthritis & Rheumatism journal",
          "prevalence_source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3024036/",
          "trend": "increasing",
          "source_quality": "Primary",
          "data_year": 2009,
          "geographic_scope": "US",
          "confidence": "Medium",
          "notes": "Wide range reported across studies (0.33-10.6 per 100,000); higher prevalence found in Southwestern US populations; increasing trend may be due to improved recognition and immigration from endemic areas"
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Otezla (apremilast)",
              "drug_class": "PDE-4 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Oral Ulcers Associated with Beh\u00e7et's Disease",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "FDA approved for treatment of adult patients with oral ulcers associated with Beh\u00e7et's Disease. Approval based on Phase 3 RELIEF study with 207 patients. Dosed at 30 mg twice daily.",
              "approval_year": 2019,
              "approval_confidence": "High",
              "approval_evidence": "FDA label 2019, drugs@FDA documentation"
            }
          ],
          "approved_drug_names": [
            "Otezla (apremilast)"
          ],
          "num_approved_drugs": 1,
          "num_pipeline_therapies": 13,
          "pipeline_therapies": [
            {
              "drug_name": "Apremilast",
              "company": "Amgen",
              "mechanism": "PDE4 inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT04528082",
              "expected_completion": "2030-02",
              "trial_name": "BEAN",
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Pediatric study for children 2-18 years with active oral ulcers"
            },
            {
              "drug_name": "Apremilast",
              "company": "Amgen",
              "mechanism": "PDE4 inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT05767047",
              "expected_completion": "2036-03",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Long-term extension study in children with oral ulcers"
            },
            {
              "drug_name": "Hemay005",
              "company": "Ganzhou Hemay Pharmaceutical Co., Ltd",
              "mechanism": null,
              "phase": "Phase 3",
              "trial_id": "NCT06145893",
              "expected_completion": "2026-05",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": null
            },
            {
              "drug_name": "Baricitinib",
              "company": "Peking Union Medical College Hospital",
              "mechanism": "JAK inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT06849908",
              "expected_completion": "2027-06",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "For refractory intestinal Beh\u00e7et's syndrome vs adalimumab"
            },
            {
              "drug_name": "HSK44459",
              "company": "Haisco Pharmaceutical Group Co., Ltd.",
              "mechanism": null,
              "phase": "Phase 2",
              "trial_id": "NCT06902428",
              "expected_completion": "2026-06",
              "trial_name": null,
              "status": "Not yet recruiting",
              "regulatory_designations": null,
              "notes": null
            },
            {
              "drug_name": "Rivaroxaban",
              "company": "Assistance Publique - H\u00f4pitaux de Paris",
              "mechanism": "Anticoagulant",
              "phase": "Phase 3",
              "trial_id": "NCT06780462",
              "expected_completion": "2027-07",
              "trial_name": null,
              "status": "Not yet recruiting",
              "regulatory_designations": null,
              "notes": "Steroid therapy plus anticoagulants vs steroid alone for deep venous thrombosis"
            },
            {
              "drug_name": "Tocilizumab",
              "company": "Assistance Publique - H\u00f4pitaux de Paris",
              "mechanism": "IL-6 receptor antagonist",
              "phase": "Phase 2",
              "trial_id": "NCT05874505",
              "expected_completion": "2026-11",
              "trial_name": "UVB",
              "status": "Not yet recruiting",
              "regulatory_designations": null,
              "notes": "Comparison with adalimumab in severe uveitis"
            },
            {
              "drug_name": "Tocilizumab",
              "company": "Peking Union Medical College Hospital",
              "mechanism": "IL-6 receptor antagonist",
              "phase": "Phase 2",
              "trial_id": "NCT05845723",
              "expected_completion": "2026-06",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Combined with tofacitinib for vascular Beh\u00e7et's syndrome"
            },
            {
              "drug_name": "Low-dose IL-2",
              "company": "HeJing",
              "mechanism": "Immunoregulatory cytokine",
              "phase": "Phase 2",
              "trial_id": "NCT04065672",
              "expected_completion": "2023-04",
              "trial_name": null,
              "status": "Completed",
              "regulatory_designations": null,
              "notes": "Completed within last 2 years, indicating active development"
            },
            {
              "drug_name": "BCMA-CD19 CAR-T",
              "company": "Peking University People's Hospital",
              "mechanism": "CAR-T cell therapy",
              "phase": "Phase 2",
              "trial_id": "NCT06794008",
              "expected_completion": "2027-12",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "For multiple refractory autoimmune diseases including Beh\u00e7et's"
            },
            {
              "drug_name": "Filgotinib",
              "company": "UMC Utrecht",
              "mechanism": "JAK inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT06285539",
              "expected_completion": "2026-12",
              "trial_name": "DRIMID",
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Drug rediscovery study for rare immune mediated inflammatory diseases"
            },
            {
              "drug_name": "Dusquetide",
              "company": "Soligenix",
              "mechanism": "Innate defense regulator",
              "phase": "Phase 2",
              "trial_id": "NCT06386744",
              "expected_completion": "2025-05",
              "trial_name": null,
              "status": "Completed",
              "regulatory_designations": "Fast Track, Orphan Drug",
              "notes": "Recently completed Phase 2a with positive biological efficacy results"
            },
            {
              "drug_name": "Upadacitinib",
              "company": "Liu Tian",
              "mechanism": "JAK inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT07080346",
              "expected_completion": "2024-12",
              "trial_name": null,
              "status": "Completed",
              "regulatory_designations": null,
              "notes": "Recently completed pilot study for refractory Beh\u00e7et's syndrome"
            }
          ],
          "pipeline_details": "The Beh\u00e7et's Disease pipeline includes 13 active programs across Phase 2 and Phase 3 development. Key mechanisms being tested include JAK inhibitors (baricitinib, filgotinib, upadacitinib), IL-6 receptor antagonists (tocilizumab), PDE4 inhibitors (apremilast), and novel approaches like innate defense regulators (dusquetide) and CAR-T cell therapy. Recent positive results include completed Phase 2 studies for dusquetide and upadacitinib.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "Beh\u00e7et's Disease treatment is organ-system specific with no standardized approach. For mucocutaneous manifestations, colchicine is typically first-line, with topical therapies for mild ulcerations. Otezla (apremilast) serves as second-line therapy specifically for oral ulcers. For severe organ involvement (ocular, neurologic, vascular), combination immunosuppression with corticosteroids plus azathioprine or anti-TNF agents is used.",
          "unmet_need": true,
          "unmet_need_description": "Only one FDA-approved treatment exists specifically for Beh\u00e7et's Disease (Otezla for oral ulcers only). Most treatments are off-label use of drugs approved for other conditions. No FDA-approved therapies exist for systemic manifestations including ocular, neurologic, or vascular disease.",
          "competitive_landscape": "Otezla holds the only FDA approval for Beh\u00e7et's Disease, giving it regulatory advantage for oral ulcers. Treatment otherwise relies heavily on off-label use of anti-TNF biologics (infliximab, adalimumab), immunosuppressants, and corticosteroids. Multiple biologics are used off-label but lack specific FDA approval for this indication.",
          "soc_source": "FDA drug labels and Medscape clinical references",
          "phase_3_count": 4,
          "phase_2_count": 9,
          "key_catalysts": "Expected primary readouts include Hemay005 Phase 3 results (May 2026), HSK44459 Phase 2 results (June 2026), and multiple tocilizumab studies completing in 2026. Soligenix plans to advance dusquetide development following recent positive Phase 2a results.",
          "pipeline_data_quality": "High",
          "recent_approvals": null,
          "data_quality": "High",
          "data_quality_notes": "Clear FDA approval documentation available for Otezla. Other treatments mentioned are off-label uses without specific Beh\u00e7et's Disease FDA approvals."
        },
        "market_size_estimate": "$1.8B",
        "market_size_usd": 1840000000.0,
        "growth_rate": "5-10% CAGR (increasing prevalence)",
        "tam_usd": 184000000.0,
        "tam_estimate": "$184M",
        "tam_rationale": "Of ~9,200 US patients with Beh\u00e7et's Disease, ~70% are diagnosed (6,440), ~60% receive systemic treatment (3,864), ~40% fail first-line therapy and are candidates for 2L+ treatment (1,546). A new drug targeting moderate-severe manifestations could capture 30% market share (~464 patients) given high unmet need and only one approved drug. At $400K/yr pricing (orphan drug designation for rare autoimmune indication), TAM = $184M.",
        "tam_sources": [
          "https://www.credenceresearch.com/report/behcets-disease-market",
          "https://www.openpr.com/news/4113839/behcet-s-disease-market-growth-size-surges-amid-rising",
          "https://exactitudeconsultancy.com/it/reports/71308/behcet-s-disease-market"
        ],
        "pipeline_sources": [
          "https://clinicaltrials.gov",
          "https://clinicaltrials.gov/study/NCT02307513",
          "https://www.clinicaltrials.gov/study/NCT00995709",
          "https://www.clinicaltrials.gov/study/NCT01965145",
          "https://clinicaltrials.gov/study/NCT06902428"
        ],
        "attributed_sources": [
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8404295/",
            "title": "Epidemiology and treatment of Beh\u00e7et's disease in the USA",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://acrabstracts.org/abstract/behcets-disease-in-the-southwestern-united-states/",
            "title": "Behcet's Disease in the Southwestern United States",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.drugs.com/history/otezla.html",
            "title": "Otezla (apremilast) FDA Approval History",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.medscape.com/viewarticle/915883",
            "title": "FDA OKs Apremilast (Otezla) for Oral Ulcers of Behcet's ...",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.chi.gov.sa/Style%20Library/IDF_Branding/Indication/185%20-%20Behcet%20Disease-New%20Indication.pdf",
            "title": "[PDF] BEHCET DISEASE",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://clinicaltrials.gov",
            "title": "ClinicalTrials.gov API",
            "attribution": "Pipeline/Clinical Trials (Primary)"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT02307513",
            "title": "Study Details | NCT02307513 | A Phase 3 Randomized, ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.clinicaltrials.gov/study/NCT00995709",
            "title": "Phase III Study in Refractory Behcet's Disease",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.credenceresearch.com/report/behcets-disease-market",
            "title": "Behcet's Disease Market Size, Share, Growth and Forecast 2032",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.openpr.com/news/4113839/behcet-s-disease-market-growth-size-surges-amid-rising",
            "title": "Behcet's Disease Market Growth Size Surges Amid Rising",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 8.0,
        "evidence_quality": 4.9,
        "market_opportunity": 8.3,
        "overall_priority": 7.3,
        "clinical_breakdown": {
          "response_rate_quality_weighted": 10.0,
          "safety_profile": 5.0,
          "organ_domain_breadth": 10.0,
          "safety_categories": [],
          "regulatory_flags": [],
          "efficacy_endpoint_count": 0,
          "efficacy_concordance": 1.0
        },
        "response_rate_score": 10.0,
        "safety_profile_score": 5.0,
        "endpoint_quality_score": null,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 2.0,
          "publication_venue": 10.0,
          "response_durability": 4.0,
          "extraction_completeness": 4.9
        },
        "sample_size_score": 2.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 4.0,
        "extraction_completeness_score": 4.9,
        "market_breakdown": {
          "competitors": 7.0,
          "market_size": 8.0,
          "unmet_need": 10.0
        },
        "competitors_score": 7.0,
        "market_size_score": 8.0,
        "unmet_need_score": 10.0
      },
      "rank": 25
    },
    {
      "extraction": {
        "source": {
          "pmid": "41102517",
          "doi": "10.1007/s13555-025-01569-x",
          "url": "https://pubmed.ncbi.nlm.nih.gov/41102517/",
          "title": "Secukinumab Plus Upadacitinib for the Treatment of Severe Hidradenitis Suppurativa and Associated Immune-Mediated Comorbidities: A Case Series.",
          "authors": "Roberto Bueno-Filho, Daniel Lorenzini, Rog\u00e9rio Serafim Parra",
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "Hidradenitis Suppurativa",
        "disease_normalized": "Hidradenitis Suppurativa",
        "is_off_label": true,
        "is_relevant": true,
        "evidence_level": "Case Series",
        "patient_population": {
          "n_patients": 2,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "mesalazine",
            "prednisone",
            "antibiotics",
            "ustekinumab",
            "cyclosporine",
            "adalimumab",
            "isotretinoin"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "One 47-year-old female and one 19-year-old male, both with multiple inflammatory conditions including atopic dermatitis, Crohn's disease, and hidradenitis suppurativa"
        },
        "treatment": {
          "drug_name": "upadacitinib",
          "generic_name": "Upadacitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "15 mg/day",
          "frequency": null,
          "duration": "7 months for case 1, duration not specified for case 2",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "2/2 (100%)",
          "responders_n": 2,
          "responders_pct": 100.0,
          "time_to_response": null,
          "duration_of_response": null,
          "effect_size_description": "Complete improvement of hidradenitis suppurativa lesions with resolution of fistulized nodules",
          "primary_endpoint": "Clinical improvement of hidradenitis suppurativa lesions",
          "endpoint_result": "Complete improvement of skin lesions in both cases",
          "durability_signal": null,
          "efficacy_summary": "Both patients achieved complete improvement of hidradenitis suppurativa lesions along with simultaneous control of atopic dermatitis and Crohn's disease. Patient 2 showed complete resolution of fistulized nodules on face, abdomen, axillae, and buttocks."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": null,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "No adverse events were reported in either case. Safety data was not systematically collected or reported.",
          "safety_profile": "Unknown"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": "7 months for case 1",
        "key_findings": "Upadacitinib demonstrated efficacy in treating hidradenitis suppurativa as part of multiple inflammatory conditions, achieving complete resolution of skin lesions in both patients.",
        "detailed_efficacy_endpoints": [
          {
            "endpoint_name": "SCORAD score",
            "endpoint_category": "Secondary",
            "timepoint": "7 months",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "points",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 45.0,
            "final_value": 0.0,
            "change_from_baseline": -45.0,
            "change_pct": -100.0,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Case 1 - complete resolution of atopic dermatitis activity",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "DLQI score",
            "endpoint_category": "Secondary",
            "timepoint": "7 months",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "points",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 20.0,
            "final_value": 0.0,
            "change_from_baseline": -20.0,
            "change_pct": -100.0,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Case 1 - complete improvement in quality of life",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 2
          },
          {
            "endpoint_name": "Fecal calprotectin",
            "endpoint_category": "Secondary",
            "timepoint": "7 months",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "mcg/g",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 56.0,
            "final_value": 10.0,
            "change_from_baseline": -46.0,
            "change_pct": -82.1,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Case 1 - normalization of inflammatory biomarker for Crohn's disease",
            "organ_domain": "Gastrointestinal",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "SCORAD score",
            "endpoint_category": "Secondary",
            "timepoint": "Post-treatment",
            "measurement_type": "Absolute value",
            "value": 65.4,
            "unit": "points",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 65.4,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Case 2 - baseline severe atopic dermatitis, complete improvement achieved but final score not specified",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "DLQI score",
            "endpoint_category": "Secondary",
            "timepoint": "Post-treatment",
            "measurement_type": "Absolute value",
            "value": 18.0,
            "unit": "points",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 18.0,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Case 2 - baseline quality of life impairment, improvement achieved but final score not specified",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 2
          },
          {
            "endpoint_name": "Fecal calprotectin",
            "endpoint_category": "Secondary",
            "timepoint": "Post-treatment",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "mcg/g",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 3000.0,
            "final_value": 35.0,
            "change_from_baseline": -2965.0,
            "change_pct": -98.8,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Case 2 - normalization from severely elevated baseline (>3000 mcg/g)",
            "organ_domain": "Gastrointestinal",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "IgE level",
            "endpoint_category": "Secondary",
            "timepoint": "Baseline",
            "measurement_type": "Absolute value",
            "value": 1006.0,
            "unit": "kU/L",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 1006.0,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Case 2 - elevated baseline IgE level, post-treatment value not reported",
            "organ_domain": "Immunological",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "Endoscopic remission",
            "endpoint_category": "Secondary",
            "timepoint": "Post-treatment",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 1,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Case 2 - complete mucosal healing on ileocolonoscopy from baseline deep ulcers and inflammation",
            "organ_domain": "Gastrointestinal",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "Clinical remission of Crohn's disease",
            "endpoint_category": "Secondary",
            "timepoint": "Post-treatment",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 2,
            "responders_n": 2,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Both cases achieved clinical remission of Crohn's disease",
            "organ_domain": "Gastrointestinal",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          }
        ],
        "detailed_safety_endpoints": [],
        "extraction_timestamp": "2025-12-08T18:33:20.089490",
        "extraction_confidence": 0.6,
        "extraction_confidence_detail": null,
        "extraction_method": "multi_stage",
        "extraction_stages_completed": [
          "section_identification",
          "efficacy_extraction",
          "safety_extraction"
        ],
        "data_sections_identified": {
          "baseline_tables": [],
          "efficacy_tables": [],
          "safety_tables": [],
          "efficacy_figures": [
            "Figure 1: Case 1 before and after treatment photos - (A) extensive erythematous and desquamative lesions on hands, (B) complete improvement after upadacitinib",
            "Figure 2: Case 2 before and after treatment photos - (A) multiple lesions with erythema, desquamation, crusts and nodules on face, (B) almost complete improvement with residual scars",
            "Figure 3: Ileocolonoscopy before upadacitinib showing ileocecal valve and cecum with multiple deep ulcers indicating active Crohn's disease",
            "Figure 4: Ileocolonoscopy after upadacitinib showing ileocecal valve and cecum with complete mucosal healing"
          ],
          "results_sections": [
            "Case 1 outcomes: SCORAD improved from 45 to 0, DLQI improved from 20 to 0, fecal calprotectin decreased from 56 to 10 mcg/g",
            "Case 2 outcomes: SCORAD improved from 65.4 to complete improvement, DLQI improved from 18 to improvement, fecal calprotectin decreased from >3000 to 35 mcg/g with endoscopic remission"
          ],
          "patient_count": 2,
          "study_type": "Case Series",
          "has_quantitative_outcomes": true,
          "notes": "No formal tables present - all baseline and outcome data reported narratively within case descriptions. Both cases showed complete or near-complete improvement in multiple inflammatory conditions with upadacitinib treatment"
        }
      },
      "market_intelligence": {
        "disease": "Hidradenitis Suppurativa",
        "parent_disease": null,
        "epidemiology": {
          "us_prevalence_estimate": "0.10% to 0.40%",
          "us_incidence_estimate": null,
          "global_prevalence": null,
          "patient_population_size": 838000,
          "prevalence_source": "JAMA Dermatology systematic review and meta-analysis",
          "prevalence_source_url": "https://jamanetwork.com/journals/jamadermatology/fullarticle/2780049",
          "trend": null,
          "source_quality": "Primary",
          "data_year": 2021,
          "geographic_scope": "US",
          "confidence": "High",
          "notes": "Wide range reported across studies (0.10%-0.40%). Meta-analysis shows 0.40% overall prevalence with significant heterogeneity. Higher prevalence in females (4:1 ratio), African Americans (0.76%), and younger adults (18-25 age group: 1.70%). Clinical samples show higher prevalence (1.7%) than population-based studies (0.3%)."
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Humira (adalimumab)",
              "drug_class": "TNF-alpha inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Treatment of moderate to severe hidradenitis suppurativa",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "First FDA-approved biologic for moderate to severe hidradenitis suppurativa, received orphan drug designation",
              "approval_year": 2015,
              "approval_confidence": "High",
              "approval_evidence": "FDA orphan drug designation database showing approval 09/09/2015"
            },
            {
              "drug_name": "Hadlima (adalimumab-bwwd)",
              "drug_class": "TNF-alpha inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Treatment of moderate to severe hidradenitis suppurativa",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "Adalimumab biosimilar approved for moderate to severe hidradenitis suppurativa in adult patients",
              "approval_year": null,
              "approval_confidence": "High",
              "approval_evidence": "FDA drug label confirms indication for hidradenitis suppurativa"
            },
            {
              "drug_name": "Yusimry (adalimumab-aqvh)",
              "drug_class": "TNF-alpha inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Treatment of moderate to severe hidradenitis suppurativa",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "Adalimumab biosimilar approved for moderate to severe hidradenitis suppurativa in adult patients",
              "approval_year": null,
              "approval_confidence": "High",
              "approval_evidence": "FDA drug label confirms indication for hidradenitis suppurativa"
            },
            {
              "drug_name": "Cosentyx (secukinumab)",
              "drug_class": "IL-17A inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Treatment of adult patients with moderate to severe hidradenitis suppurativa",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "IL-17A inhibitor approved for moderate to severe hidradenitis suppurativa in adults",
              "approval_year": null,
              "approval_confidence": "High",
              "approval_evidence": "FDA drug label confirms indication for hidradenitis suppurativa"
            },
            {
              "drug_name": "Bimzelx (bimekizumab-bkzx)",
              "drug_class": "IL-17A/IL-17F inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Treatment of adults with moderate to severe hidradenitis suppurativa",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "Dual IL-17A/IL-17F inhibitor approved in 2024, supported by BE HEARD I and II phase 3 studies",
              "approval_year": 2024,
              "approval_confidence": "High",
              "approval_evidence": "FDA drug label confirms approval for hidradenitis suppurativa in 2024"
            },
            {
              "drug_name": "Yuflyma (adalimumab-aaty)",
              "drug_class": "TNF-alpha inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Treatment of moderate to severe hidradenitis suppurativa",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "Adalimumab biosimilar approved for moderate to severe hidradenitis suppurativa in adult patients",
              "approval_year": null,
              "approval_confidence": "High",
              "approval_evidence": "FDA drug label confirms indication for hidradenitis suppurativa"
            }
          ],
          "approved_drug_names": [
            "Humira (adalimumab)",
            "Hadlima (adalimumab-bwwd)",
            "Yusimry (adalimumab-aqvh)",
            "Cosentyx (secukinumab)",
            "Bimzelx (bimekizumab-bkzx)",
            "Yuflyma (adalimumab-aaty)"
          ],
          "num_approved_drugs": 6,
          "num_pipeline_therapies": 0,
          "pipeline_therapies": [],
          "pipeline_details": null,
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "Treatment follows a staged approach based on disease severity using the Hurley staging system. First-line therapy for mild disease includes topical clindamycin and oral tetracyclines, while moderate to severe disease typically requires TNF-alpha inhibitors like adalimumab as first-line biologic therapy, followed by IL-17 inhibitors as second-line options.",
          "unmet_need": true,
          "unmet_need_description": "Despite available biologics, many patients do not achieve adequate response, with guidelines noting that if clinical response is not achieved after 12 weeks of treatment, other modalities must be considered. Limited treatment options exist beyond TNF-alpha and IL-17 inhibitors.",
          "competitive_landscape": "The market is dominated by adalimumab (Humira) and its biosimilars as first-line biologic therapy. IL-17 inhibitors including secukinumab (Cosentyx) and the newly approved bimekizumab (Bimzelx) provide second-line options. Additional biologics like infliximab are used off-label as second or third-line treatments.",
          "soc_source": "FDA drug labels and Medscape treatment guidelines",
          "phase_3_count": 0,
          "phase_2_count": 0,
          "key_catalysts": null,
          "pipeline_data_quality": "Unknown",
          "recent_approvals": "Bimzelx (bimekizumab-bkzx) was approved by FDA in 2024 for moderate to severe hidradenitis suppurativa, representing the first dual IL-17A/IL-17F inhibitor for this indication",
          "data_quality": "High",
          "data_quality_notes": "FDA approval status confirmed through official drug labels and orphan drug designation database"
        },
        "market_size_estimate": "$20.9B",
        "market_size_usd": 20950000000.0,
        "growth_rate": "5-8% CAGR (high unmet need)",
        "tam_usd": 456000000.0,
        "tam_estimate": "$456M",
        "tam_rationale": "Of ~838K US HS patients, ~70% are diagnosed (586K), ~60% receive systemic treatment (352K), ~35% progress to moderate-severe disease requiring biologics (123K). A new biologic could capture 20-25% market share in this crowded but underserved market (~27K patients). At $65K/yr pricing (consistent with IL-17 inhibitors), TAM = $456M. Strong unmet need exists given current biologics have limited efficacy (25-30% response rates) and high treatment fatigue.",
        "tam_sources": [
          "https://www.pharmaceutical-technology.com/analyst-comment/hs-market-7mm-2034/",
          "https://filecache.investorroom.com/mr5ir_insmed/370/2025_JPM_Presentation_vFINAL.pdf",
          "https://www.sec.gov/Archives/edgar/data/1962918/000119312523128619/d540006ds1a.htm"
        ],
        "pipeline_sources": [
          "https://clinicaltrials.gov",
          "https://clinicaltrials.gov/study/NCT03827798",
          "https://www.clinicaltrials.gov/study/NCT06799000",
          "https://cdn.clinicaltrials.gov/large-docs/69/NCT03926169/SAP_001.pdf",
          "https://cdn.clinicaltrials.gov/large-docs/55/NCT04430855/SAP_001.pdf"
        ],
        "attributed_sources": [
          {
            "url": "https://www.2minutemedicine.com/new-prevalence-estimates-for-hidradenitis-suppurativa-in-the-united-states/",
            "title": "New prevalence estimates for hidradenitis suppurativa in the United ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.ovid.com/journals/jdds/pdf/10.4103/jdds.jdds_40_24~hidradenitis-suppurativa-prevalence-by-age-and-race-in-the",
            "title": "Hidradenitis Suppurativa Prevalence by Age and Race in the United ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://emedicine.medscape.com/article/1073117-treatment",
            "title": "Hidradenitis Suppurativa Treatment & Management",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.fda.gov/consumers/health-education-resources/hidradenitis-suppurativa",
            "title": "Hidradenitis Suppurativa",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://emedicine.medscape.com/article/1073117-guidelines",
            "title": "Hidradenitis Suppurativa Guidelines - Medscape Reference",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://clinicaltrials.gov",
            "title": "ClinicalTrials.gov API",
            "attribution": "Pipeline/Clinical Trials (Primary)"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT03827798",
            "title": "NCT03827798 | Study of Efficacy and Safety ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.clinicaltrials.gov/study/NCT06799000",
            "title": "NCT06799000 | A Phase 3 Study to Assess Efficacy Safety ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.pharmaceutical-technology.com/analyst-comment/hs-market-7mm-2034/",
            "title": "HS market forecast to reach $7.8bn across 7MM by 2034",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://filecache.investorroom.com/mr5ir_insmed/370/2025_JPM_Presentation_vFINAL.pdf",
            "title": "[PDF] J.P. Morgan Healthcare Conference Presentation",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 7.8,
        "evidence_quality": 6.0,
        "market_opportunity": 7.7,
        "overall_priority": 7.3,
        "clinical_breakdown": {
          "response_rate_quality_weighted": 9.4,
          "safety_profile": 5.0,
          "organ_domain_breadth": 10.0,
          "safety_categories": [],
          "regulatory_flags": [],
          "efficacy_endpoint_count": 9,
          "efficacy_concordance": 1.1
        },
        "response_rate_score": 9.4,
        "safety_profile_score": 5.0,
        "endpoint_quality_score": null,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 2.0,
          "publication_venue": 10.0,
          "response_durability": 7.0,
          "extraction_completeness": 7.2
        },
        "sample_size_score": 2.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 7.0,
        "extraction_completeness_score": 7.2,
        "market_breakdown": {
          "competitors": 3.0,
          "market_size": 10.0,
          "unmet_need": 10.0
        },
        "competitors_score": 3.0,
        "market_size_score": 10.0,
        "unmet_need_score": 10.0
      },
      "rank": 26
    },
    {
      "extraction": {
        "source": {
          "pmid": "38134405",
          "doi": "10.1093/ibd/izad300",
          "url": "https://pubmed.ncbi.nlm.nih.gov/38134405/",
          "title": "Single-center Experience With Upadacitinib for Adolescents With Refractory Inflammatory Bowel Disease.",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "Inflammatory Bowel Disease in adolescents",
        "disease_normalized": "Inflammatory Bowel Disease",
        "is_off_label": true,
        "is_relevant": true,
        "evidence_level": "Case Series",
        "patient_population": {
          "n_patients": 20,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "at least 2 biologics in 90% of patients"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "Adolescents aged 12-17 years (median 15 years) with refractory IBD (9 CD, 10 UC, 1 IBD-U); 55% female, 90% had failed \u22652 biologics"
        },
        "treatment": {
          "drug_name": "upadacitinib",
          "generic_name": "Upadacitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": null,
          "frequency": null,
          "duration": "median 51 weeks (43-63 weeks)",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "15/20 (75%)",
          "responders_n": 15,
          "responders_pct": 75.0,
          "time_to_response": "12 weeks",
          "duration_of_response": "maintained at 6 months in 14/19 (74%) patients",
          "effect_size_description": "75% achieved steroid-free clinical remission at week 12, 80% had CRP normalization, 74% maintained remission at 6 months",
          "primary_endpoint": "postinduction steroid-free clinical remission at week 12 (PUCAI or PCDAI \u226410)",
          "endpoint_result": "75% achieved steroid-free clinical remission at week 12",
          "durability_signal": null,
          "efficacy_summary": "Upadacitinib demonstrated strong efficacy in highly refractory adolescent IBD patients with 75% achieving steroid-free clinical remission at week 12 and 80% achieving CRP normalization. Response was durable with 74% maintaining steroid-free remission at 6 months."
        },
        "safety": {
          "adverse_events": [
            "Cytomegalovirus colitis",
            "hyperlipidemia"
          ],
          "serious_adverse_events": [
            "Cytomegalovirus colitis requiring hospitalization"
          ],
          "sae_count": 1,
          "sae_percentage": 5.0,
          "discontinuations_n": null,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "Adverse events occurred in only 2 patients (10%): one case of CMV colitis requiring hospitalization and one case of hyperlipidemia requiring no treatment. Overall safety profile was acceptable in this adolescent population.",
          "safety_profile": "Acceptable"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": "median 51 weeks",
        "key_findings": "Upadacitinib showed strong efficacy and acceptable safety in adolescents with highly refractory IBD, with 75% achieving steroid-free remission and low adverse event rates.",
        "detailed_efficacy_endpoints": [],
        "detailed_safety_endpoints": [],
        "extraction_timestamp": "2025-12-08T18:03:12.494966",
        "extraction_confidence": 0.5,
        "extraction_confidence_detail": null,
        "extraction_method": "single_pass",
        "extraction_stages_completed": [],
        "data_sections_identified": null
      },
      "market_intelligence": {
        "disease": "Inflammatory Bowel Disease",
        "parent_disease": null,
        "epidemiology": {
          "us_prevalence_estimate": "2.4-3.1 million patients (0.72-1.3% of adults)",
          "us_incidence_estimate": "10.9 per 100,000 person-years",
          "global_prevalence": null,
          "patient_population_size": 2750000,
          "prevalence_source": "CDC",
          "prevalence_source_url": "https://www.cdc.gov/inflammatory-bowel-disease/php/facts-stats/index.html",
          "trend": "increasing",
          "source_quality": "Primary",
          "data_year": 2018,
          "geographic_scope": "US",
          "confidence": "High",
          "notes": "Estimates vary considerably by data source (2.4-2.8M from claims data, up to 3.1M from survey data). Multiple studies show consistent prevalence around 0.7-1.3%. Healthcare costs rising to $8.5 billion annually in 2018."
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Rinvoq (upadacitinib)",
              "drug_class": "JAK inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Moderately to severely active Crohn's disease",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": null,
              "notes": "First oral treatment approved for moderately to severely active Crohn's disease, approved in 2022 for ulcerative colitis",
              "approval_year": 2022,
              "approval_confidence": "High",
              "approval_evidence": "FDA approval announcement 2022 and New Drug Therapy Approvals 2022"
            },
            {
              "drug_name": "Skyrizi (risankizumab-rzaa)",
              "drug_class": "IL-23p19 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Moderately to severely active Crohn's disease",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": null,
              "notes": "Originally approved in 2019 for plaque psoriasis, expanded to Crohn's disease in 2022",
              "approval_year": 2022,
              "approval_confidence": "High",
              "approval_evidence": "New Drug Therapy Approvals 2022 - first new treatment for Crohn's disease in six years"
            },
            {
              "drug_name": "Omvoh (mirikizumab)",
              "drug_class": "IL-23p19 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Moderately to severely active Crohn's disease",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": null,
              "notes": "IL-23p19 antagonist approved in January 2025 for moderately to severe adult Crohn disease",
              "approval_year": 2025,
              "approval_confidence": "High",
              "approval_evidence": "FDA approval January 2025 based on VIVID-1 phase 3 trial"
            },
            {
              "drug_name": "Tremfya (guselkumab)",
              "drug_class": "IL-23p19 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Moderately to severely active ulcerative colitis",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": null,
              "notes": "Received FDA approval for adults with moderately to severely active ulcerative colitis in September 2024",
              "approval_year": 2024,
              "approval_confidence": "High",
              "approval_evidence": "FDA approval September 11, 2024 for ulcerative colitis"
            },
            {
              "drug_name": "Stelara (ustekinumab)",
              "drug_class": "IL-12/IL-23 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Moderately to severely active Crohn's disease",
              "efficacy_range": "34-56%",
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": null,
              "notes": "Approved for adults with moderately to severely active Crohn disease who failed or were intolerant to immunomodulators, corticosteroids, or TNF blockers",
              "approval_year": 2016,
              "approval_confidence": "High",
              "approval_evidence": "FDA approval September 2016 based on UNIFI studies"
            },
            {
              "drug_name": "Remicade (infliximab)",
              "drug_class": "TNF inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Inflammatory bowel disease",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "First FDA-approved biologic for IBD in 1998, used for both Crohn's disease and ulcerative colitis",
              "approval_year": 1998,
              "approval_confidence": "Medium",
              "approval_evidence": "FDA label mentions IBD indication and described as first FDA-approved biologic in 1998"
            }
          ],
          "approved_drug_names": [
            "Rinvoq (upadacitinib)",
            "Skyrizi (risankizumab-rzaa)",
            "Omvoh (mirikizumab)",
            "Tremfya (guselkumab)",
            "Stelara (ustekinumab)",
            "Remicade (infliximab)"
          ],
          "num_approved_drugs": 6,
          "num_pipeline_therapies": 0,
          "pipeline_therapies": [],
          "pipeline_details": null,
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "IBD treatment follows a step-up approach starting with conventional therapies like 5-ASA and corticosteroids, then advancing to immunomodulators and biologics for moderate to severe disease. The landscape has shifted toward earlier use of targeted biologics including TNF inhibitors, IL-23 inhibitors, and JAK inhibitors as first-line therapy for moderate to severe cases.",
          "unmet_need": false,
          "unmet_need_description": null,
          "competitive_landscape": "The IBD market has expanded significantly with multiple new drug classes including IL-23p19 inhibitors (risankizumab, guselkumab, mirikizumab), JAK inhibitors (upadacitinib), and established TNF inhibitors and IL-12/23 inhibitors. Recent approvals have provided more targeted treatment options with improved efficacy profiles for both Crohn's disease and ulcerative colitis.",
          "soc_source": "FDA New Drug Therapy Approvals and Medscape Clinical References",
          "phase_3_count": 0,
          "phase_2_count": 0,
          "key_catalysts": null,
          "pipeline_data_quality": "Unknown",
          "recent_approvals": "Omvoh (mirikizumab) approved January 2025 for Crohn's disease; Tremfya (guselkumab) approved September 2024 for ulcerative colitis",
          "data_quality": "Medium",
          "data_quality_notes": "Some approvals confirmed through FDA announcements but specific indication language varies between sources; costs not available in search results"
        },
        "market_size_estimate": "$68.8B",
        "market_size_usd": 68750000000.0,
        "growth_rate": "5-10% CAGR (increasing prevalence)",
        "tam_usd": 4200000000.0,
        "tam_estimate": "$4.2B",
        "tam_rationale": "Of ~2.75M US IBD patients, ~85% are diagnosed (2.34M), ~70% receive treatment (1.64M), and ~60% progress to advanced therapies where new drugs compete (985K patients). A new drug entering this established market could realistically capture 8-12% market share (~106K patients) given 6 existing competitors and evolving treatment paradigms favoring JAK/IL inhibitors. At $40K/year average pricing for IBD biologics/advanced therapies, TAM = $4.2B.",
        "tam_sources": [
          "https://www.factmr.com/report/inflammatory-bowel-disease-ibd-treatment-market",
          "https://www.gminsights.com/industry-analysis/inflammatory-bowel-disease-treatment-market",
          "https://www.researchnester.com/reports/ibd-ulcerative-colitis-and-crohns-disease-treatment-market/4685"
        ],
        "pipeline_sources": [
          "https://clinicaltrials.gov",
          "https://clinicaltrials.gov/study/NCT07113522",
          "https://clinicaltrials.gov/study/NCT06976853",
          "https://www.clinicaltrials.gov/study/NCT00820365",
          "https://clinicaltrials.gov/study/NCT05194007"
        ],
        "attributed_sources": [
          {
            "url": "https://www.cdc.gov/inflammatory-bowel-disease/php/facts-stats/index.html",
            "title": "IBD Facts and Stats - CDC",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.cdc.gov/mmwr/volumes/65/wr/mm6542a3.htm",
            "title": "Prevalence of Inflammatory Bowel Disease Among Adults Aged ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.drugs.com/condition/inflammatory-bowel-disease.html",
            "title": "Medications for Inflammatory Bowel Disease",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.fda.gov/news-events/press-announcements/fda-roundup-april-26-2024",
            "title": "FDA Roundup: April 26, 2024",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8720971/",
            "title": "Treatment of Inflammatory Bowel Disease: A Comprehensive Review",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://clinicaltrials.gov",
            "title": "ClinicalTrials.gov API",
            "attribution": "Pipeline/Clinical Trials (Primary)"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT07113522",
            "title": "NCT07113522 | A Phase 2 Study to Evaluate Therapies for ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT06976853",
            "title": "NCT06976853 | Moving Beyond Inflammation as a ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.factmr.com/report/inflammatory-bowel-disease-ibd-treatment-market",
            "title": "Inflammatory Bowel Disease (IBD) Treatment Market",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.gminsights.com/industry-analysis/inflammatory-bowel-disease-treatment-market",
            "title": "Inflammatory Bowel Disease Treatment Market Size",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 6.5,
        "evidence_quality": 8.8,
        "market_opportunity": 7.0,
        "overall_priority": 7.2,
        "clinical_breakdown": {
          "response_rate_quality_weighted": 8.0,
          "safety_profile": 3.2,
          "organ_domain_breadth": 10.0,
          "safety_categories": [
            "thromboembolic",
            "metabolic",
            "cardiovascular",
            "serious_infection"
          ],
          "regulatory_flags": [
            "thromboembolic",
            "cardiovascular",
            "serious_infection"
          ],
          "efficacy_endpoint_count": 0,
          "efficacy_concordance": 1.0
        },
        "response_rate_score": 8.0,
        "safety_profile_score": 3.2,
        "endpoint_quality_score": null,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 10.0,
          "publication_venue": 10.0,
          "response_durability": 7.0,
          "extraction_completeness": 7.2
        },
        "sample_size_score": 10.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 7.0,
        "extraction_completeness_score": 7.2,
        "market_breakdown": {
          "competitors": 3.0,
          "market_size": 10.0,
          "unmet_need": 8.0
        },
        "competitors_score": 3.0,
        "market_size_score": 10.0,
        "unmet_need_score": 8.0
      },
      "rank": 27
    },
    {
      "extraction": {
        "source": {
          "pmid": null,
          "doi": null,
          "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12155964/",
          "title": "Efficacy of Upadacitinib in Treating Alopecia Areata, Atopic ...",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Web source",
          "is_open_access": false
        },
        "disease": "Alopecia Areata",
        "disease_normalized": "Alopecia Areata",
        "is_off_label": true,
        "is_relevant": true,
        "evidence_level": "Case Series",
        "patient_population": {
          "n_patients": 3,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": null,
          "disease_severity": null,
          "comorbidities": null,
          "description": "Three adolescent patients with refractory alopecia areata and concurrent mild to moderate atopic dermatitis"
        },
        "treatment": {
          "drug_name": "upadacitinib",
          "generic_name": "Upadacitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "15 mg/day",
          "frequency": null,
          "duration": "12 months",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "3/3 (100%)",
          "responders_n": 3,
          "responders_pct": 100.0,
          "time_to_response": "1 month for initial improvement",
          "duration_of_response": "12 months follow-up",
          "effect_size_description": "Substantial regrowth of eyelashes, eyebrows, and scalp hair with significant SALT score improvements",
          "primary_endpoint": "SALT score reduction",
          "endpoint_result": "Case 1: SALT improved from 100 to 14; Case 2: SALT improved from 51.5 to 1.8; Case 3: achieved complete hair regrowth with SALT score of 100",
          "durability_signal": null,
          "efficacy_summary": "All three patients showed substantial improvement in alopecia areata with significant hair regrowth. SALT scores improved dramatically from baseline, with one patient achieving complete hair regrowth by 12 months."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": null,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "Safety outcomes were not reported in the available abstract portion of this case series.",
          "safety_profile": "Unknown"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": "12 months",
        "key_findings": "Upadacitinib 15 mg daily showed substantial efficacy in treating refractory alopecia areata in adolescents, with all patients showing significant hair regrowth by 12 months.",
        "detailed_efficacy_endpoints": [],
        "detailed_safety_endpoints": [],
        "extraction_timestamp": "2025-12-08T18:07:05.906847",
        "extraction_confidence": 0.5,
        "extraction_confidence_detail": null,
        "extraction_method": "single_pass",
        "extraction_stages_completed": [],
        "data_sections_identified": null
      },
      "market_intelligence": {
        "disease": "Alopecia Areata",
        "parent_disease": null,
        "epidemiology": {
          "us_prevalence_estimate": "0.17-0.22%",
          "us_incidence_estimate": "91-93 cases per 100,000 patient-years",
          "global_prevalence": null,
          "patient_population_size": 6700000,
          "prevalence_source": "Journal of the American Academy of Dermatology",
          "prevalence_source_url": "https://www.jaad.org/article/S0190-9622(22)01464-5/fulltext",
          "trend": "stable",
          "source_quality": "Primary",
          "data_year": 2019,
          "geographic_scope": "US",
          "confidence": "High",
          "notes": "Multiple recent US studies show consistent prevalence estimates ranging from 0.17-0.22%, with higher rates in females vs males and African Americans vs whites. Lifetime incidence risk estimated at 2%."
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Olumiant (baricitinib)",
              "drug_class": "JAK inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Alopecia Areata",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "First systemic immunotherapy approved by FDA for adults with severe alopecia areata. Recommended dosage 2 mg once daily, can increase to 4 mg daily.",
              "approval_year": 2022,
              "approval_confidence": "High",
              "approval_evidence": "FDA approval June 2022 for adults with severe alopecia areata"
            },
            {
              "drug_name": "Litfulo (ritlecitinib)",
              "drug_class": "JAK inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Alopecia Areata",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "Second JAK inhibitor approved for severe alopecia areata, approved for patients 12 years and older.",
              "approval_year": 2023,
              "approval_confidence": "High",
              "approval_evidence": "FDA approval June 2023 for patients ages 12 years and older with severe alopecia areata"
            },
            {
              "drug_name": "Leqselvi (deuruxolitinib)",
              "drug_class": "JAK inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Alopecia Areata",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "Third JAK inhibitor approved for severe alopecia areata in adults. Oral formulation.",
              "approval_year": 2024,
              "approval_confidence": "High",
              "approval_evidence": "FDA approval July 2024 for adults with severe alopecia areata"
            }
          ],
          "approved_drug_names": [
            "Olumiant (baricitinib)",
            "Litfulo (ritlecitinib)",
            "Leqselvi (deuruxolitinib)"
          ],
          "num_approved_drugs": 3,
          "num_pipeline_therapies": 9,
          "pipeline_therapies": [
            {
              "drug_name": "Microbiota Transplant Therapy",
              "company": "University of Minnesota",
              "mechanism": "Gut microbiome modulation",
              "phase": "Phase 2",
              "trial_id": "NCT06747611",
              "expected_completion": "2028-03",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Novel approach targeting microbiota in alopecia areata"
            },
            {
              "drug_name": "Ritlecitinib",
              "company": "Pfizer",
              "mechanism": "JAK3/TEC family kinase inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT06873945",
              "expected_completion": "2027-03",
              "trial_name": "ALLEGRO-100",
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Testing 50mg and 100mg doses in patients 12 years and older"
            },
            {
              "drug_name": "Tofacitinib",
              "company": "Jinnah Hospital",
              "mechanism": "JAK inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT06278402",
              "expected_completion": null,
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": null,
              "notes": "Completed January 2024, studying moderate to severe AA"
            },
            {
              "drug_name": "EQ101",
              "company": "Equillium",
              "mechanism": "CD6-targeted immunomodulator",
              "phase": "Phase 2",
              "trial_id": "NCT05589610",
              "expected_completion": null,
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": null,
              "notes": "Open-label study completed March 2024"
            },
            {
              "drug_name": "Ruxolitinib",
              "company": "National Institute of Allergy and Infectious Diseases (NIAID)",
              "mechanism": "JAK1/JAK2 inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT05398809",
              "expected_completion": "2027-12",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Specifically for APECED-associated alopecia areata"
            },
            {
              "drug_name": "STS01",
              "company": "Soterios Ltd",
              "mechanism": "Non-steroidal topical treatment",
              "phase": "Phase 2",
              "trial_id": "NCT06402630",
              "expected_completion": null,
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": null,
              "notes": "Completed April 2024, for mild-moderate AA"
            },
            {
              "drug_name": "Etrasimod",
              "company": "Pfizer",
              "mechanism": "Selective S1P receptor modulator",
              "phase": "Phase 2",
              "trial_id": "NCT04556734",
              "expected_completion": null,
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": null,
              "notes": "Completed June 2023, moderate-to-severe AA"
            },
            {
              "drug_name": "Upadacitinib",
              "company": "AbbVie",
              "mechanism": "JAK1 inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT06012240",
              "expected_completion": "2028-01",
              "trial_name": "UP-AA",
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Positive topline results reported in 2025, seeking approval"
            },
            {
              "drug_name": "Rezpegaldesleukin",
              "company": "Nektar Therapeutics",
              "mechanism": "IL-2 receptor complex agonist/Treg stimulator",
              "phase": "Phase 2",
              "trial_id": "Unknown - verify",
              "expected_completion": null,
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": "Fast Track",
              "notes": "Received FDA Fast Track designation in July 2025"
            }
          ],
          "pipeline_details": "Nine active clinical programs are in Phase 2-3 development for alopecia areata, dominated by JAK inhibitors but including novel approaches like microbiota transplant therapy and IL-2 receptor modulators. AbbVie's upadacitinib has reported positive Phase 3 results and is seeking regulatory approval, while Pfizer's ritlecitinib continues Phase 3 recruitment.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "JAK inhibitors are considered first-line treatment for severe alopecia areata (\u226550% scalp hair loss), with three FDA-approved options now available. For mild to moderate disease, topical corticosteroids and intralesional corticosteroid injections remain standard approaches, often combined with topical minoxidil.",
          "unmet_need": false,
          "unmet_need_description": null,
          "competitive_landscape": "The alopecia areata market has been rapidly transformed with three JAK inhibitors approved in just three years (2022-2024), providing systemic treatment options for severe disease. All three drugs target the same pathway but may offer different dosing or patient population advantages.",
          "soc_source": "Medscape Alopecia Areata Overview and FDA Drug Labels",
          "phase_3_count": 3,
          "phase_2_count": 6,
          "key_catalysts": "AbbVie expected to file for upadacitinib approval in 2025-2026 based on positive UP-AA Phase 3 results; Pfizer's ritlecitinib Phase 3 ALLEGRO-100 trial completion expected March 2027",
          "pipeline_data_quality": "High",
          "recent_approvals": "Olumiant (baricitinib) June 2022, Litfulo (ritlecitinib) June 2023, Leqselvi (deuruxolitinib) July 2024",
          "data_quality": "High",
          "data_quality_notes": "Multiple sources confirm FDA approvals with specific approval dates and indications. All three approvals are for severe alopecia areata specifically."
        },
        "market_size_estimate": "$167.5B",
        "market_size_usd": 167500000000.0,
        "growth_rate": "3-5% CAGR (stable prevalence)",
        "tam_usd": 850000000.0,
        "tam_estimate": "$850M",
        "tam_rationale": "Of ~6.7M US alopecia areata patients, ~80% are diagnosed (5.4M), but only ~15% have moderate-severe disease warranting systemic JAK inhibitor therapy (~810K patients). With 3 approved JAK inhibitors already established as first-line for severe cases, a new entrant could realistically capture 15-20% market share (~135K patients). At $50K/year pricing (consistent with autoimmune-dermatology benchmarks), TAM = 135K \u00d7 $50K = $675M-850M.",
        "tam_sources": [
          "https://bisresearch.com/industry-report/alopecia-areata-market.html",
          "https://www.prnewswire.com/news-releases/alopecia-areata-market-to-show-positive-growth-at-a-cagr-of-26-3-during-the-study-period-20192032-estimates-delveinsight-301853907.html",
          "https://www.giiresearch.com/report/tbrc1824572-alopecia-global-market-report.html"
        ],
        "pipeline_sources": [
          "https://clinicaltrials.gov",
          "https://clinicaltrials.gov/study/NCT03732807",
          "https://cdn.clinicaltrials.gov/large-docs/07/NCT03732807/Prot_000.pdf",
          "https://cdn.clinicaltrials.gov/large-docs/49/NCT03570749/Prot_002.pdf",
          "https://www.clinicaltrials.gov/study/NCT06012240"
        ],
        "attributed_sources": [
          {
            "url": "https://www.jaad.org/article/S0190-9622(22)01464-5/fulltext",
            "title": "33432 Prevalence estimates for alopecia areata in ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9979012/",
            "title": "Trends in Prevalence and Incidence of Alopecia Areata ... - NIH",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://emedicine.medscape.com/article/1069931-overview",
            "title": "Alopecia Areata: Practice Essentials, Background, ...",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://emedicine.medscape.com/article/1069931-medication",
            "title": "Alopecia Areata Medication: Glucocorticoids, Vasodilators ...",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3149478/",
            "title": "Alopecia areata: a new treatment plan - PMC",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://clinicaltrials.gov",
            "title": "ClinicalTrials.gov API",
            "attribution": "Pipeline/Clinical Trials (Primary)"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT03732807",
            "title": "PF-06651600 for the Treatment of Alopecia Areata",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://cdn.clinicaltrials.gov/large-docs/07/NCT03732807/Prot_000.pdf",
            "title": "a phase 2b/3 randomized, double-blind, placebo-controlled",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://bisresearch.com/industry-report/alopecia-areata-market.html",
            "title": "Alopecia Areata Market Size & Forecast | BIS Research",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.prnewswire.com/news-releases/alopecia-areata-market-to-show-positive-growth-at-a-cagr-of-26-3-during-the-study-period-20192032-estimates-delveinsight-301853907.html",
            "title": "Alopecia Areata Market to Show Positive Growth at a CAGR of 26.3 ...",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 8.0,
        "evidence_quality": 5.1,
        "market_opportunity": 7.7,
        "overall_priority": 7.2,
        "clinical_breakdown": {
          "response_rate_quality_weighted": 10.0,
          "safety_profile": 5.0,
          "organ_domain_breadth": 10.0,
          "safety_categories": [],
          "regulatory_flags": [],
          "efficacy_endpoint_count": 0,
          "efficacy_concordance": 1.0
        },
        "response_rate_score": 10.0,
        "safety_profile_score": 5.0,
        "endpoint_quality_score": null,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 4.0,
          "publication_venue": 2.0,
          "response_durability": 9.0,
          "extraction_completeness": 6.1
        },
        "sample_size_score": 4.0,
        "publication_venue_score": 2.0,
        "followup_duration_score": 9.0,
        "extraction_completeness_score": 6.1,
        "market_breakdown": {
          "competitors": 5.0,
          "market_size": 10.0,
          "unmet_need": 8.0
        },
        "competitors_score": 5.0,
        "market_size_score": 10.0,
        "unmet_need_score": 8.0
      },
      "rank": 28
    },
    {
      "extraction": {
        "source": {
          "pmid": "35102663",
          "doi": "10.1111/dth.15346",
          "url": "https://pubmed.ncbi.nlm.nih.gov/35102663/",
          "title": "Upadacitinib improved alopecia areata in a patient with atopic dermatitis: A case report.",
          "authors": "Cantelli M, Martora F, Patruno C, Nappa P, Fabbrocini G, Napolitano M",
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "alopecia areata",
        "disease_normalized": "Alopecia Areata",
        "is_off_label": true,
        "is_relevant": true,
        "evidence_level": "Case Report",
        "patient_population": {
          "n_patients": 1,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "topical corticosteroids",
            "systemic corticosteroids",
            "cyclosporine",
            "dupilumab"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "24-year-old patient with atopic dermatitis since childhood and 10 years of alopecia areata"
        },
        "treatment": {
          "drug_name": "upadacitinib",
          "generic_name": "Upadacitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "30 mg daily",
          "frequency": null,
          "duration": "3 months",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": null,
          "responders_n": 1,
          "responders_pct": 100.0,
          "time_to_response": "3 months",
          "duration_of_response": null,
          "effect_size_description": "Clinical improvement with hair regrowth throughout scalp and resolution of trichoscopic disease activity signs",
          "primary_endpoint": "SALT score improvement and clinical hair regrowth",
          "endpoint_result": "Clinical improvement in both AD and AA with regrowing hair all over scalp without signs of disease activity",
          "durability_signal": null,
          "efficacy_summary": "After 3 months of upadacitinib treatment, the patient showed clinical improvement in both atopic dermatitis and alopecia areata. Trichoscopy demonstrated regrowing hair all over the scalp without any signs of disease activity."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": 0,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "No adverse events were reported during the 3-month treatment period with upadacitinib.",
          "safety_profile": "Favorable"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Moderate",
        "comparator_baseline": null,
        "follow_up_duration": "3 months",
        "key_findings": "Upadacitinib demonstrated efficacy in treating alopecia areata concurrent with atopic dermatitis in a patient who had failed multiple prior therapies including dupilumab.",
        "detailed_efficacy_endpoints": [
          {
            "endpoint_name": "EASI score",
            "endpoint_category": "Primary",
            "timepoint": "Baseline",
            "measurement_type": "Absolute value",
            "value": 45.1,
            "unit": "points",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 45.1,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Baseline EASI score for severe atopic dermatitis",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "P-NRS",
            "endpoint_category": "Secondary",
            "timepoint": "Baseline",
            "measurement_type": "Absolute value",
            "value": 8.0,
            "unit": "points (0-10 scale)",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 8.0,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Baseline pruritus numeric rating scale",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 2
          },
          {
            "endpoint_name": "SALT score",
            "endpoint_category": "Primary",
            "timepoint": "Baseline",
            "measurement_type": "Absolute value",
            "value": 89.2,
            "unit": "points",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 89.2,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Baseline Severity of Alopecia Tool score",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "SALT score",
            "endpoint_category": "Primary",
            "timepoint": "4 months (dupilumab treatment)",
            "measurement_type": "Absolute value",
            "value": 91.5,
            "unit": "points",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 89.2,
            "final_value": 91.5,
            "change_from_baseline": 2.3,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "SALT score after 4 months of dupilumab treatment, showing no improvement in alopecia areata",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "Clinical improvement of atopic dermatitis",
            "endpoint_category": "Primary",
            "timepoint": "3 months (upadacitinib treatment)",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 1,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Clinical improvement of atopic dermatitis observed after 3 months of upadacitinib treatment",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Clinical improvement of alopecia areata",
            "endpoint_category": "Primary",
            "timepoint": "3 months (upadacitinib treatment)",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 1,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Clinical improvement with regrowing hair all over the scalp without any sign of disease activity after 3 months of upadacitinib",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          }
        ],
        "detailed_safety_endpoints": [],
        "extraction_timestamp": "2025-12-08T18:20:25.570463",
        "extraction_confidence": 0.6,
        "extraction_confidence_detail": null,
        "extraction_method": "multi_stage",
        "extraction_stages_completed": [
          "section_identification",
          "efficacy_extraction",
          "safety_extraction"
        ],
        "data_sections_identified": {
          "baseline_tables": [],
          "efficacy_tables": [],
          "safety_tables": [],
          "efficacy_figures": [
            "Figure 1: Before and after clinical photos showing (A) Eczematous and crusted lesions involving upper limbs at week 0, (B,C) Clinical and trichoscopical examination of alopecia areata at week 0, (D) Resolution of skin lesion of upper limbs after 3 months of treatment with upadacitinib, (E,F) Clinical and trichoscopical examination of alopecia areata after 3 months of treatment with upadacitinib"
          ],
          "results_sections": [
            "Case presentation describing 24-year-old patient with AD and AA",
            "Treatment progression from dupilumab to upadacitinib",
            "3-month follow-up outcomes"
          ],
          "patient_count": 1,
          "study_type": "Case Report",
          "has_quantitative_outcomes": true,
          "notes": "Single case report with quantitative disease severity scores (EASI: 45.1, P-NRS: 8/10, SALT: 89.2 at baseline). No formal tables presented - all data provided in narrative format. Figure 1 shows before/after clinical photographs demonstrating improvement in both atopic dermatitis and alopecia areata after 3 months of upadacitinib treatment."
        }
      },
      "market_intelligence": {
        "disease": "Alopecia Areata",
        "parent_disease": null,
        "epidemiology": {
          "us_prevalence_estimate": "0.17-0.22%",
          "us_incidence_estimate": "91-93 cases per 100,000 patient-years",
          "global_prevalence": null,
          "patient_population_size": 6700000,
          "prevalence_source": "Journal of the American Academy of Dermatology",
          "prevalence_source_url": "https://www.jaad.org/article/S0190-9622(22)01464-5/fulltext",
          "trend": "stable",
          "source_quality": "Primary",
          "data_year": 2019,
          "geographic_scope": "US",
          "confidence": "High",
          "notes": "Multiple recent US studies show consistent prevalence estimates ranging from 0.17-0.22%, with higher rates in females vs males and African Americans vs whites. Lifetime incidence risk estimated at 2%."
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Olumiant (baricitinib)",
              "drug_class": "JAK inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Alopecia Areata",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "First systemic immunotherapy approved by FDA for adults with severe alopecia areata. Recommended dosage 2 mg once daily, can increase to 4 mg daily.",
              "approval_year": 2022,
              "approval_confidence": "High",
              "approval_evidence": "FDA approval June 2022 for adults with severe alopecia areata"
            },
            {
              "drug_name": "Litfulo (ritlecitinib)",
              "drug_class": "JAK inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Alopecia Areata",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "Second JAK inhibitor approved for severe alopecia areata, approved for patients 12 years and older.",
              "approval_year": 2023,
              "approval_confidence": "High",
              "approval_evidence": "FDA approval June 2023 for patients ages 12 years and older with severe alopecia areata"
            },
            {
              "drug_name": "Leqselvi (deuruxolitinib)",
              "drug_class": "JAK inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Alopecia Areata",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "Third JAK inhibitor approved for severe alopecia areata in adults. Oral formulation.",
              "approval_year": 2024,
              "approval_confidence": "High",
              "approval_evidence": "FDA approval July 2024 for adults with severe alopecia areata"
            }
          ],
          "approved_drug_names": [
            "Olumiant (baricitinib)",
            "Litfulo (ritlecitinib)",
            "Leqselvi (deuruxolitinib)"
          ],
          "num_approved_drugs": 3,
          "num_pipeline_therapies": 9,
          "pipeline_therapies": [
            {
              "drug_name": "Microbiota Transplant Therapy",
              "company": "University of Minnesota",
              "mechanism": "Gut microbiome modulation",
              "phase": "Phase 2",
              "trial_id": "NCT06747611",
              "expected_completion": "2028-03",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Novel approach targeting microbiota in alopecia areata"
            },
            {
              "drug_name": "Ritlecitinib",
              "company": "Pfizer",
              "mechanism": "JAK3/TEC family kinase inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT06873945",
              "expected_completion": "2027-03",
              "trial_name": "ALLEGRO-100",
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Testing 50mg and 100mg doses in patients 12 years and older"
            },
            {
              "drug_name": "Tofacitinib",
              "company": "Jinnah Hospital",
              "mechanism": "JAK inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT06278402",
              "expected_completion": null,
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": null,
              "notes": "Completed January 2024, studying moderate to severe AA"
            },
            {
              "drug_name": "EQ101",
              "company": "Equillium",
              "mechanism": "CD6-targeted immunomodulator",
              "phase": "Phase 2",
              "trial_id": "NCT05589610",
              "expected_completion": null,
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": null,
              "notes": "Open-label study completed March 2024"
            },
            {
              "drug_name": "Ruxolitinib",
              "company": "National Institute of Allergy and Infectious Diseases (NIAID)",
              "mechanism": "JAK1/JAK2 inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT05398809",
              "expected_completion": "2027-12",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Specifically for APECED-associated alopecia areata"
            },
            {
              "drug_name": "STS01",
              "company": "Soterios Ltd",
              "mechanism": "Non-steroidal topical treatment",
              "phase": "Phase 2",
              "trial_id": "NCT06402630",
              "expected_completion": null,
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": null,
              "notes": "Completed April 2024, for mild-moderate AA"
            },
            {
              "drug_name": "Etrasimod",
              "company": "Pfizer",
              "mechanism": "Selective S1P receptor modulator",
              "phase": "Phase 2",
              "trial_id": "NCT04556734",
              "expected_completion": null,
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": null,
              "notes": "Completed June 2023, moderate-to-severe AA"
            },
            {
              "drug_name": "Upadacitinib",
              "company": "AbbVie",
              "mechanism": "JAK1 inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT06012240",
              "expected_completion": "2028-01",
              "trial_name": "UP-AA",
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Positive topline results reported in 2025, seeking approval"
            },
            {
              "drug_name": "Rezpegaldesleukin",
              "company": "Nektar Therapeutics",
              "mechanism": "IL-2 receptor complex agonist/Treg stimulator",
              "phase": "Phase 2",
              "trial_id": "Unknown - verify",
              "expected_completion": null,
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": "Fast Track",
              "notes": "Received FDA Fast Track designation in July 2025"
            }
          ],
          "pipeline_details": "Nine active clinical programs are in Phase 2-3 development for alopecia areata, dominated by JAK inhibitors but including novel approaches like microbiota transplant therapy and IL-2 receptor modulators. AbbVie's upadacitinib has reported positive Phase 3 results and is seeking regulatory approval, while Pfizer's ritlecitinib continues Phase 3 recruitment.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "JAK inhibitors are considered first-line treatment for severe alopecia areata (\u226550% scalp hair loss), with three FDA-approved options now available. For mild to moderate disease, topical corticosteroids and intralesional corticosteroid injections remain standard approaches, often combined with topical minoxidil.",
          "unmet_need": false,
          "unmet_need_description": null,
          "competitive_landscape": "The alopecia areata market has been rapidly transformed with three JAK inhibitors approved in just three years (2022-2024), providing systemic treatment options for severe disease. All three drugs target the same pathway but may offer different dosing or patient population advantages.",
          "soc_source": "Medscape Alopecia Areata Overview and FDA Drug Labels",
          "phase_3_count": 3,
          "phase_2_count": 6,
          "key_catalysts": "AbbVie expected to file for upadacitinib approval in 2025-2026 based on positive UP-AA Phase 3 results; Pfizer's ritlecitinib Phase 3 ALLEGRO-100 trial completion expected March 2027",
          "pipeline_data_quality": "High",
          "recent_approvals": "Olumiant (baricitinib) June 2022, Litfulo (ritlecitinib) June 2023, Leqselvi (deuruxolitinib) July 2024",
          "data_quality": "High",
          "data_quality_notes": "Multiple sources confirm FDA approvals with specific approval dates and indications. All three approvals are for severe alopecia areata specifically."
        },
        "market_size_estimate": "$167.5B",
        "market_size_usd": 167500000000.0,
        "growth_rate": "3-5% CAGR (stable prevalence)",
        "tam_usd": 850000000.0,
        "tam_estimate": "$850M",
        "tam_rationale": "Of ~6.7M US alopecia areata patients, ~80% are diagnosed (5.4M), but only ~15% have moderate-severe disease warranting systemic JAK inhibitor therapy (~810K patients). With 3 approved JAK inhibitors already established as first-line for severe cases, a new entrant could realistically capture 15-20% market share (~135K patients). At $50K/year pricing (consistent with autoimmune-dermatology benchmarks), TAM = 135K \u00d7 $50K = $675M-850M.",
        "tam_sources": [
          "https://bisresearch.com/industry-report/alopecia-areata-market.html",
          "https://www.prnewswire.com/news-releases/alopecia-areata-market-to-show-positive-growth-at-a-cagr-of-26-3-during-the-study-period-20192032-estimates-delveinsight-301853907.html",
          "https://www.giiresearch.com/report/tbrc1824572-alopecia-global-market-report.html"
        ],
        "pipeline_sources": [
          "https://clinicaltrials.gov",
          "https://clinicaltrials.gov/study/NCT03732807",
          "https://cdn.clinicaltrials.gov/large-docs/07/NCT03732807/Prot_000.pdf",
          "https://cdn.clinicaltrials.gov/large-docs/49/NCT03570749/Prot_002.pdf",
          "https://www.clinicaltrials.gov/study/NCT06012240"
        ],
        "attributed_sources": [
          {
            "url": "https://www.jaad.org/article/S0190-9622(22)01464-5/fulltext",
            "title": "33432 Prevalence estimates for alopecia areata in ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9979012/",
            "title": "Trends in Prevalence and Incidence of Alopecia Areata ... - NIH",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://emedicine.medscape.com/article/1069931-overview",
            "title": "Alopecia Areata: Practice Essentials, Background, ...",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://emedicine.medscape.com/article/1069931-medication",
            "title": "Alopecia Areata Medication: Glucocorticoids, Vasodilators ...",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3149478/",
            "title": "Alopecia areata: a new treatment plan - PMC",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://clinicaltrials.gov",
            "title": "ClinicalTrials.gov API",
            "attribution": "Pipeline/Clinical Trials (Primary)"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT03732807",
            "title": "PF-06651600 for the Treatment of Alopecia Areata",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://cdn.clinicaltrials.gov/large-docs/07/NCT03732807/Prot_000.pdf",
            "title": "a phase 2b/3 randomized, double-blind, placebo-controlled",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://bisresearch.com/industry-report/alopecia-areata-market.html",
            "title": "Alopecia Areata Market Size & Forecast | BIS Research",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.prnewswire.com/news-releases/alopecia-areata-market-to-show-positive-growth-at-a-cagr-of-26-3-during-the-study-period-20192032-estimates-delveinsight-301853907.html",
            "title": "Alopecia Areata Market to Show Positive Growth at a CAGR of 26.3 ...",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 8.4,
        "evidence_quality": 5.2,
        "market_opportunity": 6.7,
        "overall_priority": 7.1,
        "clinical_breakdown": {
          "response_rate_quality_weighted": 6.9,
          "safety_profile": 9.0,
          "organ_domain_breadth": 10.0,
          "safety_categories": [],
          "regulatory_flags": [],
          "efficacy_endpoint_count": 6,
          "efficacy_concordance": 0.9
        },
        "response_rate_score": 6.9,
        "safety_profile_score": 9.0,
        "endpoint_quality_score": null,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 1.0,
          "publication_venue": 10.0,
          "response_durability": 5.0,
          "extraction_completeness": 7.2
        },
        "sample_size_score": 1.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 5.0,
        "extraction_completeness_score": 7.2,
        "market_breakdown": {
          "competitors": 5.0,
          "market_size": 10.0,
          "unmet_need": 5.0
        },
        "competitors_score": 5.0,
        "market_size_score": 10.0,
        "unmet_need_score": 5.0
      },
      "rank": 29
    },
    {
      "extraction": {
        "source": {
          "pmid": "38274297",
          "doi": "10.14309/crj.0000000000001245",
          "url": "https://www.semanticscholar.org/paper/da7a397cce7dfca4a0db9d17634dcda4c742cca9",
          "title": "Efficacy and Safety of Upadacitinib in the Treatment of Chronic Pouchitis, Cuffitis, and Crohn's Disease of the Pouch",
          "authors": "N. Lan and B. Shen",
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Web source",
          "is_open_access": false
        },
        "disease": "Chronic antibiotics-refractory pouchitis (CARP), cuffitis, and Crohn's disease of the pouch",
        "disease_normalized": "Crohn's Disease",
        "is_off_label": true,
        "is_relevant": true,
        "evidence_level": "Case Series",
        "patient_population": {
          "n_patients": 6,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "antibiotics",
            "mesalamine",
            "budesonide",
            "adalimumab",
            "ustekinumab",
            "vedolizumab",
            "tofacitinib"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "6 predominantly male patients with postoperative biologics-exposed CARP or CD of the pouch"
        },
        "treatment": {
          "drug_name": "upadacitinib",
          "generic_name": "Upadacitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": null,
          "frequency": null,
          "duration": "minimal 6 weeks (range 6.5-19.4 weeks)",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "1/6 (16.7%)",
          "responders_n": 1,
          "responders_pct": 16.7,
          "time_to_response": "8 weeks",
          "duration_of_response": null,
          "effect_size_description": "minimal or no significant improvement",
          "primary_endpoint": "PDAI symptom subscores and endoscopic scores",
          "endpoint_result": "minimal or no significant improvement in clinical and endoscopic presentations",
          "durability_signal": null,
          "efficacy_summary": "After 6 weeks or more of upadacitinib treatment, patients showed minimal or no significant improvement in clinical and endoscopic presentations. Only one patient (Patient 3) showed mild improvement in pouch and urinary symptoms with mild improvement of inflammation on pouchoscopy at week 8."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": 0,
          "sae_percentage": 0.0,
          "discontinuations_n": null,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "No adverse events possibly related to upadacitinib were reported in any of the 6 patients. The treatment appeared to be well tolerated during the treatment periods ranging from 6.5 to 19.4 weeks.",
          "safety_profile": "Favorable"
        },
        "outcome_result": "Fail",
        "efficacy_signal": "Weak",
        "comparator_baseline": null,
        "follow_up_duration": "6.5-19.4 weeks",
        "key_findings": "Upadacitinib showed minimal efficacy in treating CARP and CD of the pouch, with only one patient showing mild improvement. Interestingly, upadacitinib had positive impact on extraintestinal manifestations.",
        "detailed_efficacy_endpoints": [
          {
            "endpoint_name": "PDAI symptom subscore",
            "endpoint_category": "Primary",
            "timepoint": "Baseline",
            "measurement_type": "Absolute value",
            "value": null,
            "unit": "score",
            "total_n": 6,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Individual baseline values: Patient 1=4, Patient 2=4, Patient 3=3, Patient 4=4, Patient 5=4, Patient 6=4",
            "organ_domain": "Gastrointestinal",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "PDAI symptom subscore",
            "endpoint_category": "Primary",
            "timepoint": "Post-treatment",
            "measurement_type": "Absolute value",
            "value": null,
            "unit": "score",
            "total_n": 6,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Individual post-treatment values: Patient 1=4, Patient 2=3, Patient 3=3, Patient 4=5, Patient 5=4, Patient 6=4",
            "organ_domain": "Gastrointestinal",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "PDAI endoscopy score - prepouch ileum",
            "endpoint_category": "Primary",
            "timepoint": "Baseline",
            "measurement_type": "Absolute value",
            "value": null,
            "unit": "score",
            "total_n": 6,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Individual baseline values: Patient 1=6, Patient 2=4, Patient 3=0, Patient 4=0, Patient 5=0, Patient 6=0",
            "organ_domain": "Gastrointestinal",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "PDAI endoscopy score - prepouch ileum",
            "endpoint_category": "Primary",
            "timepoint": "Post-treatment",
            "measurement_type": "Absolute value",
            "value": null,
            "unit": "score",
            "total_n": 6,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Individual post-treatment values: Patient 1=6, Patient 2=4, Patient 3=0, Patient 4=0, Patient 5=1, Patient 6=0",
            "organ_domain": "Gastrointestinal",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "PDAI endoscopy score - pouch body",
            "endpoint_category": "Primary",
            "timepoint": "Baseline",
            "measurement_type": "Absolute value",
            "value": null,
            "unit": "score",
            "total_n": 6,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Individual baseline values: Patient 1=6, Patient 2=0, Patient 3=0, Patient 4=1, Patient 5=1, Patient 6=1",
            "organ_domain": "Gastrointestinal",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "PDAI endoscopy score - pouch body",
            "endpoint_category": "Primary",
            "timepoint": "Post-treatment",
            "measurement_type": "Absolute value",
            "value": null,
            "unit": "score",
            "total_n": 6,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Individual post-treatment values: Patient 1=6, Patient 2=0, Patient 3=0, Patient 4=1, Patient 5=0, Patient 6=1",
            "organ_domain": "Gastrointestinal",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "PDAI endoscopy score - cuff",
            "endpoint_category": "Primary",
            "timepoint": "Baseline",
            "measurement_type": "Absolute value",
            "value": null,
            "unit": "score",
            "total_n": 6,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Individual baseline values: Patient 1=6, Patient 2=2, Patient 3=0, Patient 4=0, Patient 5=2, Patient 6=6",
            "organ_domain": "Gastrointestinal",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "PDAI endoscopy score - cuff",
            "endpoint_category": "Primary",
            "timepoint": "Post-treatment",
            "measurement_type": "Absolute value",
            "value": null,
            "unit": "score",
            "total_n": 6,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Individual post-treatment values: Patient 1=6, Patient 2=1, Patient 3=0, Patient 4=0, Patient 5=1, Patient 6=6",
            "organ_domain": "Gastrointestinal",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "Extraintestinal manifestation improvement - arthritis",
            "endpoint_category": "Secondary",
            "timepoint": "Post-treatment",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 2,
            "responders_n": 1,
            "responders_pct": 50.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Patient 5 had resolution of juvenile rheumatoid arthritis symptoms; Patient 3 had arthritis but improvement not specifically mentioned",
            "organ_domain": "Musculoskeletal",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Liver function improvement",
            "endpoint_category": "Secondary",
            "timepoint": "Post-treatment",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 1,
            "responders_n": 0,
            "responders_pct": 0.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Patient 6 with autoimmune hepatitis and primary sclerosing cholangitis showed no improvement in liver function tests",
            "organ_domain": "Gastrointestinal",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Treatment duration",
            "endpoint_category": "Secondary",
            "timepoint": "End of treatment",
            "measurement_type": "Absolute value",
            "value": null,
            "unit": "weeks",
            "total_n": 6,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Individual treatment durations: Patient 1=6.5, Patient 2=16.5, Patient 3=12.4, Patient 4=19.4, Patient 5=8.1, Patient 6=16.0 weeks",
            "organ_domain": "Constitutional",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Time to endoscopic evaluation",
            "endpoint_category": "Secondary",
            "timepoint": "During treatment",
            "measurement_type": "Absolute value",
            "value": null,
            "unit": "weeks",
            "total_n": 6,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Individual times to endoscopic evaluation: Patient 1=6.5, Patient 2=14.7, Patient 3=8.7, Patient 4=17.6, Patient 5=8.1, Patient 6=11.7 weeks",
            "organ_domain": "Constitutional",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          }
        ],
        "detailed_safety_endpoints": [],
        "extraction_timestamp": "2025-12-08T18:49:44.765747",
        "extraction_confidence": 0.6,
        "extraction_confidence_detail": null,
        "extraction_method": "multi_stage",
        "extraction_stages_completed": [
          "section_identification",
          "efficacy_extraction",
          "safety_extraction"
        ],
        "data_sections_identified": {
          "baseline_tables": [
            "Table 1 - Clinical presentation and response to treatment with upadacitinib (contains baseline demographics, precolectomy diagnosis, pouch characteristics, year of construction, previous treatments, and baseline PDAI scores)"
          ],
          "efficacy_tables": [
            "Table 1 - Clinical presentation and response to treatment with upadacitinib (contains PDAI symptom and endoscopy scores before and after treatment, improvement of extraintestinal manifestations, treatment duration)"
          ],
          "safety_tables": [
            "Table 1 - Clinical presentation and response to treatment with upadacitinib (contains adverse events possibly related to upadacitinib section)"
          ],
          "efficacy_figures": [],
          "results_sections": [
            "Case Reports section with individual patient descriptions",
            "Discussion section summarizing minimal to no improvement in clinical and endoscopic presentations"
          ],
          "patient_count": 6,
          "study_type": "Case Series",
          "has_quantitative_outcomes": true,
          "notes": "Single comprehensive table contains baseline, efficacy, and safety data. All 6 patients showed minimal or no significant improvement. Upadacitinib appeared to help with extraintestinal manifestations in some patients. No separate safety events were reported beyond those listed in the table."
        }
      },
      "market_intelligence": {
        "disease": "Crohn's Disease",
        "parent_disease": "Inflammatory Bowel Disease",
        "epidemiology": {
          "us_prevalence_estimate": "0.72% or 1 in 139 Americans",
          "us_incidence_estimate": "10.9 per 100,000 person-years",
          "global_prevalence": null,
          "patient_population_size": 2390000,
          "prevalence_source": "Gastroenterology journal study",
          "prevalence_source_url": "https://www.gastrojournal.org/article/S0016-5085(23)04776-5/fulltext",
          "trend": "increasing",
          "source_quality": "Primary",
          "data_year": 2020,
          "geographic_scope": "US",
          "confidence": "High",
          "notes": "Multiple sources report varying estimates ranging from 2.4-3.1 million patients; prevalence varies significantly by race/ethnicity with higher rates in non-Hispanic whites (1.4%) and Hispanics (1.2%) compared to non-Hispanic blacks (0.5%); prevalence increases with age"
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Remicade (infliximab)",
              "drug_class": "TNF inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Inflammatory Bowel Disease",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "FDA approved for inflammatory bowel disease, referenced in official FDA label",
              "approval_year": null,
              "approval_confidence": "Medium",
              "approval_evidence": "FDA label and multiple clinical sources confirm IBD indication"
            },
            {
              "drug_name": "Humira (adalimumab)",
              "drug_class": "TNF inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Inflammatory Bowel Disease",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "FDA approved for inflammatory bowel disease treatment",
              "approval_year": null,
              "approval_confidence": "Medium",
              "approval_evidence": "AGA guidelines and clinical sources confirm FDA approval for IBD"
            },
            {
              "drug_name": "Simponi (golimumab)",
              "drug_class": "TNF inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Inflammatory Bowel Disease",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "FDA approved for ulcerative colitis component of IBD",
              "approval_year": null,
              "approval_confidence": "Medium",
              "approval_evidence": "AGA guidelines list as FDA approved option for moderate-to-severe UC"
            },
            {
              "drug_name": "Entyvio (vedolizumab)",
              "drug_class": "Anti-integrin",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Inflammatory Bowel Disease",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "FDA approved for inflammatory bowel disease, gut-selective integrin antagonist",
              "approval_year": null,
              "approval_confidence": "Medium",
              "approval_evidence": "AGA guidelines and clinical sources confirm FDA approval for IBD"
            },
            {
              "drug_name": "Stelara (ustekinumab)",
              "drug_class": "IL-12/IL-23 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Inflammatory Bowel Disease",
              "efficacy_range": "34-56%",
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "FDA approved September 2016 for moderately to severely active Crohn disease and ulcerative colitis",
              "approval_year": 2016,
              "approval_confidence": "Medium",
              "approval_evidence": "FDA approval September 2016 for Crohn's disease, multiple clinical sources confirm IBD indication"
            },
            {
              "drug_name": "Xeljanz (tofacitinib)",
              "drug_class": "JAK inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Inflammatory Bowel Disease",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "FDA approved for ulcerative colitis component of IBD",
              "approval_year": null,
              "approval_confidence": "Medium",
              "approval_evidence": "AGA guidelines confirm FDA approval for moderate-to-severe UC"
            },
            {
              "drug_name": "Rinvoq (upadacitinib)",
              "drug_class": "JAK inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Inflammatory Bowel Disease",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "Approved 2022 for moderately to severely active ulcerative colitis and as first oral treatment for Crohn's disease",
              "approval_year": 2022,
              "approval_confidence": "High",
              "approval_evidence": "FDA approval 2022 for ulcerative colitis and Crohn's disease as documented in FDA new drug approvals"
            },
            {
              "drug_name": "Skyrizi (risankizumab)",
              "drug_class": "IL-23 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Inflammatory Bowel Disease",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "Approved 2022 for moderately to severely active Crohn's disease, first new CD treatment in six years",
              "approval_year": 2022,
              "approval_confidence": "High",
              "approval_evidence": "FDA new drug approvals 2022 document confirms approval for Crohn's disease"
            },
            {
              "drug_name": "Tremfya (guselkumab)",
              "drug_class": "IL-23 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Inflammatory Bowel Disease",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "FDA approved September 2024 for moderately to severely active ulcerative colitis",
              "approval_year": 2024,
              "approval_confidence": "Medium",
              "approval_evidence": "FDA approval September 2024 for ulcerative colitis as noted in clinical sources"
            }
          ],
          "approved_drug_names": [
            "Remicade (infliximab)",
            "Humira (adalimumab)",
            "Simponi (golimumab)",
            "Entyvio (vedolizumab)",
            "Stelara (ustekinumab)",
            "Xeljanz (tofacitinib)",
            "Rinvoq (upadacitinib)",
            "Skyrizi (risankizumab)",
            "Tremfya (guselkumab)"
          ],
          "num_approved_drugs": 9,
          "num_pipeline_therapies": 0,
          "pipeline_therapies": [],
          "pipeline_details": null,
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "IBD treatment follows a step-up approach starting with 5-ASA compounds for mild disease, progressing to corticosteroids for moderate disease, then to biologics (TNF inhibitors, integrin antagonists, IL-12/23 inhibitors) and JAK inhibitors for moderate-to-severe disease. The paradigm has shifted toward earlier use of biologics and targeted therapies to achieve deep remission and mucosal healing.",
          "unmet_need": true,
          "unmet_need_description": "Despite multiple therapeutic options, 20-40% of patients fail standard therapies and may require surgery. There remains need for treatments that achieve sustained remission, prevent disease progression, and minimize long-term complications.",
          "competitive_landscape": "The IBD market has expanded significantly with multiple drug classes including TNF inhibitors (infliximab, adalimumab, golimumab), integrin antagonists (vedolizumab), IL-12/23 inhibitors (ustekinumab), IL-23 selective inhibitors (risankizumab, guselkumab), and JAK inhibitors (tofacitinib, upadacitinib). Recent approvals include mirikizumab (January 2025) for Crohn's disease and guselkumab (2024) for ulcerative colitis, indicating continued innovation in this space.",
          "soc_source": "FDA New Drug Approvals 2022, AGA Guidelines, and clinical literature",
          "phase_3_count": 0,
          "phase_2_count": 0,
          "key_catalysts": null,
          "pipeline_data_quality": "Unknown",
          "recent_approvals": "Tremfya (guselkumab) approved September 2024 for ulcerative colitis; Rinvoq (upadacitinib) and Skyrizi (risankizumab) approved in 2022 for IBD indications; mirikizumab approved January 2025 for Crohn's disease",
          "data_quality": "Medium",
          "data_quality_notes": "Strong evidence for recent approvals but some approval years and specific indication details require verification from primary FDA sources. Cost data not available in sources reviewed."
        },
        "market_size_estimate": "$59.8B",
        "market_size_usd": 59750000000.0,
        "growth_rate": "5-10% CAGR (increasing prevalence)",
        "tam_usd": 3150000000.0,
        "tam_estimate": "$3.15B",
        "tam_rationale": "Of ~2.39M US Crohn's disease patients, ~85% are diagnosed (2.03M), ~70% receive systemic treatment (1.42M), ~40% progress to moderate-severe disease requiring biologics/advanced therapies (568K). A new biologic entering this crowded market (9 approved drugs) could realistically capture 10-15% market share (~70K patients). At $75K/yr pricing (consistent with IBD biologics), TAM = $5.25B peak, but given competitive intensity and step-up therapy paradigm, realistic addressable market for new entrant is $3.15B.",
        "tam_sources": [
          "https://www.factmr.com/report/crohns-disease-treatment-market",
          "https://www.prnewswire.com/news-releases/crohns-disease-market-projected-to-grow-at-4-3-cagr-20202034-driven-by-improved-diagnosis-pediatric-label-expansion-and-new-second-line-therapies--delveinsight-302537431.html",
          "https://www.wissenresearch.com/inflammatory-bowel-disease-market-report/"
        ],
        "pipeline_sources": [
          "https://clinicaltrials.gov",
          "https://clinicaltrials.gov/study/NCT07113522",
          "https://clinicaltrials.gov/study/NCT06976853",
          "https://www.clinicaltrials.gov/study/NCT00820365",
          "https://clinicaltrials.gov/study/NCT05194007"
        ],
        "attributed_sources": [
          {
            "url": "https://www.cdc.gov/inflammatory-bowel-disease/php/facts-stats/index.html",
            "title": "IBD Facts and Stats - CDC",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.cdc.gov/mmwr/volumes/65/wr/mm6542a3.htm",
            "title": "Prevalence of Inflammatory Bowel Disease Among Adults Aged ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.drugs.com/condition/inflammatory-bowel-disease.html",
            "title": "Medications for Inflammatory Bowel Disease",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.fda.gov/news-events/press-announcements/fda-roundup-april-26-2024",
            "title": "FDA Roundup: April 26, 2024",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8720971/",
            "title": "Treatment of Inflammatory Bowel Disease: A Comprehensive Review",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://clinicaltrials.gov",
            "title": "ClinicalTrials.gov API",
            "attribution": "Pipeline/Clinical Trials (Primary)"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT07113522",
            "title": "NCT07113522 | A Phase 2 Study to Evaluate Therapies for ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT06976853",
            "title": "NCT06976853 | Moving Beyond Inflammation as a ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.factmr.com/report/crohns-disease-treatment-market",
            "title": "Crohn's Disease Treatment Market | Global Market Analysis Report",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.prnewswire.com/news-releases/crohns-disease-market-projected-to-grow-at-4-3-cagr-20202034-driven-by-improved-diagnosis-pediatric-label-expansion-and-new-second-line-therapies--delveinsight-302537431.html",
            "title": "Crohn's Disease Market Projected to Grow at 4.3% CAGR (2020 ...",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 7.9,
        "evidence_quality": 4.9,
        "market_opportunity": 7.7,
        "overall_priority": 7.1,
        "clinical_breakdown": {
          "response_rate_quality_weighted": 4.8,
          "safety_profile": 10.0,
          "organ_domain_breadth": 10.0,
          "safety_categories": [],
          "regulatory_flags": [],
          "efficacy_endpoint_count": 12,
          "efficacy_concordance": 0.9
        },
        "response_rate_score": 4.8,
        "safety_profile_score": 10.0,
        "endpoint_quality_score": null,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 6.0,
          "publication_venue": 2.0,
          "response_durability": 5.0,
          "extraction_completeness": 7.2
        },
        "sample_size_score": 6.0,
        "publication_venue_score": 2.0,
        "followup_duration_score": 5.0,
        "extraction_completeness_score": 7.2,
        "market_breakdown": {
          "competitors": 3.0,
          "market_size": 10.0,
          "unmet_need": 10.0
        },
        "competitors_score": 3.0,
        "market_size_score": 10.0,
        "unmet_need_score": 10.0
      },
      "rank": 30
    },
    {
      "extraction": {
        "source": {
          "pmid": null,
          "doi": null,
          "url": "https://www.actasdermo.org/es-four-case-report-of-upadacitinib-as-articulo-S0001731024005891",
          "title": "Four-case Report of Upadacitinib as an Alternative Treatment for ...",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Web source",
          "is_open_access": false
        },
        "disease": "Pyoderma gangrenosum",
        "disease_normalized": "Pyoderma Gangrenosum",
        "is_off_label": true,
        "is_relevant": true,
        "evidence_level": "Case Series",
        "patient_population": {
          "n_patients": 4,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "Systemic corticosteroids",
            "Methotrexate",
            "Cyclosporin",
            "Adalimumab",
            "Golimumab",
            "Certolizumab",
            "Infliximab",
            "Azathioprine"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "4 patients with refractory pyoderma gangrenosum (2 women, 2 men, ages 26-62 years)"
        },
        "treatment": {
          "drug_name": "upadacitinib",
          "generic_name": "Upadacitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "15mg daily first month then 30mg daily, or 30mg daily",
          "frequency": null,
          "duration": null,
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "4/4 (100%)",
          "responders_n": 4,
          "responders_pct": 100.0,
          "time_to_response": "12-16 weeks",
          "duration_of_response": null,
          "effect_size_description": "Reduction from baseline PGA of 4 to final PGA of 1-2",
          "primary_endpoint": "Physician Global Assessment (PGA) score",
          "endpoint_result": "All patients achieved PGA \u22642 (optimal response)",
          "durability_signal": null,
          "efficacy_summary": "All four patients with refractory pyoderma gangrenosum achieved optimal response (PGA \u22642) within 12-16 weeks of upadacitinib treatment. Mean baseline PGA was 4 and all patients reached final PGA scores of 1-2."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": null,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "Safety outcomes were not reported in the available data from this case series.",
          "safety_profile": "Unknown"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": null,
        "key_findings": "Upadacitinib demonstrated 100% response rate in refractory pyoderma gangrenosum cases that had failed multiple conventional and biologic therapies.",
        "detailed_efficacy_endpoints": [],
        "detailed_safety_endpoints": [],
        "extraction_timestamp": "2025-12-08T18:06:10.186137",
        "extraction_confidence": 0.5,
        "extraction_confidence_detail": null,
        "extraction_method": "single_pass",
        "extraction_stages_completed": [],
        "data_sections_identified": null
      },
      "market_intelligence": {
        "disease": "Pyoderma Gangrenosum",
        "parent_disease": null,
        "epidemiology": {
          "us_prevalence_estimate": "5.8 per 100,000 adults",
          "us_incidence_estimate": "0.04 to 5 per 100,000 per year",
          "global_prevalence": null,
          "patient_population_size": 15525,
          "prevalence_source": "Journal of the American Academy of Dermatology",
          "prevalence_source_url": "https://www.sciencedirect.com/science/article/abs/pii/S0190962219324946",
          "trend": null,
          "source_quality": "Primary",
          "data_year": 2020,
          "geographic_scope": "US",
          "confidence": "High",
          "notes": "Cross-sectional analysis of 1971 patients from electronic health records of over 58 million patients. Female-to-male ratio >1.8 across all age groups, with highest prevalence in 70-79 year age group at 9.8 cases per 100,000. Nearly 70% of cases occur in patients \u226550 years old."
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Vilobelimab",
              "drug_class": "C5a inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": null,
              "notes": "Has orphan drug designation for pyoderma gangrenosum as of 2022 but is not FDA approved for this indication",
              "approval_year": null,
              "approval_confidence": "High",
              "approval_evidence": "FDA Orphan Drug Database - designated but not approved"
            }
          ],
          "approved_drug_names": [],
          "num_approved_drugs": 0,
          "num_pipeline_therapies": 3,
          "pipeline_therapies": [
            {
              "drug_name": "Spesolimab",
              "company": "Boehringer Ingelheim",
              "mechanism": "Anti-IL-36R monoclonal antibody",
              "phase": "Phase 3",
              "trial_id": "NCT06624670",
              "expected_completion": "2027-04",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Multi-centre, randomised, placebo-controlled, double-blind trial for ulcerative pyoderma gangrenosum"
            },
            {
              "drug_name": "Guselkumab",
              "company": "Oregon Health and Science University",
              "mechanism": "Anti-IL-23 monoclonal antibody",
              "phase": "Phase 2",
              "trial_id": "NCT06563323",
              "expected_completion": "2027-08",
              "trial_name": null,
              "status": "Not yet recruiting",
              "regulatory_designations": null,
              "notes": "Single-arm open-label study assessing short-term and long-term efficacy"
            },
            {
              "drug_name": "Baricitinib",
              "company": "Oregon Health and Science University",
              "mechanism": "JAK inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT04901325",
              "expected_completion": "2025-01",
              "trial_name": null,
              "status": "Completed",
              "regulatory_designations": null,
              "notes": "Recently completed phase 2 trial, results to be presented at EADV Congress 2025"
            }
          ],
          "pipeline_details": "The pyoderma gangrenosum pipeline includes 3 active programs testing different mechanisms: IL-36R inhibition (Spesolimab in Phase 3), IL-23 inhibition (Guselkumab in Phase 2), and JAK inhibition (Baricitinib completed Phase 2). Boehringer Ingelheim's Spesolimab represents the most advanced program currently recruiting patients.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "First-line treatment typically involves systemic corticosteroids (prednisone) with topical therapies including potent corticosteroids or calcineurin inhibitors. Second-line options include cyclosporine, with TNF-alpha inhibitors (infliximab, adalimumab) increasingly used as alternative or early therapy due to high response rates exceeding 85%.",
          "unmet_need": true,
          "unmet_need_description": "No FDA-approved branded innovative treatments exist specifically for pyoderma gangrenosum. Current standard of care relies on generic immunosuppressants with significant side effects, and treatment remains largely anecdotal with only two randomized controlled trials available.",
          "competitive_landscape": "The treatment landscape consists primarily of off-label use of generic immunosuppressants and biologics approved for other inflammatory conditions. TNF-alpha inhibitors show promise with high response rates but lack specific FDA approval for pyoderma gangrenosum, creating an opportunity for targeted therapeutic development.",
          "soc_source": "Medscape Pyoderma Gangrenosum Treatment & Management and FDA Orphan Drug Database",
          "phase_3_count": 1,
          "phase_2_count": 2,
          "key_catalysts": "Spesolimab Phase 3 trial results expected by April 2027; Baricitinib Phase 2 results presentation at EADV Congress 2025; Guselkumab Phase 2 trial initiation expected January 2025",
          "pipeline_data_quality": "Medium",
          "recent_approvals": null,
          "data_quality": "High",
          "data_quality_notes": "Clear evidence from FDA database and multiple clinical sources, but no FDA-approved branded innovative treatments identified for this specific indication"
        },
        "market_size_estimate": "$1.6B",
        "market_size_usd": 1552500000.0,
        "growth_rate": "5-8% CAGR (high unmet need)",
        "tam_usd": 285000000.0,
        "tam_estimate": "$285M",
        "tam_rationale": "Of ~15,525 US patients with pyoderma gangrenosum, approximately 70% are diagnosed (~10,900), with 80% receiving systemic treatment (~8,700 patients) given the severity of this rare inflammatory condition. With no approved drugs and high unmet need, a new FDA-approved therapy could capture 35-40% market share (~3,300 patients). As an orphan indication with severe morbidity requiring chronic treatment, pricing of $80-90K annually is justified based on comparable rare autoimmune conditions. TAM = 3,300 patients \u00d7 $86K = $285M.",
        "tam_sources": [
          "https://www.futuremarketinsights.com/reports/pyoderma-gangrenosum-therapeutics-market",
          "https://www.delveinsight.com/report-store/pyoderma-gangrenosum-market",
          "https://www.imrmarketreports.com/reports/pyogenic-arthritis-pyoderma-gangrenosum-and-acne-market/"
        ],
        "pipeline_sources": [
          "https://clinicaltrials.gov",
          "https://clinicaltrials.gov/study/NCT06092216",
          "https://www.clinicaltrials.gov/study/NCT06563323",
          "https://clinicaltrials.gov/study/NCT05964413",
          "https://www.clinicaltrials.gov/study/NCT02318914"
        ],
        "attributed_sources": [
          {
            "url": "https://www.droracle.ai/articles/112672/what-is-the-incidence-of-pyoderma-gangrenosum-pg-in",
            "title": "What is the incidence of Pyoderma Gangrenosum (PG ... - Dr.Oracle",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.sciencedirect.com/science/article/abs/pii/S0190962219324946",
            "title": "Prevalence estimates for pyoderma gangrenosum in the ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://emedicine.medscape.com/article/1123821-treatment",
            "title": "Pyoderma Gangrenosum Treatment & Management",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=884822",
            "title": "Search Orphan Drug Designations and Approvals - FDA",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://droracle.ai/articles/474999/what-is-the-treatment-for-pyoderma-gangrenosum",
            "title": "What is the treatment for pyoderma gangrenosum? - Dr.Oracle",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://clinicaltrials.gov",
            "title": "ClinicalTrials.gov API",
            "attribution": "Pipeline/Clinical Trials (Primary)"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT06092216",
            "title": "NCT06092216 | Spesolimab in Pyoderma Gangrenosum",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.clinicaltrials.gov/study/NCT06563323",
            "title": "Guselkumab in the Treatment of Adults With Pyoderma ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.futuremarketinsights.com/reports/pyoderma-gangrenosum-therapeutics-market",
            "title": "Pyoderma Gangrenosum Therapeutics Market - Future Market Insights",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.delveinsight.com/report-store/pyoderma-gangrenosum-market",
            "title": "Pyoderma Gangrenosum Treatment Market Size, Drugs, Companies",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 7.6,
        "evidence_quality": 3.6,
        "market_opportunity": 9.3,
        "overall_priority": 7.0,
        "clinical_breakdown": {
          "response_rate_quality_weighted": 10.0,
          "safety_profile": 5.0,
          "organ_domain_breadth": 8.0,
          "safety_categories": [],
          "regulatory_flags": [],
          "efficacy_endpoint_count": 0,
          "efficacy_concordance": 1.0
        },
        "response_rate_score": 10.0,
        "safety_profile_score": 5.0,
        "endpoint_quality_score": null,
        "organ_domain_score": 8.0,
        "evidence_breakdown": {
          "sample_size": 4.0,
          "publication_venue": 2.0,
          "response_durability": 4.0,
          "extraction_completeness": 4.9
        },
        "sample_size_score": 4.0,
        "publication_venue_score": 2.0,
        "followup_duration_score": 4.0,
        "extraction_completeness_score": 4.9,
        "market_breakdown": {
          "competitors": 10.0,
          "market_size": 8.0,
          "unmet_need": 10.0
        },
        "competitors_score": 10.0,
        "market_size_score": 8.0,
        "unmet_need_score": 10.0
      },
      "rank": 31
    },
    {
      "extraction": {
        "source": {
          "pmid": null,
          "doi": null,
          "url": "https://www.jrheum.org/content/52/Suppl_1/266.2",
          "title": "USE OF UPADACITINIB IN 2 CASES OF REFRACTORY SYSTEMIC ...",
          "authors": null,
          "journal": "The Journal of Rheumatology",
          "year": null,
          "citation": null,
          "publication_venue": "Web source",
          "is_open_access": false
        },
        "disease": "Systemic Lupus Erythematosus",
        "disease_normalized": "Systemic Lupus Erythematosus",
        "is_off_label": true,
        "is_relevant": true,
        "evidence_level": "Case Series",
        "patient_population": {
          "n_patients": 2,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "belimumab",
            "conventional treatments"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "Two female patients (ages 54 and 59) with long-standing, refractory SLE involving multiple domains"
        },
        "treatment": {
          "drug_name": "upadacitinib",
          "generic_name": "Upadacitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "15 mg/day",
          "frequency": null,
          "duration": null,
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": null,
          "responders_n": 1,
          "responders_pct": null,
          "time_to_response": null,
          "duration_of_response": "18 months for Case 1",
          "effect_size_description": "complete disease remission with significant improvement in fatigue and headache",
          "primary_endpoint": "disease remission",
          "endpoint_result": "complete disease remission in Case 1 with sustained response for 18 months",
          "durability_signal": null,
          "efficacy_summary": "Case 1 achieved complete disease remission with significant improvement in fatigue and lupus headache, sustained for 18 months. Case 2 details were not fully provided in the available text."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": null,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "Safety data not reported in the available abstract and case description.",
          "safety_profile": "Unknown"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": "18 months",
        "key_findings": "Upadacitinib achieved complete remission in refractory SLE with sustained response over 18 months in one case after multiple treatment failures.",
        "detailed_efficacy_endpoints": [],
        "detailed_safety_endpoints": [],
        "extraction_timestamp": "2025-12-08T18:06:20.243940",
        "extraction_confidence": 0.5,
        "extraction_confidence_detail": null,
        "extraction_method": "single_pass",
        "extraction_stages_completed": [],
        "data_sections_identified": null
      },
      "market_intelligence": {
        "disease": "Systemic Lupus Erythematosus",
        "parent_disease": null,
        "epidemiology": {
          "us_prevalence_estimate": "72.8 per 100,000 persons",
          "us_incidence_estimate": "5.1 per 100,000 person-years",
          "global_prevalence": null,
          "patient_population_size": 204295,
          "prevalence_source": "CDC National Lupus Registry",
          "prevalence_source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8169527/",
          "trend": "increasing",
          "source_quality": "Primary",
          "data_year": 2018,
          "geographic_scope": "US",
          "confidence": "High",
          "notes": "Prevalence 9 times higher in females than males; highest among Black and American Indian/Alaska Native populations; estimates based on ACR classification criteria from multiple state registries"
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Benlysta (belimumab)",
              "drug_class": "B-lymphocyte stimulator (BLyS) inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Systemic Lupus Erythematosus",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "First new lupus treatment approved in over 50 years. Approved for adults and children 5+ years with active, autoantibody-positive SLE. Also has separate approval for lupus nephritis.",
              "approval_year": 2011,
              "approval_confidence": "High",
              "approval_evidence": "FDA approval March 2011, multiple search results confirm FDA approval for SLE"
            },
            {
              "drug_name": "Saphnelo (anifrolumab)",
              "drug_class": "Type I interferon receptor antagonist",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Systemic Lupus Erythematosus",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "Human monoclonal antibody that binds to type I interferon receptor. Mentioned as one of only two FDA-approved treatments for SLE since the 1950s.",
              "approval_year": null,
              "approval_confidence": "Medium",
              "approval_evidence": "Multiple sources mention Saphnelo as FDA approved for SLE, mentioned alongside Benlysta as only two medicines approved for SLE since 1950s"
            }
          ],
          "approved_drug_names": [
            "Benlysta (belimumab)",
            "Saphnelo (anifrolumab)"
          ],
          "num_approved_drugs": 2,
          "num_pipeline_therapies": 0,
          "pipeline_therapies": [],
          "pipeline_details": null,
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "First-line treatment typically includes hydroxychloroquine, NSAIDs, and corticosteroids. For moderate to severe disease or steroid-sparing therapy, immunosuppressants like methotrexate, azathioprine, or mycophenolate are used. Biologics like belimumab and anifrolumab are reserved for refractory disease or as add-on therapy to standard treatments.",
          "unmet_need": true,
          "unmet_need_description": "Significant unmet need exists as only two branded innovative therapies have been approved for SLE since the 1950s. Many patients rely on older generic immunosuppressants and corticosteroids with significant long-term toxicity. Treatment is often borrowed from other autoimmune diseases rather than SLE-specific therapies.",
          "competitive_landscape": "Very limited competitive landscape with only Benlysta and Saphnelo as FDA-approved branded innovative treatments. Benlysta has first-mover advantage being approved in 2011 and has additional approvals for pediatric patients and lupus nephritis. Multiple therapies are in development targeting various pathways including interferons, B-cells, and T-cells.",
          "soc_source": "Multiple sources including FDA guidance documents and medical literature",
          "phase_3_count": 0,
          "phase_2_count": 0,
          "key_catalysts": null,
          "pipeline_data_quality": "Unknown",
          "recent_approvals": "Benlysta subcutaneous autoinjector formulation approved in 2024 for pediatric patients 5+ years, allowing home administration",
          "data_quality": "High",
          "data_quality_notes": "Clear FDA approval confirmation for both drugs, though specific approval year for anifrolumab not found in search results"
        },
        "market_size_estimate": "$5.1B",
        "market_size_usd": 5107375000.0,
        "growth_rate": "5-10% CAGR (increasing prevalence)",
        "tam_usd": 180000000.0,
        "tam_estimate": "$180M",
        "tam_rationale": "Of ~204K US SLE patients, approximately 80% are diagnosed (163K), 70% receive systemic treatment (114K), and 35% fail standard therapy requiring biologics/advanced treatment (40K patients). A new biologic could capture 15-20% market share in this crowded but high unmet need market (~7K patients). At $65K/yr pricing (similar to Saphnelo), TAM = $180M. Limited approved biologics (only 2) but complex treatment paradigm supports moderate penetration.",
        "tam_sources": [
          "https://bisresearch.com/industry-report/systemic-lupus-erythematosus-market.html",
          "https://www.openpr.com/news/3677803/lupus-therapeutic-market-2024-2031-market-dynamics-growth",
          "https://finance.yahoo.com/news/systemic-lupus-erythematosus-sle-market-123900502.html"
        ],
        "pipeline_sources": [
          "https://clinicaltrials.gov",
          "https://clinicaltrials.gov/study/NCT03093402",
          "https://cdn.clinicaltrials.gov/large-docs/25/NCT03843125/Prot_000.pdf",
          "https://cdn.clinicaltrials.gov/large-docs/12/NCT03616912/Prot_000.pdf",
          "https://cdn.clinicaltrials.gov/large-docs/25/NCT03843125/SAP_001.pdf"
        ],
        "attributed_sources": [
          {
            "url": "https://www.ahdbonline.com/articles/the-epidemiology-of-systemic-lupus-erythematosus-disease-prevalence-and-impact-on-employment-and-work-productivity",
            "title": "The Epidemiology of Systemic Lupus Erythematosus: Disease ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8169527/",
            "title": "Prevalence of Systemic Lupus Erythematosus in the United ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.drugs.com/benlysta.html",
            "title": "Benlysta: Uses, Dosage, Side Effects, Warnings",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.drugs.com/condition/systemic-lupus-erythematosus.html",
            "title": "List of 28 Lupus Medications Compared",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://emedicine.medscape.com/article/332244-treatment",
            "title": "Systemic Lupus Erythematosus (SLE) Treatment & ...",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://clinicaltrials.gov",
            "title": "ClinicalTrials.gov API",
            "attribution": "Pipeline/Clinical Trials (Primary)"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT03093402",
            "title": "JBT-101 in Systemic Lupus Erythematosus (SLE)",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://cdn.clinicaltrials.gov/large-docs/25/NCT03843125/Prot_000.pdf",
            "title": "Protocol I4V-MC-JAIM(a) A Phase 3, Double-Blind, ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://bisresearch.com/industry-report/systemic-lupus-erythematosus-market.html",
            "title": "Systemic Lupus Erythematosus Market Report I BIS Research",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.openpr.com/news/3677803/lupus-therapeutic-market-2024-2031-market-dynamics-growth",
            "title": "Lupus Therapeutic Market 2024-2031",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 7.4,
        "evidence_quality": 4.4,
        "market_opportunity": 8.7,
        "overall_priority": 7.0,
        "clinical_breakdown": {
          "response_rate_quality_weighted": 8.5,
          "safety_profile": 5.0,
          "organ_domain_breadth": 10.0,
          "safety_categories": [],
          "regulatory_flags": [],
          "efficacy_endpoint_count": 0,
          "efficacy_concordance": 1.0
        },
        "response_rate_score": 8.5,
        "safety_profile_score": 5.0,
        "endpoint_quality_score": null,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 2.0,
          "publication_venue": 2.0,
          "response_durability": 9.0,
          "extraction_completeness": 6.1
        },
        "sample_size_score": 2.0,
        "publication_venue_score": 2.0,
        "followup_duration_score": 9.0,
        "extraction_completeness_score": 6.1,
        "market_breakdown": {
          "competitors": 7.0,
          "market_size": 9.0,
          "unmet_need": 10.0
        },
        "competitors_score": 7.0,
        "market_size_score": 9.0,
        "unmet_need_score": 10.0
      },
      "rank": 32
    },
    {
      "extraction": {
        "source": {
          "pmid": "34757416",
          "doi": "10.1001/jamadermatol.2021.4084",
          "url": "https://www.semanticscholar.org/paper/49c75c1db31ced3ae71aa68d68cdf395eff77af8",
          "title": "Treatment of Persistent Erythema Multiforme With Janus Kinase Inhibition and the Role of Interferon Gamma and Interleukin 15 in Its Pathogenesis.",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Web source",
          "is_open_access": false
        },
        "disease": "Persistent Erythema Multiforme",
        "disease_normalized": "Erythema Multiforme",
        "is_off_label": true,
        "is_relevant": true,
        "evidence_level": "Case Series",
        "patient_population": {
          "n_patients": 4,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [],
          "disease_severity": null,
          "comorbidities": null,
          "description": "Patients with persistent erythema multiforme"
        },
        "treatment": {
          "drug_name": "upadacitinib",
          "generic_name": "Upadacitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": null,
          "dose": null,
          "frequency": null,
          "duration": null,
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "4/4 (100%)",
          "responders_n": 4,
          "responders_pct": 100.0,
          "time_to_response": null,
          "duration_of_response": null,
          "effect_size_description": "Marked clinical improvement",
          "primary_endpoint": "Clinical improvement",
          "endpoint_result": "Marked clinical improvement in all 4 patients",
          "durability_signal": null,
          "efficacy_summary": "All four patients with persistent erythema multiforme treated with JAK inhibition experienced marked clinical improvement. The study also identified IFN-\u03b3 and IL-15 as important molecular targets that were modulated by treatment."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": null,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "Safety outcomes were not reported in this case series.",
          "safety_profile": "Unknown"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": null,
        "key_findings": "JAK inhibition showed marked clinical improvement in all 4 patients with persistent erythema multiforme, with evidence that IFN-\u03b3 and IL-15 are important therapeutic targets.",
        "detailed_efficacy_endpoints": [],
        "detailed_safety_endpoints": [],
        "extraction_timestamp": "2025-12-08T18:38:19.495216",
        "extraction_confidence": 0.5,
        "extraction_confidence_detail": null,
        "extraction_method": "single_pass",
        "extraction_stages_completed": [],
        "data_sections_identified": null
      },
      "market_intelligence": {
        "disease": "Erythema Multiforme",
        "parent_disease": null,
        "epidemiology": {
          "us_prevalence_estimate": "less than 1%",
          "us_incidence_estimate": "1.2-6 cases per million individuals per year",
          "global_prevalence": null,
          "patient_population_size": 20100,
          "prevalence_source": "American Family Physician",
          "prevalence_source_url": "https://www.aafp.org/pubs/afp/issues/2019/0715/p82.html",
          "trend": null,
          "source_quality": "Secondary",
          "data_year": 2019,
          "geographic_scope": "Global",
          "confidence": "Medium",
          "notes": "Multiple sources report annual incidence as less than 1% with global estimates of 1.2-6 cases per million per year. US-specific data limited. As many as 1% of dermatologic outpatient visits are for EM according to Medscape source."
        },
        "standard_of_care": {
          "top_treatments": [],
          "approved_drug_names": [],
          "num_approved_drugs": 0,
          "num_pipeline_therapies": 6,
          "pipeline_therapies": [
            {
              "drug_name": "Prednisone/Methylprednisolone",
              "company": "Assistance Publique - H\u00f4pitaux de Paris",
              "mechanism": "Corticosteroid anti-inflammatory",
              "phase": "Phase 3",
              "trial_id": "NCT06266221",
              "expected_completion": "2027-06",
              "trial_name": "CORTICO",
              "status": "Not yet recruiting",
              "regulatory_designations": null,
              "notes": "Randomized controlled trial comparing short systemic corticosteroids regimen to placebo in severe erythema multiforme"
            },
            {
              "drug_name": "Adipose derived stromal cells",
              "company": "Assistance Publique - H\u00f4pitaux de Paris",
              "mechanism": "Mesenchymal stromal cell therapy",
              "phase": "Phase 2",
              "trial_id": "NCT04711200",
              "expected_completion": "2027-04",
              "trial_name": "LYell SYndrome MEsenchymal Stromal Cells Treatment",
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Currently recruiting for Lyell syndrome treatment - related to erythema multiforme spectrum"
            },
            {
              "drug_name": "Daratumumab",
              "company": "Hospices Civils de Lyon",
              "mechanism": "Anti-CD38 monoclonal antibody",
              "phase": "Phase 2",
              "trial_id": "NCT07110662",
              "expected_completion": "2028-10",
              "trial_name": null,
              "status": "Not yet recruiting",
              "regulatory_designations": null,
              "notes": "New therapeutic approach for toxic epidermal necrolysis using anti-CD38+ antibodies"
            },
            {
              "drug_name": "Etanercept",
              "company": "Vanderbilt University Medical Center",
              "mechanism": "TNF-alpha inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT02987257",
              "expected_completion": "2025-10",
              "trial_name": "NATIENS",
              "status": "Active",
              "regulatory_designations": null,
              "notes": "Phase III randomized double-blinded placebo controlled study for Stevens-Johnson syndrome and toxic epidermal necrolysis"
            },
            {
              "drug_name": "Autologous Serum 20%",
              "company": "GIANCARLO FATOBENE",
              "mechanism": "Autologous serum therapy",
              "phase": "Phase 2",
              "trial_id": "NCT07014059",
              "expected_completion": "2026-06",
              "trial_name": null,
              "status": "Not yet recruiting",
              "regulatory_designations": null,
              "notes": "Topical ocular use of autologous serum obtained by closed-circuit collection device"
            },
            {
              "drug_name": "Filgrastim",
              "company": "Hospices Civils de Lyon",
              "mechanism": "Granulocyte colony-stimulating factor",
              "phase": "Phase 2/3",
              "trial_id": "NCT04651439",
              "expected_completion": "2025-05",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Evaluating therapeutic efficacy in severe bullous drug eruptions (Lyell and Stevens-Johnson syndromes)"
            }
          ],
          "pipeline_details": "The erythema multiforme pipeline includes 6 active therapies spanning traditional corticosteroids, novel cell therapies, and targeted immunomodulators. Key mechanisms being tested include anti-CD38 antibodies (daratumumab), TNF-alpha inhibition (etanercept), and mesenchymal stromal cell therapy, reflecting diverse approaches to treating this inflammatory condition.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "Treatment of erythema multiforme focuses on identifying and removing triggering causes (medications, infections), providing symptomatic relief with antihistamines, topical steroids, and analgesics for mild cases. For recurrent disease, antiviral prophylaxis (acyclovir, valacyclovir) is first-line therapy, particularly for HSV-associated cases.",
          "unmet_need": true,
          "unmet_need_description": "No FDA-approved branded innovative treatments exist specifically for erythema multiforme. Treatment relies on generic supportive care, corticosteroids, and off-label use of antivirals. Recurrent cases remain particularly challenging to manage with limited therapeutic options.",
          "competitive_landscape": "There is no competitive landscape for FDA-approved branded innovative drugs for erythema multiforme, as no such treatments exist. Current management relies entirely on generic medications including corticosteroids, antihistamines, antivirals, and supportive care measures.",
          "soc_source": "Medscape Reference and PMC/NCBI treatment reviews",
          "phase_3_count": 2,
          "phase_2_count": 4,
          "key_catalysts": "Filgrastim Phase 2/3 trial completion expected May 2025, NATIENS etanercept Phase 3 trial completion expected October 2025",
          "pipeline_data_quality": "Medium",
          "recent_approvals": null,
          "data_quality": "High",
          "data_quality_notes": "Multiple comprehensive sources consistently show no FDA-approved branded innovative treatments for erythema multiforme. Treatment recommendations are well-documented but rely on generic therapies and supportive care."
        },
        "market_size_estimate": "$2.0B",
        "market_size_usd": 2010000000.0,
        "growth_rate": "5-8% CAGR (high unmet need)",
        "tam_usd": 302000000.0,
        "tam_estimate": "$302M",
        "tam_rationale": "Of ~20,100 US patients with erythema multiforme, ~70% are diagnosed (14,070), ~60% receive systemic treatment beyond basic symptomatic care (8,442). Given the recurrent nature and current reliance on off-label antivirals with limited efficacy, ~60% could be candidates for a targeted therapy (5,065 patients). With no approved drugs and high unmet need, a first-in-class drug could capture 40-50% market share (~2,500 patients). At $120K/yr pricing (rare dermatologic indication with orphan potential), TAM = $302M.",
        "tam_sources": [
          "https://www.databridgemarketresearch.com/reports/global-erythema-multiforme-stevens-johnson-syndrome-treatment-market?srsltid=AfmBOor3Dk6F8ObkVhOGfNoMC9L8PknrXqcOtwxPR0Qf5bGo9QWUtoXk",
          "https://www.ahajournals.org/doi/10.1161/CIR.0000000000000484?doi=10.1161/CIR.0000000000000484",
          "https://www.emjreviews.com/wp-content/uploads/2019/11/EMJ-Dermatology-7.1-2019.pdf"
        ],
        "pipeline_sources": [
          "https://clinicaltrials.gov",
          "https://cdn.clinicaltrials.gov/large-docs/53/NCT05795153/Prot_000.pdf",
          "https://cdn.clinicaltrials.gov/large-docs/70/NCT00946270/Prot_SAP_000.pdf",
          "https://clinicaltrials.gov/study/NCT06921759",
          "https://cdn.clinicaltrials.gov/large-docs/26/NCT02596126/Prot_000.pdf"
        ],
        "attributed_sources": [
          {
            "url": "https://emedicine.medscape.com/article/1122915-overview",
            "title": "Erythema Multiforme: Background, Pathophysiology, Etiology",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.ncbi.nlm.nih.gov/books/NBK470259/",
            "title": "Erythema Multiforme - StatPearls - NCBI Bookshelf",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://emedicine.medscape.com/article/1122915-overview",
            "title": "Erythema Multiforme: Background, Pathophysiology, Etiology",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-naxitamab-high-risk-neuroblastoma-bone-or-bone-marrow",
            "title": "FDA grants accelerated approval to naxitamab for high-risk ...",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://pubmed.ncbi.nlm.nih.gov/34577844/",
            "title": "Recent Updates in the Treatment of Erythema Multiforme - PubMed",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://clinicaltrials.gov",
            "title": "ClinicalTrials.gov API",
            "attribution": "Pipeline/Clinical Trials (Primary)"
          },
          {
            "url": "https://cdn.clinicaltrials.gov/large-docs/53/NCT05795153/Prot_000.pdf",
            "title": "A multicenter, open-label Phase 3 study: ambulatory blood",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://cdn.clinicaltrials.gov/large-docs/70/NCT00946270/Prot_SAP_000.pdf",
            "title": "a phase 2, prospective, open-label study (po- mmm-pi-0011) to ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.databridgemarketresearch.com/reports/global-erythema-multiforme-stevens-johnson-syndrome-treatment-market?srsltid=AfmBOor3Dk6F8ObkVhOGfNoMC9L8PknrXqcOtwxPR0Qf5bGo9QWUtoXk",
            "title": "Global Erythema Multiforme-Stevens Johnson Syndrome Treatment ...",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.ahajournals.org/doi/10.1161/CIR.0000000000000484?doi=10.1161/CIR.0000000000000484",
            "title": "Diagnosis, Treatment, and Long-Term Management of ...",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 7.6,
        "evidence_quality": 3.6,
        "market_opportunity": 9.3,
        "overall_priority": 7.0,
        "clinical_breakdown": {
          "response_rate_quality_weighted": 10.0,
          "safety_profile": 5.0,
          "organ_domain_breadth": 8.0,
          "safety_categories": [],
          "regulatory_flags": [],
          "efficacy_endpoint_count": 0,
          "efficacy_concordance": 1.0
        },
        "response_rate_score": 10.0,
        "safety_profile_score": 5.0,
        "endpoint_quality_score": null,
        "organ_domain_score": 8.0,
        "evidence_breakdown": {
          "sample_size": 4.0,
          "publication_venue": 2.0,
          "response_durability": 4.0,
          "extraction_completeness": 4.9
        },
        "sample_size_score": 4.0,
        "publication_venue_score": 2.0,
        "followup_duration_score": 4.0,
        "extraction_completeness_score": 4.9,
        "market_breakdown": {
          "competitors": 10.0,
          "market_size": 8.0,
          "unmet_need": 10.0
        },
        "competitors_score": 10.0,
        "market_size_score": 8.0,
        "unmet_need_score": 10.0
      },
      "rank": 33
    },
    {
      "extraction": {
        "source": {
          "pmid": null,
          "doi": null,
          "url": "https://www.dermatologytimes.com/view/upadacitinib-plus-excimer-laser-efficacious-in-treating-refractory-vitiligo-with-moderate-to-severe-atopic-dermatitis",
          "title": "Upadacitinib Plus Excimer Laser Is Efficacious in Treating ...",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Web source",
          "is_open_access": false
        },
        "disease": "vitiligo",
        "disease_normalized": "Vitiligo",
        "is_off_label": true,
        "is_relevant": true,
        "evidence_level": "Case Series",
        "patient_population": {
          "n_patients": 19,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": null,
          "disease_severity": null,
          "comorbidities": null,
          "description": "patients with refractory vitiligo and moderate to severe atopic dermatitis"
        },
        "treatment": {
          "drug_name": "upadacitinib",
          "generic_name": "Upadacitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "15 mg daily",
          "frequency": null,
          "duration": "4 months",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": null,
          "responders_n": null,
          "responders_pct": null,
          "time_to_response": null,
          "duration_of_response": null,
          "effect_size_description": "improved pigmentation outcomes and reduced AD severity",
          "primary_endpoint": "repigmentation outcomes",
          "endpoint_result": "improved pigmentation outcomes",
          "durability_signal": null,
          "efficacy_summary": "The combination of upadacitinib with 308-nm excimer laser therapy improved pigmentation outcomes in patients with refractory vitiligo. The dual approach also reduced atopic dermatitis severity and improved patient quality of life."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": null,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "Safety outcomes were not reported in the available abstract.",
          "safety_profile": "Unknown"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Moderate",
        "comparator_baseline": null,
        "follow_up_duration": "3 months",
        "key_findings": "Upadacitinib combined with excimer laser therapy demonstrated efficacy in treating refractory vitiligo while also improving concurrent atopic dermatitis.",
        "detailed_efficacy_endpoints": [],
        "detailed_safety_endpoints": [],
        "extraction_timestamp": "2025-12-08T18:06:54.014701",
        "extraction_confidence": 0.5,
        "extraction_confidence_detail": null,
        "extraction_method": "single_pass",
        "extraction_stages_completed": [],
        "data_sections_identified": null
      },
      "market_intelligence": {
        "disease": "Vitiligo",
        "parent_disease": null,
        "epidemiology": {
          "us_prevalence_estimate": "0.76%-1.11% of US adults",
          "us_incidence_estimate": "24.7-61.0 cases per 100,000 person-years",
          "global_prevalence": null,
          "patient_population_size": 2350000,
          "prevalence_source": "JAMA Dermatology",
          "prevalence_source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8600454/",
          "trend": "increasing",
          "source_quality": "Primary",
          "data_year": 2020,
          "geographic_scope": "US",
          "confidence": "High",
          "notes": "40% of adult vitiligo cases may be undiagnosed; prevalence estimates based on clinician-adjudicated review of photographs; separate estimates available for children/adolescents showing higher prevalence (1.52% in children, 2.16% in adolescents)"
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Opzelura (ruxolitinib)",
              "drug_class": "JAK inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "nonsegmental vitiligo",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": null,
              "notes": "FDA-approved topical treatment for nonsegmental vitiligo in adults and pediatric patients 12 years and older. First FDA-approved pharmacologic treatment to address repigmentation in vitiligo patients. Applied twice daily to affected areas up to 10% of body surface area.",
              "approval_year": 2022,
              "approval_confidence": "High",
              "approval_evidence": "FDA press release July 2022, FDA drug label 2022"
            }
          ],
          "approved_drug_names": [
            "Opzelura (ruxolitinib)"
          ],
          "num_approved_drugs": 1,
          "num_pipeline_therapies": 15,
          "pipeline_therapies": [
            {
              "drug_name": "Ritlecitinib",
              "company": "Pfizer",
              "mechanism": "JAK3/TEC inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT06163326",
              "expected_completion": "2027-04",
              "trial_name": "TRANQUILLO Extension",
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "52-week extension study with randomized withdrawal and dose-up titration"
            },
            {
              "drug_name": "Upadacitinib",
              "company": "AbbVie",
              "mechanism": "JAK1 inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT06118411",
              "expected_completion": "2025-09",
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": null,
              "notes": "Met co-primary efficacy endpoints in Phase 3 trials"
            },
            {
              "drug_name": "Povorcitinib",
              "company": "Incyte Corporation",
              "mechanism": "JAK1 inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT06113445",
              "expected_completion": "2026-02",
              "trial_name": "STOP-V1",
              "status": "Active",
              "regulatory_designations": null,
              "notes": "Oral selective JAK1 inhibitor, 52-week placebo-controlled study"
            },
            {
              "drug_name": "Ruxolitinib cream",
              "company": "Incyte Corporation",
              "mechanism": "JAK1/JAK2 inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT06548360",
              "expected_completion": "2026-08",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Pediatric study in nonsegmental vitiligo"
            },
            {
              "drug_name": "Afamelanotide",
              "company": "Clinuvel, Inc.",
              "mechanism": "\u03b1-MSH analog",
              "phase": "Phase 3",
              "trial_id": "NCT06109649",
              "expected_completion": "2025-12",
              "trial_name": "CUV105",
              "status": "Active",
              "regulatory_designations": null,
              "notes": "SCENESSE combined with narrow-band UVB light therapy"
            },
            {
              "drug_name": "ICP-332",
              "company": "Beijing InnoCare Pharma Tech Co., Ltd.",
              "mechanism": "TYK2 inhibitor",
              "phase": "Phase 2/3",
              "trial_id": "NCT07047612",
              "expected_completion": "2029-04",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Adaptive design, multi-center study with oral TYK2 inhibitor"
            },
            {
              "drug_name": "SHR0302",
              "company": "Jiangsu HengRui Medicine Co., Ltd.",
              "mechanism": "JAK inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT06790862",
              "expected_completion": "2026-03",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Topical gel formulation for nonsegmental vitiligo"
            },
            {
              "drug_name": "VYN201",
              "company": "Vyne Therapeutics Inc.",
              "mechanism": null,
              "phase": "Phase 2",
              "trial_id": "NCT06493578",
              "expected_completion": "2025-07",
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": null,
              "notes": "Phase 2b randomized, double-blind, vehicle-controlled trial"
            },
            {
              "drug_name": "SYHX1901",
              "company": "CSPC Ouyi Pharmaceutical Co., Ltd.",
              "mechanism": "TYK2 inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT06511739",
              "expected_completion": "2025-08",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Novel oral TYK2 inhibitor for immune-mediated diseases"
            },
            {
              "drug_name": "Zasocitinib",
              "company": "Takeda",
              "mechanism": "JAK inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT07108283",
              "expected_completion": "2027-10",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Dose-ranging trial in nonsegmental vitiligo"
            },
            {
              "drug_name": "Roflumilast",
              "company": "Derm Texas, PLLC",
              "mechanism": "PDE4 inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT07105254",
              "expected_completion": "2026-05",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "0.3% foam formulation for pediatric nonsegmental vitiligo"
            },
            {
              "drug_name": "Deucravacitinib",
              "company": "Centre Hospitalier Universitaire de Nice",
              "mechanism": "TYK2 inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT06327321",
              "expected_completion": "2026-05",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Targeting TYK2 mediated responses, approved for psoriasis"
            },
            {
              "drug_name": "Anifrolumab",
              "company": "University Hospital, Bordeaux",
              "mechanism": "Anti-IFN-\u03b1 monoclonal antibody",
              "phase": "Phase 2",
              "trial_id": "NCT05917561",
              "expected_completion": "2026-05",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "300mg IV every four weeks combined with phototherapy"
            },
            {
              "drug_name": "EI-001",
              "company": "Elixiron Immunotherapeutics (Hong Kong) Ltd.",
              "mechanism": null,
              "phase": "Phase 2",
              "trial_id": "NCT07223229",
              "expected_completion": "2026-12",
              "trial_name": null,
              "status": "Not yet recruiting",
              "regulatory_designations": null,
              "notes": "Proof-of-concept study in nonsegmental vitiligo"
            },
            {
              "drug_name": "MH004",
              "company": "Minghui Pharmaceutical (Hangzhou) Ltd",
              "mechanism": null,
              "phase": "Phase 2",
              "trial_id": "NCT07181187",
              "expected_completion": "2025-10",
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": null,
              "notes": "Topical ointment for nonsegmental vitiligo"
            }
          ],
          "pipeline_details": "The vitiligo pipeline includes 16 active therapies with 5 in Phase 3 and 11 in Phase 2/2b development. JAK inhibitors dominate the landscape with multiple companies advancing oral and topical formulations, while TYK2 inhibitors represent an emerging mechanism class. Key Phase 3 readouts are expected from AbbVie's upadacitinib (2025), Incyte's povorcitinib (2026), and Pfizer's ritlecitinib extension studies (2027).",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "First-line treatment typically includes potent topical corticosteroids, topical calcineurin inhibitors, and phototherapy. For nonsegmental vitiligo, Opzelura (ruxolitinib cream) is the first FDA-approved pharmacologic treatment for repigmentation. Combination therapies and phototherapy are commonly used for more extensive disease.",
          "unmet_need": true,
          "unmet_need_description": "Prior to 2022, the only FDA-approved treatment was monobenzone for depigmentation rather than repigmentation. Most treatments were used off-label with limited FDA-approved options for achieving repigmentation.",
          "competitive_landscape": "Opzelura represents the first breakthrough in FDA-approved vitiligo repigmentation therapy. Traditional treatments include off-label use of topical corticosteroids, calcineurin inhibitors, and various phototherapy modalities. The approval of ruxolitinib cream marks a significant advancement in providing patients with an FDA-approved option specifically for vitiligo repigmentation.",
          "soc_source": "FDA drug approval announcements and Medscape Reference",
          "phase_3_count": 5,
          "phase_2_count": 11,
          "key_catalysts": "AbbVie's upadacitinib Phase 3 results expected September 2025, Incyte's povorcitinib Phase 3 data due February 2026, and Clinuvel's afamelanotide Phase 3 results anticipated second half 2026",
          "pipeline_data_quality": "High",
          "recent_approvals": "Opzelura (ruxolitinib) cream approved by FDA in July 2022 for nonsegmental vitiligo in patients 12 years and older",
          "data_quality": "High",
          "data_quality_notes": "Clear FDA approval documentation available with specific indication and approval date confirmed"
        },
        "market_size_estimate": "$58.8B",
        "market_size_usd": 58750000000.0,
        "growth_rate": "5-10% CAGR (increasing prevalence)",
        "tam_usd": 588000000.0,
        "tam_estimate": "$588M",
        "tam_rationale": "Of ~2.35M US vitiligo patients, ~75% are diagnosed (1.76M), ~40% receive treatment beyond basic topicals (704K patients). A new drug would likely be positioned as 2L+ therapy for moderate-severe patients (~282K). With only one approved drug (Opzelura) and high unmet need, a new entrant could capture 15-25% market share (~52K patients). At $45K/yr pricing (dermatology specialty tier), TAM = $588M.",
        "tam_sources": [
          "https://straitsresearch.com/report/vitiligo-treatment-market",
          "https://www.strategicmarketresearch.com/market-report/vitiligo-treatment-market",
          "https://www.openpr.com/news/4038064/vitiligo-treatment-market-size-share-forecast-2024-2031"
        ],
        "pipeline_sources": [
          "https://clinicaltrials.gov",
          "https://clinicaltrials.gov/study/NCT06163326",
          "https://clinicaltrials.gov/study/NCT06768840?cond=Vitiligo&aggFilters=phase:2%203,studyType:int&page=6&rank=53",
          "https://clinicaltrials.gov/study/NCT03715829",
          "https://www.clinicaltrials.gov/study/NCT05583526"
        ],
        "attributed_sources": [
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8600454/",
            "title": "Prevalence of Vitiligo Among Adults in the United States",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.healio.com/news/dermatology/20211124/study-finds-40-of-vitiligo-patients-in-us-may-not-be-diagnosed",
            "title": "Study finds 40% of vitiligo patients in US may not be ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-topical-treatment-addressing-repigmentation-vitiligo-patients-aged-12-and-older",
            "title": "FDA approves topical treatment",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://emedicine.medscape.com/article/1068962-treatment",
            "title": "Vitiligo Treatment & Management",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://applications.emro.who.int/imemrf/J_Pak_Assoc_Dermatol/J_Pak_Assoc_Dermatol_2014_24_1_68_78.pdf",
            "title": "[PDF] Guidelines for the management of vitiligo",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://clinicaltrials.gov",
            "title": "ClinicalTrials.gov API",
            "attribution": "Pipeline/Clinical Trials (Primary)"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT06163326",
            "title": "NCT06163326 | A 52-Week Study to Learn About the ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT06768840?cond=Vitiligo&aggFilters=phase:2%203,studyType:int&page=6&rank=53",
            "title": "NCT06768840 | Vitiligo, New Treatment and Serum s100B",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://straitsresearch.com/report/vitiligo-treatment-market",
            "title": "Vitiligo Treatment Market Size & Outlook, 2025-2033",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.strategicmarketresearch.com/market-report/vitiligo-treatment-market",
            "title": "Vitiligo Treatment Market 2024-2030",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 6.4,
        "evidence_quality": 5.7,
        "market_opportunity": 9.0,
        "overall_priority": 6.9,
        "clinical_breakdown": {
          "response_rate_quality_weighted": 6.0,
          "safety_profile": 5.0,
          "organ_domain_breadth": 10.0,
          "safety_categories": [],
          "regulatory_flags": [],
          "efficacy_endpoint_count": 0,
          "efficacy_concordance": 1.0
        },
        "response_rate_score": 6.0,
        "safety_profile_score": 5.0,
        "endpoint_quality_score": null,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 9.0,
          "publication_venue": 2.0,
          "response_durability": 5.0,
          "extraction_completeness": 5.5
        },
        "sample_size_score": 9.0,
        "publication_venue_score": 2.0,
        "followup_duration_score": 5.0,
        "extraction_completeness_score": 5.5,
        "market_breakdown": {
          "competitors": 7.0,
          "market_size": 10.0,
          "unmet_need": 10.0
        },
        "competitors_score": 7.0,
        "market_size_score": 10.0,
        "unmet_need_score": 10.0
      },
      "rank": 34
    },
    {
      "extraction": {
        "source": {
          "pmid": "37965867",
          "doi": "10.1093/ecco-jcc/jjad194",
          "url": "https://www.semanticscholar.org/paper/5eba3cbe07ef96b42dcf89b94e435ae78b41d44f",
          "title": "Treatment of antibiotic refractory chronic pouchitis with JAK inhibitors and S1P receptor modulators: an ECCO CONFER Multicentre Case Series.",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Web source",
          "is_open_access": false
        },
        "disease": "antibiotic refractory chronic pouchitis",
        "disease_normalized": "Crohn's Disease",
        "is_off_label": true,
        "is_relevant": true,
        "evidence_level": "Case Series",
        "patient_population": {
          "n_patients": 6,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "infliximab",
            "adalimumab",
            "vedolizumab",
            "ustekinumab",
            "antibiotics"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "patients with chronic antibiotic refractory pouchitis treated with upadacitinib, part of larger cohort of 15 patients treated with JAK inhibitors or S1P modulators"
        },
        "treatment": {
          "drug_name": "upadacitinib",
          "generic_name": "Upadacitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": null,
          "dose": null,
          "frequency": null,
          "duration": null,
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": null,
          "responders_n": null,
          "responders_pct": null,
          "time_to_response": null,
          "duration_of_response": null,
          "effect_size_description": "moderate clinical response rates with pooled JAK inhibitor data",
          "primary_endpoint": "steroid and antibiotics-free clinical response and remission at three and twelve months",
          "endpoint_result": "clinical response 53.3% at 3 months for all JAK inhibitors combined",
          "durability_signal": null,
          "efficacy_summary": "Upadacitinib was one of three JAK inhibitors used in this case series. When pooled with other JAK inhibitors, steroid and antibiotics-free clinical response was achieved in 53.3% at 3 months and 50% at 12 months. Individual upadacitinib efficacy data was not separately reported."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": null,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "No side effects were reported for any of the treatments in this case series. Safety data was limited to this brief statement.",
          "safety_profile": "Favorable"
        },
        "outcome_result": "Mixed",
        "efficacy_signal": "Moderate",
        "comparator_baseline": null,
        "follow_up_duration": "at least 12 months",
        "key_findings": "Upadacitinib, as part of JAK inhibitor class, showed potential efficacy in antibiotic refractory chronic pouchitis with no reported adverse events, though individual drug efficacy data was not provided.",
        "detailed_efficacy_endpoints": [],
        "detailed_safety_endpoints": [],
        "extraction_timestamp": "2025-12-08T18:38:52.960733",
        "extraction_confidence": 0.5,
        "extraction_confidence_detail": null,
        "extraction_method": "single_pass",
        "extraction_stages_completed": [],
        "data_sections_identified": null
      },
      "market_intelligence": {
        "disease": "Crohn's Disease",
        "parent_disease": "Inflammatory Bowel Disease",
        "epidemiology": {
          "us_prevalence_estimate": "0.72% or 1 in 139 Americans",
          "us_incidence_estimate": "10.9 per 100,000 person-years",
          "global_prevalence": null,
          "patient_population_size": 2390000,
          "prevalence_source": "Gastroenterology journal study",
          "prevalence_source_url": "https://www.gastrojournal.org/article/S0016-5085(23)04776-5/fulltext",
          "trend": "increasing",
          "source_quality": "Primary",
          "data_year": 2020,
          "geographic_scope": "US",
          "confidence": "High",
          "notes": "Multiple sources report varying estimates ranging from 2.4-3.1 million patients; prevalence varies significantly by race/ethnicity with higher rates in non-Hispanic whites (1.4%) and Hispanics (1.2%) compared to non-Hispanic blacks (0.5%); prevalence increases with age"
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Remicade (infliximab)",
              "drug_class": "TNF inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Inflammatory Bowel Disease",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "FDA approved for inflammatory bowel disease, referenced in official FDA label",
              "approval_year": null,
              "approval_confidence": "Medium",
              "approval_evidence": "FDA label and multiple clinical sources confirm IBD indication"
            },
            {
              "drug_name": "Humira (adalimumab)",
              "drug_class": "TNF inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Inflammatory Bowel Disease",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "FDA approved for inflammatory bowel disease treatment",
              "approval_year": null,
              "approval_confidence": "Medium",
              "approval_evidence": "AGA guidelines and clinical sources confirm FDA approval for IBD"
            },
            {
              "drug_name": "Simponi (golimumab)",
              "drug_class": "TNF inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Inflammatory Bowel Disease",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "FDA approved for ulcerative colitis component of IBD",
              "approval_year": null,
              "approval_confidence": "Medium",
              "approval_evidence": "AGA guidelines list as FDA approved option for moderate-to-severe UC"
            },
            {
              "drug_name": "Entyvio (vedolizumab)",
              "drug_class": "Anti-integrin",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Inflammatory Bowel Disease",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "FDA approved for inflammatory bowel disease, gut-selective integrin antagonist",
              "approval_year": null,
              "approval_confidence": "Medium",
              "approval_evidence": "AGA guidelines and clinical sources confirm FDA approval for IBD"
            },
            {
              "drug_name": "Stelara (ustekinumab)",
              "drug_class": "IL-12/IL-23 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Inflammatory Bowel Disease",
              "efficacy_range": "34-56%",
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "FDA approved September 2016 for moderately to severely active Crohn disease and ulcerative colitis",
              "approval_year": 2016,
              "approval_confidence": "Medium",
              "approval_evidence": "FDA approval September 2016 for Crohn's disease, multiple clinical sources confirm IBD indication"
            },
            {
              "drug_name": "Xeljanz (tofacitinib)",
              "drug_class": "JAK inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Inflammatory Bowel Disease",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "FDA approved for ulcerative colitis component of IBD",
              "approval_year": null,
              "approval_confidence": "Medium",
              "approval_evidence": "AGA guidelines confirm FDA approval for moderate-to-severe UC"
            },
            {
              "drug_name": "Rinvoq (upadacitinib)",
              "drug_class": "JAK inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Inflammatory Bowel Disease",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "Approved 2022 for moderately to severely active ulcerative colitis and as first oral treatment for Crohn's disease",
              "approval_year": 2022,
              "approval_confidence": "High",
              "approval_evidence": "FDA approval 2022 for ulcerative colitis and Crohn's disease as documented in FDA new drug approvals"
            },
            {
              "drug_name": "Skyrizi (risankizumab)",
              "drug_class": "IL-23 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Inflammatory Bowel Disease",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "Approved 2022 for moderately to severely active Crohn's disease, first new CD treatment in six years",
              "approval_year": 2022,
              "approval_confidence": "High",
              "approval_evidence": "FDA new drug approvals 2022 document confirms approval for Crohn's disease"
            },
            {
              "drug_name": "Tremfya (guselkumab)",
              "drug_class": "IL-23 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Inflammatory Bowel Disease",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "FDA approved September 2024 for moderately to severely active ulcerative colitis",
              "approval_year": 2024,
              "approval_confidence": "Medium",
              "approval_evidence": "FDA approval September 2024 for ulcerative colitis as noted in clinical sources"
            }
          ],
          "approved_drug_names": [
            "Remicade (infliximab)",
            "Humira (adalimumab)",
            "Simponi (golimumab)",
            "Entyvio (vedolizumab)",
            "Stelara (ustekinumab)",
            "Xeljanz (tofacitinib)",
            "Rinvoq (upadacitinib)",
            "Skyrizi (risankizumab)",
            "Tremfya (guselkumab)"
          ],
          "num_approved_drugs": 9,
          "num_pipeline_therapies": 0,
          "pipeline_therapies": [],
          "pipeline_details": null,
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "IBD treatment follows a step-up approach starting with 5-ASA compounds for mild disease, progressing to corticosteroids for moderate disease, then to biologics (TNF inhibitors, integrin antagonists, IL-12/23 inhibitors) and JAK inhibitors for moderate-to-severe disease. The paradigm has shifted toward earlier use of biologics and targeted therapies to achieve deep remission and mucosal healing.",
          "unmet_need": true,
          "unmet_need_description": "Despite multiple therapeutic options, 20-40% of patients fail standard therapies and may require surgery. There remains need for treatments that achieve sustained remission, prevent disease progression, and minimize long-term complications.",
          "competitive_landscape": "The IBD market has expanded significantly with multiple drug classes including TNF inhibitors (infliximab, adalimumab, golimumab), integrin antagonists (vedolizumab), IL-12/23 inhibitors (ustekinumab), IL-23 selective inhibitors (risankizumab, guselkumab), and JAK inhibitors (tofacitinib, upadacitinib). Recent approvals include mirikizumab (January 2025) for Crohn's disease and guselkumab (2024) for ulcerative colitis, indicating continued innovation in this space.",
          "soc_source": "FDA New Drug Approvals 2022, AGA Guidelines, and clinical literature",
          "phase_3_count": 0,
          "phase_2_count": 0,
          "key_catalysts": null,
          "pipeline_data_quality": "Unknown",
          "recent_approvals": "Tremfya (guselkumab) approved September 2024 for ulcerative colitis; Rinvoq (upadacitinib) and Skyrizi (risankizumab) approved in 2022 for IBD indications; mirikizumab approved January 2025 for Crohn's disease",
          "data_quality": "Medium",
          "data_quality_notes": "Strong evidence for recent approvals but some approval years and specific indication details require verification from primary FDA sources. Cost data not available in sources reviewed."
        },
        "market_size_estimate": "$59.8B",
        "market_size_usd": 59750000000.0,
        "growth_rate": "5-10% CAGR (increasing prevalence)",
        "tam_usd": 3150000000.0,
        "tam_estimate": "$3.15B",
        "tam_rationale": "Of ~2.39M US Crohn's disease patients, ~85% are diagnosed (2.03M), ~70% receive systemic treatment (1.42M), ~40% progress to moderate-severe disease requiring biologics/advanced therapies (568K). A new biologic entering this crowded market (9 approved drugs) could realistically capture 10-15% market share (~70K patients). At $75K/yr pricing (consistent with IBD biologics), TAM = $5.25B peak, but given competitive intensity and step-up therapy paradigm, realistic addressable market for new entrant is $3.15B.",
        "tam_sources": [
          "https://www.factmr.com/report/crohns-disease-treatment-market",
          "https://www.prnewswire.com/news-releases/crohns-disease-market-projected-to-grow-at-4-3-cagr-20202034-driven-by-improved-diagnosis-pediatric-label-expansion-and-new-second-line-therapies--delveinsight-302537431.html",
          "https://www.wissenresearch.com/inflammatory-bowel-disease-market-report/"
        ],
        "pipeline_sources": [
          "https://clinicaltrials.gov",
          "https://clinicaltrials.gov/study/NCT07113522",
          "https://clinicaltrials.gov/study/NCT06976853",
          "https://www.clinicaltrials.gov/study/NCT00820365",
          "https://clinicaltrials.gov/study/NCT05194007"
        ],
        "attributed_sources": [
          {
            "url": "https://www.cdc.gov/inflammatory-bowel-disease/php/facts-stats/index.html",
            "title": "IBD Facts and Stats - CDC",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.cdc.gov/mmwr/volumes/65/wr/mm6542a3.htm",
            "title": "Prevalence of Inflammatory Bowel Disease Among Adults Aged ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.drugs.com/condition/inflammatory-bowel-disease.html",
            "title": "Medications for Inflammatory Bowel Disease",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.fda.gov/news-events/press-announcements/fda-roundup-april-26-2024",
            "title": "FDA Roundup: April 26, 2024",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8720971/",
            "title": "Treatment of Inflammatory Bowel Disease: A Comprehensive Review",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://clinicaltrials.gov",
            "title": "ClinicalTrials.gov API",
            "attribution": "Pipeline/Clinical Trials (Primary)"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT07113522",
            "title": "NCT07113522 | A Phase 2 Study to Evaluate Therapies for ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT06976853",
            "title": "NCT06976853 | Moving Beyond Inflammation as a ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.factmr.com/report/crohns-disease-treatment-market",
            "title": "Crohn's Disease Treatment Market | Global Market Analysis Report",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.prnewswire.com/news-releases/crohns-disease-market-projected-to-grow-at-4-3-cagr-20202034-driven-by-improved-diagnosis-pediatric-label-expansion-and-new-second-line-therapies--delveinsight-302537431.html",
            "title": "Crohn's Disease Market Projected to Grow at 4.3% CAGR (2020 ...",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 7.2,
        "evidence_quality": 5.6,
        "market_opportunity": 7.7,
        "overall_priority": 6.9,
        "clinical_breakdown": {
          "response_rate_quality_weighted": 6.0,
          "safety_profile": 9.0,
          "organ_domain_breadth": 6.0,
          "safety_categories": [],
          "regulatory_flags": [],
          "efficacy_endpoint_count": 0,
          "efficacy_concordance": 1.0
        },
        "response_rate_score": 6.0,
        "safety_profile_score": 9.0,
        "endpoint_quality_score": null,
        "organ_domain_score": 6.0,
        "evidence_breakdown": {
          "sample_size": 6.0,
          "publication_venue": 2.0,
          "response_durability": 9.0,
          "extraction_completeness": 4.9
        },
        "sample_size_score": 6.0,
        "publication_venue_score": 2.0,
        "followup_duration_score": 9.0,
        "extraction_completeness_score": 4.9,
        "market_breakdown": {
          "competitors": 3.0,
          "market_size": 10.0,
          "unmet_need": 10.0
        },
        "competitors_score": 3.0,
        "market_size_score": 10.0,
        "unmet_need_score": 10.0
      },
      "rank": 35
    },
    {
      "extraction": {
        "source": {
          "pmid": "40251797",
          "doi": "10.1111/1756-185X.70231",
          "url": "https://pubmed.ncbi.nlm.nih.gov/40251797/",
          "title": "Case Report: Successful Remission With Upadacitinib in Beh\u00e7et's Syndrome Following a History of PFAPA Syndrome.",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "Beh\u00e7et's syndrome",
        "disease_normalized": "Beh\u00e7et's Disease",
        "is_off_label": true,
        "is_relevant": true,
        "evidence_level": "Case Report",
        "patient_population": {
          "n_patients": 1,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "adalimumab"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "18-year-old female with history of PFAPA syndrome, presenting with oral ulcers, arthralgia, rash, and abdominal pain with ileocecal ulceration"
        },
        "treatment": {
          "drug_name": "upadacitinib",
          "generic_name": "Upadacitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": null,
          "dose": null,
          "frequency": null,
          "duration": null,
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "1/1 (100%)",
          "responders_n": 1,
          "responders_pct": 100.0,
          "time_to_response": null,
          "duration_of_response": null,
          "effect_size_description": "complete remission",
          "primary_endpoint": "remission",
          "endpoint_result": "achieved remission",
          "durability_signal": null,
          "efficacy_summary": "The patient achieved remission after upadacitinib therapy following failure of adalimumab treatment. This represents a successful therapeutic outcome in a case of Beh\u00e7et's spectrum disorder."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": null,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "No safety data reported in this case report.",
          "safety_profile": "Unknown"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Moderate",
        "comparator_baseline": null,
        "follow_up_duration": null,
        "key_findings": "Upadacitinib achieved remission in Beh\u00e7et's syndrome after adalimumab failure, suggesting JAK inhibition may be effective through blocking IL-10, IL-12, and IL-23 pathways.",
        "detailed_efficacy_endpoints": [],
        "detailed_safety_endpoints": [],
        "extraction_timestamp": "2025-12-08T18:32:03.459572",
        "extraction_confidence": 0.5,
        "extraction_confidence_detail": null,
        "extraction_method": "single_pass",
        "extraction_stages_completed": [],
        "data_sections_identified": null
      },
      "market_intelligence": {
        "disease": "Beh\u00e7et's Disease",
        "parent_disease": null,
        "epidemiology": {
          "us_prevalence_estimate": "0.33 to 5.2 per 100,000 population",
          "us_incidence_estimate": "0.38 per 100,000 population",
          "global_prevalence": null,
          "patient_population_size": 9200,
          "prevalence_source": "Arthritis & Rheumatism journal",
          "prevalence_source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3024036/",
          "trend": "increasing",
          "source_quality": "Primary",
          "data_year": 2009,
          "geographic_scope": "US",
          "confidence": "Medium",
          "notes": "Wide range reported across studies (0.33-10.6 per 100,000); higher prevalence found in Southwestern US populations; increasing trend may be due to improved recognition and immigration from endemic areas"
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Otezla (apremilast)",
              "drug_class": "PDE-4 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Oral Ulcers Associated with Beh\u00e7et's Disease",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "FDA approved for treatment of adult patients with oral ulcers associated with Beh\u00e7et's Disease. Approval based on Phase 3 RELIEF study with 207 patients. Dosed at 30 mg twice daily.",
              "approval_year": 2019,
              "approval_confidence": "High",
              "approval_evidence": "FDA label 2019, drugs@FDA documentation"
            }
          ],
          "approved_drug_names": [
            "Otezla (apremilast)"
          ],
          "num_approved_drugs": 1,
          "num_pipeline_therapies": 13,
          "pipeline_therapies": [
            {
              "drug_name": "Apremilast",
              "company": "Amgen",
              "mechanism": "PDE4 inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT04528082",
              "expected_completion": "2030-02",
              "trial_name": "BEAN",
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Pediatric study for children 2-18 years with active oral ulcers"
            },
            {
              "drug_name": "Apremilast",
              "company": "Amgen",
              "mechanism": "PDE4 inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT05767047",
              "expected_completion": "2036-03",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Long-term extension study in children with oral ulcers"
            },
            {
              "drug_name": "Hemay005",
              "company": "Ganzhou Hemay Pharmaceutical Co., Ltd",
              "mechanism": null,
              "phase": "Phase 3",
              "trial_id": "NCT06145893",
              "expected_completion": "2026-05",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": null
            },
            {
              "drug_name": "Baricitinib",
              "company": "Peking Union Medical College Hospital",
              "mechanism": "JAK inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT06849908",
              "expected_completion": "2027-06",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "For refractory intestinal Beh\u00e7et's syndrome vs adalimumab"
            },
            {
              "drug_name": "HSK44459",
              "company": "Haisco Pharmaceutical Group Co., Ltd.",
              "mechanism": null,
              "phase": "Phase 2",
              "trial_id": "NCT06902428",
              "expected_completion": "2026-06",
              "trial_name": null,
              "status": "Not yet recruiting",
              "regulatory_designations": null,
              "notes": null
            },
            {
              "drug_name": "Rivaroxaban",
              "company": "Assistance Publique - H\u00f4pitaux de Paris",
              "mechanism": "Anticoagulant",
              "phase": "Phase 3",
              "trial_id": "NCT06780462",
              "expected_completion": "2027-07",
              "trial_name": null,
              "status": "Not yet recruiting",
              "regulatory_designations": null,
              "notes": "Steroid therapy plus anticoagulants vs steroid alone for deep venous thrombosis"
            },
            {
              "drug_name": "Tocilizumab",
              "company": "Assistance Publique - H\u00f4pitaux de Paris",
              "mechanism": "IL-6 receptor antagonist",
              "phase": "Phase 2",
              "trial_id": "NCT05874505",
              "expected_completion": "2026-11",
              "trial_name": "UVB",
              "status": "Not yet recruiting",
              "regulatory_designations": null,
              "notes": "Comparison with adalimumab in severe uveitis"
            },
            {
              "drug_name": "Tocilizumab",
              "company": "Peking Union Medical College Hospital",
              "mechanism": "IL-6 receptor antagonist",
              "phase": "Phase 2",
              "trial_id": "NCT05845723",
              "expected_completion": "2026-06",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Combined with tofacitinib for vascular Beh\u00e7et's syndrome"
            },
            {
              "drug_name": "Low-dose IL-2",
              "company": "HeJing",
              "mechanism": "Immunoregulatory cytokine",
              "phase": "Phase 2",
              "trial_id": "NCT04065672",
              "expected_completion": "2023-04",
              "trial_name": null,
              "status": "Completed",
              "regulatory_designations": null,
              "notes": "Completed within last 2 years, indicating active development"
            },
            {
              "drug_name": "BCMA-CD19 CAR-T",
              "company": "Peking University People's Hospital",
              "mechanism": "CAR-T cell therapy",
              "phase": "Phase 2",
              "trial_id": "NCT06794008",
              "expected_completion": "2027-12",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "For multiple refractory autoimmune diseases including Beh\u00e7et's"
            },
            {
              "drug_name": "Filgotinib",
              "company": "UMC Utrecht",
              "mechanism": "JAK inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT06285539",
              "expected_completion": "2026-12",
              "trial_name": "DRIMID",
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Drug rediscovery study for rare immune mediated inflammatory diseases"
            },
            {
              "drug_name": "Dusquetide",
              "company": "Soligenix",
              "mechanism": "Innate defense regulator",
              "phase": "Phase 2",
              "trial_id": "NCT06386744",
              "expected_completion": "2025-05",
              "trial_name": null,
              "status": "Completed",
              "regulatory_designations": "Fast Track, Orphan Drug",
              "notes": "Recently completed Phase 2a with positive biological efficacy results"
            },
            {
              "drug_name": "Upadacitinib",
              "company": "Liu Tian",
              "mechanism": "JAK inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT07080346",
              "expected_completion": "2024-12",
              "trial_name": null,
              "status": "Completed",
              "regulatory_designations": null,
              "notes": "Recently completed pilot study for refractory Beh\u00e7et's syndrome"
            }
          ],
          "pipeline_details": "The Beh\u00e7et's Disease pipeline includes 13 active programs across Phase 2 and Phase 3 development. Key mechanisms being tested include JAK inhibitors (baricitinib, filgotinib, upadacitinib), IL-6 receptor antagonists (tocilizumab), PDE4 inhibitors (apremilast), and novel approaches like innate defense regulators (dusquetide) and CAR-T cell therapy. Recent positive results include completed Phase 2 studies for dusquetide and upadacitinib.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "Beh\u00e7et's Disease treatment is organ-system specific with no standardized approach. For mucocutaneous manifestations, colchicine is typically first-line, with topical therapies for mild ulcerations. Otezla (apremilast) serves as second-line therapy specifically for oral ulcers. For severe organ involvement (ocular, neurologic, vascular), combination immunosuppression with corticosteroids plus azathioprine or anti-TNF agents is used.",
          "unmet_need": true,
          "unmet_need_description": "Only one FDA-approved treatment exists specifically for Beh\u00e7et's Disease (Otezla for oral ulcers only). Most treatments are off-label use of drugs approved for other conditions. No FDA-approved therapies exist for systemic manifestations including ocular, neurologic, or vascular disease.",
          "competitive_landscape": "Otezla holds the only FDA approval for Beh\u00e7et's Disease, giving it regulatory advantage for oral ulcers. Treatment otherwise relies heavily on off-label use of anti-TNF biologics (infliximab, adalimumab), immunosuppressants, and corticosteroids. Multiple biologics are used off-label but lack specific FDA approval for this indication.",
          "soc_source": "FDA drug labels and Medscape clinical references",
          "phase_3_count": 4,
          "phase_2_count": 9,
          "key_catalysts": "Expected primary readouts include Hemay005 Phase 3 results (May 2026), HSK44459 Phase 2 results (June 2026), and multiple tocilizumab studies completing in 2026. Soligenix plans to advance dusquetide development following recent positive Phase 2a results.",
          "pipeline_data_quality": "High",
          "recent_approvals": null,
          "data_quality": "High",
          "data_quality_notes": "Clear FDA approval documentation available for Otezla. Other treatments mentioned are off-label uses without specific Beh\u00e7et's Disease FDA approvals."
        },
        "market_size_estimate": "$1.8B",
        "market_size_usd": 1840000000.0,
        "growth_rate": "5-10% CAGR (increasing prevalence)",
        "tam_usd": 184000000.0,
        "tam_estimate": "$184M",
        "tam_rationale": "Of ~9,200 US patients with Beh\u00e7et's Disease, ~70% are diagnosed (6,440), ~60% receive systemic treatment (3,864), ~40% fail first-line therapy and are candidates for 2L+ treatment (1,546). A new drug targeting moderate-severe manifestations could capture 30% market share (~464 patients) given high unmet need and only one approved drug. At $400K/yr pricing (orphan drug designation for rare autoimmune indication), TAM = $184M.",
        "tam_sources": [
          "https://www.credenceresearch.com/report/behcets-disease-market",
          "https://www.openpr.com/news/4113839/behcet-s-disease-market-growth-size-surges-amid-rising",
          "https://exactitudeconsultancy.com/it/reports/71308/behcet-s-disease-market"
        ],
        "pipeline_sources": [
          "https://clinicaltrials.gov",
          "https://clinicaltrials.gov/study/NCT02307513",
          "https://www.clinicaltrials.gov/study/NCT00995709",
          "https://www.clinicaltrials.gov/study/NCT01965145",
          "https://clinicaltrials.gov/study/NCT06902428"
        ],
        "attributed_sources": [
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8404295/",
            "title": "Epidemiology and treatment of Beh\u00e7et's disease in the USA",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://acrabstracts.org/abstract/behcets-disease-in-the-southwestern-united-states/",
            "title": "Behcet's Disease in the Southwestern United States",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.drugs.com/history/otezla.html",
            "title": "Otezla (apremilast) FDA Approval History",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.medscape.com/viewarticle/915883",
            "title": "FDA OKs Apremilast (Otezla) for Oral Ulcers of Behcet's ...",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.chi.gov.sa/Style%20Library/IDF_Branding/Indication/185%20-%20Behcet%20Disease-New%20Indication.pdf",
            "title": "[PDF] BEHCET DISEASE",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://clinicaltrials.gov",
            "title": "ClinicalTrials.gov API",
            "attribution": "Pipeline/Clinical Trials (Primary)"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT02307513",
            "title": "Study Details | NCT02307513 | A Phase 3 Randomized, ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.clinicaltrials.gov/study/NCT00995709",
            "title": "Phase III Study in Refractory Behcet's Disease",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.credenceresearch.com/report/behcets-disease-market",
            "title": "Behcet's Disease Market Size, Share, Growth and Forecast 2032",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.openpr.com/news/4113839/behcet-s-disease-market-growth-size-surges-amid-rising",
            "title": "Behcet's Disease Market Growth Size Surges Amid Rising",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 7.2,
        "evidence_quality": 4.6,
        "market_opportunity": 8.3,
        "overall_priority": 6.8,
        "clinical_breakdown": {
          "response_rate_quality_weighted": 10.0,
          "safety_profile": 5.0,
          "organ_domain_breadth": 6.0,
          "safety_categories": [],
          "regulatory_flags": [],
          "efficacy_endpoint_count": 0,
          "efficacy_concordance": 1.0
        },
        "response_rate_score": 10.0,
        "safety_profile_score": 5.0,
        "endpoint_quality_score": null,
        "organ_domain_score": 6.0,
        "evidence_breakdown": {
          "sample_size": 1.0,
          "publication_venue": 10.0,
          "response_durability": 4.0,
          "extraction_completeness": 4.9
        },
        "sample_size_score": 1.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 4.0,
        "extraction_completeness_score": 4.9,
        "market_breakdown": {
          "competitors": 7.0,
          "market_size": 8.0,
          "unmet_need": 10.0
        },
        "competitors_score": 7.0,
        "market_size_score": 8.0,
        "unmet_need_score": 10.0
      },
      "rank": 36
    },
    {
      "extraction": {
        "source": {
          "pmid": "36968984",
          "doi": "10.1177/2050313X231160926",
          "url": "https://www.semanticscholar.org/paper/1fac9678b08ed9b9775c55720b776e63bfdc0c74",
          "title": "A case of drug-induced bullous pemphigoid secondary to immunotherapy treated with upadacitinib: A case report",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Web source",
          "is_open_access": false
        },
        "disease": "Drug-induced bullous pemphigoid",
        "disease_normalized": "Bullous Pemphigoid",
        "is_off_label": true,
        "is_relevant": true,
        "evidence_level": "Case Report",
        "patient_population": {
          "n_patients": 1,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "oral prednisone 70 mg/day",
            "topical corticosteroids",
            "prednisone 50 mg/day"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "74-year-old female with recurrent metastatic PD-L1-positive squamous cell carcinoma of head and neck undergoing immunotherapy"
        },
        "treatment": {
          "drug_name": "upadacitinib",
          "generic_name": "Upadacitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "15 mg/day",
          "frequency": null,
          "duration": "4 weeks",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "1/1 (100%)",
          "responders_n": 1,
          "responders_pct": 100.0,
          "time_to_response": "1-4 weeks",
          "duration_of_response": "At least 4 weeks (patient died from cancer)",
          "effect_size_description": "Good clinical response with resolution of active blistering and healing of lesions",
          "primary_endpoint": "Clinical response of bullous pemphigoid lesions",
          "endpoint_result": "Good response with resolving urticoid eruption, scattered healing erosions, and no active bullae",
          "durability_signal": null,
          "efficacy_summary": "The patient demonstrated initial good response to upadacitinib 15 mg/day after 4 weeks, with resolving urticoid eruption, healing erosions, and no active bullae. This was the first reported case of JAK inhibitor use for bullous pemphigoid treatment."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": 0,
          "sae_percentage": 0.0,
          "discontinuations_n": 0,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "No adverse events were reported during the 4-week treatment period with upadacitinib. However, this was exceptional use in a palliative care setting, and JAK inhibitors are not recommended in malignancy.",
          "safety_profile": "Unknown"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Moderate",
        "comparator_baseline": null,
        "follow_up_duration": "4 weeks",
        "key_findings": "This is the first reported case of upadacitinib successfully treating drug-induced bullous pemphigoid refractory to high-dose corticosteroids. JAK inhibitors showed rapid onset of action within 1-4 weeks.",
        "detailed_efficacy_endpoints": [
          {
            "endpoint_name": "Clinical response",
            "endpoint_category": "Exploratory",
            "timepoint": "Week 4",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 1,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Clinical response defined as resolving urticoid eruption, scattered healing erosions, and no active bullae or mucosal progression following upadacitinib 15 mg/day",
            "organ_domain": "Mucocutaneous",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          }
        ],
        "detailed_safety_endpoints": [
          {
            "event_name": "Death",
            "event_category": "SAE",
            "severity_grade": null,
            "patients_affected_n": 1,
            "patients_affected_pct": null,
            "events_total": 1,
            "relatedness": "Unrelated",
            "outcome": "Fatal",
            "action_taken": null,
            "notes": "Patient succumbed to metastatic cancer 1 month after starting upadacitinib; death attributed to underlying malignancy, not drug",
            "category_soc": "Death",
            "infection_type": null,
            "malignancy_type": null,
            "cv_type": null,
            "thromboembolic_type": null,
            "is_class_effect": false
          }
        ],
        "extraction_timestamp": "2025-12-08T18:42:56.849000",
        "extraction_confidence": 0.6,
        "extraction_confidence_detail": null,
        "extraction_method": "multi_stage",
        "extraction_stages_completed": [
          "section_identification",
          "efficacy_extraction",
          "safety_extraction"
        ],
        "data_sections_identified": {
          "baseline_tables": [],
          "efficacy_tables": [],
          "safety_tables": [],
          "efficacy_figures": [
            "Figure 4 - Resolving urticoid papules and plaques with few scant bullae and hemorrhagic crusts following upadacitinib 15 mg per day for 4 weeks"
          ],
          "results_sections": [
            "Case report section describing clinical presentation and treatment response",
            "Discussion section analyzing treatment outcomes and therapeutic rationale"
          ],
          "patient_count": 1,
          "study_type": "Case Report",
          "has_quantitative_outcomes": false,
          "notes": "Single patient case report with clinical photographs showing disease progression and improvement. No formal tables present. Figures 1-3 show disease presentation and progression, Figure 4 shows clinical improvement after upadacitinib treatment. Patient died from underlying cancer 1 month after showing initial response to treatment."
        }
      },
      "market_intelligence": {
        "disease": "Bullous Pemphigoid",
        "parent_disease": null,
        "epidemiology": {
          "us_prevalence_estimate": "12 per 100,000 adults",
          "us_incidence_estimate": "6 to 13 new cases per million people annually",
          "global_prevalence": null,
          "patient_population_size": 40200,
          "prevalence_source": "Journal of the American Academy of Dermatology",
          "prevalence_source_url": "https://pubmed.ncbi.nlm.nih.gov/30165164/",
          "trend": "increasing",
          "source_quality": "Primary",
          "data_year": 2018,
          "geographic_scope": "US",
          "confidence": "High",
          "notes": "Prevalence varies significantly by age group, with highest prevalence (123.6 per 100,000) in patients \u226590 years. Analysis based on electronic health data which might result in disease misclassification."
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Dupixent (dupilumab)",
              "drug_class": "IL-4/IL-13 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "treatment of adult patients with bullous pemphigoid (BP)",
              "efficacy_range": "87-92%",
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "First and only targeted treatment approved by FDA specifically for bullous pemphigoid in adults. Administered by subcutaneous injection. Also has orphan drug designation.",
              "approval_year": 2025,
              "approval_confidence": "High",
              "approval_evidence": "FDA approval June 20, 2025 confirmed by Regeneron press release and FDA orphan drug database"
            }
          ],
          "approved_drug_names": [
            "Dupixent (dupilumab)"
          ],
          "num_approved_drugs": 1,
          "num_pipeline_therapies": 5,
          "pipeline_therapies": [
            {
              "drug_name": "Stapokibart",
              "company": "Chengdu Kangnuoxing Biopharma,Inc.",
              "mechanism": null,
              "phase": "Phase 3",
              "trial_id": "NCT07210554",
              "expected_completion": "2028-03",
              "trial_name": null,
              "status": "Not yet recruiting",
              "regulatory_designations": null,
              "notes": "Randomized, double-blind, placebo-controlled study in moderate to severe bullous pemphigoid"
            },
            {
              "drug_name": "Efgartigimod PH20 SC",
              "company": "argenx",
              "mechanism": "FcRn antagonist",
              "phase": "Phase 2/3",
              "trial_id": "NCT05267600",
              "expected_completion": null,
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": null,
              "notes": "Recently completed Phase 2/3 study, follow-up Phase 3 long-term safety study ongoing (BALLAD+)"
            },
            {
              "drug_name": "Avdoralimab (IPH5401)",
              "company": "Centre Hospitalier Universitaire de Nice",
              "mechanism": "Anti-C5aR1 monoclonal antibody",
              "phase": "Phase 2",
              "trial_id": "NCT04563923",
              "expected_completion": null,
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": null,
              "notes": "Completed Phase 2 study targeting complement pathway"
            },
            {
              "drug_name": "Dupilumab",
              "company": "Regeneron Pharmaceuticals",
              "mechanism": "Anti-IL-4R\u03b1 monoclonal antibody",
              "phase": "Phase 2/3",
              "trial_id": "NCT04206553",
              "expected_completion": null,
              "trial_name": "LIBERTY-BP ADEPT",
              "status": "Active",
              "regulatory_designations": null,
              "notes": "Recently approved by FDA June 2025 as first targeted treatment for bullous pemphigoid"
            },
            {
              "drug_name": "Dexamethasone in Mucolox",
              "company": "University of California, San Francisco",
              "mechanism": "Topical corticosteroid formulation",
              "phase": "Phase 2",
              "trial_id": "NCT04540133",
              "expected_completion": null,
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": null,
              "notes": "Topical formulation for oral inflammatory ulcerative diseases including bullous pemphigoid"
            }
          ],
          "pipeline_details": "The bullous pemphigoid pipeline includes 5 active programs with diverse mechanisms including FcRn antagonism (efgartigimod), complement inhibition (avdoralimab), and IL-4/IL-13 blockade (dupilumab). Dupilumab recently achieved FDA approval in June 2025 as the first targeted treatment, while efgartigimod continues in Phase 3 long-term studies and stapokibart prepares for Phase 3 initiation.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "Traditional first-line treatment consists of high-potency topical corticosteroids for localized disease and systemic corticosteroids for generalized disease. Dupilumab represents the first targeted biologic approved specifically for bullous pemphigoid and is positioned as an emerging first-line agent, particularly suitable for frail or immunosuppressed patients who may not tolerate corticosteroids.",
          "unmet_need": false,
          "unmet_need_description": "With the recent approval of dupilumab in 2025, the major unmet need for a targeted treatment has been addressed, though long-term real-world data is still needed.",
          "competitive_landscape": "Dupixent is currently the only FDA-approved targeted treatment for bullous pemphigoid, giving it a monopoly position in the branded innovative treatment space. Other biologics like omalizumab and rituximab are used off-label but lack specific FDA approval for this indication.",
          "soc_source": "Medscape, FDA Orphan Drug Database, and Regeneron press releases",
          "phase_3_count": 1,
          "phase_2_count": 4,
          "key_catalysts": "Stapokibart Phase 3 trial initiation expected November 2025, efgartigimod BALLAD+ Phase 3 long-term safety data expected 2025-2026",
          "pipeline_data_quality": "High",
          "recent_approvals": "Dupixent (dupilumab) approved June 20, 2025 for treatment of adult patients with bullous pemphigoid",
          "data_quality": "High",
          "data_quality_notes": "FDA approval clearly documented with exact approval date and indication from multiple authoritative sources including FDA database and manufacturer press releases"
        },
        "market_size_estimate": "$4.0B",
        "market_size_usd": 4020000000.0,
        "growth_rate": "5-10% CAGR (increasing prevalence)",
        "tam_usd": 204000000.0,
        "tam_estimate": "$204M",
        "tam_rationale": "Of ~40,200 global BP patients, ~70% are diagnosed (28K), ~80% receive systemic treatment (22.4K), positioning for chronic therapy. With Dupilumab as first biologic and traditional corticosteroids having tolerability issues, a new drug could capture 25-30% market share (~6.8K patients). At $30K/yr pricing (typical autoimmune dermatology), TAM = $204M. Market growth driven by aging population and shift toward targeted biologics.",
        "tam_sources": [
          "https://www.360iresearch.com/library/intelligence/bullous-pemphigoid",
          "https://www.mordorintelligence.com/industry-reports/pemphigus-vulgaris-therapeutics-market",
          "https://www.dennisgong.com/blog/newmedicines/"
        ],
        "pipeline_sources": [
          "https://clinicaltrials.gov",
          "https://www.clinicaltrials.gov/study/NCT05061771",
          "http://clinicaltrials.gov/show/NCT04117932",
          "https://clinicaltrials.gov/study/NCT05267600",
          "https://www.clinicaltrials.gov/study/NCT05984381?cond=Bullous%20pemphigoid&rank=5"
        ],
        "attributed_sources": [
          {
            "url": "https://pubmed.ncbi.nlm.nih.gov/30165164/",
            "title": "Prevalence estimates for pemphigoid in the United States - PubMed",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.ncbi.nlm.nih.gov/books/NBK535374/",
            "title": "Bullous Pemphigoid - StatPearls - NCBI Bookshelf",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.medscape.com/viewarticle/fda-approves-dupilumab-bullous-pemphigoid-2025a1000gji",
            "title": "FDA Approves Dupilumab for Bullous Pemphigoid",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://emedicine.medscape.com/article/1062790-overview",
            "title": "Drug-Induced Bullous Disorders",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2018.00238/full",
            "title": "Comorbidities and Treatment Strategies in Bullous Pemphigoid",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://clinicaltrials.gov",
            "title": "ClinicalTrials.gov API",
            "attribution": "Pipeline/Clinical Trials (Primary)"
          },
          {
            "url": "https://www.clinicaltrials.gov/study/NCT05061771",
            "title": "Study Details | NCT05061771 | Nomacopan Therapy in ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "http://clinicaltrials.gov/show/NCT04117932",
            "title": "Efficacy and Safety of Ustekinumab in Bullous Pemphigoid",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.360iresearch.com/library/intelligence/bullous-pemphigoid",
            "title": "Bullous pemphigoid Market Size & Share 2025-2032 - 360iResearch",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.mordorintelligence.com/industry-reports/pemphigus-vulgaris-therapeutics-market",
            "title": "Pemphigus Vulgaris Therapeutics Market Size & Share Analysis",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 9.0,
        "evidence_quality": 2.5,
        "market_opportunity": 6.7,
        "overall_priority": 6.8,
        "clinical_breakdown": {
          "response_rate_quality_weighted": 10.0,
          "safety_profile": 7.5,
          "organ_domain_breadth": 10.0,
          "safety_categories": [
            "death"
          ],
          "regulatory_flags": [
            "death"
          ],
          "efficacy_endpoint_count": 1,
          "efficacy_concordance": 1.0
        },
        "response_rate_score": 10.0,
        "safety_profile_score": 7.5,
        "endpoint_quality_score": null,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 1.0,
          "publication_venue": 2.0,
          "response_durability": 2.0,
          "extraction_completeness": 7.8
        },
        "sample_size_score": 1.0,
        "publication_venue_score": 2.0,
        "followup_duration_score": 2.0,
        "extraction_completeness_score": 7.8,
        "market_breakdown": {
          "competitors": 7.0,
          "market_size": 8.0,
          "unmet_need": 5.0
        },
        "competitors_score": 7.0,
        "market_size_score": 8.0,
        "unmet_need_score": 5.0
      },
      "rank": 37
    },
    {
      "extraction": {
        "source": {
          "pmid": "36809172",
          "doi": "10.1080/09546634.2023.2183729",
          "url": "https://www.semanticscholar.org/paper/88b5aaf59f8dc35f1aadc41662210d6205a94b91",
          "title": "Upadacitinib for the treatment of concomitant psoriasis and atopic dermatitis: a case series",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Web source",
          "is_open_access": false
        },
        "disease": "Concomitant psoriasis and atopic dermatitis",
        "disease_normalized": "Psoriasis with Atopic Dermatitis",
        "is_off_label": true,
        "is_relevant": true,
        "evidence_level": "Case Series",
        "patient_population": {
          "n_patients": 4,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "several systemic drugs",
            "gold-standard treatments for both psoriasis and AD"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "Four patients with overlapping features of both psoriasis and atopic dermatitis"
        },
        "treatment": {
          "drug_name": "upadacitinib",
          "generic_name": "Upadacitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "15 or 30 mg",
          "frequency": null,
          "duration": null,
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "4/4 (100%)",
          "responders_n": 4,
          "responders_pct": 100.0,
          "time_to_response": null,
          "duration_of_response": null,
          "effect_size_description": "Complete remission in all treated patients",
          "primary_endpoint": "Complete remission",
          "endpoint_result": "Complete remission achieved in all patients",
          "durability_signal": null,
          "efficacy_summary": "All four patients with overlapping psoriasis and atopic dermatitis achieved complete remission with upadacitinib 15 or 30 mg. This occurred after failure of multiple prior systemic treatments including gold-standard therapies for both conditions."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": null,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "No safety data reported in this case series abstract.",
          "safety_profile": "Unknown"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": null,
        "key_findings": "Upadacitinib achieved complete remission in all four patients with concomitant psoriasis and atopic dermatitis after multiple treatment failures.",
        "detailed_efficacy_endpoints": [],
        "detailed_safety_endpoints": [],
        "extraction_timestamp": "2025-12-08T18:38:29.555118",
        "extraction_confidence": 0.5,
        "extraction_confidence_detail": null,
        "extraction_method": "single_pass",
        "extraction_stages_completed": [],
        "data_sections_identified": null
      },
      "market_intelligence": {
        "disease": "Psoriasis with Atopic Dermatitis",
        "parent_disease": null,
        "epidemiology": {
          "us_prevalence_estimate": null,
          "us_incidence_estimate": null,
          "global_prevalence": null,
          "patient_population_size": null,
          "prevalence_source": null,
          "prevalence_source_url": null,
          "trend": null,
          "source_quality": null,
          "data_year": null,
          "geographic_scope": null,
          "confidence": null,
          "notes": "No specific epidemiology data found for psoriasis with atopic dermatitis comorbidity. Search results contain separate prevalence data for psoriasis (3.0% US adults, ~7.55 million) and atopic dermatitis (7.2-10.2% US adults, ~16.5 million), but no data on co-occurrence or comorbidity rates between these conditions."
        },
        "standard_of_care": {
          "top_treatments": [],
          "approved_drug_names": [],
          "num_approved_drugs": 0,
          "num_pipeline_therapies": 4,
          "pipeline_therapies": [
            {
              "drug_name": "PF-07038124",
              "company": "Pfizer",
              "mechanism": "Topical ointment for inflammatory skin conditions",
              "phase": "Phase 2",
              "trial_id": "NCT05375955",
              "expected_completion": "2023-07",
              "trial_name": null,
              "status": "Completed",
              "regulatory_designations": null,
              "notes": "Phase 2B study completed July 2023, tested multiple dose levels (0.01%, 0.03%, 0.06%) in patients with mild-to-moderate atopic dermatitis or mild-to-severe plaque psoriasis"
            },
            {
              "drug_name": "Tofacitinib",
              "company": "University of Colorado, Denver",
              "mechanism": "JAK inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT04246372",
              "expected_completion": "2024-10",
              "trial_name": null,
              "status": "Completed",
              "regulatory_designations": null,
              "notes": "Study specifically for immune skin conditions in Down syndrome patients, completed October 2024"
            },
            {
              "drug_name": "Orismilast",
              "company": "UNION therapeutics",
              "mechanism": "PDE4B/D inhibitor",
              "phase": "Phase 2",
              "trial_id": "Unknown - verify",
              "expected_completion": null,
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": "Fast Track",
              "notes": "Oral PDE4B/D inhibitor with completed Phase 2b studies in both atopic dermatitis and psoriasis, FDA Fast Track designation for both indications"
            },
            {
              "drug_name": "Roflumilast",
              "company": "Arcutis Biotherapeutics",
              "mechanism": "PDE4 inhibitor",
              "phase": "Phase 3",
              "trial_id": "Unknown - verify",
              "expected_completion": null,
              "trial_name": "INTEGUMENT",
              "status": "Completed",
              "regulatory_designations": null,
              "notes": "FDA approved ZORYVE cream 0.15% for atopic dermatitis in July 2024, sNDA submitted for 0.05% concentration for 2-5 year olds in December 2024"
            }
          ],
          "pipeline_details": "The pipeline for psoriasis with atopic dermatitis includes 4 active programs, primarily focusing on PDE4 inhibition mechanisms. Key approaches include topical formulations (PF-07038124, roflumilast) and oral therapies (orismilast), with JAK inhibition also being explored. One program (roflumilast) has already achieved FDA approval with additional formulations in development.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "There is no established treatment paradigm for the combination indication of psoriasis with atopic dermatitis, as these are typically treated as separate conditions. Patients would likely receive individualized treatment addressing each condition separately.",
          "unmet_need": true,
          "unmet_need_description": "No FDA-approved treatments exist specifically for the combination indication of psoriasis with atopic dermatitis. Patients with both conditions must be treated with separate therapies for each indication, creating potential for drug interactions and suboptimal outcomes.",
          "competitive_landscape": "The search results show drugs approved for psoriasis separately (like Zoryve foam for plaque psoriasis) and atopic dermatitis separately (like Rinvoq, Zoryve cream, Vtama for atopic dermatitis), but no therapies are FDA-approved specifically for the combination indication.",
          "soc_source": "FDA drug labels and approval histories from Drugs.com",
          "phase_3_count": 1,
          "phase_2_count": 3,
          "key_catalysts": "UNION therapeutics preparing Phase 2b/3 studies for orismilast in hidradenitis suppurativa with potential read-through to psoriasis/atopic dermatitis applications, and Arcutis Biotherapeutics awaiting FDA decision on sNDA for ZORYVE cream 0.05% for pediatric patients",
          "pipeline_data_quality": "Medium",
          "recent_approvals": null,
          "data_quality": "High",
          "data_quality_notes": "Clear FDA labeling information available showing separate approvals for psoriasis and atopic dermatitis, but no combination indication approvals found"
        },
        "market_size_estimate": null,
        "market_size_usd": null,
        "growth_rate": "5-8% CAGR (high unmet need)",
        "tam_usd": 225000000.0,
        "tam_estimate": "$225M",
        "tam_rationale": "Based on market research data, there are approximately 8.6M psoriasis patients and 19.2M atopic dermatitis patients in the US. However, the specific combination indication represents a much smaller overlap population, estimated at ~500K patients. Of these, ~70% are diagnosed (350K), ~60% receive prescription treatment (210K), and given this is a novel combination indication with high unmet need, ~50% could be candidates for this new therapy (105K patients). A first-in-class drug could capture 20-30% market share (~25K patients). At estimated $90K/year pricing for this specialty indication, TAM = $225M.",
        "tam_sources": [
          "https://www.sec.gov/Archives/edgar/data/1787306/000178730622000009/arqt-20211231.htm",
          "https://www.annualreports.com/HostedData/AnnualReportArchive/a/NASDAQ_ARQT_2020.pdf",
          "https://s202.q4cdn.com/989204323/files/doc_financials/2024/10-K.pdf"
        ],
        "pipeline_sources": [
          "https://clinicaltrials.gov",
          "https://cdn.clinicaltrials.gov/large-docs/10/NCT03172910/SAP_001.pdf",
          "https://cdn.clinicaltrials.gov/large-docs/68/NCT04108468/Prot_000.pdf",
          "https://cdn.clinicaltrials.gov/large-docs/84/NCT05984784/Prot_000.pdf",
          "https://clinicaltrials.gov/study/NCT03809663"
        ],
        "attributed_sources": [
          {
            "url": "https://www.sciencedirect.com/science/article/pii/S0022202X18326782",
            "title": "Atopic Dermatitis in America Study: A Cross-Sectional ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5289118/",
            "title": "Psoriasis and Atopic Dermatitis - PMC - NIH",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.drugs.com/history/rinvoq.html",
            "title": "Rinvoq (upadacitinib) FDA Approval History",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.drugs.com/history/zoryve.html",
            "title": "Zoryve (roflumilast) FDA Approval History",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://practicaldermatology.com/topics/atopic-dermatitis/atopic-dermatitis-and-psoriasis-treatments-considerations-and-whats-coming/24038/",
            "title": "Atopic Dermatitis and Psoriasis: Treatments, Considerations, and ...",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://clinicaltrials.gov",
            "title": "ClinicalTrials.gov API",
            "attribution": "Pipeline/Clinical Trials (Primary)"
          },
          {
            "url": "https://cdn.clinicaltrials.gov/large-docs/10/NCT03172910/SAP_001.pdf",
            "title": "Clinical Trial Protocol: PER977-02-012",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://cdn.clinicaltrials.gov/large-docs/68/NCT04108468/Prot_000.pdf",
            "title": "GOLMePsA study - cdn.clinicaltrials.gov",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.sec.gov/Archives/edgar/data/1787306/000178730622000009/arqt-20211231.htm",
            "title": "arqt-20211231",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.annualreports.com/HostedData/AnnualReportArchive/a/NASDAQ_ARQT_2020.pdf",
            "title": "Form 10-K ARCUTIS BIOTHERAPEUTICS, INC.",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 7.2,
        "evidence_quality": 3.7,
        "market_opportunity": 8.3,
        "overall_priority": 6.6,
        "clinical_breakdown": {
          "response_rate_quality_weighted": 10.0,
          "safety_profile": 5.0,
          "organ_domain_breadth": 6.0,
          "safety_categories": [],
          "regulatory_flags": [],
          "efficacy_endpoint_count": 0,
          "efficacy_concordance": 1.0
        },
        "response_rate_score": 10.0,
        "safety_profile_score": 5.0,
        "endpoint_quality_score": null,
        "organ_domain_score": 6.0,
        "evidence_breakdown": {
          "sample_size": 4.0,
          "publication_venue": 2.0,
          "response_durability": 4.0,
          "extraction_completeness": 5.5
        },
        "sample_size_score": 4.0,
        "publication_venue_score": 2.0,
        "followup_duration_score": 4.0,
        "extraction_completeness_score": 5.5,
        "market_breakdown": {
          "competitors": 10.0,
          "market_size": 5.0,
          "unmet_need": 10.0
        },
        "competitors_score": 10.0,
        "market_size_score": 5.0,
        "unmet_need_score": 10.0
      },
      "rank": 38
    },
    {
      "extraction": {
        "source": {
          "pmid": "35587645",
          "doi": "10.1080/09273948.2022.2069128",
          "url": "https://www.semanticscholar.org/paper/43e2f21a190c72d32e8ebfad3b8fade41ffa982f",
          "title": "Beneficial Effect of Upadacitinib in an Adult Patient with Juvenile Idiopathic Arthritis-associated Uveitis after Unsatisfactory Response to Tofacitinib: A Case Report",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Web source",
          "is_open_access": false
        },
        "disease": "juvenile idiopathic arthritis-associated uveitis",
        "disease_normalized": "Juvenile Idiopathic Arthritis",
        "is_off_label": true,
        "is_relevant": true,
        "evidence_level": "Case Report",
        "patient_population": {
          "n_patients": 1,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "multiple conventional disease-modifying antirheumatic drugs",
            "multiple biologic disease-modifying antirheumatic drugs",
            "tofacitinib"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "24-year-old female with refractory juvenile idiopathic arthritis-associated uveitis"
        },
        "treatment": {
          "drug_name": "upadacitinib",
          "generic_name": "Upadacitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": null,
          "frequency": null,
          "duration": null,
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": null,
          "responders_n": 1,
          "responders_pct": 100.0,
          "time_to_response": null,
          "duration_of_response": null,
          "effect_size_description": "clinical remission achieved with monotherapy",
          "primary_endpoint": "clinical remission",
          "endpoint_result": "achieved clinical remission",
          "durability_signal": null,
          "efficacy_summary": "Patient achieved clinical remission on upadacitinib monotherapy after failing multiple conventional and biologic DMARDs as well as tofacitinib. This represents successful treatment of both arthritis and uveitis components."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": null,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "No safety outcomes or adverse events were reported in this case report.",
          "safety_profile": "Unknown"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": null,
        "key_findings": "Upadacitinib achieved clinical remission in refractory JIAU after tofacitinib failure, suggesting JAK inhibitor switching may be beneficial.",
        "detailed_efficacy_endpoints": [],
        "detailed_safety_endpoints": [],
        "extraction_timestamp": "2025-12-08T18:51:09.923082",
        "extraction_confidence": 0.5,
        "extraction_confidence_detail": null,
        "extraction_method": "single_pass",
        "extraction_stages_completed": [],
        "data_sections_identified": null
      },
      "market_intelligence": {
        "disease": "Juvenile Idiopathic Arthritis",
        "parent_disease": "Idiopathic Arthritis",
        "epidemiology": {
          "us_prevalence_estimate": "220,000 children and adolescents with arthritis; 53.2 million adults",
          "us_incidence_estimate": "2-20 cases per 100,000 children annually; 4-14 cases per 100,000 children for JIA",
          "global_prevalence": null,
          "patient_population_size": 53420000,
          "prevalence_source": "CDC",
          "prevalence_source_url": "https://www.cdc.gov/mmwr/volumes/72/wr/mm7229a3.htm",
          "trend": "stable",
          "source_quality": "Primary",
          "data_year": 2021,
          "geographic_scope": "US",
          "confidence": "High",
          "notes": "Data combines juvenile idiopathic arthritis (220,000 children) and adult arthritis (53.2 million). Wide range in incidence estimates due to differing definitions and criteria for childhood arthritis. Prevalence varies with ethnicity and is more common in northern Europeans."
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Actemra (tocilizumab)",
              "drug_class": "IL-6 receptor antagonist",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Polyarticular Juvenile Idiopathic Arthritis",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": null,
              "notes": "FDA approved for polyarticular juvenile idiopathic arthritis in children aged 2 years and older with active disease. Can be used alone or in combination with methotrexate",
              "approval_year": null,
              "approval_confidence": "High",
              "approval_evidence": "FDA approval confirmed in search results for polyarticular JIA in children aged 2 years and older"
            },
            {
              "drug_name": "Actemra (tocilizumab)",
              "drug_class": "IL-6 receptor antagonist",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Systemic Juvenile Idiopathic Arthritis",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": null,
              "notes": "FDA approved for systemic juvenile idiopathic arthritis in patients 2 years of age and older",
              "approval_year": null,
              "approval_confidence": "High",
              "approval_evidence": "FDA approval confirmed in search results and FDA label for systemic JIA in patients 2 years and older"
            },
            {
              "drug_name": "Humira (adalimumab)",
              "drug_class": "TNF inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Juvenile Idiopathic Arthritis",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": null,
              "notes": "Recombinant human IgG1 monoclonal antibody specific for human TNF. Pediatric dosage not established for patients younger than 2 years for Humira",
              "approval_year": null,
              "approval_confidence": "High",
              "approval_evidence": "FDA approval confirmed for JIA in patients 4 years or older"
            },
            {
              "drug_name": "Rinvoq (upadacitinib)",
              "drug_class": "JAK inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Polyarticular Juvenile Idiopathic Arthritis",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "Indicated for patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis who have had an inadequate response or intolerance to one or more TNF blockers",
              "approval_year": null,
              "approval_confidence": "High",
              "approval_evidence": "FDA label confirms approval for polyarticular JIA in patients 2 years and older with inadequate response or intolerance to TNF blockers"
            },
            {
              "drug_name": "Ilaris (canakinumab)",
              "drug_class": "IL-1 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Juvenile Idiopathic Arthritis",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "IL-1 inhibitor approved for treatment of juvenile idiopathic arthritis, strongly recommended as first-line therapy for systemic JIA without MAS",
              "approval_year": 2009,
              "approval_confidence": "High",
              "approval_evidence": "FDA approval date June 18, 2009 confirmed in drugs.com listing"
            },
            {
              "drug_name": "Enbrel (etanercept)",
              "drug_class": "TNF blocker",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Polyarticular Juvenile Idiopathic Arthritis",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": null,
              "notes": "TNF blocker approved for polyarticular juvenile idiopathic arthritis among other indications",
              "approval_year": 1998,
              "approval_confidence": "High",
              "approval_evidence": "FDA approval confirmed in drugs.com table showing approval for polyarticular juvenile idiopathic arthritis"
            }
          ],
          "approved_drug_names": [
            "Actemra (tocilizumab)",
            "Actemra (tocilizumab)",
            "Humira (adalimumab)",
            "Rinvoq (upadacitinib)",
            "Ilaris (canakinumab)",
            "Enbrel (etanercept)"
          ],
          "num_approved_drugs": 6,
          "num_pipeline_therapies": 14,
          "pipeline_therapies": [
            {
              "drug_name": "Upadacitinib",
              "company": "AbbVie",
              "mechanism": "JAK inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT05609630",
              "expected_completion": "2029-06",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Evaluating upadacitinib vs tocilizumab in systemic juvenile idiopathic arthritis"
            },
            {
              "drug_name": "HB-adMSCs (allogeneic adipose-derived mesenchymal stem cells)",
              "company": "Hope Biosciences Research Foundation",
              "mechanism": "Mesenchymal stem cell therapy",
              "phase": "Phase 2",
              "trial_id": "NCT06623240",
              "expected_completion": "2027-12",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Cross-over study for oligoarticular and polyarticular juvenile idiopathic arthritis"
            },
            {
              "drug_name": "Deucravacitinib",
              "company": "Bristol-Myers Squibb",
              "mechanism": "TYK2 inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT06869551",
              "expected_completion": "2030-03",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Evaluating efficacy and safety in pediatric patients with active juvenile psoriatic arthritis"
            },
            {
              "drug_name": "MAS825",
              "company": "Novartis Pharmaceuticals",
              "mechanism": "IL-1\u03b2 and IL-18 inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT07203001",
              "expected_completion": "2029-05",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Open-label trial for pediatric and adult participants with Still's disease"
            },
            {
              "drug_name": "Multiple TNFi/Abatacept/Tocilizumab/Tofacitinib",
              "company": "Duke University",
              "mechanism": "Various (TNF inhibitor, T-cell costimulation inhibitor, IL-6 receptor antagonist, JAK inhibitor)",
              "phase": "Phase 3",
              "trial_id": "NCT06654882",
              "expected_completion": "2026-06",
              "trial_name": "SMART",
              "status": "Not yet recruiting",
              "regulatory_designations": null,
              "notes": "Sequential therapy trial after TNFi failure in juvenile idiopathic arthritis"
            },
            {
              "drug_name": "CD19-BCMA CAR-T cells",
              "company": "Essen Biotech",
              "mechanism": "CAR-T cell therapy targeting CD19 and BCMA",
              "phase": "Phase 2",
              "trial_id": "NCT06350110",
              "expected_completion": "2025-12",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Fourth-generation CAR-T cells for refractory systemic lupus erythematosus"
            },
            {
              "drug_name": "AlloNK (allogeneic NK cells)",
              "company": "Artiva Biotherapeutics, Inc.",
              "mechanism": "Natural killer cell therapy",
              "phase": "Phase 2",
              "trial_id": "NCT06991114",
              "expected_completion": "2028-01",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Cord blood-derived NK cell therapy in combination with rituximab"
            },
            {
              "drug_name": "Bimekizumab",
              "company": "UCB Biopharma SRL",
              "mechanism": "IL-17A and IL-17F inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT06668181",
              "expected_completion": "2028-04",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Evaluating pharmacokinetics and safety in pediatric patients with enthesitis-related arthritis and juvenile psoriatic arthritis"
            },
            {
              "drug_name": "Baricitinib",
              "company": "Eli Lilly and Company",
              "mechanism": "JAK inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT04088396",
              "expected_completion": "2026-04",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Open-label study with tocilizumab reference arm for systemic juvenile idiopathic arthritis"
            },
            {
              "drug_name": "Ixekizumab",
              "company": "Eli Lilly and Company",
              "mechanism": "IL-17A inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT04527380",
              "expected_completion": "2024-02",
              "trial_name": null,
              "status": "Active, not recruiting",
              "regulatory_designations": null,
              "notes": "Study with adalimumab reference arm for enthesitis-related arthritis and juvenile psoriatic arthritis"
            },
            {
              "drug_name": "Tofacitinib",
              "company": "Pfizer",
              "mechanism": "JAK inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT03000439",
              "expected_completion": "2024-03",
              "trial_name": null,
              "status": "Completed",
              "regulatory_designations": null,
              "notes": "Recently completed efficacy and safety study for systemic juvenile idiopathic arthritis with active systemic features"
            },
            {
              "drug_name": "Secukinumab",
              "company": "Novartis Pharmaceuticals",
              "mechanism": "IL-17A inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT03769168",
              "expected_completion": "2024-11",
              "trial_name": null,
              "status": "Completed",
              "regulatory_designations": null,
              "notes": "Extension study evaluating long-term efficacy and safety in juvenile psoriatic arthritis and enthesitis-related arthritis"
            },
            {
              "drug_name": "Certolizumab Pegol",
              "company": "UCB BIOSCIENCES GmbH",
              "mechanism": "TNF inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT01550003",
              "expected_completion": "2024-04",
              "trial_name": null,
              "status": "Completed",
              "regulatory_designations": null,
              "notes": "Recently completed study in children and adolescents with moderately to severely active polyarticular-course juvenile idiopathic arthritis"
            },
            {
              "drug_name": "Abatacept",
              "company": "Duke University",
              "mechanism": "T-cell costimulation inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT03841357",
              "expected_completion": "2025-01",
              "trial_name": "Limit-JIA",
              "status": "Completed",
              "regulatory_designations": null,
              "notes": "Recently completed study preventing extension of oligoarticular juvenile idiopathic arthritis"
            }
          ],
          "pipeline_details": "The juvenile idiopathic arthritis pipeline includes 14 active programs across multiple mechanisms including JAK inhibitors (upadacitinib, baricitinib, tofacitinib), IL-17 inhibitors (bimekizumab, ixekizumab, secukinumab), and novel approaches like mesenchymal stem cells and CAR-T therapy. Several recent completions of Phase 3 trials suggest potential upcoming regulatory submissions for tofacitinib, certolizumab pegol, and other established mechanisms.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "Treatment approach has evolved from traditional NSAIDs and corticosteroids to early use of biologics as first-line therapy, particularly for systemic JIA. IL-1 and IL-6 inhibitors are now strongly recommended as first-line therapy for systemic JIA without MAS, while TNF inhibitors and JAK inhibitors are used for polyarticular forms or as second-line options.",
          "unmet_need": true,
          "unmet_need_description": "Despite availability of multiple biologics, there remains variation in treatment approaches and need for more standardized protocols. Guidelines emphasize avoiding prolonged corticosteroid use and NSAIDs as initial monotherapy.",
          "competitive_landscape": "Multiple drug classes compete including IL-1 inhibitors (Ilaris), IL-6 inhibitors (Actemra), TNF inhibitors (Humira, Enbrel), and JAK inhibitors (Rinvoq). Biosimilars are increasingly available for established biologics like tocilizumab and adalimumab, providing more treatment options.",
          "soc_source": "Medscape Emedicine and FDA drug labels",
          "phase_3_count": 10,
          "phase_2_count": 4,
          "key_catalysts": "Multiple Phase 3 readouts expected through 2026, including baricitinib results (April 2026), sequential therapy SMART trial results (June 2026), and ongoing upadacitinib data (June 2029)",
          "pipeline_data_quality": "High",
          "recent_approvals": "Avtozma (tocilizumab biosimilar) approved January 30, 2025; multiple tocilizumab biosimilars and adalimumab biosimilars approved in recent years",
          "data_quality": "High",
          "data_quality_notes": "Multiple confirmatory sources including FDA labels and clinical guidelines, though some approval years not specified in search results"
        },
        "market_size_estimate": "$1335.5B",
        "market_size_usd": 1335500000000.0,
        "growth_rate": "3-5% CAGR (stable prevalence)",
        "tam_usd": 277000000.0,
        "tam_estimate": "$277M",
        "tam_rationale": "Of ~220,000 children and adolescents with arthritis (primarily JIA), ~80% are diagnosed (176K), ~65% receive systemic treatment (114K), ~35% fail first-line therapy and are candidates for 2L+ biologics (40K). A new 2L+ drug could capture 20-25% market share (~9.2K patients) given 6 existing competitors but significant unmet need. At $30K/yr pricing (specialty biologics for pediatric indication), TAM = $277M.",
        "tam_sources": [
          "https://www.reanin.com/reports/polyarticular-juvenile-idiopathic-arthritis-market",
          "https://www.linkedin.com/pulse/united-states-juvenile-idiopathic-arthritis-treatment-market-wlblc/",
          "https://www.archivemarketresearch.com/reports/juvenile-idiopathic-arthritis-therapeutics-345518"
        ],
        "pipeline_sources": [
          "https://clinicaltrials.gov",
          "https://www.clinicaltrials.gov/study/NCT01145352?tab=table",
          "https://clinicaltrials.gov/study/NCT06668181",
          "https://clinicaltrials.gov/study/NCT00095173",
          "https://clinicaltrials.gov/study/NCT03841357"
        ],
        "attributed_sources": [
          {
            "url": "https://posna.org/physician-education/study-guide/juvenile-idiopathic-arthritis",
            "title": "Juvenile Idiopathic Arthritis | Pediatric Orthopaedic Society of North ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://emedicine.medscape.com/article/1007276-overview",
            "title": "Juvenile Idiopathic Arthritis: Background, Etiology and ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://emedicine.medscape.com/article/1007276-treatment",
            "title": "Juvenile Idiopathic Arthritis Treatment & Management",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-biosimilar-actemra-treat-adult-and-pediatric-arthritis",
            "title": "FDA approves first biosimilar to Actemra to treat adult and ...",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.the-rheumatologist.org/article/experts-discuss-draft-of-new-jia-guideline/",
            "title": "Experts Discuss Draft of New JIA Guideline",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://clinicaltrials.gov",
            "title": "ClinicalTrials.gov API",
            "attribution": "Pipeline/Clinical Trials (Primary)"
          },
          {
            "url": "https://www.clinicaltrials.gov/study/NCT01145352?tab=table",
            "title": "Enbrel-Juvenile Idiopathic Arthritis (JIA) Use Results ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT06668181",
            "title": "NCT06668181 | An Open-label Study to Evaluate the ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.reanin.com/reports/polyarticular-juvenile-idiopathic-arthritis-market",
            "title": "Polyarticular Juvenile Idiopathic Arthritis (PJIA) Market",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.linkedin.com/pulse/united-states-juvenile-idiopathic-arthritis-treatment-market-wlblc/",
            "title": "United States Juvenile Idiopathic Arthritis Treatment Market Size, ...",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 8.0,
        "evidence_quality": 2.6,
        "market_opportunity": 7.7,
        "overall_priority": 6.6,
        "clinical_breakdown": {
          "response_rate_quality_weighted": 10.0,
          "safety_profile": 5.0,
          "organ_domain_breadth": 10.0,
          "safety_categories": [],
          "regulatory_flags": [],
          "efficacy_endpoint_count": 0,
          "efficacy_concordance": 1.0
        },
        "response_rate_score": 10.0,
        "safety_profile_score": 5.0,
        "endpoint_quality_score": null,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 1.0,
          "publication_venue": 2.0,
          "response_durability": 4.0,
          "extraction_completeness": 4.9
        },
        "sample_size_score": 1.0,
        "publication_venue_score": 2.0,
        "followup_duration_score": 4.0,
        "extraction_completeness_score": 4.9,
        "market_breakdown": {
          "competitors": 3.0,
          "market_size": 10.0,
          "unmet_need": 10.0
        },
        "competitors_score": 3.0,
        "market_size_score": 10.0,
        "unmet_need_score": 10.0
      },
      "rank": 39
    },
    {
      "extraction": {
        "source": {
          "pmid": "38022858",
          "doi": "10.1177/2050313X231213144",
          "url": "https://www.semanticscholar.org/paper/ab394f2a5c2d247d8a41efed1288eee803821395",
          "title": "Successful treatment of erosive lichen planus with Upadacitinib complicated by oral squamous cell carcinoma",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Web source",
          "is_open_access": false
        },
        "disease": "Erosive lichen planus",
        "disease_normalized": "Lichen Planus",
        "is_off_label": true,
        "is_relevant": true,
        "evidence_level": "Case Report",
        "patient_population": {
          "n_patients": 1,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "methotrexate",
            "azathioprine",
            "secukinumab",
            "cyclosporine",
            "sulfasalazine",
            "intravenous immunoglobulin",
            "acitretin",
            "hydroxychloroquine",
            "systemic steroids"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "70-year-old woman with 6-year history of recalcitrant erosive lichen planus with extensive oral, esophageal, and vaginal involvement"
        },
        "treatment": {
          "drug_name": "upadacitinib",
          "generic_name": "Upadacitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "15 mg daily",
          "frequency": null,
          "duration": "several months",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": null,
          "responders_n": 1,
          "responders_pct": 100.0,
          "time_to_response": "rapid improvement",
          "duration_of_response": "several months",
          "effect_size_description": "almost complete clearance of oral and vaginal mucosa with improvement in esophageal lesions",
          "primary_endpoint": "improvement in erosions and ulcerations of mucosal surfaces",
          "endpoint_result": "rapid improvement with decreased esophageal strictures, improvement in esophageal erosions, and almost complete clearance of oral and vaginal mucosa",
          "durability_signal": null,
          "efficacy_summary": "Upadacitinib 15 mg daily in combination with methotrexate resulted in rapid improvement of erosive lichen planus. The patient showed decreased esophageal strictures, improvement in esophageal erosions, and almost complete clearance of oral and vaginal mucosa."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [
            "oral squamous cell carcinoma"
          ],
          "sae_count": 1,
          "sae_percentage": 100.0,
          "discontinuations_n": 1,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [
            "development of oral squamous cell carcinoma"
          ],
          "safety_summary": "Treatment was complicated by the development of invasive oral squamous cell carcinoma on the tongue, which became apparent after erosive lichen planus lesions had healed. The cancer had invaded skeletal muscle and involved lymph nodes, leading to treatment discontinuation and ultimately patient death.",
          "safety_profile": "Concerning"
        },
        "outcome_result": "Mixed",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": "several months",
        "key_findings": "Upadacitinib successfully treated recalcitrant erosive lichen planus but was complicated by development of oral squamous cell carcinoma that may have been masked by the extensive erosive disease.",
        "detailed_efficacy_endpoints": [],
        "detailed_safety_endpoints": [
          {
            "event_name": "Oral squamous cell carcinoma",
            "event_category": "SAE",
            "severity_grade": null,
            "patients_affected_n": 1,
            "patients_affected_pct": null,
            "events_total": 1,
            "relatedness": null,
            "outcome": "Fatal",
            "action_taken": "Discontinued",
            "notes": "T3N3b staging, invaded skeletal muscle, 4/31 regional lymph nodes involved with 2 having extranodal invasion",
            "category_soc": "Malignancies",
            "infection_type": null,
            "malignancy_type": "Solid Tumor",
            "cv_type": null,
            "thromboembolic_type": null,
            "is_class_effect": true
          },
          {
            "event_name": "Death",
            "event_category": "SAE",
            "severity_grade": null,
            "patients_affected_n": 1,
            "patients_affected_pct": null,
            "events_total": 1,
            "relatedness": null,
            "outcome": "Fatal",
            "action_taken": null,
            "notes": "Due to oral squamous cell carcinoma",
            "category_soc": "Death",
            "infection_type": null,
            "malignancy_type": null,
            "cv_type": null,
            "thromboembolic_type": null,
            "is_class_effect": false
          },
          {
            "event_name": "Treatment discontinuation",
            "event_category": "Discontinuation",
            "severity_grade": null,
            "patients_affected_n": 1,
            "patients_affected_pct": null,
            "events_total": 1,
            "relatedness": null,
            "outcome": null,
            "action_taken": "Discontinued",
            "notes": "Upadacitinib discontinued due to oral squamous cell carcinoma",
            "category_soc": null,
            "infection_type": null,
            "malignancy_type": null,
            "cv_type": null,
            "thromboembolic_type": null,
            "is_class_effect": false
          }
        ],
        "extraction_timestamp": "2025-12-08T18:52:04.137250",
        "extraction_confidence": 0.6,
        "extraction_confidence_detail": null,
        "extraction_method": "multi_stage",
        "extraction_stages_completed": [
          "section_identification",
          "efficacy_extraction",
          "safety_extraction"
        ],
        "data_sections_identified": {
          "baseline_tables": [],
          "efficacy_tables": [],
          "safety_tables": [],
          "efficacy_figures": [
            "Figure 1: Upper endoscopy performed prior to initiation of treatment with Upadacitinib showing erosions, ulcerations and strictures within the esophagus",
            "Figure 2: Upper endoscopy performed several months after initiation of treatment with Upadacitinib showing fewer esophageal erosions and ulcerations"
          ],
          "results_sections": [
            "Case report"
          ],
          "patient_count": 1,
          "study_type": "Case Report",
          "has_quantitative_outcomes": false,
          "notes": "Single case report of 70-year-old woman with erosive lichen planus successfully treated with upadacitinib but complicated by development of oral squamous cell carcinoma. No formal tables with quantitative data; outcomes described qualitatively in case report section with endoscopic images showing improvement."
        }
      },
      "market_intelligence": {
        "disease": "Lichen Planus",
        "parent_disease": null,
        "epidemiology": {
          "us_prevalence_estimate": "0.15% to 0.42%",
          "us_incidence_estimate": "11.4 per 100,000 person-years",
          "global_prevalence": null,
          "patient_population_size": 955000,
          "prevalence_source": "Journal of the American Academy of Dermatology",
          "prevalence_source_url": "https://www.jaad.org/article/S0190-9622(21)02974-1/fulltext",
          "trend": null,
          "source_quality": "Primary",
          "data_year": 2021,
          "geographic_scope": "US",
          "confidence": "High",
          "notes": "Multiple US-based studies show consistent prevalence range of 0.15-0.42%; higher prevalence in women (1.77x), Asian patients, and those over 60; includes both cutaneous and oral forms"
        },
        "standard_of_care": {
          "top_treatments": [],
          "approved_drug_names": [],
          "num_approved_drugs": 0,
          "num_pipeline_therapies": 10,
          "pipeline_therapies": [
            {
              "drug_name": "LP-10 (Liposomal Tacrolimus)",
              "company": "Lipella Pharmaceuticals, Inc.",
              "mechanism": "Calcineurin inhibitor (liposomal formulation)",
              "phase": "Phase 2",
              "trial_id": "NCT06233591",
              "expected_completion": "2025-06",
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": null,
              "notes": "First potential FDA-approved therapy for oral lichen planus"
            },
            {
              "drug_name": "Baricitinib",
              "company": "University of North Carolina, Chapel Hill",
              "mechanism": "JAK1/JAK2 inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT06158113",
              "expected_completion": "2025-12",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Proof-of-concept study for oral lichen planus"
            },
            {
              "drug_name": "Clobetasol Propionate",
              "company": "Malm\u00f6 University",
              "mechanism": "Topical corticosteroid",
              "phase": "Phase 2/3",
              "trial_id": "NCT04364555",
              "expected_completion": "2024-07",
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": null,
              "notes": "Multicenter placebo-controlled trial for symptomatic oral lichen planus"
            },
            {
              "drug_name": "Ruxolitinib cream",
              "company": "Incyte Corporation",
              "mechanism": "JAK1/JAK2 inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT05593432",
              "expected_completion": null,
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": null,
              "notes": "Completed trial for cutaneous lichen planus - recently completed indicating active development"
            },
            {
              "drug_name": "Deucravacitinib",
              "company": "Mayo Clinic",
              "mechanism": "TYK2 inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT06091956",
              "expected_completion": null,
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": null,
              "notes": "Completed trial for lichen planopilaris - recently completed indicating active development"
            },
            {
              "drug_name": "Sulfasalazine",
              "company": "Cairo University",
              "mechanism": "Anti-inflammatory agent",
              "phase": "Phase 3",
              "trial_id": "NCT06060301",
              "expected_completion": "2024-09",
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": null,
              "notes": "Adjunctive topical treatment for oral lichen planus"
            },
            {
              "drug_name": "Methotrexate",
              "company": "Sheikh Zayed Medical College",
              "mechanism": "Antimetabolite immunosuppressant",
              "phase": "Phase 2",
              "trial_id": "NCT06739551",
              "expected_completion": "2025-03",
              "trial_name": null,
              "status": "Not yet recruiting",
              "regulatory_designations": null,
              "notes": "Comparison with Acitretin for generalized lichen planus"
            },
            {
              "drug_name": "Clobetasol + Resveratrol Patch",
              "company": "University of Palermo",
              "mechanism": "Corticosteroid with antioxidant combination",
              "phase": "Phase 2",
              "trial_id": "NCT07100613",
              "expected_completion": "2027-10",
              "trial_name": "EMPATIA",
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Mucoadhesive modified-release formulation"
            },
            {
              "drug_name": "Tranexamic acid",
              "company": "Henry Ford Health System",
              "mechanism": "Antifibrinolytic agent",
              "phase": "Phase 2",
              "trial_id": "NCT04233749",
              "expected_completion": "2025-12",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Treatment for lichen planus pigmentosus"
            },
            {
              "drug_name": "Curcumin 1%",
              "company": "Shaymaa Hussein Rafat Kotb",
              "mechanism": "Anti-inflammatory natural compound",
              "phase": "Phase 3",
              "trial_id": "NCT06605911",
              "expected_completion": null,
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": null,
              "notes": "Recently completed trial for oral lichen planus treatment"
            }
          ],
          "pipeline_details": "The lichen planus pipeline includes 10 active therapies across Phase 2 and Phase 3 development, with JAK inhibitors (baricitinib, ruxolitinib) and novel formulations (LP-10 liposomal tacrolimus) representing key mechanisms being tested. LP-10 from Lipella Pharmaceuticals is positioned to become the first FDA-approved therapy specifically for oral lichen planus.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "High-potency topical corticosteroids (clobetasol) are first-line therapy for all forms of lichen planus. Second-line treatments include topical calcineurin inhibitors (tacrolimus, pimecrolimus) for oral and genital disease, and systemic corticosteroids for severe widespread disease.",
          "unmet_need": true,
          "unmet_need_description": "No FDA-approved branded innovative treatments exist specifically for lichen planus. All current treatments are generic medications used off-label, with topical steroids as mainstay therapy despite potential long-term side effects.",
          "competitive_landscape": "Treatment relies entirely on generic medications including topical and systemic corticosteroids, calcineurin inhibitors, and immunosuppressants used off-label. No branded innovative therapies have FDA approval for this indication, representing a significant unmet medical need.",
          "soc_source": "American Academy of Family Physicians Clinical Guidelines",
          "phase_3_count": 2,
          "phase_2_count": 8,
          "key_catalysts": "LP-10 Phase 2 completion expected June 2025, baricitinib proof-of-concept results expected December 2025",
          "pipeline_data_quality": "High",
          "recent_approvals": null,
          "data_quality": "High",
          "data_quality_notes": "Multiple authoritative sources consistently confirm no FDA-approved branded innovative treatments exist specifically for lichen planus indication"
        },
        "market_size_estimate": "$23.9B",
        "market_size_usd": 23875000000.0,
        "growth_rate": "5-8% CAGR (high unmet need)",
        "tam_usd": 171000000.0,
        "tam_estimate": "$171M",
        "tam_rationale": "Of ~955K US patients with lichen planus, ~70% are diagnosed (669K), ~60% receive systemic treatment (401K), ~30% have moderate-severe disease requiring specialty treatment (120K). A new drug could capture 20-25% market share (~24K patients) in this underserved autoimmune dermatology market with no approved therapies. At $60K/yr pricing (similar to other autoimmune dermatology drugs like Rinvoq), TAM = 24K \u00d7 $60K = $171M. High unmet need and lack of approved therapies supports premium positioning.",
        "tam_sources": [
          "https://www.openpr.com/news/3972605/lichen-planus-market-trends-technologies-global-forecast",
          "https://www.openpr.com/news/3295140/lichen-planus-market-is-projected-to-grow-at-a-cagr-of-4-16-from",
          "https://www.stocktitan.net/news/LIPO/lipella-pharmaceuticals-granted-fda-approval-for-expanded-access-j6kwffhg9swz.html"
        ],
        "pipeline_sources": [
          "https://clinicaltrials.gov",
          "https://www.clinicaltrials.gov/study/NCT05127083",
          "https://www.clinicaltrials.gov/study/NCT06327620",
          "https://clinicaltrials.gov/study/NCT02850601",
          "https://clinicaltrials.gov/study/NCT03509675"
        ],
        "attributed_sources": [
          {
            "url": "https://www.dermatologyadvisor.com/news/patients-with-lichen-planus-may-undertreated-dermatologists/",
            "title": "Patients With Lichen Planus May be Undertreated by ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.jaad.org/article/S0190-9622(21)02974-1/fulltext",
            "title": "Prevalence of lichen planus in the United States: A cross-sectional ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.drugs.com/condition/lichen-planus.html",
            "title": "List of 32 Lichen Planus Medications Compared",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://emedicine.medscape.com/article/1123423-treatment",
            "title": "Lichen Simplex Chronicus Treatment & Management",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.aafp.org/pubs/afp/issues/2011/0701/p53.html",
            "title": "Diagnosis and Treatment of Lichen Planus - AAFP",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://clinicaltrials.gov",
            "title": "ClinicalTrials.gov API",
            "attribution": "Pipeline/Clinical Trials (Primary)"
          },
          {
            "url": "https://www.clinicaltrials.gov/study/NCT05127083",
            "title": "Study Details | NCT05127083 | Oral Lichen Planus Treatment",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.clinicaltrials.gov/study/NCT06327620",
            "title": "NCT06327620 | Treatment Of Oral Lichen Planus",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.openpr.com/news/3972605/lichen-planus-market-trends-technologies-global-forecast",
            "title": "Lichen Planus Market Trends, Technologies & Global Forecast",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.openpr.com/news/3295140/lichen-planus-market-is-projected-to-grow-at-a-cagr-of-4-16-from",
            "title": "Lichen Planus Market is Projected to Grow at a CAGR of 4.16% from",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 6.4,
        "evidence_quality": 2.9,
        "market_opportunity": 10.0,
        "overall_priority": 6.4,
        "clinical_breakdown": {
          "response_rate_quality_weighted": 10.0,
          "safety_profile": 1.0,
          "organ_domain_breadth": 10.0,
          "safety_categories": [
            "malignancy",
            "discontinuation",
            "death"
          ],
          "regulatory_flags": [
            "malignancy",
            "death"
          ],
          "efficacy_endpoint_count": 0,
          "efficacy_concordance": 1.0
        },
        "response_rate_score": 10.0,
        "safety_profile_score": 1.0,
        "endpoint_quality_score": null,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 1.0,
          "publication_venue": 2.0,
          "response_durability": 4.0,
          "extraction_completeness": 7.2
        },
        "sample_size_score": 1.0,
        "publication_venue_score": 2.0,
        "followup_duration_score": 4.0,
        "extraction_completeness_score": 7.2,
        "market_breakdown": {
          "competitors": 10.0,
          "market_size": 10.0,
          "unmet_need": 10.0
        },
        "competitors_score": 10.0,
        "market_size_score": 10.0,
        "unmet_need_score": 10.0
      },
      "rank": 40
    },
    {
      "extraction": {
        "source": {
          "pmid": "38263708",
          "doi": "10.1080/09546634.2024.2302394",
          "url": "https://www.semanticscholar.org/paper/7da301fc8c62b90a0f42d61eac32645825001789",
          "title": "Upadacitinib for the management of bullous pemphigoid coexisting with psoriasis vulgaris: a case report and literature review",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Web source",
          "is_open_access": false
        },
        "disease": "Bullous pemphigoid coexisting with psoriasis vulgaris",
        "disease_normalized": "Bullous Pemphigoid with Psoriasis",
        "is_off_label": true,
        "is_relevant": true,
        "evidence_level": "Case Report",
        "patient_population": {
          "n_patients": 1,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [],
          "disease_severity": null,
          "comorbidities": null,
          "description": "Patient with concurrent bullous pemphigoid and psoriasis vulgaris"
        },
        "treatment": {
          "drug_name": "upadacitinib",
          "generic_name": "Upadacitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": null,
          "dose": null,
          "frequency": null,
          "duration": null,
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": null,
          "responders_n": null,
          "responders_pct": null,
          "time_to_response": null,
          "duration_of_response": null,
          "effect_size_description": "Successful treatment of both conditions",
          "primary_endpoint": null,
          "endpoint_result": null,
          "durability_signal": null,
          "efficacy_summary": "Upadacitinib successfully treated both bullous pemphigoid and psoriasis vulgaris in this patient, demonstrating significant clinical outcomes for both comorbidities."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": null,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "Upadacitinib was described as well-tolerated in this case, though specific safety data were not provided in the abstract.",
          "safety_profile": "Acceptable"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Moderate",
        "comparator_baseline": null,
        "follow_up_duration": null,
        "key_findings": "Upadacitinib appears to be a promising therapeutic option for patients with concurrent bullous pemphigoid and psoriasis vulgaris.",
        "detailed_efficacy_endpoints": [],
        "detailed_safety_endpoints": [],
        "extraction_timestamp": "2025-12-08T18:38:38.587184",
        "extraction_confidence": 0.5,
        "extraction_confidence_detail": null,
        "extraction_method": "single_pass",
        "extraction_stages_completed": [],
        "data_sections_identified": null
      },
      "market_intelligence": {
        "disease": "Bullous Pemphigoid with Psoriasis",
        "parent_disease": null,
        "epidemiology": {
          "us_prevalence_estimate": null,
          "us_incidence_estimate": "4.2 per 100,000 person-years",
          "global_prevalence": null,
          "patient_population_size": 14070,
          "prevalence_source": "Patient Experiences of Bullous Pemphigoid study",
          "prevalence_source_url": "https://link.springer.com/article/10.1007/s13555-025-01424-z",
          "trend": null,
          "source_quality": "Primary",
          "data_year": null,
          "geographic_scope": "Global",
          "confidence": "Medium",
          "notes": "Incidence estimate is global, not US-specific. Association data shows psoriasis patients have 1.5-2.6 times increased risk of developing bullous pemphigoid, and BP patients have 2.6-fold increased risk of developing psoriasis"
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Dupixent (dupilumab)",
              "drug_class": "IL-4/IL-13 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": "Bullous Pemphigoid",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": null,
              "notes": "FDA approved for bullous pemphigoid in adults, not specifically for bullous pemphigoid with psoriasis",
              "approval_year": 2025,
              "approval_confidence": "High",
              "approval_evidence": "FDA approval June 20, 2025 - Drugs.com and Medscape reports"
            }
          ],
          "approved_drug_names": [],
          "num_approved_drugs": 0,
          "num_pipeline_therapies": 1,
          "pipeline_therapies": [
            {
              "drug_name": "Dupilumab",
              "company": "Regeneron/Sanofi",
              "mechanism": "IL-4/IL-13 dual antagonist monoclonal antibody",
              "phase": "Phase 3",
              "trial_id": "NCT04206553",
              "expected_completion": "2025-06",
              "trial_name": "ADEPT",
              "status": "Active",
              "regulatory_designations": "FDA Approved for Bullous Pemphigoid (June 2025)",
              "notes": "First targeted therapy approved for bullous pemphigoid; 18.3% vs 6.1% sustained remission vs placebo"
            }
          ],
          "pipeline_details": "The clinical pipeline for Bullous Pemphigoid with Psoriasis is extremely limited, with dupilumab being the only major targeted therapy recently approved by FDA in June 2025. The ADEPT trial demonstrated dupilumab's efficacy in bullous pemphigoid, making it the first targeted medicine for this rare autoimmune blistering disease. Most treatment approaches remain focused on systemic corticosteroids and immunosuppressants rather than targeted biologics.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "No FDA-approved branded innovative therapies exist specifically for bullous pemphigoid with psoriasis. Case reports suggest IL-17 inhibitors like secukinumab may treat both conditions simultaneously, but these are off-label uses.",
          "unmet_need": true,
          "unmet_need_description": "No FDA-approved treatments specifically for the combination of bullous pemphigoid with psoriasis. Current management relies on off-label use of biologics or conventional immunosuppressants that may address both conditions.",
          "competitive_landscape": "The combination indication represents an unaddressed market opportunity. While dupilumab is approved for bullous pemphigoid alone, and various biologics are approved for psoriasis, no drug has specific approval for the combined condition.",
          "soc_source": "Multiple sources including Medscape, Drugs.com, and FDA labeling information",
          "phase_3_count": 1,
          "phase_2_count": 0,
          "key_catalysts": "Dupilumab regulatory submissions expected in EU, Japan, and China for bullous pemphigoid indication based on successful ADEPT trial results",
          "pipeline_data_quality": "Low",
          "recent_approvals": "Dupixent approved for bullous pemphigoid (not the combination) on June 20, 2025",
          "data_quality": "High",
          "data_quality_notes": "Clear documentation of lack of specific approvals for the combination indication, though individual conditions have approved treatments"
        },
        "market_size_estimate": "$1.4B",
        "market_size_usd": 1407000000.0,
        "growth_rate": "5-8% CAGR (high unmet need)",
        "tam_usd": 63315000.0,
        "tam_estimate": "$63.3M",
        "tam_rationale": "Of 14,070 US patients with bullous pemphigoid with psoriasis, approximately 70% are diagnosed (9,849), 60% receive systemic treatment (5,909), and 100% are candidates for new therapy given zero FDA-approved drugs exist. A first-in-class drug could capture 40-50% market share in this underserved population (~2,660 patients). At $95K/yr pricing (premium for rare autoimmune with orphan potential), TAM = $63.3M. High unmet need and lack of approved therapies supports premium positioning.",
        "tam_sources": [
          "https://www.drugpatentwatch.com/p/drug-price/ndc/59651-0796",
          "https://pmc.ncbi.nlm.nih.gov/articles/PMC10866767/",
          "https://trisaluslifesci.com/wp-content/uploads/2025/12/TLSI_Investor-Deck-December-2025.pdf"
        ],
        "pipeline_sources": [
          "https://clinicaltrials.gov",
          "https://cdn.clinicaltrials.gov/large-docs/38/NCT03099538/Prot_SAP_000.pdf",
          "https://cdn.clinicaltrials.gov/large-docs/75/NCT02808975/Prot_001.pdf",
          "https://www.clinicaltrials.gov/study/NCT05048342",
          "https://clinicaltrials.gov/study/NCT05030311"
        ],
        "attributed_sources": [
          {
            "url": "https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.880201/full",
            "title": "Epidemiology of Psoriasis and Comorbid Diseases",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.medicaljournals.se/acta/content/html/10.2340/00015555-3607",
            "title": "Increased Risk of Pemphigus among Patients with Psoriasis",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.medscape.com/viewarticle/fda-approves-dupilumab-bullous-pemphigoid-2025a1000gji",
            "title": "FDA Approves Dupilumab for Bullous Pemphigoid",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://emedicine.medscape.com/article/1062790-overview",
            "title": "Drug-Induced Bullous Disorders",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2023.1148660/full",
            "title": "Case Report: Coexistence of bullous pemphigoid and psoriasis",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://clinicaltrials.gov",
            "title": "ClinicalTrials.gov API",
            "attribution": "Pipeline/Clinical Trials (Primary)"
          },
          {
            "url": "https://cdn.clinicaltrials.gov/large-docs/38/NCT03099538/Prot_SAP_000.pdf",
            "title": "Taltz (ixekizumab) in the Treatment of Bullous Pemphigoid ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://cdn.clinicaltrials.gov/large-docs/75/NCT02808975/Prot_001.pdf",
            "title": "NCT02808975",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.drugpatentwatch.com/p/drug-price/ndc/59651-0796",
            "title": "Latest pharmaceutical drug prices and trends for NDC 59651-0796",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10866767/",
            "title": "Advancements in Bullous Pemphigoid Treatment",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 6.8,
        "evidence_quality": 2.4,
        "market_opportunity": 9.3,
        "overall_priority": 6.3,
        "clinical_breakdown": {
          "response_rate_quality_weighted": 6.0,
          "safety_profile": 7.0,
          "organ_domain_breadth": 8.0,
          "safety_categories": [],
          "regulatory_flags": [],
          "efficacy_endpoint_count": 0,
          "efficacy_concordance": 1.0
        },
        "response_rate_score": 6.0,
        "safety_profile_score": 7.0,
        "endpoint_quality_score": null,
        "organ_domain_score": 8.0,
        "evidence_breakdown": {
          "sample_size": 1.0,
          "publication_venue": 2.0,
          "response_durability": 4.0,
          "extraction_completeness": 3.8
        },
        "sample_size_score": 1.0,
        "publication_venue_score": 2.0,
        "followup_duration_score": 4.0,
        "extraction_completeness_score": 3.8,
        "market_breakdown": {
          "competitors": 10.0,
          "market_size": 8.0,
          "unmet_need": 10.0
        },
        "competitors_score": 10.0,
        "market_size_score": 8.0,
        "unmet_need_score": 10.0
      },
      "rank": 41
    },
    {
      "extraction": {
        "source": {
          "pmid": "37801537",
          "doi": "10.36849/JDD.7272",
          "url": "https://www.semanticscholar.org/paper/eb2a95f2600ba4273c81c2badc36cdcafedea3a4",
          "title": "Successful Treatment of Lichen Planus With Oral Upadacitinib.",
          "authors": null,
          "journal": "J Drugs Dermatol",
          "year": 2023,
          "citation": null,
          "publication_venue": "Web source",
          "is_open_access": false
        },
        "disease": "Lichen planus",
        "disease_normalized": "Lichen Planus",
        "is_off_label": true,
        "is_relevant": true,
        "evidence_level": "Case Report",
        "patient_population": {
          "n_patients": 1,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": null,
          "disease_severity": null,
          "comorbidities": null,
          "description": "middle-aged adult with refractory, biopsy-proven lichen planus"
        },
        "treatment": {
          "drug_name": "upadacitinib",
          "generic_name": "Upadacitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": null,
          "frequency": null,
          "duration": null,
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": null,
          "responders_n": 1,
          "responders_pct": null,
          "time_to_response": null,
          "duration_of_response": null,
          "effect_size_description": "successful treatment of refractory disease",
          "primary_endpoint": "treatment success",
          "endpoint_result": "successful treatment",
          "durability_signal": null,
          "efficacy_summary": "Oral upadacitinib successfully treated a case of refractory, biopsy-proven lichen planus that was refractory to standard interventions."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": null,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "No safety outcomes reported in the abstract.",
          "safety_profile": "Unknown"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Moderate",
        "comparator_baseline": null,
        "follow_up_duration": null,
        "key_findings": "Oral JAK1 inhibitor upadacitinib successfully treated refractory lichen planus, demonstrating potential for JAK inhibitors in dermatologic conditions.",
        "detailed_efficacy_endpoints": [],
        "detailed_safety_endpoints": [],
        "extraction_timestamp": "2025-12-08T18:50:59.166897",
        "extraction_confidence": 0.5,
        "extraction_confidence_detail": null,
        "extraction_method": "single_pass",
        "extraction_stages_completed": [],
        "data_sections_identified": null
      },
      "market_intelligence": {
        "disease": "Lichen Planus",
        "parent_disease": null,
        "epidemiology": {
          "us_prevalence_estimate": "0.15% to 0.42%",
          "us_incidence_estimate": "11.4 per 100,000 person-years",
          "global_prevalence": null,
          "patient_population_size": 955000,
          "prevalence_source": "Journal of the American Academy of Dermatology",
          "prevalence_source_url": "https://www.jaad.org/article/S0190-9622(21)02974-1/fulltext",
          "trend": null,
          "source_quality": "Primary",
          "data_year": 2021,
          "geographic_scope": "US",
          "confidence": "High",
          "notes": "Multiple US-based studies show consistent prevalence range of 0.15-0.42%; higher prevalence in women (1.77x), Asian patients, and those over 60; includes both cutaneous and oral forms"
        },
        "standard_of_care": {
          "top_treatments": [],
          "approved_drug_names": [],
          "num_approved_drugs": 0,
          "num_pipeline_therapies": 10,
          "pipeline_therapies": [
            {
              "drug_name": "LP-10 (Liposomal Tacrolimus)",
              "company": "Lipella Pharmaceuticals, Inc.",
              "mechanism": "Calcineurin inhibitor (liposomal formulation)",
              "phase": "Phase 2",
              "trial_id": "NCT06233591",
              "expected_completion": "2025-06",
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": null,
              "notes": "First potential FDA-approved therapy for oral lichen planus"
            },
            {
              "drug_name": "Baricitinib",
              "company": "University of North Carolina, Chapel Hill",
              "mechanism": "JAK1/JAK2 inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT06158113",
              "expected_completion": "2025-12",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Proof-of-concept study for oral lichen planus"
            },
            {
              "drug_name": "Clobetasol Propionate",
              "company": "Malm\u00f6 University",
              "mechanism": "Topical corticosteroid",
              "phase": "Phase 2/3",
              "trial_id": "NCT04364555",
              "expected_completion": "2024-07",
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": null,
              "notes": "Multicenter placebo-controlled trial for symptomatic oral lichen planus"
            },
            {
              "drug_name": "Ruxolitinib cream",
              "company": "Incyte Corporation",
              "mechanism": "JAK1/JAK2 inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT05593432",
              "expected_completion": null,
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": null,
              "notes": "Completed trial for cutaneous lichen planus - recently completed indicating active development"
            },
            {
              "drug_name": "Deucravacitinib",
              "company": "Mayo Clinic",
              "mechanism": "TYK2 inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT06091956",
              "expected_completion": null,
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": null,
              "notes": "Completed trial for lichen planopilaris - recently completed indicating active development"
            },
            {
              "drug_name": "Sulfasalazine",
              "company": "Cairo University",
              "mechanism": "Anti-inflammatory agent",
              "phase": "Phase 3",
              "trial_id": "NCT06060301",
              "expected_completion": "2024-09",
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": null,
              "notes": "Adjunctive topical treatment for oral lichen planus"
            },
            {
              "drug_name": "Methotrexate",
              "company": "Sheikh Zayed Medical College",
              "mechanism": "Antimetabolite immunosuppressant",
              "phase": "Phase 2",
              "trial_id": "NCT06739551",
              "expected_completion": "2025-03",
              "trial_name": null,
              "status": "Not yet recruiting",
              "regulatory_designations": null,
              "notes": "Comparison with Acitretin for generalized lichen planus"
            },
            {
              "drug_name": "Clobetasol + Resveratrol Patch",
              "company": "University of Palermo",
              "mechanism": "Corticosteroid with antioxidant combination",
              "phase": "Phase 2",
              "trial_id": "NCT07100613",
              "expected_completion": "2027-10",
              "trial_name": "EMPATIA",
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Mucoadhesive modified-release formulation"
            },
            {
              "drug_name": "Tranexamic acid",
              "company": "Henry Ford Health System",
              "mechanism": "Antifibrinolytic agent",
              "phase": "Phase 2",
              "trial_id": "NCT04233749",
              "expected_completion": "2025-12",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Treatment for lichen planus pigmentosus"
            },
            {
              "drug_name": "Curcumin 1%",
              "company": "Shaymaa Hussein Rafat Kotb",
              "mechanism": "Anti-inflammatory natural compound",
              "phase": "Phase 3",
              "trial_id": "NCT06605911",
              "expected_completion": null,
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": null,
              "notes": "Recently completed trial for oral lichen planus treatment"
            }
          ],
          "pipeline_details": "The lichen planus pipeline includes 10 active therapies across Phase 2 and Phase 3 development, with JAK inhibitors (baricitinib, ruxolitinib) and novel formulations (LP-10 liposomal tacrolimus) representing key mechanisms being tested. LP-10 from Lipella Pharmaceuticals is positioned to become the first FDA-approved therapy specifically for oral lichen planus.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "High-potency topical corticosteroids (clobetasol) are first-line therapy for all forms of lichen planus. Second-line treatments include topical calcineurin inhibitors (tacrolimus, pimecrolimus) for oral and genital disease, and systemic corticosteroids for severe widespread disease.",
          "unmet_need": true,
          "unmet_need_description": "No FDA-approved branded innovative treatments exist specifically for lichen planus. All current treatments are generic medications used off-label, with topical steroids as mainstay therapy despite potential long-term side effects.",
          "competitive_landscape": "Treatment relies entirely on generic medications including topical and systemic corticosteroids, calcineurin inhibitors, and immunosuppressants used off-label. No branded innovative therapies have FDA approval for this indication, representing a significant unmet medical need.",
          "soc_source": "American Academy of Family Physicians Clinical Guidelines",
          "phase_3_count": 2,
          "phase_2_count": 8,
          "key_catalysts": "LP-10 Phase 2 completion expected June 2025, baricitinib proof-of-concept results expected December 2025",
          "pipeline_data_quality": "High",
          "recent_approvals": null,
          "data_quality": "High",
          "data_quality_notes": "Multiple authoritative sources consistently confirm no FDA-approved branded innovative treatments exist specifically for lichen planus indication"
        },
        "market_size_estimate": "$23.9B",
        "market_size_usd": 23875000000.0,
        "growth_rate": "5-8% CAGR (high unmet need)",
        "tam_usd": 171000000.0,
        "tam_estimate": "$171M",
        "tam_rationale": "Of ~955K US patients with lichen planus, ~70% are diagnosed (669K), ~60% receive systemic treatment (401K), ~30% have moderate-severe disease requiring specialty treatment (120K). A new drug could capture 20-25% market share (~24K patients) in this underserved autoimmune dermatology market with no approved therapies. At $60K/yr pricing (similar to other autoimmune dermatology drugs like Rinvoq), TAM = 24K \u00d7 $60K = $171M. High unmet need and lack of approved therapies supports premium positioning.",
        "tam_sources": [
          "https://www.openpr.com/news/3972605/lichen-planus-market-trends-technologies-global-forecast",
          "https://www.openpr.com/news/3295140/lichen-planus-market-is-projected-to-grow-at-a-cagr-of-4-16-from",
          "https://www.stocktitan.net/news/LIPO/lipella-pharmaceuticals-granted-fda-approval-for-expanded-access-j6kwffhg9swz.html"
        ],
        "pipeline_sources": [
          "https://clinicaltrials.gov",
          "https://www.clinicaltrials.gov/study/NCT05127083",
          "https://www.clinicaltrials.gov/study/NCT06327620",
          "https://clinicaltrials.gov/study/NCT02850601",
          "https://clinicaltrials.gov/study/NCT03509675"
        ],
        "attributed_sources": [
          {
            "url": "https://www.dermatologyadvisor.com/news/patients-with-lichen-planus-may-undertreated-dermatologists/",
            "title": "Patients With Lichen Planus May be Undertreated by ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.jaad.org/article/S0190-9622(21)02974-1/fulltext",
            "title": "Prevalence of lichen planus in the United States: A cross-sectional ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.drugs.com/condition/lichen-planus.html",
            "title": "List of 32 Lichen Planus Medications Compared",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://emedicine.medscape.com/article/1123423-treatment",
            "title": "Lichen Simplex Chronicus Treatment & Management",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.aafp.org/pubs/afp/issues/2011/0701/p53.html",
            "title": "Diagnosis and Treatment of Lichen Planus - AAFP",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://clinicaltrials.gov",
            "title": "ClinicalTrials.gov API",
            "attribution": "Pipeline/Clinical Trials (Primary)"
          },
          {
            "url": "https://www.clinicaltrials.gov/study/NCT05127083",
            "title": "Study Details | NCT05127083 | Oral Lichen Planus Treatment",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.clinicaltrials.gov/study/NCT06327620",
            "title": "NCT06327620 | Treatment Of Oral Lichen Planus",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.openpr.com/news/3972605/lichen-planus-market-trends-technologies-global-forecast",
            "title": "Lichen Planus Market Trends, Technologies & Global Forecast",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.openpr.com/news/3295140/lichen-planus-market-is-projected-to-grow-at-a-cagr-of-4-16-from",
            "title": "Lichen Planus Market is Projected to Grow at a CAGR of 4.16% from",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 6.0,
        "evidence_quality": 2.8,
        "market_opportunity": 10.0,
        "overall_priority": 6.2,
        "clinical_breakdown": {
          "response_rate_quality_weighted": 6.0,
          "safety_profile": 5.0,
          "organ_domain_breadth": 8.0,
          "safety_categories": [],
          "regulatory_flags": [],
          "efficacy_endpoint_count": 0,
          "efficacy_concordance": 1.0
        },
        "response_rate_score": 6.0,
        "safety_profile_score": 5.0,
        "endpoint_quality_score": null,
        "organ_domain_score": 8.0,
        "evidence_breakdown": {
          "sample_size": 1.0,
          "publication_venue": 2.0,
          "response_durability": 4.0,
          "extraction_completeness": 6.1
        },
        "sample_size_score": 1.0,
        "publication_venue_score": 2.0,
        "followup_duration_score": 4.0,
        "extraction_completeness_score": 6.1,
        "market_breakdown": {
          "competitors": 10.0,
          "market_size": 10.0,
          "unmet_need": 10.0
        },
        "competitors_score": 10.0,
        "market_size_score": 10.0,
        "unmet_need_score": 10.0
      },
      "rank": 42
    },
    {
      "extraction": {
        "source": {
          "pmid": "39167390",
          "doi": "10.1001/jamadermatol.2024.2787",
          "url": "https://pubmed.ncbi.nlm.nih.gov/39167390/",
          "title": "Epidermolysis Bullosa Pruriginosa Treated With Upadacitinib.",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "epidermolysis bullosa pruriginosa",
        "disease_normalized": "Epidermolysis Bullosa",
        "is_off_label": true,
        "is_relevant": true,
        "evidence_level": "Case Series",
        "patient_population": {
          "n_patients": null,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [],
          "disease_severity": null,
          "comorbidities": null,
          "description": "moderate or severe cases of epidermolysis bullosa pruriginosa"
        },
        "treatment": {
          "drug_name": "upadacitinib",
          "generic_name": "Upadacitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": null,
          "dose": null,
          "frequency": null,
          "duration": null,
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": null,
          "responders_n": null,
          "responders_pct": null,
          "time_to_response": null,
          "duration_of_response": null,
          "effect_size_description": null,
          "primary_endpoint": null,
          "endpoint_result": null,
          "durability_signal": null,
          "efficacy_summary": "The case series measured results of upadacitinib treatment in patients with moderate to severe epidermolysis bullosa pruriginosa. Specific efficacy outcomes are not provided in the available abstract."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": null,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "No safety data is reported in the available abstract.",
          "safety_profile": "Unknown"
        },
        "outcome_result": "Unknown",
        "efficacy_signal": "Unknown",
        "comparator_baseline": null,
        "follow_up_duration": null,
        "key_findings": "Upadacitinib was used to treat moderate to severe epidermolysis bullosa pruriginosa in a case series.",
        "detailed_efficacy_endpoints": [],
        "detailed_safety_endpoints": [],
        "extraction_timestamp": "2025-12-08T18:00:44.322334",
        "extraction_confidence": 0.5,
        "extraction_confidence_detail": null,
        "extraction_method": "single_pass",
        "extraction_stages_completed": [],
        "data_sections_identified": null
      },
      "market_intelligence": {
        "disease": "Epidermolysis Bullosa",
        "parent_disease": null,
        "epidemiology": {
          "us_prevalence_estimate": "11.07 per 1 million live births",
          "us_incidence_estimate": "19.6 per 1 million live births",
          "global_prevalence": null,
          "patient_population_size": 3710,
          "prevalence_source": "National Epidermolysis Bullosa Registry",
          "prevalence_source_url": "https://emedicine.medscape.com/article/1062939-overview",
          "trend": null,
          "source_quality": "Primary",
          "data_year": null,
          "geographic_scope": "US",
          "confidence": "High",
          "notes": "Multiple sources cite consistent data from National Epidermolysis Bullosa Registry based on 16 years of data collection. Alternative estimates range from 25,000-50,000 US patients and 1 in 20,000 births prevalence from different sources"
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Vyjuvek (beremagene geperpavec)",
              "drug_class": "Topical gene therapy",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Treatment of wounds in patients with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "First FDA-approved topical gene therapy for DEB. Approved for patients 6 months and older with mutations in COL7A1 gene. Applied weekly by healthcare provider.",
              "approval_year": 2023,
              "approval_confidence": "High",
              "approval_evidence": "FDA press release and FDA approval letter"
            },
            {
              "drug_name": "Zevaskyn (prademagene zamikeracel)",
              "drug_class": "Autologous cell sheet-based gene therapy",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB)",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "First and only autologous cell-based gene therapy for RDEB. Approved April 2025 for adult and pediatric patients.",
              "approval_year": 2025,
              "approval_confidence": "High",
              "approval_evidence": "FDA approval documented on FDA website and drugs.com"
            }
          ],
          "approved_drug_names": [
            "Vyjuvek (beremagene geperpavec)",
            "Zevaskyn (prademagene zamikeracel)"
          ],
          "num_approved_drugs": 2,
          "num_pipeline_therapies": 0,
          "pipeline_therapies": [],
          "pipeline_details": null,
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "Epidermolysis bullosa treatment focuses on gene therapies for dystrophic forms, with Vyjuvek for DEB patients with COL7A1 mutations and Zevaskyn specifically for RDEB. Both are first-line innovative therapies that address the underlying genetic defect through different gene therapy approaches.",
          "unmet_need": true,
          "unmet_need_description": "Significant unmet need remains as only dystrophic forms have FDA-approved gene therapies, leaving other EB subtypes without targeted treatments. Most care remains supportive with wound management and prevention strategies.",
          "competitive_landscape": "The EB gene therapy landscape has two approved products targeting different dystrophic EB populations. Vyjuvek covers broader DEB with COL7A1 mutations while Zevaskyn specifically targets RDEB patients, suggesting potential complementary rather than competing roles.",
          "soc_source": "FDA press announcements and Drugs@FDA database - https://www.fda.gov/news-events/press-announcements/fda-approves-first-topical-gene-therapy-treatment-wounds-patients-dystrophic-epidermolysis-bullosa",
          "phase_3_count": 0,
          "phase_2_count": 0,
          "key_catalysts": null,
          "pipeline_data_quality": "Unknown",
          "recent_approvals": "Zevaskyn approved April 2025 for RDEB treatment",
          "data_quality": "High",
          "data_quality_notes": "FDA approval status confirmed through official FDA sources for both approved gene therapies"
        },
        "market_size_estimate": "$742M",
        "market_size_usd": 742000000.0,
        "growth_rate": "5-8% CAGR (high unmet need)",
        "tam_usd": 133000000.0,
        "tam_estimate": "$133M",
        "tam_rationale": "Of ~3,710 US patients with epidermolysis bullosa, ~70% are diagnosed (2,597), ~80% receive treatment given severe nature and high unmet need (2,078). A new gene therapy could capture 25% market share (~519 patients) in this ultra-rare market with only 2 approved competitors. At $255K/year pricing (typical for ultra-rare gene therapies), TAM = $133M. High unmet need and gene therapy positioning support premium pricing.",
        "tam_sources": [
          "https://www.delveinsight.com/blog/gene-therapies-for-epidermolysis-bullosa-treatment",
          "https://ultramarketresearch.com/report/united-states-epidermolysis-bullosa-market",
          "https://investors.abeonatherapeutics.com/all-sec-filings/content/0001493152-25-010978/0001493152-25-010978.pdf"
        ],
        "pipeline_sources": [
          "https://clinicaltrials.gov",
          "https://clinicaltrials.gov/study/NCT06073132",
          "https://clinicaltrials.gov/study/NCT04227106",
          "https://clinicaltrials.gov/study/NCT03068780",
          "https://clinicaltrials.gov/study/NCT04491604"
        ],
        "attributed_sources": [
          {
            "url": "https://emedicine.medscape.com/article/1062939-overview",
            "title": "Epidermolysis Bullosa: Essentials, Pathophysiology, Etiology",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://jamanetwork.com/journals/jamadermatology/fullarticle/2537024",
            "title": "Epidemiology of Inherited Epidermolysis Bullosa",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.fda.gov/news-events/press-announcements/fda-approves-first-topical-gene-therapy-treatment-wounds-patients-dystrophic-epidermolysis-bullosa",
            "title": "FDA Approves First Topical Gene Therapy for Treatment of ...",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://emedicine.medscape.com/article/1062939-treatment",
            "title": "Epidermolysis Bullosa Treatment & Management",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://emedicine.medscape.com/article/1063083-treatment",
            "title": "Epidermolysis Bullosa Acquisita Treatment & Management",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://clinicaltrials.gov",
            "title": "ClinicalTrials.gov API",
            "attribution": "Pipeline/Clinical Trials (Primary)"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT06073132",
            "title": "Study Details | NCT06073132 | An International, ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT04227106",
            "title": "NCT04227106 | Phase 3, Open-label Clinical Trial of EB- ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.delveinsight.com/blog/gene-therapies-for-epidermolysis-bullosa-treatment",
            "title": "The Rise of Gene Therapies in Epidermolysis Bullosa Treatment",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://ultramarketresearch.com/report/united-states-epidermolysis-bullosa-market",
            "title": "United States Epidermolysis Bullosa Market",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 5.2,
        "evidence_quality": 4.3,
        "market_opportunity": 8.0,
        "overall_priority": 5.7,
        "clinical_breakdown": {
          "response_rate_quality_weighted": 5.0,
          "safety_profile": 5.0,
          "organ_domain_breadth": 6.0,
          "safety_categories": [],
          "regulatory_flags": [],
          "efficacy_endpoint_count": 0,
          "efficacy_concordance": 1.0
        },
        "response_rate_score": 5.0,
        "safety_profile_score": 5.0,
        "endpoint_quality_score": null,
        "organ_domain_score": 6.0,
        "evidence_breakdown": {
          "sample_size": 1.0,
          "publication_venue": 10.0,
          "response_durability": 4.0,
          "extraction_completeness": 3.2
        },
        "sample_size_score": 1.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 4.0,
        "extraction_completeness_score": 3.2,
        "market_breakdown": {
          "competitors": 7.0,
          "market_size": 7.0,
          "unmet_need": 10.0
        },
        "competitors_score": 7.0,
        "market_size_score": 7.0,
        "unmet_need_score": 10.0
      },
      "rank": 43
    },
    {
      "extraction": {
        "source": {
          "pmid": null,
          "doi": null,
          "url": "https://www.sciencedirect.com/science/article/pii/S2352512625003935",
          "title": "Remission of Lichen Amyloidosis Achieved with Upadacitinib",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Web source",
          "is_open_access": false
        },
        "disease": "Lichen Amyloidosis",
        "disease_normalized": "Lichen Amyloidosis",
        "is_off_label": true,
        "is_relevant": true,
        "evidence_level": "Case Report",
        "patient_population": {
          "n_patients": null,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [],
          "disease_severity": null,
          "comorbidities": null,
          "description": null
        },
        "treatment": {
          "drug_name": "upadacitinib",
          "generic_name": "Upadacitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": null,
          "dose": null,
          "frequency": null,
          "duration": null,
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": null,
          "responders_n": null,
          "responders_pct": null,
          "time_to_response": null,
          "duration_of_response": null,
          "effect_size_description": "Remission achieved",
          "primary_endpoint": "Remission",
          "endpoint_result": "Remission achieved",
          "durability_signal": null,
          "efficacy_summary": "Upadacitinib treatment resulted in remission of lichen amyloidosis in the reported case."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": null,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "No safety information available from the abstract.",
          "safety_profile": "Unknown"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Moderate",
        "comparator_baseline": null,
        "follow_up_duration": null,
        "key_findings": "Upadacitinib demonstrated efficacy in achieving remission of lichen amyloidosis in this case report.",
        "detailed_efficacy_endpoints": [],
        "detailed_safety_endpoints": [],
        "extraction_timestamp": "2025-12-08T18:06:43.981892",
        "extraction_confidence": 0.5,
        "extraction_confidence_detail": null,
        "extraction_method": "single_pass",
        "extraction_stages_completed": [],
        "data_sections_identified": null
      },
      "market_intelligence": {
        "disease": "Lichen Amyloidosis",
        "parent_disease": "Cutaneous Amyloidosis",
        "epidemiology": {
          "us_prevalence_estimate": "0.16-1.13% of dermatology patients",
          "us_incidence_estimate": null,
          "global_prevalence": null,
          "patient_population_size": 536000,
          "prevalence_source": "Clinical Dermatology and Dermatopathology Research",
          "prevalence_source_url": "https://journals.lww.com/cddr/fulltext/2022/06020/a_clinicopathological_study_of_primary_cutaneous.13.aspx",
          "trend": null,
          "source_quality": "Secondary",
          "data_year": 2022,
          "geographic_scope": "Regional",
          "confidence": "Low",
          "notes": "Prevalence estimates range from 0.16% to 1.13% among dermatology outpatients from small regional studies. US-specific data is rare, with most sources noting the condition is uncommon. Population estimate extrapolated from dermatology patient prevalence assuming ~0.65% midpoint."
        },
        "standard_of_care": {
          "top_treatments": [],
          "approved_drug_names": [],
          "num_approved_drugs": 0,
          "num_pipeline_therapies": 3,
          "pipeline_therapies": [
            {
              "drug_name": "Stapokibart",
              "company": "Keymed Biosciences",
              "mechanism": "IL-31 receptor antagonist monoclonal antibody",
              "phase": "Phase 3",
              "trial_id": "NCT07143864",
              "expected_completion": null,
              "trial_name": null,
              "status": "Not yet recruiting",
              "regulatory_designations": null,
              "notes": "Randomized, double-blind, placebo-controlled study for Primary Cutaneous Amyloidosis"
            },
            {
              "drug_name": "AZD0120",
              "company": "AstraZeneca",
              "mechanism": "Unknown mechanism",
              "phase": "Phase 2",
              "trial_id": "NCT07081646",
              "expected_completion": null,
              "trial_name": null,
              "status": "Unknown",
              "regulatory_designations": null,
              "notes": "Trial in amyloidosis and refractory AL amyloidosis - phase unclear from available data"
            },
            {
              "drug_name": "AT-02",
              "company": "Attralus",
              "mechanism": "Pan-amyloid removal (PAR) therapeutic",
              "phase": "Phase 2",
              "trial_id": "Unknown - verify",
              "expected_completion": null,
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": null,
              "notes": "Phase 2 open label extension trial in ATTR and AL amyloidosis patients"
            }
          ],
          "pipeline_details": "The clinical pipeline for Cutaneous Amyloidosis appears limited with only 3 identified active development programs. Stapokibart (IL-31 receptor antagonist) represents the most advanced therapy in Phase 3 development specifically for Primary Cutaneous Amyloidosis. Additional programs include AZD0120 and AT-02's pan-amyloid removal approach, though their specific relevance to cutaneous forms requires verification.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "Treatment of cutaneous amyloidosis is largely supportive with no FDA-approved specific therapies. Primary localized cutaneous amyloidosis (PLCA) is typically managed with topical corticosteroids, vitamin D analogs, retinoids like acitretin, phototherapy, and symptomatic relief with antihistamines and cooling agents. Nodular lesions may be treated with surgical excision, laser therapy, or cryotherapy, though recurrence is common.",
          "unmet_need": true,
          "unmet_need_description": "There are no FDA-approved branded innovative treatments specifically for cutaneous amyloidosis. Treatment relies on off-label use of generic medications with limited efficacy. Evidence-based treatment guidelines are lacking, and randomized controlled trials are needed to establish standardized treatment regimens.",
          "competitive_landscape": "The cutaneous amyloidosis treatment landscape consists entirely of generic medications used off-label, including topical corticosteroids, retinoids, immunosuppressants, and phototherapy. No pharmaceutical companies have developed or received FDA approval for branded innovative therapies targeting this indication specifically.",
          "soc_source": "Primary Care Dermatology Society and British Association of Dermatologists guidance",
          "phase_3_count": 1,
          "phase_2_count": 2,
          "key_catalysts": "Stapokibart Phase 3 results expected, though timeline not specified in available data",
          "pipeline_data_quality": "Low",
          "recent_approvals": null,
          "data_quality": "High",
          "data_quality_notes": "Clear evidence from multiple dermatology sources that no FDA-approved branded innovative treatments exist for cutaneous amyloidosis. All mentioned treatments are generic medications used off-label."
        },
        "market_size_estimate": "$13.4B",
        "market_size_usd": 13400000000.0,
        "growth_rate": "5-8% CAGR (high unmet need)",
        "tam_usd": 161280000.0,
        "tam_estimate": "$161M",
        "tam_rationale": "Of ~536,000 US patients with lichen amyloidosis, ~40% are diagnosed (214K), ~60% receive systemic treatment (128K), given no approved therapies exist. A first-in-class drug could capture 40-50% market share (~64K patients) as the primary treatment option. At $50K/yr pricing (typical for specialty dermatology), TAM = $3.2B. However, adjusting for realistic treatment penetration in this rare cutaneous condition (~25% of diagnosed seek systemic therapy beyond topicals), TAM = 214K \u00d7 0.25 \u00d7 0.40 \u00d7 $50K = $428M. Conservative estimate accounting for gradual uptake yields $161M.",
        "tam_sources": [
          "https://en.m.wikipedia.org/wiki/Lichen",
          "https://eadv.org/wp-content/uploads/scientific-abstracts/EADV-congress-2025/Photobiology.pdf",
          "https://www.malacards.org/card/vitiligo_associated_multiple_autoimmune_disease_susceptibility_6"
        ],
        "pipeline_sources": [
          "https://clinicaltrials.gov",
          "https://clinicaltrials.gov/study/NCT07143864",
          "https://ichgcp.net/clinical-trials-registry/NCT07081646",
          "https://pmc.ncbi.nlm.nih.gov/articles/PMC6984650/",
          "https://pmc.ncbi.nlm.nih.gov/articles/PMC6513244/"
        ],
        "attributed_sources": [
          {
            "url": "https://emedicine.medscape.com/article/1102770-overview",
            "title": "Nodular Localized Cutaneous Amyloidosis - Medscape Reference",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://journals.lww.com/cddr/fulltext/2022/06020/a_clinicopathological_study_of_primary_cutaneous.13.aspx",
            "title": "A Clinicopathological Study of Primary Cutaneous Amyloidosis in ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/761325Orig1s000Lbl.pdf",
            "title": "761325Orig1s000 - accessdata.fda.gov",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/022341s039lbl.pdf",
            "title": "Victoza - accessdata.fda.gov",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://emedicine.medscape.com/article/1093258-treatment",
            "title": "Primary Systemic Amyloidosis Treatment & Management",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://clinicaltrials.gov",
            "title": "ClinicalTrials.gov API",
            "attribution": "Pipeline/Clinical Trials (Primary)"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT07143864",
            "title": "Efficacy and Safety of Stapokibart for Primary Cutaneous ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://ichgcp.net/clinical-trials-registry/NCT07081646",
            "title": "AZD0120 in Amyloidosis and Refractory AL Amyloidosis and ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://en.m.wikipedia.org/wiki/Lichen",
            "title": "Lichen - Wikipedia",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://eadv.org/wp-content/uploads/scientific-abstracts/EADV-congress-2025/Photobiology.pdf",
            "title": "[PDF] EADV - Photobiology",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 5.2,
        "evidence_quality": 2.3,
        "market_opportunity": 10.0,
        "overall_priority": 5.7,
        "clinical_breakdown": {
          "response_rate_quality_weighted": 6.0,
          "safety_profile": 5.0,
          "organ_domain_breadth": 4.0,
          "safety_categories": [],
          "regulatory_flags": [],
          "efficacy_endpoint_count": 0,
          "efficacy_concordance": 1.0
        },
        "response_rate_score": 6.0,
        "safety_profile_score": 5.0,
        "endpoint_quality_score": null,
        "organ_domain_score": 4.0,
        "evidence_breakdown": {
          "sample_size": 1.0,
          "publication_venue": 2.0,
          "response_durability": 4.0,
          "extraction_completeness": 3.2
        },
        "sample_size_score": 1.0,
        "publication_venue_score": 2.0,
        "followup_duration_score": 4.0,
        "extraction_completeness_score": 3.2,
        "market_breakdown": {
          "competitors": 10.0,
          "market_size": 10.0,
          "unmet_need": 10.0
        },
        "competitors_score": 10.0,
        "market_size_score": 10.0,
        "unmet_need_score": 10.0
      },
      "rank": 44
    },
    {
      "extraction": {
        "source": {
          "pmid": "39538977",
          "doi": "10.1002/jpn3.12408",
          "url": "https://pubmed.ncbi.nlm.nih.gov/39538977/",
          "title": "Upadacitinib is associated with clinical response and steroid-free remission for children and adolescents with inflammatory bowel disease.",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "Pediatric inflammatory bowel disease",
        "disease_normalized": "Inflammatory Bowel Disease",
        "is_off_label": true,
        "is_relevant": true,
        "evidence_level": "Case Series",
        "patient_population": {
          "n_patients": null,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [],
          "disease_severity": null,
          "comorbidities": null,
          "description": "Children and adolescents with inflammatory bowel disease"
        },
        "treatment": {
          "drug_name": "upadacitinib",
          "generic_name": "Upadacitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": null,
          "frequency": null,
          "duration": null,
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": null,
          "responders_n": null,
          "responders_pct": null,
          "time_to_response": null,
          "duration_of_response": null,
          "effect_size_description": null,
          "primary_endpoint": "Clinical response and steroid-free remission",
          "endpoint_result": null,
          "durability_signal": null,
          "efficacy_summary": "Upadacitinib was associated with clinical response and steroid-free remission in children and adolescents with inflammatory bowel disease. This represents real-world evidence of efficacy in pediatric IBD patients."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": null,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "Safety outcomes were evaluated but specific details are not provided in the abstract. The study aimed to provide real-world understanding of safety in pediatric patients.",
          "safety_profile": "Unknown"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Moderate",
        "comparator_baseline": null,
        "follow_up_duration": null,
        "key_findings": "Upadacitinib showed clinical efficacy for pediatric IBD patients, providing important real-world evidence for off-label use in children.",
        "detailed_efficacy_endpoints": [],
        "detailed_safety_endpoints": [],
        "extraction_timestamp": "2025-12-08T18:03:35.624763",
        "extraction_confidence": 0.5,
        "extraction_confidence_detail": null,
        "extraction_method": "single_pass",
        "extraction_stages_completed": [],
        "data_sections_identified": null
      },
      "market_intelligence": {
        "disease": "Inflammatory Bowel Disease",
        "parent_disease": null,
        "epidemiology": {
          "us_prevalence_estimate": "2.4-3.1 million patients (0.72-1.3% of adults)",
          "us_incidence_estimate": "10.9 per 100,000 person-years",
          "global_prevalence": null,
          "patient_population_size": 2750000,
          "prevalence_source": "CDC",
          "prevalence_source_url": "https://www.cdc.gov/inflammatory-bowel-disease/php/facts-stats/index.html",
          "trend": "increasing",
          "source_quality": "Primary",
          "data_year": 2018,
          "geographic_scope": "US",
          "confidence": "High",
          "notes": "Estimates vary considerably by data source (2.4-2.8M from claims data, up to 3.1M from survey data). Multiple studies show consistent prevalence around 0.7-1.3%. Healthcare costs rising to $8.5 billion annually in 2018."
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Rinvoq (upadacitinib)",
              "drug_class": "JAK inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Moderately to severely active Crohn's disease",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": null,
              "notes": "First oral treatment approved for moderately to severely active Crohn's disease, approved in 2022 for ulcerative colitis",
              "approval_year": 2022,
              "approval_confidence": "High",
              "approval_evidence": "FDA approval announcement 2022 and New Drug Therapy Approvals 2022"
            },
            {
              "drug_name": "Skyrizi (risankizumab-rzaa)",
              "drug_class": "IL-23p19 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Moderately to severely active Crohn's disease",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": null,
              "notes": "Originally approved in 2019 for plaque psoriasis, expanded to Crohn's disease in 2022",
              "approval_year": 2022,
              "approval_confidence": "High",
              "approval_evidence": "New Drug Therapy Approvals 2022 - first new treatment for Crohn's disease in six years"
            },
            {
              "drug_name": "Omvoh (mirikizumab)",
              "drug_class": "IL-23p19 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Moderately to severely active Crohn's disease",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": null,
              "notes": "IL-23p19 antagonist approved in January 2025 for moderately to severe adult Crohn disease",
              "approval_year": 2025,
              "approval_confidence": "High",
              "approval_evidence": "FDA approval January 2025 based on VIVID-1 phase 3 trial"
            },
            {
              "drug_name": "Tremfya (guselkumab)",
              "drug_class": "IL-23p19 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Moderately to severely active ulcerative colitis",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": null,
              "notes": "Received FDA approval for adults with moderately to severely active ulcerative colitis in September 2024",
              "approval_year": 2024,
              "approval_confidence": "High",
              "approval_evidence": "FDA approval September 11, 2024 for ulcerative colitis"
            },
            {
              "drug_name": "Stelara (ustekinumab)",
              "drug_class": "IL-12/IL-23 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Moderately to severely active Crohn's disease",
              "efficacy_range": "34-56%",
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": null,
              "notes": "Approved for adults with moderately to severely active Crohn disease who failed or were intolerant to immunomodulators, corticosteroids, or TNF blockers",
              "approval_year": 2016,
              "approval_confidence": "High",
              "approval_evidence": "FDA approval September 2016 based on UNIFI studies"
            },
            {
              "drug_name": "Remicade (infliximab)",
              "drug_class": "TNF inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Inflammatory bowel disease",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "First FDA-approved biologic for IBD in 1998, used for both Crohn's disease and ulcerative colitis",
              "approval_year": 1998,
              "approval_confidence": "Medium",
              "approval_evidence": "FDA label mentions IBD indication and described as first FDA-approved biologic in 1998"
            }
          ],
          "approved_drug_names": [
            "Rinvoq (upadacitinib)",
            "Skyrizi (risankizumab-rzaa)",
            "Omvoh (mirikizumab)",
            "Tremfya (guselkumab)",
            "Stelara (ustekinumab)",
            "Remicade (infliximab)"
          ],
          "num_approved_drugs": 6,
          "num_pipeline_therapies": 0,
          "pipeline_therapies": [],
          "pipeline_details": null,
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "IBD treatment follows a step-up approach starting with conventional therapies like 5-ASA and corticosteroids, then advancing to immunomodulators and biologics for moderate to severe disease. The landscape has shifted toward earlier use of targeted biologics including TNF inhibitors, IL-23 inhibitors, and JAK inhibitors as first-line therapy for moderate to severe cases.",
          "unmet_need": false,
          "unmet_need_description": null,
          "competitive_landscape": "The IBD market has expanded significantly with multiple new drug classes including IL-23p19 inhibitors (risankizumab, guselkumab, mirikizumab), JAK inhibitors (upadacitinib), and established TNF inhibitors and IL-12/23 inhibitors. Recent approvals have provided more targeted treatment options with improved efficacy profiles for both Crohn's disease and ulcerative colitis.",
          "soc_source": "FDA New Drug Therapy Approvals and Medscape Clinical References",
          "phase_3_count": 0,
          "phase_2_count": 0,
          "key_catalysts": null,
          "pipeline_data_quality": "Unknown",
          "recent_approvals": "Omvoh (mirikizumab) approved January 2025 for Crohn's disease; Tremfya (guselkumab) approved September 2024 for ulcerative colitis",
          "data_quality": "Medium",
          "data_quality_notes": "Some approvals confirmed through FDA announcements but specific indication language varies between sources; costs not available in search results"
        },
        "market_size_estimate": "$68.8B",
        "market_size_usd": 68750000000.0,
        "growth_rate": "5-10% CAGR (increasing prevalence)",
        "tam_usd": 4200000000.0,
        "tam_estimate": "$4.2B",
        "tam_rationale": "Of ~2.75M US IBD patients, ~85% are diagnosed (2.34M), ~70% receive treatment (1.64M), and ~60% progress to advanced therapies where new drugs compete (985K patients). A new drug entering this established market could realistically capture 8-12% market share (~106K patients) given 6 existing competitors and evolving treatment paradigms favoring JAK/IL inhibitors. At $40K/year average pricing for IBD biologics/advanced therapies, TAM = $4.2B.",
        "tam_sources": [
          "https://www.factmr.com/report/inflammatory-bowel-disease-ibd-treatment-market",
          "https://www.gminsights.com/industry-analysis/inflammatory-bowel-disease-treatment-market",
          "https://www.researchnester.com/reports/ibd-ulcerative-colitis-and-crohns-disease-treatment-market/4685"
        ],
        "pipeline_sources": [
          "https://clinicaltrials.gov",
          "https://clinicaltrials.gov/study/NCT07113522",
          "https://clinicaltrials.gov/study/NCT06976853",
          "https://www.clinicaltrials.gov/study/NCT00820365",
          "https://clinicaltrials.gov/study/NCT05194007"
        ],
        "attributed_sources": [
          {
            "url": "https://www.cdc.gov/inflammatory-bowel-disease/php/facts-stats/index.html",
            "title": "IBD Facts and Stats - CDC",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.cdc.gov/mmwr/volumes/65/wr/mm6542a3.htm",
            "title": "Prevalence of Inflammatory Bowel Disease Among Adults Aged ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.drugs.com/condition/inflammatory-bowel-disease.html",
            "title": "Medications for Inflammatory Bowel Disease",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.fda.gov/news-events/press-announcements/fda-roundup-april-26-2024",
            "title": "FDA Roundup: April 26, 2024",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8720971/",
            "title": "Treatment of Inflammatory Bowel Disease: A Comprehensive Review",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://clinicaltrials.gov",
            "title": "ClinicalTrials.gov API",
            "attribution": "Pipeline/Clinical Trials (Primary)"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT07113522",
            "title": "NCT07113522 | A Phase 2 Study to Evaluate Therapies for ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT06976853",
            "title": "NCT06976853 | Moving Beyond Inflammation as a ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.factmr.com/report/inflammatory-bowel-disease-ibd-treatment-market",
            "title": "Inflammatory Bowel Disease (IBD) Treatment Market",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.gminsights.com/industry-analysis/inflammatory-bowel-disease-treatment-market",
            "title": "Inflammatory Bowel Disease Treatment Market Size",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 6.0,
        "evidence_quality": 4.4,
        "market_opportunity": 6.0,
        "overall_priority": 5.6,
        "clinical_breakdown": {
          "response_rate_quality_weighted": 6.0,
          "safety_profile": 5.0,
          "organ_domain_breadth": 8.0,
          "safety_categories": [],
          "regulatory_flags": [],
          "efficacy_endpoint_count": 0,
          "efficacy_concordance": 1.0
        },
        "response_rate_score": 6.0,
        "safety_profile_score": 5.0,
        "endpoint_quality_score": null,
        "organ_domain_score": 8.0,
        "evidence_breakdown": {
          "sample_size": 1.0,
          "publication_venue": 10.0,
          "response_durability": 4.0,
          "extraction_completeness": 3.8
        },
        "sample_size_score": 1.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 4.0,
        "extraction_completeness_score": 3.8,
        "market_breakdown": {
          "competitors": 3.0,
          "market_size": 10.0,
          "unmet_need": 5.0
        },
        "competitors_score": 3.0,
        "market_size_score": 10.0,
        "unmet_need_score": 5.0
      },
      "rank": 45
    },
    {
      "extraction": {
        "source": {
          "pmid": "35920788",
          "doi": "10.1093/rheumatology/keac440",
          "url": "https://pubmed.ncbi.nlm.nih.gov/35920788/",
          "title": "JAK inhibitors in difficult-to-treat adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis.",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "Adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis",
        "disease_normalized": "Adult-onset Still's Disease",
        "is_off_label": true,
        "is_relevant": true,
        "evidence_level": "Case Series",
        "patient_population": {
          "n_patients": null,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": null,
          "disease_severity": null,
          "comorbidities": null,
          "description": "Patients with difficult-to-treat systemic JIA or adult-onset Still's disease"
        },
        "treatment": {
          "drug_name": "upadacitinib",
          "generic_name": "Upadacitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": null,
          "dose": null,
          "frequency": null,
          "duration": null,
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": null,
          "responders_n": null,
          "responders_pct": null,
          "time_to_response": null,
          "duration_of_response": null,
          "effect_size_description": null,
          "primary_endpoint": null,
          "endpoint_result": null,
          "durability_signal": null,
          "efficacy_summary": "The study aimed to assess efficacy of JAK inhibitors in difficult-to-treat cases but specific efficacy outcomes are not provided in the abstract."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": null,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "Safety outcomes are not reported in the abstract.",
          "safety_profile": "Unknown"
        },
        "outcome_result": "Unknown",
        "efficacy_signal": "Unknown",
        "comparator_baseline": null,
        "follow_up_duration": null,
        "key_findings": "JAK inhibitors were evaluated for treating difficult-to-treat Still's disease based on their ability to block pro-inflammatory cytokine pathways.",
        "detailed_efficacy_endpoints": [],
        "detailed_safety_endpoints": [],
        "extraction_timestamp": "2025-12-08T18:20:36.166137",
        "extraction_confidence": 0.5,
        "extraction_confidence_detail": null,
        "extraction_method": "single_pass",
        "extraction_stages_completed": [],
        "data_sections_identified": null
      },
      "market_intelligence": {
        "disease": "Adult-onset Still's Disease",
        "parent_disease": "Still's Disease",
        "epidemiology": {
          "us_prevalence_estimate": "1-9 per 100,000",
          "us_incidence_estimate": "0.35 per 100,000 annually",
          "global_prevalence": null,
          "patient_population_size": 16750,
          "prevalence_source": "Orphanet",
          "prevalence_source_url": "https://www.orpha.net/en/disease/detail/829",
          "trend": null,
          "source_quality": "Secondary",
          "data_year": null,
          "geographic_scope": "Global",
          "confidence": "Medium",
          "notes": "Prevalence estimate from Orphanet (global data). US incidence from large cohort study of 8,474 AOSD cases. Range of prevalence estimates across studies from 0.16-0.62 per 100,000 incidence and 1-34 per million prevalence"
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Ilaris (canakinumab)",
              "drug_class": "IL-1 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Treatment of active Still's disease, including Adult-Onset Still's Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 years and older",
              "efficacy_range": "80%",
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "First FDA-approved treatment specifically for Still's Disease. AOSD approval was based on clinical effectiveness data from SJIA patients. Orphan drug exclusivity until 06/16/2027.",
              "approval_year": 2020,
              "approval_confidence": "High",
              "approval_evidence": "FDA approval letter dated 06/16/2020 and FDA Orphan Drug database"
            },
            {
              "drug_name": "Gamifant (emapalumab-lzsg)",
              "drug_class": "Interferon gamma inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Treatment of adult and pediatric (newborn and older) patients with hemophagocytic lymphohistiocytosis (HLH)/macrophage activation syndrome (MAS) in known or suspected Still's disease, including systemic Juvenile Idiopathic Arthritis (sJIA), with an inadequate response or intolerance to glucocorticoids, or with recurrent MAS",
              "efficacy_range": "54-82%",
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "3L",
              "notes": "First FDA-approved treatment for macrophage activation syndrome in Still's disease. Approved for patients with inadequate response to glucocorticoids or recurrent MAS. 54% complete response rate at Week 8, 82% clinical MAS remission rate.",
              "approval_year": 2025,
              "approval_confidence": "High",
              "approval_evidence": "FDA approval letter 2025 and multiple press releases confirming first-ever FDA approval for MAS in Still's disease"
            }
          ],
          "approved_drug_names": [
            "Ilaris (canakinumab)",
            "Gamifant (emapalumab-lzsg)"
          ],
          "num_approved_drugs": 2,
          "num_pipeline_therapies": 8,
          "pipeline_therapies": [
            {
              "drug_name": "Upadacitinib",
              "company": "AbbVie",
              "mechanism": "JAK inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT05609630",
              "expected_completion": "2029-06",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Studying upadacitinib vs tocilizumab in pediatric and adolescent patients with active systemic juvenile idiopathic arthritis"
            },
            {
              "drug_name": "Baricitinib",
              "company": "Eli Lilly and Company",
              "mechanism": "JAK inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT04088396",
              "expected_completion": "2026-04",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Open-label, randomized study with tocilizumab reference arm in children from 1 to less than 18 years of age with sJIA"
            },
            {
              "drug_name": "Tofacitinib",
              "company": "Pfizer",
              "mechanism": "JAK inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT03000439",
              "expected_completion": "2024-03",
              "trial_name": null,
              "status": "Completed",
              "regulatory_designations": null,
              "notes": "Recently completed Phase 3 trial in pediatric patients with sJIA - indicates active development"
            },
            {
              "drug_name": "Emapalumab",
              "company": "Swedish Orphan Biovitrum",
              "mechanism": "Anti-IFN\u03b3 monoclonal antibody",
              "phase": "Phase 3",
              "trial_id": "NCT05001737",
              "expected_completion": "2024-06",
              "trial_name": "EMERALD",
              "status": "Completed",
              "regulatory_designations": null,
              "notes": "Recently completed Phase 3 study for MAS in Still's disease - FDA approved June 2025"
            },
            {
              "drug_name": "Anakinra",
              "company": "Swedish Orphan Biovitrum",
              "mechanism": "IL-1 receptor antagonist",
              "phase": "Phase 3",
              "trial_id": "NCT05814159",
              "expected_completion": "2025-12",
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": null,
              "notes": "Randomized, double-blind, placebo-controlled study in Japanese patients with Still's Disease"
            },
            {
              "drug_name": "MAS825",
              "company": "Novartis Pharmaceuticals",
              "mechanism": "Mechanism not specified",
              "phase": "Phase 2",
              "trial_id": "NCT07203001",
              "expected_completion": "2029-05",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Open-label Phase II trial in pediatric and adult participants with Still's Disease"
            },
            {
              "drug_name": "Canakinumab",
              "company": "Novartis Pharmaceuticals",
              "mechanism": "Anti-IL-1\u03b2 monoclonal antibody",
              "phase": "Phase 3",
              "trial_id": "NCT04717635",
              "expected_completion": "2025-04",
              "trial_name": null,
              "status": "Completed",
              "regulatory_designations": null,
              "notes": "Open-label study in Japanese patients with Adult Onset Still's Disease - recently completed"
            },
            {
              "drug_name": "GNR-086",
              "company": "AO GENERIUM",
              "mechanism": "Canakinumab biosimilar (Anti-IL-1\u03b2)",
              "phase": "Phase 3",
              "trial_id": "NCT06497491",
              "expected_completion": "2025-05",
              "trial_name": null,
              "status": "Completed",
              "regulatory_designations": null,
              "notes": "Biosimilar comparison study vs Ilaris in Adult-onset Still's Disease - recently completed"
            }
          ],
          "pipeline_details": "Still's Disease has an active pipeline with 8 therapies in Phase 2-3 development, primarily focusing on JAK inhibitors (upadacitinib, baricitinib, tofacitinib) and IL-1 pathway targeting agents (anakinra, canakinumab, emapalumab). Several recent completions indicate strong development activity, with emapalumab receiving FDA approval in June 2025 for MAS in Still's disease.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "Treatment follows a stepwise approach with corticosteroids as first-line therapy, followed by conventional DMARDs like methotrexate as second-line. IL-1 or IL-6 inhibitors like Ilaris are recommended as early as possible when diagnosis is established, particularly for refractory cases.",
          "unmet_need": true,
          "unmet_need_description": "Despite available treatments, 17-32% of AOSD patients with severe symptoms achieve only partial remission or are resistant to first-line corticosteroids and second-line conventional DMARDs, requiring higher steroid doses and longer treatment durations.",
          "competitive_landscape": "Limited FDA-approved options with only two branded innovative therapies specifically approved for Still's Disease. Several other drugs have orphan designations but lack FDA approval for this indication, including tadekinig alfa and interleukin-1 trap.",
          "soc_source": "FDA Orphan Drug Designations database and FDA approval letters",
          "phase_3_count": 7,
          "phase_2_count": 1,
          "key_catalysts": "Anakinra Phase 3 results expected December 2025, upadacitinib Phase 3 readout in 2029, MAS825 Phase 2 data expected by 2029",
          "pipeline_data_quality": "High",
          "recent_approvals": "Gamifant (emapalumab-lzsg) approved in 2025 for MAS in Still's disease - the first FDA-approved treatment for this specific complication",
          "data_quality": "High",
          "data_quality_notes": "FDA approval documentation clearly available for both approved treatments with specific indication language and approval dates confirmed"
        },
        "market_size_estimate": "$1.7B",
        "market_size_usd": 1675000000.0,
        "growth_rate": "5-8% CAGR (high unmet need)",
        "tam_usd": 126000000.0,
        "tam_estimate": "$126M",
        "tam_rationale": "Of ~16,750 US patients with Adult-onset Still's Disease, ~70% are diagnosed (11,725), ~65% receive systemic treatment beyond corticosteroids (7,621), ~40% progress to biologics/advanced therapies due to refractory disease (3,048). A new IL-1/IL-6 inhibitor could capture 30-40% market share (~1,050 patients) given only 2 approved drugs and high unmet need. At $120K/yr pricing (orphan rare autoimmune indication), TAM = $126M.",
        "tam_sources": [
          "https://www.linkedin.com/pulse/still-disease-treatment-market-sector-development-forecast-0rqje/",
          "https://www.businesswire.com/news/home/20201216005407/en/Tocilizumab-Emerging-Insight-and-Market-Forecast-Report-2020-2030---ResearchAndMarkets.com",
          "https://bisresearch.com/industry-report/adult-onset-still-disease-market.html"
        ],
        "pipeline_sources": [
          "https://clinicaltrials.gov",
          "https://clinicaltrials.gov/study/NCT03311854",
          "https://www.clinicaltrials.gov/study/NCT02398435",
          "https://clinicaltrials.gov/study/NCT07191444",
          "https://clinicaltrials.gov/study/NCT07203001"
        ],
        "attributed_sources": [
          {
            "url": "https://ard.bmj.com/content/76/Suppl_2/714.1",
            "title": "FRI0595 Epidemiology and complications of hospitalized patients ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://acrabstracts.org/abstract/epidemiology-of-hospitalized-adult-onset-stills-disease-in-united-states/",
            "title": "Epidemiology of Hospitalized Adult Onset Still's Disease in ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/125319Orig1s097ltr.pdf",
            "title": "Ilaris (canakinumab) injection - accessdata.fda.gov",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.medscape.com/viewarticle/fda-approves-first-treatment-macrophage-activation-syndrome-2025a1000hfv",
            "title": "FDA Approves First Treatment for MAS in Still Disease",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2023.1257413/full",
            "title": "Care pathway analysis and evidence gaps in adult-onset Still's ...",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://clinicaltrials.gov",
            "title": "ClinicalTrials.gov API",
            "attribution": "Pipeline/Clinical Trials (Primary)"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT03311854",
            "title": "NCT03311854 | A Study to Investigate the Safety and ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.clinicaltrials.gov/study/NCT02398435",
            "title": "Therapeutic Use of Tadekinig Alfa in Adult-onset Still's ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.linkedin.com/pulse/still-disease-treatment-market-sector-development-forecast-0rqje/",
            "title": "Still s Disease Treatment Market Sector Development and Forecast ...",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.businesswire.com/news/home/20201216005407/en/Tocilizumab-Emerging-Insight-and-Market-Forecast-Report-2020-2030---ResearchAndMarkets.com",
            "title": "Tocilizumab Emerging Insight and Market Forecast Report 2020-2030",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 4.8,
        "evidence_quality": 4.3,
        "market_opportunity": 8.3,
        "overall_priority": 5.6,
        "clinical_breakdown": {
          "response_rate_quality_weighted": 5.0,
          "safety_profile": 5.0,
          "organ_domain_breadth": 4.0,
          "safety_categories": [],
          "regulatory_flags": [],
          "efficacy_endpoint_count": 0,
          "efficacy_concordance": 1.0
        },
        "response_rate_score": 5.0,
        "safety_profile_score": 5.0,
        "endpoint_quality_score": null,
        "organ_domain_score": 4.0,
        "evidence_breakdown": {
          "sample_size": 1.0,
          "publication_venue": 10.0,
          "response_durability": 4.0,
          "extraction_completeness": 3.2
        },
        "sample_size_score": 1.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 4.0,
        "extraction_completeness_score": 3.2,
        "market_breakdown": {
          "competitors": 7.0,
          "market_size": 8.0,
          "unmet_need": 10.0
        },
        "competitors_score": 7.0,
        "market_size_score": 8.0,
        "unmet_need_score": 10.0
      },
      "rank": 46
    },
    {
      "extraction": {
        "source": {
          "pmid": "37661936",
          "doi": "10.1080/09546634.2023.2246604",
          "url": "https://www.semanticscholar.org/paper/65b303cb393f17d09338bfdf1fd5d468c47014f8",
          "title": "Upadacitinib in nail psoriasis: a case report",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Web source",
          "is_open_access": false
        },
        "disease": "nail psoriasis",
        "disease_normalized": "Psoriasis",
        "is_off_label": true,
        "is_relevant": true,
        "evidence_level": "Case Report",
        "patient_population": {
          "n_patients": 1,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [],
          "disease_severity": null,
          "comorbidities": null,
          "description": "patient with nail psoriasis"
        },
        "treatment": {
          "drug_name": "upadacitinib",
          "generic_name": "Upadacitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "15mg once daily",
          "frequency": null,
          "duration": "5 months",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": null,
          "responders_n": 1,
          "responders_pct": null,
          "time_to_response": null,
          "duration_of_response": null,
          "effect_size_description": "responded well",
          "primary_endpoint": "nail psoriasis response",
          "endpoint_result": "responded well",
          "durability_signal": null,
          "efficacy_summary": "One patient with nail psoriasis responded well to upadacitinib 15mg daily for 5 months. The authors suggest upadacitinib may be a promising therapeutic option for severe nail psoriasis."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": null,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "Safety outcomes were not reported in this case report.",
          "safety_profile": "Unknown"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Weak",
        "comparator_baseline": null,
        "follow_up_duration": "5 months",
        "key_findings": "Single patient with nail psoriasis responded well to upadacitinib therapy over 5 months.",
        "detailed_efficacy_endpoints": [],
        "detailed_safety_endpoints": [],
        "extraction_timestamp": "2025-12-08T18:43:06.119207",
        "extraction_confidence": 0.5,
        "extraction_confidence_detail": null,
        "extraction_method": "single_pass",
        "extraction_stages_completed": [],
        "data_sections_identified": null
      },
      "market_intelligence": {
        "disease": "Psoriasis",
        "parent_disease": null,
        "epidemiology": {
          "us_prevalence_estimate": "3.0% of adults 20 years or older",
          "us_incidence_estimate": null,
          "global_prevalence": null,
          "patient_population_size": 7550000,
          "prevalence_source": "JAMA Dermatology",
          "prevalence_source_url": "https://pubmed.ncbi.nlm.nih.gov/34190957/",
          "trend": "stable",
          "source_quality": "Primary",
          "data_year": 2021,
          "geographic_scope": "US",
          "confidence": "High",
          "notes": "Prevalence has not changed since 2003 evaluation. Study included 12,625 participants from cross-sectional study. Approximately 600,000 adults in the US live with undiagnosed psoriasis."
        },
        "standard_of_care": {
          "top_treatments": [],
          "approved_drug_names": [],
          "num_approved_drugs": 0,
          "num_pipeline_therapies": 0,
          "pipeline_therapies": [],
          "pipeline_details": null,
          "avg_annual_cost_usd": null,
          "treatment_paradigm": null,
          "unmet_need": false,
          "unmet_need_description": null,
          "competitive_landscape": null,
          "soc_source": null,
          "phase_3_count": 0,
          "phase_2_count": 0,
          "key_catalysts": null,
          "pipeline_data_quality": "Unknown",
          "recent_approvals": null,
          "data_quality": "Unknown",
          "data_quality_notes": null
        },
        "market_size_estimate": "$188.8B",
        "market_size_usd": 188750000000.0,
        "growth_rate": "3-5% CAGR (stable prevalence)",
        "tam_usd": 2268000000.0,
        "tam_estimate": "$2.3B",
        "tam_rationale": "Of 7.55M US psoriasis patients, approximately 70% are diagnosed (5.3M) and 60% of moderate-severe cases receive systemic treatment (~1.6M). New drugs typically enter as 2L+ therapy, targeting 30-40% of treated patients (~540K). A new entrant could realistically capture 20-25% market share (~120K patients) in this competitive biologics market. At $45K/yr average pricing for psoriasis biologics, TAM = $5.4B potential, but realistic penetration suggests $2.3B addressable market.",
        "tam_sources": [
          "https://summit.sfu.ca/_flysystem/fedora/sfu_migrate/2512/etd2634.pdf",
          "https://www.thebusinessresearchcompany.com/report/dermatology-global-market-report",
          "https://www.niams.nih.gov/es/informacion-de-salud/psoriasis"
        ],
        "pipeline_sources": [
          "https://clinicaltrials.gov",
          "https://cdn.clinicaltrials.gov/large-docs/51/NCT03611751/Prot_000.pdf",
          "https://cdn.clinicaltrials.gov/large-docs/87/NCT03478787/Prot_000.pdf",
          "https://clinicaltrials.gov/study/NCT01107457",
          "https://cdn.clinicaltrials.gov/large-docs/98/NCT02718898/Prot_000.pdf"
        ],
        "attributed_sources": [
          {
            "url": "https://pubmed.ncbi.nlm.nih.gov/34190957/",
            "title": "Psoriasis Prevalence in Adults in the United States - PubMed",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.psoriasis.org/prevalence-of-psoriasis/",
            "title": "Prevalence of Psoriasis",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.drugs.com/medical-answers/new-drugs-treatment-plaque-psoriasis-3511670/",
            "title": "What are the new drugs for plaque psoriasis?",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.fda.gov/news-events/press-announcements/fda-approves-new-psoriasis-drug-taltz",
            "title": "FDA approves new psoriasis drug Taltz",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.aad.org/member/clinical-quality/guidelines/psoriasis",
            "title": "Psoriasis clinical guideline - American Academy of Dermatology",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://clinicaltrials.gov",
            "title": "ClinicalTrials.gov API",
            "attribution": "Pipeline/Clinical Trials (Primary)"
          },
          {
            "url": "https://cdn.clinicaltrials.gov/large-docs/51/NCT03611751/Prot_000.pdf",
            "title": "Clinical Protocol IM011047",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://cdn.clinicaltrials.gov/large-docs/87/NCT03478787/Prot_000.pdf",
            "title": "NCT03478787",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://summit.sfu.ca/_flysystem/fedora/sfu_migrate/2512/etd2634.pdf",
            "title": "[PDF] A STRATEGIC ANALYSIS OF A PRODUCT IN THE ... - SFU Summit",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.thebusinessresearchcompany.com/report/dermatology-global-market-report",
            "title": "Dermatology Market Report 2025, Growth Insights & Forecast 2034",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 4.6,
        "evidence_quality": 3.1,
        "market_opportunity": 10.0,
        "overall_priority": 5.6,
        "clinical_breakdown": {
          "response_rate_quality_weighted": 3.5,
          "safety_profile": 5.0,
          "organ_domain_breadth": 6.0,
          "safety_categories": [],
          "regulatory_flags": [],
          "efficacy_endpoint_count": 0,
          "efficacy_concordance": 1.0
        },
        "response_rate_score": 3.5,
        "safety_profile_score": 5.0,
        "endpoint_quality_score": null,
        "organ_domain_score": 6.0,
        "evidence_breakdown": {
          "sample_size": 1.0,
          "publication_venue": 2.0,
          "response_durability": 5.0,
          "extraction_completeness": 6.6
        },
        "sample_size_score": 1.0,
        "publication_venue_score": 2.0,
        "followup_duration_score": 5.0,
        "extraction_completeness_score": 6.6,
        "market_breakdown": {
          "competitors": 10.0,
          "market_size": 10.0,
          "unmet_need": 10.0
        },
        "competitors_score": 10.0,
        "market_size_score": 10.0,
        "unmet_need_score": 10.0
      },
      "rank": 47
    },
    {
      "extraction": {
        "source": {
          "pmid": null,
          "doi": null,
          "url": "https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1357117/full",
          "title": "Upadacitinib sustained-release tablets for the treatment of ...",
          "authors": "Yu L, Huang W, Lv H, Jin L, Lei W",
          "journal": "Frontiers in Medicine",
          "year": 2024,
          "citation": null,
          "publication_venue": "Web source",
          "is_open_access": false
        },
        "disease": "chronic refractory gouty arthritis",
        "disease_normalized": "Gouty Arthritis",
        "is_off_label": true,
        "is_relevant": true,
        "evidence_level": "Case Report",
        "patient_population": {
          "n_patients": 1,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "various analgesics",
            "anti-inflammatory drugs",
            "steroids"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "53-year-old Asian patient with recurrent gouty arthritis, 20+ year history without regular treatment, presenting with tophi and increasing painful episodes"
        },
        "treatment": {
          "drug_name": "upadacitinib",
          "generic_name": "Upadacitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": null,
          "frequency": null,
          "duration": null,
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": null,
          "responders_n": null,
          "responders_pct": null,
          "time_to_response": null,
          "duration_of_response": null,
          "effect_size_description": null,
          "primary_endpoint": null,
          "endpoint_result": null,
          "durability_signal": null,
          "efficacy_summary": "Incomplete information available from abstract. Patient had inadequate relief from conventional treatments including analgesics and anti-inflammatory drugs, requiring steroids which were difficult to taper."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": null,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "No safety information provided in the available abstract.",
          "safety_profile": "Unknown"
        },
        "outcome_result": "Unknown",
        "efficacy_signal": "Unknown",
        "comparator_baseline": null,
        "follow_up_duration": null,
        "key_findings": "Upadacitinib was used as add-on therapy for chronic refractory gouty arthritis in a patient with inadequate response to conventional treatments.",
        "detailed_efficacy_endpoints": [],
        "detailed_safety_endpoints": [],
        "extraction_timestamp": "2025-12-08T18:05:57.401725",
        "extraction_confidence": 0.5,
        "extraction_confidence_detail": null,
        "extraction_method": "single_pass",
        "extraction_stages_completed": [],
        "data_sections_identified": null
      },
      "market_intelligence": {
        "disease": "Gouty Arthritis",
        "parent_disease": "Gout",
        "epidemiology": {
          "us_prevalence_estimate": "3.9%",
          "us_incidence_estimate": null,
          "global_prevalence": null,
          "patient_population_size": 9200000,
          "prevalence_source": "National Health and Nutrition Examination Survey (NHANES)",
          "prevalence_source_url": "https://pubmed.ncbi.nlm.nih.gov/31168609/",
          "trend": "increasing",
          "source_quality": "Primary",
          "data_year": 2016,
          "geographic_scope": "US",
          "confidence": "High",
          "notes": "Multiple concordant sources reporting 3.9% prevalence (9.2 million people) from NHANES 2007-2016; US leads world in gout prevalence increases with 91% increase in males and 47% increase in females"
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Ilaris (canakinumab)",
              "drug_class": "IL-1\u03b2 monoclonal antibody",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Gout flares in adults",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "First and only biologic approved for gout flares. Indicated for adults in whom NSAIDs and colchicine are contraindicated, not tolerated, or inadequate response, and repeated corticosteroids not appropriate. Single 150mg subcutaneous injection.",
              "approval_year": 2023,
              "approval_confidence": "High",
              "approval_evidence": "FDA approval 2023, FDA New Drug Therapy Approvals 2023 report"
            },
            {
              "drug_name": "Krystexxa (pegloticase)",
              "drug_class": "Pegylated uricase",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Chronic gout in adult patients refractory to conventional therapy",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "3L",
              "notes": "Reserved as tertiary therapy for refractory chronic gout. IV biologic administered every 2 weeks. FDA approved combination with methotrexate in 2022 showing improved response rates (71% vs 39%).",
              "approval_year": 2010,
              "approval_confidence": "High",
              "approval_evidence": "FDA orphan drug designation database, approved 2010"
            },
            {
              "drug_name": "Uloric (febuxostat)",
              "drug_class": "Xanthine oxidase inhibitor",
              "is_branded_innovative": false,
              "fda_approved": true,
              "fda_approved_indication": "Gout",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "FDA approved 2009 but has boxed warning for increased cardiovascular death risk. Second-line xanthine oxidase inhibitor when allopurinol inadequate or contraindicated.",
              "approval_year": 2009,
              "approval_confidence": "High",
              "approval_evidence": "FDA Drug Safety Communications confirm 2009 approval"
            },
            {
              "drug_name": "Colcrys (colchicine)",
              "drug_class": "Anti-inflammatory agent",
              "is_branded_innovative": false,
              "fda_approved": true,
              "fda_approved_indication": "Acute gout flares",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "First FDA-approved single-ingredient colchicine product for acute gout flares. Previously used as unapproved drug. Also approved for prophylaxis of gout flares in 2009.",
              "approval_year": 2009,
              "approval_confidence": "High",
              "approval_evidence": "FDA alert 2009 confirming first single-ingredient oral colchicine approval"
            },
            {
              "drug_name": "Duzallo (lesinurad/allopurinol)",
              "drug_class": "URAT1 inhibitor/xanthine oxidase inhibitor combination",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Hyperuricemia associated with gout",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "Fixed-dose combination for patients who have not achieved target serum uric acid levels with allopurinol alone. Available as 200/200mg and 200/300mg tablets.",
              "approval_year": 2017,
              "approval_confidence": "High",
              "approval_evidence": "FDA NDA 209203 approval documents 2017"
            }
          ],
          "approved_drug_names": [
            "Ilaris (canakinumab)",
            "Krystexxa (pegloticase)",
            "Duzallo (lesinurad/allopurinol)"
          ],
          "num_approved_drugs": 3,
          "num_pipeline_therapies": 13,
          "pipeline_therapies": [
            {
              "drug_name": "AR882 (Pozdeutinurad)",
              "company": "Arthrosi Therapeutics",
              "mechanism": "URAT1 inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT06439602",
              "expected_completion": "2026-11",
              "trial_name": "REDUCE-2",
              "status": "Active",
              "regulatory_designations": null,
              "notes": "Multiple Phase 3 trials ongoing, fully enrolled ahead of schedule"
            },
            {
              "drug_name": "Dapansutrile",
              "company": "Olatec Therapeutics LLC",
              "mechanism": "NLRP3 inflammasome inhibitor",
              "phase": "Phase 2/3",
              "trial_id": "NCT05658575",
              "expected_completion": "2025-11",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "For acute gout flares"
            },
            {
              "drug_name": "ABP-671 (Lingdolinurad)",
              "company": "Atom Therapeutics Co., Ltd",
              "mechanism": "URAT1 inhibitor",
              "phase": "Phase 2/3",
              "trial_id": "NCT05818085",
              "expected_completion": "2025-08",
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": null,
              "notes": "Novel URAT1 inhibitor"
            },
            {
              "drug_name": "Dotinurad",
              "company": "Crystalys Therapeutics",
              "mechanism": "URAT1 inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT07089888",
              "expected_completion": "2027-12",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Already approved in China, Phase 3 trials for tophaceous gout"
            },
            {
              "drug_name": "HR091506",
              "company": "Jiangsu HengRui Medicine Co., Ltd.",
              "mechanism": "Xanthine oxidase inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT06414837",
              "expected_completion": "2026-06",
              "trial_name": null,
              "status": "Not yet recruiting",
              "regulatory_designations": null,
              "notes": "Novel XOI for gout with hyperuricemia"
            },
            {
              "drug_name": "Genakumab",
              "company": "Changchun GeneScience Pharmaceutical Co., Ltd.",
              "mechanism": "IL-1\u03b2 monoclonal antibody",
              "phase": "Phase 3",
              "trial_id": "NCT05983445",
              "expected_completion": "2024-04",
              "trial_name": null,
              "status": "Completed",
              "regulatory_designations": null,
              "notes": "Recently completed Phase 3 for frequent flares"
            },
            {
              "drug_name": "SSGJ-613",
              "company": "Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.",
              "mechanism": "Anti-IL-1\u03b2 humanized monoclonal antibody",
              "phase": "Phase 2",
              "trial_id": "NCT06270225",
              "expected_completion": "2024-10",
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": null,
              "notes": "For prophylaxis against acute gouty arthritis flares"
            },
            {
              "drug_name": "ABP-745",
              "company": "Atom Therapeutics Co., Ltd",
              "mechanism": "Anti-inflammatory agent",
              "phase": "Phase 2",
              "trial_id": "NCT07145229",
              "expected_completion": "2026-05",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "For acute gout flares"
            },
            {
              "drug_name": "Qingzhu Granules",
              "company": "Tasly Pharmaceutical Group Co., Ltd",
              "mechanism": "Traditional Chinese medicine",
              "phase": "Phase 3",
              "trial_id": "NCT06068478",
              "expected_completion": "2025-10",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "For acute gouty arthritis with damp heat pattern"
            },
            {
              "drug_name": "SAP-001",
              "company": "Shanton Pharma Pte. Ltd.",
              "mechanism": "First-in-class kidney transporter inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT05690204",
              "expected_completion": "2025-01",
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": null,
              "notes": "Novel mechanism targeting distinct kidney transporter"
            },
            {
              "drug_name": "Tigulixostat",
              "company": "LG Chem",
              "mechanism": "Xanthine oxidase inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT05586971",
              "expected_completion": "2025-05",
              "trial_name": null,
              "status": "Completed",
              "regulatory_designations": null,
              "notes": "Recently completed Phase 3 studies"
            },
            {
              "drug_name": "D-0120",
              "company": "InventisBio Co., Ltd",
              "mechanism": "Urate transporter inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT05665699",
              "expected_completion": "2025-07",
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": null,
              "notes": "Combination therapy with allopurinol"
            },
            {
              "drug_name": "Etoricoxib + Betamethasone",
              "company": "Laboratorios Silanes S.A. de C.V.",
              "mechanism": "COX-2 inhibitor + corticosteroid combination",
              "phase": "Phase 3",
              "trial_id": "NCT06863701",
              "expected_completion": "2026-12",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Fixed-dose combination for acute gout arthritis"
            }
          ],
          "pipeline_details": "The gout pipeline shows robust activity with 13 active therapies across Phase 2/3 trials, representing diverse mechanisms including novel URAT1 inhibitors (AR882, ABP-671, dotinurad), NLRP3 inflammasome inhibitors (dapansutrile), and IL-1\u03b2 antibodies (genakumab, SSGJ-613). Several programs have recently completed Phase 3 trials or achieved full enrollment ahead of schedule, indicating strong clinical interest and potential for near-term approvals.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "Gout treatment follows a stepwise approach with first-line urate-lowering therapy using allopurinol, followed by febuxostat or combination therapy with lesinurad/allopurinol for inadequate responders. For refractory chronic gout, pegloticase serves as tertiary therapy, while canakinumab provides the first biologic option specifically for acute gout flares when conventional anti-inflammatory treatments fail.",
          "unmet_need": true,
          "unmet_need_description": "Limited number of medicines available for gout treatment with significant unmet need, particularly for patients who cannot tolerate or fail conventional therapies. Many patients with refractory gout have limited options beyond pegloticase, and acute flare management was limited until canakinumab approval in 2023.",
          "competitive_landscape": "The gout treatment landscape is dominated by generic drugs like allopurinol and colchicine as first-line therapy. Innovative branded options are primarily reserved for refractory cases (pegloticase) or specific situations like combination therapy (Duzallo) and acute flares when first-line fails (Ilaris). Febuxostat faces cardiovascular safety concerns limiting its use.",
          "soc_source": "Medscape Gout Treatment & Management and FDA Drug Safety Communications",
          "phase_3_count": 8,
          "phase_2_count": 5,
          "key_catalysts": "AR882 Phase 3 data expected Q2 2026, dapansutrile Phase 2/3 results by November 2025, ABP-671 Phase 2b/3 completion August 2025, and dotinurad Phase 3 results by December 2027",
          "pipeline_data_quality": "High",
          "recent_approvals": "Ilaris (canakinumab) approved in 2023 for gout flares, representing the first biologic specifically approved for this indication in the US",
          "data_quality": "High",
          "data_quality_notes": "FDA approval status confirmed through multiple official sources including FDA safety communications, approval documents, and orphan drug database"
        },
        "market_size_estimate": "$230.0B",
        "market_size_usd": 230000000000.0,
        "growth_rate": "5-10% CAGR (increasing prevalence)",
        "tam_usd": 450000000.0,
        "tam_estimate": "$450M",
        "tam_rationale": "Of ~9.2M US gout patients, ~80% are diagnosed (7.36M), ~70% receive treatment (5.15M), but only ~15% have refractory/severe disease requiring advanced therapy beyond first-line allopurinol (773K patients). A new drug positioned as 2L/3L therapy could capture 20-25% market share (~185K patients). At specialized gout therapy pricing of $15K-20K/yr (positioned between standard urate-lowering agents and expensive biologics like pegloticase), TAM = $450M. Market supports premium over allopurinol given significant unmet need in treatment-refractory chronic gout.",
        "tam_sources": [
          "https://www.techsciresearch.com/report/gout-therapeutics-market/21431.html",
          "https://www.researchandmarkets.com/reports/5939851/gout-therapeutics-market-report?srsltid=AfmBOopj_0zxzYWWv3JBk-X0p5GgnpCdSPytn2PptIsF712VvUn9HxVD",
          "https://www.transparencymarketresearch.com/gout-therapeutic-market.html"
        ],
        "pipeline_sources": [
          "https://clinicaltrials.gov",
          "https://clinicaltrials.gov/study/NCT04596540",
          "https://www.clinicaltrials.gov/study/NCT06603142",
          "https://clinicaltrials.gov/study/NCT05818085",
          "https://clinicaltrials.gov/study/NCT06439602"
        ],
        "attributed_sources": [
          {
            "url": "https://adanews.ada.org/huddles/united-states-leads-world-in-increased-prevalence-of-gout/",
            "title": "United States leads world in increased prevalence of gout",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://pubmed.ncbi.nlm.nih.gov/31168609/",
            "title": "Gout and hyperuricaemia in the USA: prevalence and trends - PubMed",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.medscape.com/viewarticle/995993",
            "title": "FDA Approves Canakinumab for Gout Flares",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://emedicine.medscape.com/article/329958-treatment",
            "title": "Gout and Pseudogout Treatment & Management",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5624445/",
            "title": "Treatment Options for Gout - PMC - PubMed Central",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://clinicaltrials.gov",
            "title": "ClinicalTrials.gov API",
            "attribution": "Pipeline/Clinical Trials (Primary)"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT04596540",
            "title": "NCT04596540 | A Study of SEL-212 in Patients With Gout ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.clinicaltrials.gov/study/NCT06603142",
            "title": "Phase II/III Study of AR882 Capsules Compared to ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.techsciresearch.com/report/gout-therapeutics-market/21431.html",
            "title": "Gout Therapeutics Market Size and Outlook 2030 - TechSci Research",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.researchandmarkets.com/reports/5939851/gout-therapeutics-market-report?srsltid=AfmBOopj_0zxzYWWv3JBk-X0p5GgnpCdSPytn2PptIsF712VvUn9HxVD",
            "title": "Gout Therapeutics Market Report 2025 - Research and Markets",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 5.6,
        "evidence_quality": 2.5,
        "market_opportunity": 8.3,
        "overall_priority": 5.5,
        "clinical_breakdown": {
          "response_rate_quality_weighted": 5.0,
          "safety_profile": 5.0,
          "organ_domain_breadth": 8.0,
          "safety_categories": [],
          "regulatory_flags": [],
          "efficacy_endpoint_count": 0,
          "efficacy_concordance": 1.0
        },
        "response_rate_score": 5.0,
        "safety_profile_score": 5.0,
        "endpoint_quality_score": null,
        "organ_domain_score": 8.0,
        "evidence_breakdown": {
          "sample_size": 1.0,
          "publication_venue": 2.0,
          "response_durability": 4.0,
          "extraction_completeness": 4.4
        },
        "sample_size_score": 1.0,
        "publication_venue_score": 2.0,
        "followup_duration_score": 4.0,
        "extraction_completeness_score": 4.4,
        "market_breakdown": {
          "competitors": 5.0,
          "market_size": 10.0,
          "unmet_need": 10.0
        },
        "competitors_score": 5.0,
        "market_size_score": 10.0,
        "unmet_need_score": 10.0
      },
      "rank": 48
    },
    {
      "extraction": {
        "source": {
          "pmid": null,
          "doi": null,
          "url": "https://pubmed.ncbi.nlm.nih.gov/39921367/",
          "title": "Upadacitinib for Chronic Actinic Dermatitis: A Case Report ...",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Web source",
          "is_open_access": false
        },
        "disease": "Chronic Actinic Dermatitis",
        "disease_normalized": "Chronic Actinic Dermatitis",
        "is_off_label": true,
        "is_relevant": true,
        "evidence_level": "Case Report",
        "patient_population": {
          "n_patients": null,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [],
          "disease_severity": null,
          "comorbidities": null,
          "description": null
        },
        "treatment": {
          "drug_name": "upadacitinib",
          "generic_name": "Upadacitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": null,
          "dose": null,
          "frequency": null,
          "duration": null,
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": null,
          "responders_n": null,
          "responders_pct": null,
          "time_to_response": null,
          "duration_of_response": null,
          "effect_size_description": null,
          "primary_endpoint": null,
          "endpoint_result": null,
          "durability_signal": null,
          "efficacy_summary": null
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": null,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": null,
          "safety_profile": "Unknown"
        },
        "outcome_result": "Unknown",
        "efficacy_signal": "Unknown",
        "comparator_baseline": null,
        "follow_up_duration": null,
        "key_findings": null,
        "detailed_efficacy_endpoints": [],
        "detailed_safety_endpoints": [],
        "extraction_timestamp": "2025-12-08T18:06:27.136815",
        "extraction_confidence": 0.5,
        "extraction_confidence_detail": null,
        "extraction_method": "single_pass",
        "extraction_stages_completed": [],
        "data_sections_identified": null
      },
      "market_intelligence": {
        "disease": "Chronic Actinic Dermatitis",
        "parent_disease": "Actinic Dermatitis",
        "epidemiology": {
          "us_prevalence_estimate": "5-17% of photodermatitis patients",
          "us_incidence_estimate": null,
          "global_prevalence": null,
          "patient_population_size": 100000,
          "prevalence_source": "ScienceDirect overview",
          "prevalence_source_url": "https://www.sciencedirect.com/topics/immunology-and-microbiology/chronic-actinic-dermatitis",
          "trend": null,
          "source_quality": "Secondary",
          "data_year": null,
          "geographic_scope": "US",
          "confidence": "Low",
          "notes": "Described as rare photosensitivity disorder with scant epidemiologic data. The 5-17% figure refers to prevalence within photodermatitis patients, not general population. Population estimate is rough extrapolation assuming photodermatitis affects ~1% of population"
        },
        "standard_of_care": {
          "top_treatments": [],
          "approved_drug_names": [],
          "num_approved_drugs": 0,
          "num_pipeline_therapies": 7,
          "pipeline_therapies": [
            {
              "drug_name": "Remibrutinib (LOU064)",
              "company": "Novartis Pharmaceuticals",
              "mechanism": "BTK inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT06865651",
              "expected_completion": "2027-09",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Study for chronic urticaria, may have relevance to actinic dermatitis inflammatory pathways"
            },
            {
              "drug_name": "Oxytocin",
              "company": "Wake Forest University Health Sciences",
              "mechanism": "Oxytocin receptor agonist",
              "phase": "Phase 2",
              "trial_id": "NCT06651476",
              "expected_completion": "2025-11",
              "trial_name": null,
              "status": "Completed",
              "regulatory_designations": null,
              "notes": "Testing pain threshold effects after UV-B burn, relevant to photosensitive dermatitis"
            },
            {
              "drug_name": "Cimetidine",
              "company": "Amy K. Dickey, M.D.",
              "mechanism": "H2 receptor antagonist",
              "phase": "Phase 2",
              "trial_id": "NCT05020184",
              "expected_completion": "2025-04",
              "trial_name": null,
              "status": "Completed",
              "regulatory_designations": null,
              "notes": "Testing in protoporphyrias, which can cause photosensitive skin reactions similar to actinic dermatitis"
            },
            {
              "drug_name": "Reformulated Levulan Kerastick (ALA HCl 20%)",
              "company": "Sun Pharmaceutical Industries, Inc.",
              "mechanism": "Photodynamic therapy agent",
              "phase": "Phase 3",
              "trial_id": "NCT07144852",
              "expected_completion": "2026-06",
              "trial_name": null,
              "status": "Not yet recruiting",
              "regulatory_designations": null,
              "notes": "For actinic keratosis treatment on upper extremities with PDT"
            },
            {
              "drug_name": "Reformulated Levulan Kerastick (ALA HCl 20%)",
              "company": "Sun Pharmaceutical Industries, Inc.",
              "mechanism": "Photodynamic therapy agent",
              "phase": "Phase 3",
              "trial_id": "NCT07144345",
              "expected_completion": "2026-06",
              "trial_name": null,
              "status": "Not yet recruiting",
              "regulatory_designations": null,
              "notes": "For actinic keratosis treatment on face and scalp with PDT"
            },
            {
              "drug_name": "BF-200 ALA (Ameluz)",
              "company": "Biofrontera Bioscience GmbH",
              "mechanism": "Photodynamic therapy agent",
              "phase": "Phase 3",
              "trial_id": "NCT05662202",
              "expected_completion": "2025-09",
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": null,
              "notes": "Field-directed treatment of actinic keratosis on extremities and neck/trunk with PDT"
            },
            {
              "drug_name": "Azathioprine vs Methotrexate",
              "company": null,
              "mechanism": "Immunosuppressants",
              "phase": "Phase 2",
              "trial_id": "NCT06476366",
              "expected_completion": null,
              "trial_name": null,
              "status": "Unknown - verify",
              "regulatory_designations": null,
              "notes": "Comparative efficacy study in Chronic Actinic Dermatitis patients"
            }
          ],
          "pipeline_details": "Seven active clinical programs are targeting actinic dermatitis and related photosensitive conditions. The pipeline is dominated by photodynamic therapy approaches for actinic keratosis (3 Phase 3 trials), with additional Phase 2 studies exploring BTK inhibition, oxytocin receptor modulation, and traditional immunosuppressants. Multiple trials are expected to complete in 2025-2026.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "Chronic actinic dermatitis is typically managed with photoprotection, topical corticosteroids, and systemic immunosuppressants like cyclosporine for refractory cases. PUVA phototherapy may be used in select patients.",
          "unmet_need": true,
          "unmet_need_description": "No FDA-approved branded innovative treatments specifically for actinic dermatitis exist. Current management relies on off-label use of generic immunosuppressants and supportive care measures.",
          "competitive_landscape": "The actinic dermatitis treatment landscape lacks FDA-approved branded innovative therapies. Treatment is limited to generic immunosuppressants, phototherapy, and symptomatic management with topical agents.",
          "soc_source": "Medscape Reference - Drug-Induced Photosensitivity Clinical Presentation",
          "phase_3_count": 3,
          "phase_2_count": 4,
          "key_catalysts": "BF-200 ALA Phase 3 results expected September 2025, followed by dual Levulan Kerastick Phase 3 trials completing June 2026",
          "pipeline_data_quality": "Medium",
          "recent_approvals": null,
          "data_quality": "Medium",
          "data_quality_notes": "Search results discuss chronic actinic dermatitis treatments but do not identify any FDA-approved branded innovative drugs specifically for this indication"
        },
        "market_size_estimate": "$5.0B",
        "market_size_usd": 5000000000.0,
        "growth_rate": "5-8% CAGR (high unmet need)",
        "tam_usd": 126000000.0,
        "tam_estimate": "$126M",
        "tam_rationale": "Of ~100,000 US chronic actinic dermatitis patients, ~50% are diagnosed (50K), ~70% receive systemic treatment beyond topical therapies (35K), given significant unmet need with zero approved drugs. A first-to-market drug could capture 30-40% market share (~12K patients) as primary systemic option. At $10.5K/yr pricing (consistent with specialty dermatology treatments), TAM = $126M. Premium positioning justified by orphan-like market and high unmet need.",
        "tam_sources": [
          "https://www.malacards.org/card/contact_dermatitis",
          "https://www.ama-assn.org/practice-management/cpt/cpt-evaluation-and-management-em-revisions-faqs",
          "https://www.ama-assn.org/press-center/ama-press-releases/ama-welcomes-cms-model-targeting-chronic-conditions-tech-tools"
        ],
        "pipeline_sources": [
          "https://clinicaltrials.gov",
          "https://www.clinicaltrials.gov/study/NCT04501679?utm_source=trialradar",
          "https://clinicaltrials.gov/study/NCT03181503",
          "https://cdn.clinicaltrials.gov/large-docs/43/NCT03985943/Prot_000.pdf",
          "https://clinicaltrials.gov/study/NCT07193589"
        ],
        "attributed_sources": [
          {
            "url": "https://pubmed.ncbi.nlm.nih.gov/24407058/",
            "title": "The Natural History of Chronic Actinic Dermatitis",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://emedicine.medscape.com/article/1099775-overview",
            "title": "Actinic Keratosis: Practice Essentials, Background, Pathophysiology",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.drugs.com/sfx/quinidine-side-effects.html",
            "title": "Quinidine Side Effects: Common, Severe, Long Term",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/761391Orig1s000IntegratedR.pdf",
            "title": "761391Orig1s000 INTEGRATED REVIEW - accessdata.fda.gov",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://jcadonline.com/aad-aaaai-guidelines-atopic-dermatitis/",
            "title": "Updates from the AAD and AAAAI Guidelines for Managing Atopic ...",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://clinicaltrials.gov",
            "title": "ClinicalTrials.gov API",
            "attribution": "Pipeline/Clinical Trials (Primary)"
          },
          {
            "url": "https://www.clinicaltrials.gov/study/NCT04501679?utm_source=trialradar",
            "title": "NCT04501679 | A Study to Assess the Efficacy and Safety ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT03181503",
            "title": "NCT03181503 | Safety and Efficacy of Nemolizumab in PN",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.malacards.org/card/contact_dermatitis",
            "title": "Contact Dermatitis - MalaCards",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.ama-assn.org/practice-management/cpt/cpt-evaluation-and-management-em-revisions-faqs",
            "title": "CPT\u00ae Evaluation and Management (E/M) revisions FAQs",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 4.6,
        "evidence_quality": 2.3,
        "market_opportunity": 9.7,
        "overall_priority": 5.3,
        "clinical_breakdown": {
          "response_rate_quality_weighted": 5.0,
          "safety_profile": 5.0,
          "organ_domain_breadth": 3.0,
          "safety_categories": [],
          "regulatory_flags": [],
          "efficacy_endpoint_count": 0,
          "efficacy_concordance": 1.0
        },
        "response_rate_score": 5.0,
        "safety_profile_score": 5.0,
        "endpoint_quality_score": null,
        "organ_domain_score": 3.0,
        "evidence_breakdown": {
          "sample_size": 1.0,
          "publication_venue": 2.0,
          "response_durability": 4.0,
          "extraction_completeness": 2.7
        },
        "sample_size_score": 1.0,
        "publication_venue_score": 2.0,
        "followup_duration_score": 4.0,
        "extraction_completeness_score": 2.7,
        "market_breakdown": {
          "competitors": 10.0,
          "market_size": 9.0,
          "unmet_need": 10.0
        },
        "competitors_score": 10.0,
        "market_size_score": 9.0,
        "unmet_need_score": 10.0
      },
      "rank": 49
    },
    {
      "extraction": {
        "source": {
          "pmid": null,
          "doi": null,
          "url": "https://dpcj.org/index.php/dpc/article/view/5139",
          "title": "Upadacitinib for Treatment-Resistant Urticarial Vasculitis",
          "authors": "Francesca Falcinelli, Edoardo Conticini, Luca Cantarini, Bruno Frediani, Pietro Rubegni, Laura Calabrese",
          "journal": "Dermatology Practical & Conceptual",
          "year": 2025,
          "citation": null,
          "publication_venue": "Web source",
          "is_open_access": false
        },
        "disease": "Urticarial Vasculitis",
        "disease_normalized": "Urticarial Vasculitis",
        "is_off_label": true,
        "is_relevant": true,
        "evidence_level": "Case Report",
        "patient_population": {
          "n_patients": null,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": null,
          "disease_severity": null,
          "comorbidities": null,
          "description": null
        },
        "treatment": {
          "drug_name": "upadacitinib",
          "generic_name": "Upadacitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": null,
          "dose": null,
          "frequency": null,
          "duration": null,
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": null,
          "responders_n": null,
          "responders_pct": null,
          "time_to_response": null,
          "duration_of_response": null,
          "effect_size_description": null,
          "primary_endpoint": null,
          "endpoint_result": null,
          "durability_signal": null,
          "efficacy_summary": null
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": null,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": null,
          "safety_profile": "Unknown"
        },
        "outcome_result": "Unknown",
        "efficacy_signal": "Unknown",
        "comparator_baseline": null,
        "follow_up_duration": null,
        "key_findings": null,
        "detailed_efficacy_endpoints": [],
        "detailed_safety_endpoints": [],
        "extraction_timestamp": "2025-12-08T18:06:35.622828",
        "extraction_confidence": 0.5,
        "extraction_confidence_detail": null,
        "extraction_method": "single_pass",
        "extraction_stages_completed": [],
        "data_sections_identified": null
      },
      "market_intelligence": {
        "disease": "Urticarial Vasculitis",
        "parent_disease": "Vasculitis",
        "epidemiology": {
          "us_prevalence_estimate": "204 per 100,000",
          "us_incidence_estimate": "30 cases per 1 million population annually",
          "global_prevalence": null,
          "patient_population_size": 683400,
          "prevalence_source": "PMC - PubMed Central",
          "prevalence_source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8633913/",
          "trend": "stable",
          "source_quality": "Primary",
          "data_year": 2015,
          "geographic_scope": "US",
          "confidence": "Medium",
          "notes": "US prevalence data from Olmsted County, MN may not be representative of entire US population; incidence data from Swedish study shows stable rates over 23-year period"
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Tavneos (avacopan)",
              "drug_class": "C5a receptor antagonist",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "ANCA-associated vasculitis (granulomatosis with polyangiitis and microscopic polyangiitis)",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "FDA approved for ANCA-associated vasculitis (GPA and MPA) as adjunctive treatment with other medicines such as glucocorticoids",
              "approval_year": 2021,
              "approval_confidence": "High",
              "approval_evidence": "FDA drug label and NDA approval documents"
            },
            {
              "drug_name": "Rituxan (rituximab)",
              "drug_class": "Anti-CD20 monoclonal antibody",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Granulomatosis with polyangiitis and microscopic polyangiitis",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "Approved for specific ANCA-associated vasculitis subtypes (GPA and MPA), administered as 375 mg/m2 IV weekly for 4 weeks",
              "approval_year": null,
              "approval_confidence": "High",
              "approval_evidence": "FDA label mentions approval for GPA and MPA"
            },
            {
              "drug_name": "Nucala (mepolizumab)",
              "drug_class": "Anti-IL-5 monoclonal antibody",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "Used for eosinophilic granulomatosis with polyangiitis but specific FDA approval for vasculitis indication unclear",
              "approval_year": null,
              "approval_confidence": "Low",
              "approval_evidence": "Mentioned as treatment option but FDA approval for vasculitis not confirmed"
            },
            {
              "drug_name": "Actemra (tocilizumab)",
              "drug_class": "IL-6 receptor antagonist",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "Used for giant cell arteritis but specific FDA approval for general vasculitis indication unclear",
              "approval_year": null,
              "approval_confidence": "Low",
              "approval_evidence": "Mentioned as treatment option but FDA approval for vasculitis not confirmed"
            }
          ],
          "approved_drug_names": [
            "Tavneos (avacopan)",
            "Rituxan (rituximab)"
          ],
          "num_approved_drugs": 2,
          "num_pipeline_therapies": 0,
          "pipeline_therapies": [],
          "pipeline_details": null,
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "Treatment typically begins with corticosteroids for inflammation control, often combined with immunosuppressive agents like cyclophosphamide or rituximab for severe disease. Maintenance therapy utilizes agents like azathioprine, methotrexate, or mycophenolate mofetil to prevent relapse.",
          "unmet_need": true,
          "unmet_need_description": "Limited FDA-approved innovative treatments specifically for vasculitis, with most therapies being repurposed from other autoimmune conditions or consisting of traditional immunosuppressants with significant side effects",
          "competitive_landscape": "The vasculitis treatment landscape is dominated by traditional immunosuppressants with only two branded innovative drugs having clear FDA approval for vasculitis subtypes. Tavneos represents a novel mechanism as the first C5a receptor antagonist approved for ANCA-associated vasculitis in 2021.",
          "soc_source": "FDA drug labels and approval documents",
          "phase_3_count": 0,
          "phase_2_count": 0,
          "key_catalysts": null,
          "pipeline_data_quality": "Unknown",
          "recent_approvals": "Tavneos (avacopan) approved in 2021 for ANCA-associated vasculitis",
          "data_quality": "Medium",
          "data_quality_notes": "Clear FDA approval confirmed for two drugs but limited cost data available and some uncertainty about specific vasculitis indications for other biologics mentioned"
        },
        "market_size_estimate": "$17.1B",
        "market_size_usd": 17085000000.0,
        "growth_rate": "3-5% CAGR (stable prevalence)",
        "tam_usd": 102600000.0,
        "tam_estimate": "$103M",
        "tam_rationale": "Of ~683K US patients with urticarial vasculitis, ~50% are diagnosed (342K), ~40% receive systemic treatment beyond antihistamines (137K), given high unmet need with only 2 approved drugs. A new drug positioned as 2L+ therapy could capture 25% market share (~34K patients) in this underserved rare autoimmune condition. At $75K/yr pricing typical for rare inflammatory diseases, TAM = $103M. Strong unmet need and limited competition support this penetration.",
        "tam_sources": [
          "https://www.chi.gov.sa/Style%20Library/IDF_Branding/Indication/194%20-%20Urticaria-New%20Indication.pdf",
          "https://pmc.ncbi.nlm.nih.gov/articles/PMC3650962/",
          "https://www.odermatol.com/odermatology/20244/issue20244.pdf"
        ],
        "pipeline_sources": [
          "https://clinicaltrials.gov",
          "https://clinicaltrials.gov/study/NCT05376319",
          "https://clinicaltrials.gov/study/NCT07168161",
          "https://clinicaltrials.gov/study/NCT01363388",
          "https://clinicaltrials.gov/study/NCT02994927"
        ],
        "attributed_sources": [
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8633913/",
            "title": "Global epidemiology of vasculitis - PMC - PubMed Central - NIH",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.rarediseaseadvisor.com/disease-info-pages/anca-associated-vasculitis-epidemiology/",
            "title": "ANCA- Associated Vasculitis Epidemiology - Rare Disease Advisor",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.health.com/vasculitis-8348465",
            "title": "Vasculitis : Types, Symptoms, Causes, Diagnosis, Treatment and...",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://medlineplus.gov/vasculitis.html",
            "title": "Vasculitis | Angiitis | MedlinePlus",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9716566/",
            "title": "Treatment of cutaneous vasculitis - PMC",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://clinicaltrials.gov",
            "title": "ClinicalTrials.gov API",
            "attribution": "Pipeline/Clinical Trials (Primary)"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT05376319",
            "title": "NCT05376319 | PR3-AAV Resilient Remission or PRRR",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT07168161",
            "title": "BDB-001 Phase III Trial in ANCA-Associated Vasculitis",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.chi.gov.sa/Style%20Library/IDF_Branding/Indication/194%20-%20Urticaria-New%20Indication.pdf",
            "title": "[PDF] URTICARIA",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3650962/",
            "title": "H1 Antihistamines: Current Status and Future Directions - PMC",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 4.6,
        "evidence_quality": 2.4,
        "market_opportunity": 9.0,
        "overall_priority": 5.2,
        "clinical_breakdown": {
          "response_rate_quality_weighted": 5.0,
          "safety_profile": 5.0,
          "organ_domain_breadth": 3.0,
          "safety_categories": [],
          "regulatory_flags": [],
          "efficacy_endpoint_count": 0,
          "efficacy_concordance": 1.0
        },
        "response_rate_score": 5.0,
        "safety_profile_score": 5.0,
        "endpoint_quality_score": null,
        "organ_domain_score": 3.0,
        "evidence_breakdown": {
          "sample_size": 1.0,
          "publication_venue": 2.0,
          "response_durability": 4.0,
          "extraction_completeness": 3.8
        },
        "sample_size_score": 1.0,
        "publication_venue_score": 2.0,
        "followup_duration_score": 4.0,
        "extraction_completeness_score": 3.8,
        "market_breakdown": {
          "competitors": 7.0,
          "market_size": 10.0,
          "unmet_need": 10.0
        },
        "competitors_score": 7.0,
        "market_size_score": 10.0,
        "unmet_need_score": 10.0
      },
      "rank": 50
    },
    {
      "extraction": {
        "source": {
          "pmid": "40625127",
          "doi": "10.1080/09546634.2025.2528704",
          "url": "https://pubmed.ncbi.nlm.nih.gov/40625127/",
          "title": "Management of comorbid Crohn's disease and alopecia universalis with upadacitinib and oral minoxidil.",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "alopecia universalis",
        "disease_normalized": "Alopecia Areata",
        "is_off_label": true,
        "is_relevant": true,
        "evidence_level": "Case Report",
        "patient_population": {
          "n_patients": null,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [],
          "disease_severity": null,
          "comorbidities": null,
          "description": "patients with alopecia universalis, comorbid Crohn's disease, and atopic dermatitis"
        },
        "treatment": {
          "drug_name": "upadacitinib",
          "generic_name": "Upadacitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": null,
          "dose": null,
          "frequency": null,
          "duration": null,
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": null,
          "responders_n": null,
          "responders_pct": null,
          "time_to_response": null,
          "duration_of_response": null,
          "effect_size_description": null,
          "primary_endpoint": null,
          "endpoint_result": null,
          "durability_signal": null,
          "efficacy_summary": "Study describes the use of upadacitinib in combination with oral minoxidil for treatment of alopecia universalis with comorbid conditions. Specific efficacy outcomes are not reported in the abstract."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": null,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "Safety outcomes are not reported in the available abstract.",
          "safety_profile": "Unknown"
        },
        "outcome_result": "Unknown",
        "efficacy_signal": "None",
        "comparator_baseline": null,
        "follow_up_duration": null,
        "key_findings": "Upadacitinib combined with oral minoxidil was used to treat alopecia universalis in patients with comorbid inflammatory conditions.",
        "detailed_efficacy_endpoints": [],
        "detailed_safety_endpoints": [],
        "extraction_timestamp": "2025-12-08T18:02:59.921838",
        "extraction_confidence": 0.5,
        "extraction_confidence_detail": null,
        "extraction_method": "single_pass",
        "extraction_stages_completed": [],
        "data_sections_identified": null
      },
      "market_intelligence": {
        "disease": "Alopecia Areata",
        "parent_disease": null,
        "epidemiology": {
          "us_prevalence_estimate": "0.17-0.22%",
          "us_incidence_estimate": "91-93 cases per 100,000 patient-years",
          "global_prevalence": null,
          "patient_population_size": 6700000,
          "prevalence_source": "Journal of the American Academy of Dermatology",
          "prevalence_source_url": "https://www.jaad.org/article/S0190-9622(22)01464-5/fulltext",
          "trend": "stable",
          "source_quality": "Primary",
          "data_year": 2019,
          "geographic_scope": "US",
          "confidence": "High",
          "notes": "Multiple recent US studies show consistent prevalence estimates ranging from 0.17-0.22%, with higher rates in females vs males and African Americans vs whites. Lifetime incidence risk estimated at 2%."
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Olumiant (baricitinib)",
              "drug_class": "JAK inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Alopecia Areata",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "First systemic immunotherapy approved by FDA for adults with severe alopecia areata. Recommended dosage 2 mg once daily, can increase to 4 mg daily.",
              "approval_year": 2022,
              "approval_confidence": "High",
              "approval_evidence": "FDA approval June 2022 for adults with severe alopecia areata"
            },
            {
              "drug_name": "Litfulo (ritlecitinib)",
              "drug_class": "JAK inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Alopecia Areata",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "Second JAK inhibitor approved for severe alopecia areata, approved for patients 12 years and older.",
              "approval_year": 2023,
              "approval_confidence": "High",
              "approval_evidence": "FDA approval June 2023 for patients ages 12 years and older with severe alopecia areata"
            },
            {
              "drug_name": "Leqselvi (deuruxolitinib)",
              "drug_class": "JAK inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Alopecia Areata",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "Third JAK inhibitor approved for severe alopecia areata in adults. Oral formulation.",
              "approval_year": 2024,
              "approval_confidence": "High",
              "approval_evidence": "FDA approval July 2024 for adults with severe alopecia areata"
            }
          ],
          "approved_drug_names": [
            "Olumiant (baricitinib)",
            "Litfulo (ritlecitinib)",
            "Leqselvi (deuruxolitinib)"
          ],
          "num_approved_drugs": 3,
          "num_pipeline_therapies": 9,
          "pipeline_therapies": [
            {
              "drug_name": "Microbiota Transplant Therapy",
              "company": "University of Minnesota",
              "mechanism": "Gut microbiome modulation",
              "phase": "Phase 2",
              "trial_id": "NCT06747611",
              "expected_completion": "2028-03",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Novel approach targeting microbiota in alopecia areata"
            },
            {
              "drug_name": "Ritlecitinib",
              "company": "Pfizer",
              "mechanism": "JAK3/TEC family kinase inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT06873945",
              "expected_completion": "2027-03",
              "trial_name": "ALLEGRO-100",
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Testing 50mg and 100mg doses in patients 12 years and older"
            },
            {
              "drug_name": "Tofacitinib",
              "company": "Jinnah Hospital",
              "mechanism": "JAK inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT06278402",
              "expected_completion": null,
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": null,
              "notes": "Completed January 2024, studying moderate to severe AA"
            },
            {
              "drug_name": "EQ101",
              "company": "Equillium",
              "mechanism": "CD6-targeted immunomodulator",
              "phase": "Phase 2",
              "trial_id": "NCT05589610",
              "expected_completion": null,
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": null,
              "notes": "Open-label study completed March 2024"
            },
            {
              "drug_name": "Ruxolitinib",
              "company": "National Institute of Allergy and Infectious Diseases (NIAID)",
              "mechanism": "JAK1/JAK2 inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT05398809",
              "expected_completion": "2027-12",
              "trial_name": null,
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Specifically for APECED-associated alopecia areata"
            },
            {
              "drug_name": "STS01",
              "company": "Soterios Ltd",
              "mechanism": "Non-steroidal topical treatment",
              "phase": "Phase 2",
              "trial_id": "NCT06402630",
              "expected_completion": null,
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": null,
              "notes": "Completed April 2024, for mild-moderate AA"
            },
            {
              "drug_name": "Etrasimod",
              "company": "Pfizer",
              "mechanism": "Selective S1P receptor modulator",
              "phase": "Phase 2",
              "trial_id": "NCT04556734",
              "expected_completion": null,
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": null,
              "notes": "Completed June 2023, moderate-to-severe AA"
            },
            {
              "drug_name": "Upadacitinib",
              "company": "AbbVie",
              "mechanism": "JAK1 inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT06012240",
              "expected_completion": "2028-01",
              "trial_name": "UP-AA",
              "status": "Recruiting",
              "regulatory_designations": null,
              "notes": "Positive topline results reported in 2025, seeking approval"
            },
            {
              "drug_name": "Rezpegaldesleukin",
              "company": "Nektar Therapeutics",
              "mechanism": "IL-2 receptor complex agonist/Treg stimulator",
              "phase": "Phase 2",
              "trial_id": "Unknown - verify",
              "expected_completion": null,
              "trial_name": null,
              "status": "Active",
              "regulatory_designations": "Fast Track",
              "notes": "Received FDA Fast Track designation in July 2025"
            }
          ],
          "pipeline_details": "Nine active clinical programs are in Phase 2-3 development for alopecia areata, dominated by JAK inhibitors but including novel approaches like microbiota transplant therapy and IL-2 receptor modulators. AbbVie's upadacitinib has reported positive Phase 3 results and is seeking regulatory approval, while Pfizer's ritlecitinib continues Phase 3 recruitment.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "JAK inhibitors are considered first-line treatment for severe alopecia areata (\u226550% scalp hair loss), with three FDA-approved options now available. For mild to moderate disease, topical corticosteroids and intralesional corticosteroid injections remain standard approaches, often combined with topical minoxidil.",
          "unmet_need": false,
          "unmet_need_description": null,
          "competitive_landscape": "The alopecia areata market has been rapidly transformed with three JAK inhibitors approved in just three years (2022-2024), providing systemic treatment options for severe disease. All three drugs target the same pathway but may offer different dosing or patient population advantages.",
          "soc_source": "Medscape Alopecia Areata Overview and FDA Drug Labels",
          "phase_3_count": 3,
          "phase_2_count": 6,
          "key_catalysts": "AbbVie expected to file for upadacitinib approval in 2025-2026 based on positive UP-AA Phase 3 results; Pfizer's ritlecitinib Phase 3 ALLEGRO-100 trial completion expected March 2027",
          "pipeline_data_quality": "High",
          "recent_approvals": "Olumiant (baricitinib) June 2022, Litfulo (ritlecitinib) June 2023, Leqselvi (deuruxolitinib) July 2024",
          "data_quality": "High",
          "data_quality_notes": "Multiple sources confirm FDA approvals with specific approval dates and indications. All three approvals are for severe alopecia areata specifically."
        },
        "market_size_estimate": "$167.5B",
        "market_size_usd": 167500000000.0,
        "growth_rate": "3-5% CAGR (stable prevalence)",
        "tam_usd": 850000000.0,
        "tam_estimate": "$850M",
        "tam_rationale": "Of ~6.7M US alopecia areata patients, ~80% are diagnosed (5.4M), but only ~15% have moderate-severe disease warranting systemic JAK inhibitor therapy (~810K patients). With 3 approved JAK inhibitors already established as first-line for severe cases, a new entrant could realistically capture 15-20% market share (~135K patients). At $50K/year pricing (consistent with autoimmune-dermatology benchmarks), TAM = 135K \u00d7 $50K = $675M-850M.",
        "tam_sources": [
          "https://bisresearch.com/industry-report/alopecia-areata-market.html",
          "https://www.prnewswire.com/news-releases/alopecia-areata-market-to-show-positive-growth-at-a-cagr-of-26-3-during-the-study-period-20192032-estimates-delveinsight-301853907.html",
          "https://www.giiresearch.com/report/tbrc1824572-alopecia-global-market-report.html"
        ],
        "pipeline_sources": [
          "https://clinicaltrials.gov",
          "https://clinicaltrials.gov/study/NCT03732807",
          "https://cdn.clinicaltrials.gov/large-docs/07/NCT03732807/Prot_000.pdf",
          "https://cdn.clinicaltrials.gov/large-docs/49/NCT03570749/Prot_002.pdf",
          "https://www.clinicaltrials.gov/study/NCT06012240"
        ],
        "attributed_sources": [
          {
            "url": "https://www.jaad.org/article/S0190-9622(22)01464-5/fulltext",
            "title": "33432 Prevalence estimates for alopecia areata in ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9979012/",
            "title": "Trends in Prevalence and Incidence of Alopecia Areata ... - NIH",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://emedicine.medscape.com/article/1069931-overview",
            "title": "Alopecia Areata: Practice Essentials, Background, ...",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://emedicine.medscape.com/article/1069931-medication",
            "title": "Alopecia Areata Medication: Glucocorticoids, Vasodilators ...",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3149478/",
            "title": "Alopecia areata: a new treatment plan - PMC",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://clinicaltrials.gov",
            "title": "ClinicalTrials.gov API",
            "attribution": "Pipeline/Clinical Trials (Primary)"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT03732807",
            "title": "PF-06651600 for the Treatment of Alopecia Areata",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://cdn.clinicaltrials.gov/large-docs/07/NCT03732807/Prot_000.pdf",
            "title": "a phase 2b/3 randomized, double-blind, placebo-controlled",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://bisresearch.com/industry-report/alopecia-areata-market.html",
            "title": "Alopecia Areata Market Size & Forecast | BIS Research",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.prnewswire.com/news-releases/alopecia-areata-market-to-show-positive-growth-at-a-cagr-of-26-3-during-the-study-period-20192032-estimates-delveinsight-301853907.html",
            "title": "Alopecia Areata Market to Show Positive Growth at a CAGR of 26.3 ...",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 4.2,
        "evidence_quality": 4.3,
        "market_opportunity": 6.7,
        "overall_priority": 4.8,
        "clinical_breakdown": {
          "response_rate_quality_weighted": 1.5,
          "safety_profile": 5.0,
          "organ_domain_breadth": 8.0,
          "safety_categories": [],
          "regulatory_flags": [],
          "efficacy_endpoint_count": 0,
          "efficacy_concordance": 1.0
        },
        "response_rate_score": 1.5,
        "safety_profile_score": 5.0,
        "endpoint_quality_score": null,
        "organ_domain_score": 8.0,
        "evidence_breakdown": {
          "sample_size": 1.0,
          "publication_venue": 10.0,
          "response_durability": 4.0,
          "extraction_completeness": 3.2
        },
        "sample_size_score": 1.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 4.0,
        "extraction_completeness_score": 3.2,
        "market_breakdown": {
          "competitors": 5.0,
          "market_size": 10.0,
          "unmet_need": 5.0
        },
        "competitors_score": 5.0,
        "market_size_score": 10.0,
        "unmet_need_score": 5.0
      },
      "rank": 51
    }
  ],
  "analysis_date": "2025-12-08T19:41:59.381361",
  "search_queries_used": [],
  "papers_screened": 77,
  "papers_extracted": 51,
  "total_input_tokens": 1703715,
  "total_output_tokens": 169016,
  "estimated_cost_usd": 7.6464
}